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ABSTRACT  
Depression increases the risk of suicide death and non-fatal suicide 
attempt. Between 2 - 6% of persons with depression will die by suicide1 and 25 - 
31% of persons with depression will make a non-fatal suicide attempt during their 
lifetime.2,3 Despite the strong association between depression and suicidal 
behavior, the vast majority of persons with depression will not engage in suicidal 
behavior, making it difficult to accurately predict who is at risk for suicide and non-
fatal suicide attempt. Identifying high risk persons who should be connected to 
suicide prevention interventions is an important public health goal. Furthermore, 
depression often co-occurs with other mental disorders, which may exert an 
interactive influence on the risk of suicide and suicide attempt. Understanding the 
joint influence of depression and other mental disorders on suicide outcomes may 
inform prevention strategies. The goals of this dissertation were to predict suicide 
and non-fatal suicide attempt among persons with depression and to quantify the 
causal joint effect of depression and comorbid psychiatric disorders on suicide and 
suicide attempt. For all three studies, we used data from Danish registries, which 
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routinely collect high-quality data in a setting of universal health care with long-
term follow-up and registration of most health and life events.4 
In Study 1, we predicted suicide deaths among men and women diagnosed 
with depression using a case-cohort design (n = 14,737). Approximately 800 
predictors were included in the machine learning models (classification trees and 
random forests), spanning demographic characteristics, income, employment, 
immigrant status, citizenship, family suicidal history (parent or spouse), previous 
suicide attempts, mental disorders, physical health disorders, surgeries, 
prescription drugs, and psychotherapy. In depressed men, we found interactions 
between hypnotics and sedatives, analgesics and antipyretics, and previous 
poisonings that were associated with a high risk of suicide. In depressed women, 
there were interactions between poisoning and anxiolytics and between anxiolytics 
and hypnotics and sedatives that were associated with suicide risk. The variables 
in the random forests that contributed the most to prediction accuracy in depressed 
men were previous poisoning diagnoses and prescriptions of hypnotics and 
sedatives and anxiolytics. In depressed women, the most important predictors of 
suicide were receipt of state pension, prescriptions for psychiatric medications 
(anxiolytics and antipsychotics) and diagnoses of poisoning, alcohol related 
disorders, and reaction to severe stress and adjustment disorders. Prescriptions 
of analgesics and antipyretics (e.g., acetaminophen) and antithrombotic agents 




Study 2 predicted non-fatal suicide attempts among men and women 
diagnosed with depression using a case-cohort design (n = 17,995). Among 
depressed men, there was a high risk of suicide attempt among those who 
received a state pension and were diagnosed with toxic effects of substances. 
There was also an interaction between reaction to severe stress and adjustment 
disorder and not receiving psychological help that was associated with suicide 
attempt risk among depressed men. In depressed women, suicide attempt risk was 
high in those who were prescribed antipsychotics, diagnosed with specific 
personality disorders, did not have a poisoning diagnosis, and were not receiving 
a state pension. For both men and women, the random forest results showed that 
the strongest contributors to prediction accuracy of suicide attempts were 
poisonings, alcohol related disorders, reaction to severe stress and adjustment 
disorders, drugs used to treat psychiatric disorders (e.g., drugs used in addictive 
disorders, anxiolytics, hypnotics and sedatives), anti-inflammatory medications, 
receipt of state pension, and remaining single.  
Study 3 examined the joint effect of depression and other mental disorders 
on suicide and non-fatal suicide attempts using a case-cohort design (suicide 
death analysis n = 279,286; suicide attempt analysis n = 288,157). We examined 
pairwise combinations of depression with: 1) organic disorders, 2) substance use 
disorders, 3) schizophrenia, 4) bipolar disorder, 5) neurotic disorders, 6) eating 
disorders, 7) personality disorders, 8) intellectual disabilities, 9) developmental 
disorders, and 10) behavioral disorders. We fit sex-stratified joint marginal 
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structural Cox models to account for time-varying confounding. We observed large 
hazard ratios for the joint effect of depression and comorbid mental disorders on 
suicide and suicide attempts, the effect of depression in the absence of comorbid 
mental disorders, and for the effect of comorbid mental disorders in the absence 
of depression. We observed positive and negative interdependence between 
different combinations of depression and comorbid mental disorders on the rate of 
suicide and suicide attempt, with variation by sex. Overall, depression and 
comorbid mental disorders are harmful exposures, both independently and jointly.  
All of the studies in this dissertation highlight the important role of 
interactions between risk factors in suicidal behavior among persons with 
depression. Depression is one of the most commonly assessed risk factors for 
suicide,5,6 and our findings underscore the value of considering additional risk 
factors such as other psychiatric disorders, psychiatric medications, and social 
factors in combination with depression. The results of this dissertation may help 
inform potential risk identification strategies which may facilitate the targeting of 




TABLE OF CONTENTS 
ACKNOWLEDGMENTS ...................................................................................... iv	
ABSTRACT ......................................................................................................... vi	
TABLE OF CONTENTS ....................................................................................... x	
LIST OF TABLES .............................................................................................. xiv	
LIST OF FIGURES ............................................................................................ xvi	
LIST OF ABBREVIATIONS............................................................................. xviii	
CHAPTER 1. INTRODUCTION ............................................................................ 1	
CHAPTER 2. COMPREHENSIVE METHODS ..................................................... 9	
STUDY DESIGN AND SAMPLE ....................................................................... 9	
DATA SOURCES ............................................................................................ 10	
VARIABLE DEFINITIONS ............................................................................... 13	
STATISTICAL ANALYSES .............................................................................. 14	
Studies 1 and 2 ............................................................................................ 14	
Study 3 ........................................................................................................ 18	
CHAPTER 3. PREDICTING SUICIDE DEATH AMONG MEN AND WOMEN 
WITH DEPRESSION .......................................................................................... 22	
INTRODUCTION ............................................................................................. 22	
METHODS ...................................................................................................... 26	
Study Design and Sample ........................................................................... 26	
Predictors..................................................................................................... 26	
Descriptive Analyses ................................................................................... 28	
	
	 xi 
Machine Learning Analyses ......................................................................... 28	
RESULTS ........................................................................................................ 31	
Descriptive Results ...................................................................................... 31	
Classification Trees ..................................................................................... 31	
Random Forests .......................................................................................... 33	
DISCUSSION .................................................................................................. 34	
CHAPTER 4. PREDICTING SUICIDE ATTEMPT AMONG MEN AND WOMEN 
WITH DEPRESSION .......................................................................................... 52	
INTRODUCTION ............................................................................................. 52	
METHODS ...................................................................................................... 55	
Study Design and Sample ........................................................................... 55	
Predictors..................................................................................................... 56	
Descriptive Analyses ................................................................................... 57	
Machine Learning Analyses ......................................................................... 57	
RESULTS ........................................................................................................ 59	
Descriptive Results ...................................................................................... 59	
Classification Trees ..................................................................................... 60	
Random Forests .......................................................................................... 61	
DISCUSSION .................................................................................................. 63	
CHAPTER 5. THE JOINT EFFECTS OF DEPRESSION AND COMORBID 
PSYCHIATRIC DISORDERS ON SUICIDE DEATHS AND NON-FATAL 




Study Design and Sample ........................................................................... 87	
Exposures .................................................................................................... 87	
Confounders ................................................................................................ 89	
Statistical Analysis ....................................................................................... 90	
Bias Analysis ............................................................................................... 94	
RESULTS ........................................................................................................ 96	
Descriptive Results ...................................................................................... 96	
Crude Cox Proportional Hazards Regression Results ................................. 98	
Marginal Structural Cox Regression Model Results ................................... 103	
Assessment of Competitive Antagonism ................................................... 107	
Sensitivity and Bias Analysis ..................................................................... 108	
DISCUSSION ................................................................................................ 109	
CHAPTER 6. CONCLUSIONS ......................................................................... 150	














LIST OF TABLES 
Table 3.1 Characteristics of the suicide cases and the subcohort, Denmark, 
January 1, 1995. .......................................................................................... 47 
Table 4.1 Characteristics of the suicide attempt cases and the subcohort, 
Denmark, January 1, 1995........................................................................... 78 
Table 5.1 Baseline demographic characteristics of depressed and non-depressed 
men and women in Denmark in the analysis of suicide deaths, January 1, 
1995. .......................................................................................................... 121	
Table 5.2 Psychiatric disorders in depressed and non-depressed men and 
women in Denmark in the analysis of suicide deaths, January 1, 1995 - 
December 31, 2015. .................................................................................. 122	
Table 5.3 Baseline demographic characteristics of depressed and non-depressed 
men and women in Denmark in the analysis of suicide attempts, January 1, 
1995. .......................................................................................................... 123	
Table 5.4 Psychiatric disorders in depressed and non-depressed men and 
women in Denmark over study period in the analysis of suicide attempts, 
January 1, 1995 - December 31, 2015. ..................................................... 124	
Table 5.5 Sex-specific crude hazard ratios for the joint effects of depression and 
comorbid mental disorders on suicide death, Denmark, January 1, 1995 - 
December 31, 2015. .................................................................................. 125	
Table 5.6 Sex-specific crude hazard ratios for the joint effects of depression and 
comorbid mental disorders on non-fatal suicide attempts, Denmark, January 
1, 1995 - December 31, 2015. .................................................................. 127	
Table 5.7 Sex-specific adjusted hazard ratios for the joint effects of depression 
and comorbid mental disorders on suicide death, Denmark, January 1, 1995 
- December 31, 2015. ............................................................................... 129	
Table 5.8 Sex-specific adjusted hazard ratios for the joint effects of depression 
and comorbid mental disorders on non-fatal suicide attempts, Denmark, 
January 1, 1995 - December 31, 2015. ..................................................... 131	
Table 5.9 Response types for two binary exposure variables and a binary 
outcome. .................................................................................................... 133	
Table 5.10 Assessment of the presence of competitive antagonism for the 
observed negative RERIs in the analysis of suicide deaths. ...................... 134	
	
	 xv 
Table 5.11 Assessment of the presence of competitive antagonism for the 
observed negative RERIs in the analysis of suicide attempts. ................... 136	
Table 5.12 Bias analysis of non-differential misclassification of mental disorders 
in the analysis of suicide deaths. ............................................................... 137	
Table 5.13 Bias analysis of non-differential misclassification of mental disorders 
in the analysis of suicide attempts. ............................................................ 138	
Table 5.14 Summary of sex-specific interdependence findings for suicide deaths 





LIST OF FIGURES 
Figure 2.1. Directed acyclic graph for the effect of depression and substance use 
disorder on suicide and suicide attempt. ...................................................... 21 
Figure 3.1 Classification tree depicting suicide predictors in depressed men in 
Denmark, 1995 - 2015. ............................................................................... 48	
Figure 3.2 Classification tree depicting suicide predictors in depressed women in 
Denmark, 1995 - 2015. ............................................................................... 49	
Figure 3.3 Variable importance of suicide predictors in depressed men in 
Denmark from 10-fold cross-validation, 1995 - 2015. ................................. 50	
Figure 3.4 Variable importance of suicide predictors in depressed women in 
Denmark from 10-fold cross-validation, 1995 - 2015. ................................. 51 
Figure 4.1 Classification tree depicting suicide attempt predictors in depressed 
men in Denmark, 1995 - 2015. .................................................................... 79	
Figure 4.2 Classification tree depicting suicide attempt predictors in depressed 
women in Denmark, 1995 - 2015. ............................................................... 80	
Figure 4.3 Variable importance of suicide attempt predictors in depressed men in 
Denmark from 10-fold cross-validation, 1995 - 2015. ................................. 81	
Figure 4.4 Variable importance of suicide attempt predictors in depressed women 
in Denmark from 10-fold cross-validation, 1995 - 2015. .............................. 82 
Figure 5.1 Exposed and unexposed person-time for depression. ..................... 140	
Figure 5.2 Exposed and unexposed person-time for psychiatric comorbidity. .. 141	
Figure 5.3 Additive interaction between depression and comorbid mental 
disorders on the risk of suicide death from crude Cox models in men. ...... 142	
Figure 5.4 Additive interaction between depression and comorbid mental 
disorders on the risk of suicide death from crude Cox models in women. . 143	
Figure 5.5 Additive interaction between depression and comorbid mental 




Figure 5.6 Additive interaction between depression and comorbid mental 
disorders on the risk of non-fatal suicide attempts from crude Cox models in 
women. ...................................................................................................... 145	
Figure 5.7 Additive interaction between depression and comorbid mental 
disorders on the risk of suicide death from marginal structural models in 
men. ........................................................................................................... 146	
Figure 5.8 Additive interaction between depression and comorbid mental 
disorders on the risk of suicide death from marginal structural models in 
women. ...................................................................................................... 147	
Figure 5.9 Additive interaction between depression and comorbid mental 
disorders on the risk of non-fatal suicide attempts from marginal structural 
models in men. .......................................................................................... 148	
Figure 5.10 Additive interaction between depression and comorbid mental 
disorders on the risk of non-fatal suicide attempts from marginal structural 





LIST OF ABBREVIATIONS 
ATC ............................................................. Anatomical Therapeutic Classification  
AUC ............................... Area Under the Receiver Operating Characteristic Curve 
C-CASA ........................ Columbia Classification Algorithm of Suicide Assessment 
CI ............................................................................................. Confidence Interval  
HR ...................................................................................................... Hazard Ratio 
ICD-10 ................................ International Classification of Diseases, 10th Revision 
IPCW ................................................... Inverse Probability of Continuation Weight  
IPTW ........................................................ Inverse Probability of Treatment Weight 
MDA ........................................................................... Mean Decrease in Accuracy 
NCS-R .................................................... National Comorbidity Survey Replication 
OR ........................................................................................................ Odds Ratio  
PPV .................................................................................. Positive Predictive Value 
PTSD ...................................................................... Posttraumatic Stress Disorder 
RERI ............................................... Relative Excess Risk due to Interdependence 
R(I) ............................................................................ Risk due to Interdependence 
SD .............................................................................................Standard Deviation 
UP ............ Unified Protocol for Transdiagnostic Treatment of Emotional Disorders 
U.S. ................................................................................................... United States 
VA ................................................................................................. Veterans Affairs  
wAUC ............ Weighted Area Under the Receiver Operating Characteristic Curve 
	
	 1 
CHAPTER 1. INTRODUCTION 
Suicide deaths and non-fatal suicide attempts are severe public health 
problems. Approximately 800,000 persons die by suicide each year globally.7 For 
every adult who dies by suicide, it is estimated that there are 20 non-fatal suicide 
attempts.7 Non-fatal suicide attempts are a leading cause of injury globally and are 
associated with an increased risk of dying by suicide in a future attempt.8 There is 
also a large economic cost associated with suicidal behavior.9–11 In the United 
States (U.S.), the cost of suicide and suicide attempts was $58 billion in 2013 and 
may be even greater now as the rates of suicide and attempts have increased.9,12–
14 Given the large burden of suicidal behavior, there is increased interest in 
studying these events in those with psychiatric conditions who are at high risk of 
suicidal behavior,15 with the goal of identifying persons for targeted preventive 
interventions.  
Depression is one of the most common mental disorders, with 
approximately 300 million people living with depressive disorders globally in 
2016.16 Depression has a well-established, strong association with suicide and 
non-fatal suicide attempts.1,5,17 The suicide rate among persons with depression is 
nearly 20 times the suicide rate in the general population.18 Persons living with 
depression may view their situation as untenable or hopeless to the extent that 
suicide is the only possible solution.19 Given its strong association with suicidal 
behavior, depression is commonly used in risk factor guidelines developed by 
major national and international organizations to assess the risk of suicidal 
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behavior.5 For example, in 2014, the U.S. Preventive Task Force recommended 
that primary care suicide-risk assessments only be conducted during depression 
screenings.6 However, accurate prediction of suicidal behavior among persons 
with depression remains challenging5 because while depression is a common 
disorder, the vast majority of persons with depression will not engage in suicidal 
behavior. The cumulative lifetime risk of dying by suicide is 6.7% (95% CI =  5.7%,  
7.8%) in men with depressive disorders and 3.8% (95% CI = 3.1%, 4.7%) in 
women with depressive disorders.20 According to a meta-analysis of 65 studies, 
the lifetime prevalence of suicide attempts among persons with major depressive 
disorder was 31% (95% confidence interval [CI] = 27%, 34%).3  
Accurate identification of depressed persons at risk of fatal and non-fatal 
suicide attempts is essential for clinicians to identify persons at greatest risk and 
intervene appropriately, especially since monitoring and interventions in high-risk 
patients may reduce rates of suicide and suicide attempts.21,22 A 2017 meta-
analysis of the past five decades of research on suicidal behavior found that much 
of existing statistical models’ ability to predict suicide and suicide attempts has 
remained only slightly better than chance (weighted area under the receiver 
operating characteristic curve [wAUC] for predicting suicide deaths = 0.55; wAUC 
for predicting suicide attempts = 0.58).23 The field has been limited by an 
overreliance on traditional statistical approaches which allow only conscribed sets 
of variables to be examined simultaneously, which constrains researchers to the 
use of inflexible models for prediction.23 The majority of studies tested risk factors 
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in isolation, and individual risk factors have limited ability to predict suicide 
outcomes.6 Suicide and suicide attempts are the result of a myriad of factors,24,25 
and as such, accurate prediction of suicide may require consideration of hundreds 
of variables and their interactions.23,26 Traditional statistical techniques (e.g., 
logistic regression) are not able to detect interactions without a priori specification 
and they cannot examine large sets of variables without violating statistical 
assumptions (e.g., linear relationships, absence of collinearity).26 This prevents the 
consideration of numerous interactions that are likely present in the development 
of risk for suicide and suicide attempts. 
To help address the limitations of traditional statistical methods, 
researchers in psychiatry have relatively recently started using machine learning 
methods. Machine learning is a branch of computer science that aims to construct 
computer programs that automatically improve with experience (i.e., more data).27  
Machine learning allows for simultaneous testing of numerous variables and can 
detect complex patterns without a priori specification. Machine learning has 
previously been used to predict suicide and suicide attempts in various groups 
such as the general population,28 veterans and army members who experienced 
a mental health inpatient or outpatient visit,29–31 the general population after a visit 
to psychiatric specialty care,32 and hospital/medical center populations26,33 and 
more. These studies found that machine learning can predict suicide and suicide 
attempts accurately with AUC values ranging from 0.71 to 0.88 for suicide 
deaths28–30 and 0.80 to 0.97 for suicide attempts, surpassing the wAUCs for suicide 
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deaths (wAUC = 0.55) and suicide attempts (wAUC = 0.58) from a meta-analysis 
of existing studies using traditional statistical methods.26,32,33 In a direct 
comparison of machine learning and traditional methods, Walsh and colleagues 
predicted suicide attempts over time and found that multiple logistic regression 
(AUC: 0.66 to 0.68) performed worse than random forests (AUC: 0.80 to 0.84).26 
Moreover, machine learning studies have allowed researchers to identify several 
novel predictors such as gastrointestinal problems34 and hospitalization for any 
physical health problem, in addition to documenting important predictors (e.g., 
psychiatric disorders and medications) that are consistent with existing knowledge 
of risk factors for suicide and suicide attempts. An important next step for the field 
of suicide risk prediction is to develop prediction models in specific, high-risk 
groups such as persons with psychiatric disorders (e.g., depression) to improve 
linkage to interventions.15 Machine learning may reveal novel constellations of risk 
factors that are highly predictive of suicide and suicide attempts among persons 
with depression.  
Although the application of machine learning holds promise for further 
developing our understanding of suicidal behavior in high-risk subpopulations, 
additional considerations are necessary to ground this work in the current 
knowledge base. For example, within the field of suicide epidemiology, suicide 
death and non-fatal suicide attempts are believed to be, and almost always studied 
as, separate outcomes.35 Approximately 60% of persons who die by suicide never 
made a prior non-fatal suicide attempt and 15% of persons who make a non-fatal 
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suicide attempt eventually die by suicide.36,37 Furthermore, persons who die by 
suicide tend to have different characteristics compared to persons who make a 
non-fatal suicide attempt, including older age, male sex, alcohol use disorders, 
comorbid health problems, and severe suicidal ideation.38–40 Our previous work 
examining suicide and suicide attempts in the Danish population found that there 
were distinct risk factor profiles for each outcome.28 Thus, separate prediction 
models for suicide and non-fatal suicide attempts are necessary.   
In addition to developing separate models for suicide and suicide attempt, 
accurate risk detection may require separate prediction models for men and 
women because risk of suicidal behavior differs by sex. Although the risk of suicide 
attempts among women is two to three times the risk among men,41 men are more 
likely to die by suicide than women.42 A meta-analysis of sex differences in suicidal 
behavior found that the risk factors that were more prominent in women than men 
included having an eating disorder, posttraumatic stress disorder (PTSD), and a 
previous abortion, and experiencing dating violence.43 Risk factors for suicidal 
behavior that were important among men compared to women included disruptive 
behavior/conduct problems, hopelessness, parental separation/divorce, friend’s 
suicidal behavior, and access to means.43 Our previous work on predicting suicide 
in the general population of Denmark found distinct risk profiles for men and 
women,28 further documenting the need for sex-stratified examination. 
Accordingly, Study 1 of this dissertation developed sex-specific machine learning 
algorithms to predict suicide deaths among men and women with depression. 
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Study 2 of this dissertation developed sex-specific machine learning algorithms to 
predict non-fatal suicide attempts among men and women with depression. The 
machine learning results can be used to generate hypotheses about novel risk 
factors and interactions between risk factors that confer increased risk of suicide 
and non-fatal suicide attempt. Upon replication of our findings, insights from this 
study may inform future research that can aid clinicians in identifying high-risk 
patients who should be connected with suicide prevention interventions. 
Although machine learning can be used to identify novel interactions, these 
interactions may not necessarily be causal because of confounding. Traditional 
epidemiologic methods are necessary for quantifying the causal effects of 
interactions. Furthermore, pre-specification of interactions may help us identify 
those that have causal relations with suicidal behavior but did not emerge in 
machine learning prediction models as important predictors due to confounding. A 
specific interaction of interest is the joint role of depression and other mental 
disorders,44–47 which may have an interactive effect on risk of fatal and non-fatal 
suicide attempts. The National Comorbidity Survey Replication study, a U.S. 
nationally representative survey, found that nearly 75% of respondents with 
lifetime major depressive disorder also met criteria for at least one other mental 
disorder.48 Another U.S. nationally representative survey, the National 
Epidemiologic Survey on Alcohol and Related Conditions III, found that among 
persons with major depressive disorder, 58% also had lifetime substance use 
disorder, 37% had anxiety disorder, 16% had PTSD, and 27% had borderline 
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personality disorder.49 A recent study examining comorbidity within mental 
disorders in Denmark found that all mental disorders were associated with an 
increased risk of all other mental disorders, and risk was especially high during the 
first year after the onset of the first disorder.50 A psychological autopsy study found 
that the most prevalent mental disorder among suicide decedents was depressive 
disorders (59%), and among those with major depression, 28% had alcohol abuse 
and dependence.51 This study also found that comorbidity was more common 
among male suicide decedents (91%) than among female suicide decedents 
(79%).51 Among suicide attempters who were administered diagnostic interviews 
for mental disorders after receiving medical treatment for their attempt, the most 
common disorder was depression (85% in female attempters and 64% in male 
attempters).52 Among female suicide attempters with major depression, 41% had 
also alcohol abuse or dependence, 15% had anxiety disorder, and 37% had a 
personality disorder.52 Among male suicide attempters with major depression, 69% 
had alcohol abuse or dependence, 12% had anxiety disorder, and 12% had a 
personality disorder.52 
Although psychiatric comorbidity is common, much of the existing literature 
has focused on the individual associations between depression and 
suicide/suicide attempts and statistically controlled for psychiatric comorbidity in 
their analyses.21,53–55 However, the joint effect of comorbidity between depression 
and other mental disorders might be important to quantify and consider in planning 
treatment strategies for suicide prevention. Existing studies of psychiatric 
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comorbidity in relation to suicide and non-fatal suicide attempts have been cross-
sectional or retrospective with respect to the collection of exposure information 
after the outcome has occurred.37,51,52,56 Prospectively collected data are 
necessary for establishing the temporal ordering of mental disorders, which is 
particularly important given that comorbid mental disorders are likely to act as 
confounders, mediators, effect modifiers, and colliders of the association between 
any specific mental disorder and suicide/suicide attempts.57 Depression and other 
mental disorders are both time-varying exposures and are subject to time-varying 
confounding, which arises when there is a time dependent covariate that is a risk 
factor of the outcome and also predicts subsequent exposure. Time-varying 
confounding poses a challenge to estimating the effect of psychiatric comorbidity 
on suicide outcomes because we cannot stratify on time-varying covariates 
because they are intermediates, but ignoring these covariates would lead to 
uncontrolled confounding. Novel analytic methods such as g-methods may be 
necessary to address time-varying confounding and avoid the bias that may occur 
with standard adjustment of a time-varying confounder affected by prior 
exposure.58 To address these gaps in the literature, Study 3 of this dissertation 
examined the joint effect of depression and other psychiatric disorders on the risk 
of fatal and non-fatal suicide attempts in men and women using a marginal 





CHAPTER 2. COMPREHENSIVE METHODS 
 
STUDY DESIGN AND SAMPLE 
We used data from an existing parent case-cohort study28 in which the 
source population was all persons born or legally residing in Denmark on January 
1, 1995 (n = 5,303,674). The investigators of the parent study implemented a case-
cohort study because it is an efficient study design for studying rare outcomes 
without having to obtain and analyze information for all persons in the source 
population.59,60 Another advantage of the case-cohort design is that it facilitates 
the conduct of multiple case-control studies from a single cohort using the same 
control group for all studies.60 The control group (a sample from the cohort at the 
beginning of study period) can be compared with any number of case groups and 
matching is unnecessary.  
The investigators of the parent study chose 1995 as the start of the study 
period for two reasons: 1) Denmark adopted the International Classification of 
Diseases, 10th Revision (ICD-10) in 1994 and 2) 1995 was the start of reporting of 
all hospital outpatient clinic visits to the Danish National Patient Registry and 
Danish Psychiatric Central Research Registry.61 Two case groups were obtained: 
1) suicide deaths and 2) non-fatal suicide attempts. Suicide cases were all 
individuals who died by suicide (n = 14,103) and suicide attempt cases were all 
individuals who made a non-fatal suicide attempt (n = 22,974) between January 1, 
1995 and December 31, 2015 in Denmark. The subcohort was a 5% random 
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sample of the source population in Denmark on January 1, 1995 (n = 265,183). 
The same comparison subcohort was used for both case groups. The exposure 
distribution among persons in the comparison subcohort will, on average, reflect 
the exposure (i.e., predictor) distribution among all persons followed in the source 
population.60 In a case-cohort study, a person who is selected as a control (i.e., 
comparison subcohort) may also be a case. This is theoretically coherent with the 
conduct of a cohort study in which every person in the numerator (i.e., cases) is 
also included in the denominator (i.e., source population).60 In this study, there 
were 630 persons who were in both the suicide case group and the comparison 
subcohort and there were 1,114 persons who were in both the suicide attempt 
case group and the comparison subcohort. The analytic samples for each study 
are described in further detail in the following chapters.   
 
DATA SOURCES 
All three studies used data from Danish medical and social registries. 
Universal medical coverage is provided for the entire Danish population through a 
tax-supported healthcare system.61,62 Redistributionist taxation finances the 
majority of healthcare access to general practitioners, hospitals, outpatient 
specialty clinics, and partial reimbursement of prescribed medications in 
Denmark.61 Over 90% of the Danish population has at least one contact with the 
healthcare system in a given year.63 Receipt of healthcare services is recorded in 
national medical and administrative registries.64,65 To merge data across Danish 
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registries, the 10-digit Central Personal Register number (unique individual-level 
identifiers assigned to all Danish residents) is used.66 Central Personal Register 
numbers and demographic data are maintained by the Danish Civil Registration 
System. The Civil Registration System has been updated daily since 1989 with the 
vital status of each resident. It also maintains data on sex, date of birth, citizenship, 
vital status, immigration status, generation of citizenship, and marital status.67,68  
The Danish Cause of Death Registry has been maintained by the National 
Board of Health since 1875 and has kept computerized individual records since 
1970.69 This registry maintains data on age at death, manner of death, place of 
death, and autopsy results.69 We used this registry to obtain suicide death cases. 
Classification of cause(s) of death is conducted in accordance with rules of the 
World Health Organization (e.g., death certificates shall state the underlying cause 
of death and contributory causes of death may also be stated) since 1994 using 
ICD-10 codes.  
 The Danish Psychiatric Central Research Registry records data on all 
psychiatric inpatient, outpatient, and emergency room treatment data since 1995, 
including treatment dates and primary and secondary diagnoses.70 It records up to 
20 diagnoses per treatment episode and the dates of all inpatient psychiatric stays 
and outpatient psychiatric visits.70 We used this registry to obtain all psychiatric 
diagnoses using two-digit ICD-10 codes. Studies have documented the high 
quality of diagnoses in the Danish Psychiatric Central Research Registry.70,71 
 The Danish National Patient Registry records data on all inpatient 
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hospitalizations in non-psychiatric hospitals and hospital outpatient and 
emergency room visits since 1995.61 It contains treatment dates and up to 20 
primary and secondary diagnostic codes, surgery codes, and examination codes 
per treatment episode.61,72 Diagnoses from this registry were obtained using 
second-level ICD-10 diagnosis groups. Validation studies have documented the 
high validity of many diagnoses in the Danish National Patient Registry.61,73 
However, we removed emergency room diagnoses due to their low positive 
predictive value (PPV).74,75 
 The Danish National Prescription Registry contains data on prescription 
drugs sold in pharmacies since 1994 and includes data on dispensing date, 
product name, and Anatomical Therapeutic Classification (ATC) codes. We 
obtained data on prescription drugs using level 3 ATC codes (pharmacological 
subgroup). Reimbursement-driven record-keeping provides high-quality data on 
dispensed drugs.76   
The Income Statistics Register was established in 1970 and contains 
variables related to income (e.g., salary). Income data are generally of high 
quality.77 The Integrated Database for Labor Market Research records information 
on employment (e.g., occupation) beginning in 1980.78 Both validity and coverage 





We obtained depression diagnoses from the Danish Psychiatric Central 
Research Register and the Danish National Patient Registry. Depressive disorders 
(hereafter referred to as depression) were recorded as ICD-10 codes major 
depressive disorder, single episode (F32), major depressive disorder, recurrent 
(F33), persistent mood disorders (F34) and unspecified mood disorder (F39). We 
included persistent mood disorders (F34) and unspecified mood disorder (F39) in 
our variable definition of depression because sub-threshold forms of depression 
are prevalent and are associated with morbidity and functional impairment.80 
Persistent mood disorders (F34) are persistent and fluctuating disorders of mood 
in which the majority of individual episodes are not severe enough to warrant a 
depressive episode diagnosis.81 However, persistent mood disorders may last for 
many years and involve considerable distress and disability.81 Similarly, 
unspecified mood disorders (F39) is also diagnosed for persons with atypical mood 
conditions not meeting the criteria for a major depressive episode but can still be 
impairing.81 Given that depression is the most common mental disorder and has a 
high prevalence,18 prioritizing sensitivity of depression will reduce 
misclassification.  
The outcome of interest was suicide death in Study 1, non-fatal suicide 
attempt in Study 2, and both suicide and non-fatal suicide attempt (analyzed 
separately) in Study 3. We obtained suicide cases from the Danish Cause of Death 
Registry using ICD-10 codes X60 - X84.69 In a validation study, 92% of the deaths 
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recorded as suicides were confirmed by experts (forensic pathologists, 
psychiatrists, and expert coders) as suicide deaths.82 Incident suicide attempt 
cases were identified using inpatient and outpatient ICD-10 codes X60 - X84 in 
the Danish National Patient Registry or Psychiatric Central Research Register 
without a death recorded in the Danish Cause of Death Registry in the 30 days 
after the suicide attempt date. In a validation study, 73% of recorded suicide 
attempts (as ascertained by ICD-10 codes X60 - X84) were confirmed to be 
suicide attempts using the Columbia Classification Algorithm of Suicide 
Assessment as the gold standard.83 The sensitivity of suicide attempt classification 
in the Danish registries remains unknown and underregistration of suicide attempts 
is suspected given the difficulty of differentiating between suicide attempts and 
acts of self-harm without intention to die.83  




Studies 1 and 2 
Data Reduction 
The methods and statistical analyses were fundamentally the same for 
studies 1 and 2. We first performed data reduction to reduce the risk of model 
overfitting, which occurs when a model is too specific to the data on which it is built 
and is not useful for predicting events in new samples. Data reduction was 
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performed at the individual variable level and involved elimination of rare 
predictors. Rare predictors may lead to model overfit if, for example, there are 10 
non-suicide cases with a particular combination of risk factors that none of the 
suicide cases have. In this case, this combination of predictors will appear to be 
highly protective against suicide, but that information may only be applicable to the 
current sample. We removed rare predictors by generating 2x2 tables (i.e., cross-
tabulation of each individual predictor and the outcome) and eliminating predictors 
that had a cell count with 10 or fewer observations.29,84  
 
Overview of Machine Learning Methods 
Unlike traditional regression models, machine learning models do not 
require pre-specification of interactions, which is preferable when our goal is to 
discover patterns present in data rather than test a priori hypotheses. For the 
current study we used two supervised machine learning techniques: classification 
trees and random forests. Supervised machine learning involves predicting an 
outcome when the outcome (e.g., suicide/attempts) is known.27 Classification trees 
and random forests are recursive partitioning techniques that automatize the 
detection of nonlinear associations and interactions among variables, which may 
potentially elucidate novel interactions between risk factors that are predictive of 
suicidal behavior. 
Classification trees are a non-parametric method that allow us to visualize 
the structure of the data. Classification trees are used to create a series of decision 
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rules based on categorical or continuous input variables to predict a categorical 
outcome. Recursive splitting is used to construct classification trees such that the 
algorithm applies a splitting rule on successively smaller partitions of the data, 
forming parent and child nodes.85 The splitting process repeats until the tree has 
the lowest classification error rate.86 We used 10-fold cross validation to estimate 
suicide risk. 10-fold cross validation involves randomly dividing the observations 
into 10 subsamples (i.e., folds), of approximately equal size.87 The first fold is 
treated as a validation set and the classification tree is fit on the remaining nine 
folds. Predictions are then made for the observations in the held-out fold. This 
procedure is performed 10 times and each time, a different group of observations 
is treated as the validation set. The predictions are then averaged across the 10 
held-out folds.85  
Although classification trees are visually interpretable, a disadvantage is 
that they are sensitive to small changes in the data because of greediness.87,88  
Classification trees are “greedy” because at each step of the tree-building process, 
the best split is made at that particular step (i.e., node), rather than looking ahead 
and picking a split that will lead to a better tree later on.87 Thus, if a single higher-
level node changes, the resulting tree can look quite different.88 Classification trees 
are also prone to overfitting and their utility depends on appropriate pruning and/or 
stopping criteria.89 Ensemble-based decision trees, such as random forests, can 
mitigate these concerns but they do not produce a single, easily interpretable tree. 
This project will use both classification trees and random forests to borrow strength 
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from each algorithm.  
Random forests are an ensemble machine learning method that involves 
creating bootstrapped copies of the original data and then training a classification 
tree on each bootstrapped copy. This process is known as bagging and will create 
a collection of trees. Each tree uses two thirds of the observations to train the 
model and the remaining one third of the observations (i.e., out-of-bag 
observations) are used for testing the model, which reduces the risk of overfitting 
since the model is tested on observations not used to train the model. Random 
forests also decorrelate the trees in the collection by reducing the number of 
predictors considered at each split. This is important because if there is one very 
strong predictor, most or all of the trees in the collection will choose this variable 
to be the top split and all of the bagged trees will end up looking similar to each 
other, thus creating highly correlated predictions.87 By forcing each split to consider 
only a subset of the predictors (e.g., the square root of the total number of 
predictors), weaker predictors will have more of a chance to be selected as split 
candidates. When building decision trees in the bootstrapped training samples, a 
fresh sample of predictors is chosen as split candidates from the full set of 
predictors at each split. This process decorrelates the trees and makes the 
resulting trees less variable and more reliable.87 Details of the modeling 





Although we used a case-cohort design to ascertain the study sample, the 
data will be analyzed as though it were from a cohort.90–92 We first conducted 
stratified analyses to observe the distributions of important confounders and 
modifiers by exposure status. We then combined a case-cohort design with inverse 
probability-weighted estimation of a marginal structural Cox proportional hazards 
model following the approach of Cole et al. (2012).90 We examined pairwise 
combinations of depression with 1) organic disorders, 2) substance use disorders, 
3) schizophrenia, 4) bipolar disorder, 5) neurotic disorders, 6) eating disorders, 7) 
personality disorders, 8) intellectual disabilities, 9) developmental disorders, and 
10) behavioral disorders.  
 
Directed Acyclic Graph  
Figure 2.1 displays a directed acyclic graph depicting an example of the 
relation between depression, and effect modifying disorder, and suicide/suicide 
attempts. We used substance use disorders an example of an effect modifying 
disorder. Depression and substance use disorders are both time-varying 
exposures and are subject to time-varying confounding. Li represents a vector of 
measured confounders including age, marital status, employment, income, 
physical health status, and neurotic disorders. Ui represents a vector of 
unmeasured confounders including stressful life events (e.g., relationship 
difficulties), loneliness, and hopelessness. It is not possible to estimate the causal 
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effect of depression and substance use disorders using standard regression 
analysis because Li is both a confounder and a mediator of the relationship 
between depression, substance use disorder and suicide. Failure to adjust for Li 
will result in biased estimates, but adjusting for Li will also lead to bias.93,94 To avoid 
the bias introduced by standard adjustment of a time-varying confounder affected 
by prior exposure, we used inverse probability weighting and marginal structural 
models to estimate the joint effects58 of depression and each of the other mental 
disorders on suicide and non-fatal suicide attempts. 
 
Inverse Probability Weighting and Marginal Structural Models 
Marginal structural models are used to estimate the causal effect of a time-
dependent exposure in the presence of time-dependent variables that may 
simultaneously be confounders and intermediate variables.58 Rather than stratify, 
marginal structural models use weighting to weight each person by the inverse 
probability of the exposure they received, ultimately creating a pseudopopulation 
in which there is a null association between the confounder and exposure. The 
inverse probability of treatment weights (IPTWs) are the inverse probability of 
being exposed (or unexposed) at each physician visit. IPTWs were used to create 
a weighted sample in which exposure assignment was not confounded by 
measured covariates. In other words, weighting removed confounding without 
needing stratify. This corresponds with the disappearance of the arrows from Li to 
Depressioni and Substance use disorderi at each timepoint in the DAG in Figure 
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2.1. The IPTWs were used to estimate the parameters of a joint marginal structural 
Cox proportional hazards model with a robust variance estimator.  
 
Effect Measure Modification 
To assess effect measure modification of the association of depression with 
suicide/suicide attempts by other mental disorders, we calculated the relative 
excess risk due to interdependence (RERI). We calculated the RERI instead of the 
risk due to interdependence because rates cannot be estimated directly in a case-
control study and the variables were time-varying, making it complex to calculate 
the risk due to interdependence. The RERI is used to assess the direction and 
scaled magnitude of interdependence. Interdependence (i.e., “biologic interaction” 
or “mechanistic interaction”) is defined as the interdependent operation of two or 
more biological causes to produce, prevent, or control an effect.60 Departure from 
additivity is used to refer to the phenomenon when the risk in the doubly exposed 
(e.g., persons with both depression and PTSD) cannot be explained by the 
independent effects of two single exposures (depression or PTSD). The RERI is 
calculated using the following formula: 
R(I) / R(E-, M-) = OR(E+, M+) - [OR(E-, M+) - 1] - [OR(E+, M-) - 1] - 1 
where OR(E+, M+) is the ratio of the odds of the outcome in the doubly exposed 
to the odds of the outcome in the doubly unexposed, OR(E-, M+) is the ratio of the 
odds of the outcome in the unexposed, modifier positive stratum to the odds of the 
outcome in the doubly unexposed, and OR(E+, M-) is the ratio of the odds of the 
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outcome in the exposed, modifier negative stratum to the odds of the outcome in 
the doubly unexposed. R(I) is the risk due to interdependence and R(E-, M-) is the 
risk in the doubly unexposed. The RERI is simply the risk due to interdependence 
divided by the risk in the doubly unexposed. A positive RERI indicates that there 
are more cases in the doubly exposed than would be expected from the two 
exposures alone (super-additivity). A negative RERI indicates that there are fewer 
cases in the doubly exposed than would be expected from the two exposures alone 
(sub-additivity). A RERI equal to zero indicates that there is no interdependence 
between the exposure and the modifier. The RERIs were calculated from the 
weighted Cox proportional hazards regression models adjusting for confounders 
and we computed 95% confidence intervals for the RERIs. Additional details about 
the analytic procedure are provided in Chapter 5.
Figure 2.1. Directed acyclic graph for the effect of depression and 
substance use disorder on suicide and suicide attempt.  
	
 
Note: Li1, Li2, Li3, and Lik represent vectors of measured time-varying covariates for 
individual i at each time until the end of follow-up, respectively. Ui1, Ui2, Ui3, and Uik 
represent vectors of unmeasured time-varying covariates for individual i at each time until 





CHAPTER 3. PREDICTING SUICIDE DEATH AMONG MEN AND WOMEN 
WITH DEPRESSION  
 
INTRODUCTION 
Depression is one of the most important risk factors for suicide,5 and 
numerous studies have found that depression is the most prevalent psychiatric 
disorder among suicide decedents.51,95,96 Although persons with depression are a 
high risk group for suicide, accurate prediction of suicide among this group remains 
a challenge because suicide is rare, while depression is common. Knowledge of a 
patient experiencing a depressive episode does little to help clinicians distinguish 
between those at high risk of suicide and those who are not, which in turn makes 
it difficult for clinicians to decide which patients should receive suicide prevention 
interventions.  
Brief interventions such as safety planning and follow-up phone calls may 
help reduce suicidal behavior and increase behavioral health treatment 
engagement.97,98 Personalized safety planning involves developing a plan to limit 
access to lethal means including firearms and poisons.99 Follow-up phone calls 
that involve further suicide screening and support may also reduce the risk of 
suicide.97,98 In addition to brief interventions, psychosocial interventions such as 
cognitive behavioral therapy and dialectical behavior therapy may also reduce 
suicidal behavior by helping persons learn new skills to deal with stressful and 
upsetting experiences, recognize thought patterns, and consider alternative 
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options when thoughts of suicide arise.100,101 Medications such as antidepressants 
may also play an important role in suicide risk.102 Knowledge of who is at high risk 
for suicide among persons with depression may facilitate the prioritization and 
targeting of suicide prevention efforts to those most vulnerable.  
 Much of the burgeoning machine learning literature focused on advancing 
suicide prediction has found that depression is among the most important 
predictors of suicide,28,29,32,103 but few studies have focused on predicting suicide 
specifically among persons with depression. To the best of our knowledge, there 
is only one study to date that focused on predicting suicide among persons with 
depression.104 Ilgen and colleagues conducted an exploratory analysis to identify 
subgroups of patients, characterized by clusters of specific risk factors, with 
particularly high or low rates of suicide among Veterans Affairs (VA) health system 
patients treated for depression.104 They examined eight risk factors available from 
patient treatment records including age, race, sex, substance use disorder 
diagnosis, PTSD diagnosis, prior VA hospitalization, service connection, and 
baseline somatic comorbidity. They identified the strongest predictors of suicide 
and derived a decision tree with patients grouped based on similarities in suicide 
risk level. Substance use disorders emerged as the most important risk factor of 
suicide among depressed veterans. The patients at the highest risk of suicide were 
those with a substance use disorder, who were non-African American 
(predominantly white), and had an inpatient psychiatric stay within the past 12 
months (suicide rate = 247 deaths per 100,000 person years).104 Sex differences 
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in the risk profiles for suicide were not observable because none of the included 
risk factors reliably identified women at differing levels of risk. The authors noted 
that the lack of adequate representation of women in the sample was a limitation 
that may have prevented detection of sex differences. The authors did not report 
metrics of model performance (e.g., area under the receiver operating 
characteristic curve [AUC]) so the accuracy of their models remains unclear. 
A separate, more recent study conducted by Chen and colleagues predicted 
suicidal events among persons with various psychiatric disorders (with depression 
being one of the most common disorders) in the general population.32 Chen et al. 
sought to predict suicidal events (either suicide attempt or death by suicide) in the 
30 days and 90 days following a visit to psychiatric specialty care using Swedish 
registry data.32 Major depressive disorder was one of the most common psychiatric 
diagnoses at the visit (17%). Chen et al. trained four separate prediction models 
and then used an ensemble method to combine the performance of the trained 
models. A total of 425 predictors were included in the algorithms, spanning 
demographic characteristics, socioeconomic status, type of visit 
(planned/unplanned, in-/outpatient visit), psychiatric and somatic disorder 
diagnoses, self-harm, dispensed medications, criminality, and family history of 
disease and crime. There was substantial overlap in the top-ranked predictors in 
the 30 days and 90 days after a psychiatric specialty care visit. The top predictors 
included intentional self-harm prior to the visit, family history of intentional self-
harm, an unplanned healthcare visit, family history of mental disorders, psychiatric 
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disorder diagnoses (e.g., personality disorders, depression, substance use 
disorder), and dispensed psychiatric medications (e.g., antidepressants, 
anxiolytics, and antipsychotics).32 The timing of these risk factors may also play a 
role in predicting suicidal events such that temporally close predictors to the visit 
were ranked higher than distal ones. The AUC was 0.89 (95% confidence interval 
[CI] = 0.88, 0.90) for the model predicting a suicidal event in the 30 days after a 
visit to psychiatric specialty care and was 0.88 (95% CI = 0.87, 0.89) for the model 
predicting a suicidal event in the 90 days after a visit. Given that these models 
were able to predict suicidal events among persons who received psychiatric 
specialty care for a wide range of psychiatric conditions with good discrimination, 
an important next step is to develop prediction models in persons with specific 
psychiatric diagnoses (e.g., depression), which may more relevant to clinicians 
treating specific mental disorders.15 Furthermore, Chen et al. grouped suicide 
death and suicide attempts together to form a single outcome variable, which 
contrasts with most evidence suggesting that suicide deaths and attempts are 
separate outcomes with mostly non-overlapping populations.35–37 Thus, additional 
work is needed to assess death by suicide and suicide attempt separately.  
The purpose of the current study was to identify novel risk factors and 
interactions that are predictive of suicide among men and women diagnosed with 
depression using classification trees and random forests. We conducted sex-
stratified analyses because men are more likely to die by suicide than women and 
they have different distributions of risk factors (as discussed in the Introduction 
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chapter),43 which may result in different risk factor profiles. We used data from 
Danish registries, which routinely collect high-quality, longitudinal data on health 
and life events.4  
 
METHODS 
Study Design and Sample 
The case-cohort study design and data sources were described in the 
Comprehensive Methods chapter. For this study, we included all cases of suicide 
death who had an incident depression diagnosis in Denmark between January 1, 
1995 and December 31, 2015 (n = 2,774). The comparison subcohort was a 5% 
random sample of all individuals born or residing in Denmark on January 1, 1995, 
restricted to persons with an incident depression diagnosis between January 1, 
1995 and December 31, 2015 (n = 11,963). As described in the Comprehensive 
Methods chapter, suicide deaths were ascertained using ICD-10 codes X60 – X84 
and depression diagnoses were ascertained using the following ICD-10 codes: 
F32 (major depressive disorder, single episode), F33 (major depressive disorder, 
recurrent), F34 (persistent mood disorders), and F39 (unspecified mood disorder).  
 
Predictors 
We examined the following variables as predictors in the machine learning 
models: age, marital status, immigrant status, citizenship, family suicidal history 
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(parent or spouse), prior suicide attempt, employment, income, mental disorders, 
physical health disorders, surgeries, prescription drugs, and psychotherapy. We 
used the Danish Civil Registration System67 to obtain data on age, marital status, 
immigrant status, generation of citizenship, and family suicidal history. We used 
the Integrated Database for Labor Market Research78 and Income Statistics 
Register to ascertain baseline data on employment and income.77 We obtained 
psychiatric disorder diagnoses using two-digit ICD-10 codes from the Danish 
Psychiatric Central Research Register70 and Danish National Patient Registry 
(e.g., code F23 was used to capture brief psychotic disorder).61 We also used the 
Danish National Patient Registry to obtain physical health diagnoses as recorded 
by second-level ICD-10 groupings (e.g., code C50 was used to capture malignant 
neoplasms of breast). Surgery procedure codes from the Danish National Patient 
Registry were examined according to body system (e.g., musculoskeletal system 
surgeries). We obtained data on prescription drugs from the Danish National 
Prescription Registry.76,105 Prescription drugs for this study were coded according 
to level three Anatomical Therapeutic Classification codes (e.g., code C09A was 
used to capture ACE inhibitors, plain). A more detailed description of the registries 
is available in the Comprehensive Methods chapter. Appendix 1 contains all codes 
analyzed in this study. 
We analyzed some predictors in a time-varying fashion. For suicide cases, 
we dummy-coded variables to create time-varying predictors with intervals of 0–6, 
0–12, 0–24, and 0–48 months before the date of death. For comparison subcohort 
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members, we randomly selected a date between their depression diagnosis date 
and the end of follow-up and then calculated the prevalence of each predictor 0–
6, 0–12, 0–24, and 0–48 months before the selected date to estimate the 
prevalence of each predictor in the person-time that gave rise to cases. Several 
predictors including age and immigrant status were not dummy coded as time-
varying predictors. Employment and income were defined in the year before the 
date of death for suicide cases and in the year before the selected date between 
depression diagnosis and end of follow-up for comparison subcohort members. All 
predictors were evaluated in the machine learning models simultaneously.  
 
Descriptive Analyses 
We examined the sex-stratified distribution of demographic characteristics 
for the suicide cases and comparison subcohort. We calculated the mean and 
standard deviation of age and we calculated the number and proportion of people 
in each category of marital status, immigrant status, income, and employment 
status at baseline on January 1, 1995.  
 
Machine Learning Analyses 
We performed data reduction to reduce the risk of overfitting, which occurs 
when a model performs well on the data for which it was developed but performs 
poorly on a new dataset not used in model development. We removed rare 
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predictors that had 10 or fewer observations in any cell of a 2x2 contingency table 
of the predictor and suicide for men and women separately. The initial analytic 
dataset contained 2547 predictors. After removing rare predictors, the number of 
included predictors was 780 for men and 803 for women. Appendix 1 contains the 
considered and retained predictors. 
We then used classification trees to visually evaluate the data structure and 
identify interactions between variables that predicted suicide among men and 
women. Classification trees are a nonparametric method that builds a decision tree 
using predictors and their interactions that result in the highest probability of 
differentiating suicide cases from non-cases. To reduce the risk of model overfit 
and improve interpretability, we set the maximum tree depth to five and the 
minimum number of observations in any node to 10. We used equal priors to 
address class imbalance,106 which refers to an unequal distribution of classes, 
since suicide is a rare event and there are more non-cases than cases of suicide. 
The risk of suicide was calculated for each combination of predictors (“branch”) in 
the classification tree. We used the R package rpart, which performs a 10-fold 
cross validation procedure107.  
 Random forests are a recursive partitioning method that is comprised of a 
set of decision trees generated using bootstrapped samples of the data. Each 
forest was built with 1000 trees and a minimum of 10 observations were required 
to make a split. The number of variables sampled as split candidates at each node 
were 28 for both men and women (i.e., the square root of the total number of 
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predictors for men and women). Each individual tree in the random forest used 
equal proportions of suicide observations and non-suicide observations to mitigate 
class imbalance using the “sample.fraction” tuning parameter of the R package 
ranger.108 We calculated the mean decrease in accuracy (MDA) of each variable, 
which represents the reduction in accuracy if a predictor were permuted.86 The 
larger the MDA is when a predictor is permuted, the more important that variable 
is for accurate suicide prediction. We evaluated AUC using 10-fold cross validation 
using the R package caret109 and estimated the 95% confidence interval (CI) for 
the cross-validated AUC using bootstrapping in 1000 replicates.110 We ordered the 
predicted probabilities from the cross-validated random forests and we calculated 
the operating characteristics among persons in each ventile of the predicted risk 
distribution. We calculated the proportion of all suicide cases that occurred in the 
top 5%, 10%, and 20% of the predicted probabilities for suicide. We then calculated 
the proportion of all non-cases that occurred in the bottom 95%, 90%, and 80% of 
the predicted probabilities for suicide. All analyses were stratified by sex. The 
analyses were conducted in in SAS version 9.4 and R version 3.5.2.111,112 This 
study was determined to be exempt from review by the Boston University IRB 






There were 1,606 male suicide cases who had an incident depression 
diagnosis in Denmark during the study period and there were 4,281 men in the 
corresponding comparison subcohort. For women, there were 1,168 suicide cases 
who had a depression diagnosis during the study period and there were 7,682 
members of the corresponding comparison subcohort. For both men and women, 
suicide cases were on average older than the comparison subcohort and a greater 
proportion of cases were employed and married or in a registered partnership at 
baseline (Table 3.1).  
 
Classification Trees 
Among men who were diagnosed with depression, the highest risk of 
suicide was found in persons with a diagnosis of poisoning by, adverse effect of, 
and underdosing of drugs, medications, and biological substances (hereafter 
referred to as “poisoning”) in the preceding six and 48 months, but without 
recorded prescriptions for hypnotics and sedatives in the preceding six months (n 
= 123; risk = 87%). The next highest risk group was men who were prescribed 
hypnotics and sedatives in the preceding six months, prescribed other analgesics 
and antipyretics in the preceding 48 months, and were diagnosed with poisoning 
in the preceding 48 months (n = 96; risk = 81%). According to the ATC system, 
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“other analgesics and antipyretics” are a pharmacologic subgroup of analgesics. 
The analgesics category also includes opioids and antimigraine preparations. 
Other analgesics and antipyretics include salicylic acid and derivatives, 
pyrazolones, anilides, and other medications. There was a much lower suicide risk 
among men who were prescribed other analgesics and antipyretics in the 
preceding twelve months but were not prescribed hypnotics and sedatives and 
anxiolytics in the preceding six months and were not diagnosed with poisoning in 
the preceding 48 months (n = 540; risk = 11%). Figure 3.1 shows other 
combinations of characteristics associated with suicide in men diagnosed with 
depression (AUC = 0.71 [95% CI = 0.69, 0.73]). 
The highest risk of suicide among women diagnosed with depression was 
in those who had a poisoning diagnosis in the preceding 48 months and were 
prescribed anxiolytics in the preceding 12 months (n = 438; risk = 91%). The 
second highest risk group was women who had a poisoning diagnosis in the 
preceding 48 months and were not prescribed anxiolytics in the preceding 12 
months or hormonal contraceptives for systemic use in the preceding six months 
(n = 405; risk = 82%). The characteristics of the next highest risk group included 
prescriptions for anxiolytics in the preceding 12 months and hypnotics and 
sedatives in the preceding six months, but no diagnosis of poisoning or aplastic 
and other anemias and no prescription for other analgesics and antipyretics (n = 
584; risk = 77%). Other combinations of variables associated with suicide among 
women diagnosed with depression are displayed in Figure 3.2 (AUC = 0.74 [95% 
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CI = 0.72, 0.76]).  
 
Random Forests 
The random forests results for men revealed that the most important 
predictors were prescriptions of hypnotics and sedatives and anxiolytics and 
previous poisoning diagnoses at all time intervals. Figure 3.3 displays the top 30 
most important predictors after 10-fold cross-validation (average MDA value of all 
predictors = 2.6; standard deviation [SD] = 7.8). Moderately predictive variables 
among men diagnosed with depression included prescriptions for analgesics, 
antipyretics and antithrombotic agents, and antipsychotics and diagnoses of 
alcohol related disorders and reaction to severe stress and adjustment disorders. 
The cross-validated AUC for the random forest model for men was 0.70 (95% CI 
= 0.68, 0.72).  
Among women with a depression diagnosis, the most important predictors 
were receipt of state pension, prescriptions for psychiatric medications (anxiolytics 
and antipsychotics) and diagnoses of poisoning, alcohol related disorders, and 
reaction to severe stress and adjustment disorders. Prescriptions of antithrombotic 
agents, other analgesics and antipyretics, and hormonal contraceptives for 
systemic use emerged as important predictors of suicide among women diagnosed 
with depression. Similar to the findings in men, antidepressants prescribed in the 
preceding 12 months was the 30th most important predictor for women. Figure 3.4 
displays the top 30 most important predictors among women (average MDA value 
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of all predictors = 39 [SD = 6]). The cross-validated AUC for the random forest 
model for women was 0.75 (95% CI = 0.73, 0.78).  
Men in the top 5%, 10%, and 20% of predicted risk accounted for 14%, 
26%, and 44% of all suicide cases among men, respectively. Men in the bottom 
95%, 90%, and 80% of predicted suicide risk accounted for 98%, 96%, and 89% 
of all men diagnosed with depression who did not die by suicide, respectively. 
Women in the top 5%, 10%, and 20% of predicted risk accounted for 26%, 41%, 
and 62% of all suicide cases among women, respectively. Women in the bottom 
95%, 90%, and 80% of predicted suicide risk accounted for 98%, 95%, and 86% 
of all women diagnosed with depression who did not die by suicide, respectively. 
 
DISCUSSION 
This study found that among men and women with depression, there are 
characteristics that may help distinguish those at high risk of suicide. In men 
diagnosed with depression, there were interactions between hypnotics and 
sedatives, other analgesics and antipyretics (e.g., salicylic acid and derivatives, 
pyrazolones, anilides, and other medications), and previous poisonings that were 
associated with a high risk of suicide. It is noteworthy that other analgesics and 
antipyretics appeared to be associated with a low risk of suicide when not occurring 
in combination with hypnotics and sedatives and previous poisonings. This 
suggests that other analgesics and antipyretics are only associated with a high risk 
of suicide in men when these additional psychiatric risk factors are present. In 
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women diagnosed with depression, we found an interaction between poisoning 
and anxiolytics and an interaction between anxiolytics and hypnotics and sedatives 
that were associated with an elevated suicide risk. 
These results are consistent with those of Chen and colleagues who also 
found that poisonings and anxiolytics were ranked as top predictors of suicide and 
suicide attempts among persons receiving general psychiatric specialty care in 
Sweden.32 Poisonings may capture some prior non-fatal suicide attempts in these 
data, and as a result, these findings may suggest that men and women with 
prescriptions for various psychiatric medications and a history of non-fatal suicide 
attempts are at high risk of suicide. These findings are aligned with previous work 
documenting an increased risk of suicide after suicide attempts in depressed 
persons.113 These combinations of risk factors should be replicated in future 
machine learning studies because they may represent patient risk profiles 
associated with elevated suicide risk among depressed persons that could be 
relevant to clinicians.   
Hypnotics and sedatives were the most predictive of suicide among men 
diagnosed with depression in the cross-validated random forests. In women, 
hypnotics and sedatives were less predictive (ranked 25th most important predictor) 
relative to the other variables in the suicide prediction model. Hypnotics and 
sedatives such as benzodiazepines are used to treat anxiety, which commonly co-
occurs with depression, and to induce and/or maintain sleep. Toxicologic studies 
of suicide cases have found hypnotics and sedatives and alcohol were common at 
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the time of death.114–116 Hypnotic medications may increase suicide risk through 
cognitive impairment involving confusion, amnesia, hallucination, or paranoia 
during the time of peak drug effect (in the first few hours after ingestion of a 
hypnotic).117 However, hypnotics may also reduce suicidal ideation after 
appropriate drug metabolism and improve insomnia.117 Our machine learning 
analyses were unable to discern whether the drug itself (e.g., hypnotics and 
sedatives) or the underlying psychiatric condition (e.g., anxiety; sleep disorder) 
was causally related with  suicide risk. According to a 2017 review article, the link 
between hypnotics and sedatives and suicidality is ambiguous regarding whether 
hypnotics and sedatives may induce or exacerbate suicidality by altering 
consciousness or disinhibition or reduce suicidal ideation in persons with insomnia 
and mental illness.117 Our finding that hypnotics and sedatives were the most 
important to suicide prediction among men is worthy of additional research for 
replication in machine learning studies and also in traditional etiologic studies to 
understand the direction and magnitude of their association with suicide after 
adjustment for confounding for psychiatric conditions.  
In women diagnosed with depression, receipt of state pension was the most 
predictive of suicide. The Danish state pension is paid by public authorities to 
residents who reached state pension age (average age 65 years).118 Chang and 
colleagues found that having no pension was associated with a higher suicide risk 
among adults aged 60 years and older in data from the Global Burden of Disease 
Study 2015.119 The provision of a state pension improves financial security and is 
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expected to buffer suicide risk. However, risk of suicide increases with age, and 
suicide risk in late adulthood is potentially due to social isolation from widowhood, 
diminished social ties and obligations when adult children leave home, the end of 
careers, and declining health.120,121 Our finding that receipt of state pension was 
the most predictive of suicide among women diagnosed with depression may 
reflect the social isolation is associated with late adulthood and confers suicide 
risk. Additional work is needed to replicate this finding and examine the effect of 
receipt of state pension on suicide risk in traditional etiologic study designs. 
An important  predictor of suicide among both men and women was the use 
of analgesics and antipyretics (e.g., acetaminophen) and antithrombotic agents 
(e.g., aspirin). These drugs are used to treat pain and reduce inflammation from a 
variety of chronic conditions. Chronic pain is a risk factor for suicide122 and can 
lead to increased depressive symptoms and psychological pain.123,124 
Helplessness and hopelessness over chronic pain may lead to the belief that 
suicide is an escape from the pain that is causing extreme suffering.125,126 Drawing 
on the interpersonal-psychological theory of suicide, it has been proposed that 
chronic pain may lead to fearlessness about death124 through suffering, isolation, 
and diminished quality of life. Having a decreased sense of belongingness, feeling 
like a burden to loved ones, and a feeling of needing to escape may lead to 
suicide.124 There may also be fatal prescription opioid overdose in persons with 
chronic pain.126 Clinicians should be aware of the presence of depression and the 
risk of suicide when prescribing medications including opioids and 
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benzodiazepines. In addition to chronic pain, prescriptions for anti-inflammatory 
medications may also be a proxy for inflammation. There is an extensive literature 
demonstrating the bidirectional relationship between depression and 
inflammation.127–132 Previous studies have found that persons with major 
depression who are otherwise physically healthy have activated inflammatory 
pathways (e.g., increased proinflammatory cytokines such as interleukin (IL)-
6).133,134 In addition, persons with depression have increased concentrations of C-
reactive protein and other acute phase proteins found in blood plasma that rise in 
response to inflammation.135–137 Inflammation may also cause dysregulation of 
neurobiological systems (e.g., hyperactivation of the hypothalamus-pituitary 
adrenal axis) that may cause changes in emotion and behavior (e.g., depressive 
symptoms), which in turn could affect suicide risk.138–141 In the current study, anti-
inflammatory drugs may represent a proxy for inflammation potentially due to 
depression and/or other psychiatric and somatic conditions, and reflect the 
importance of inflammation in predicting suicide among persons diagnosed with 
depression. In addition, a review of inflammatory responses in the pathophysiology 
of depression highlighted targeting proinflammatory cytokines and their signaling 
pathways as a potential method of treating depression.127 Anti-inflammatory 
treatments could be a new line of treatment options for persons with depression 
and inflammation, with a growing literature on using anti-inflammatory treatments 
(e.g., non-steroid anti-inflammatory drugs) that were initially approved for other 
conditions to also treat depression.138,142,143 More research is necessary to 
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understand the mechanisms underlying the association between depression and 
inflammation and to quantify the effect of anti-inflammatory medications on suicide 
risk among persons with depression and inflammation.   
It is noteworthy that antidepressants did not appear in the classification 
trees for men and women given our knowledge that antidepressants play a role in 
suicidal behavior.102,144,145 In the random forests, antidepressant prescriptions in 
the preceding 12 months appeared as the 30th most important predictor of suicide 
for both men and women with a depression diagnosis. These results suggest that 
compared with other psychiatric medications (e.g., hypnotics and sedatives, 
anxiolytics, antipsychotics), antidepressants are a less powerful predictor of 
suicide among persons diagnosed with depression. Another potential explanation 
is that there was little variability in antidepressants in our study sample. 
Antidepressants were prescribed to approximately 94% of suicide cases and 95% 
of the comparison subcohort members. The high prevalence of antidepressants is 
not surprising since everyone in the study sample was diagnosed with depression. 
Given the ubiquity of antidepressant medication prescription in our study, the 
classification trees and random forests did not identify antidepressants as a factor 
that helped discern suicide risk among persons with depression. In general, 
variables that are common to all study observations are unlikely to be identified as 
an important predictor in machine learning even if traditional etiologic studies have 
documented their associations with the outcome. Thus, other less ubiquitous 
variables may be necessary to stratify risk of the outcome. Since nearly everyone 
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in the study sample was prescribed antidepressants, it can be assumed that the 
other psychiatric medications that appeared in the classification trees and random 
forests may influence suicide risk among persons prescribed antidepressants. 
Previous work has called for the investigation of a combination antidepressants 
and other psychiatric medications as a potential strategy to treat depressed 
patients at risk of suicide.144 The findings from our exploratory study provide 
specific interactions (e.g., hypnotics and sedatives with anxiolytics) that could be 
examined in future research to quantify the joint effects of multiple psychiatric 
medications on suicide risk among persons with depression.   
The cross-validated classification trees and random forests were 
moderately accurate. The AUCs of the classification trees were 0.71 (95% CI = 
0.69, 0.73) for men and 0.74 (95% CI = 0.72, 0.76) for women. The random forest 
AUCs were 0.70 (95% CI = 0.68, 0.72) for men and 0.75 (95% CI = 0.73, 0.78) for 
women. These AUCs are lower than those found in Chen et al.’s study in which 
the AUC of the ensemble of four algorithms was 0.89 (95% CI = 0.88, 0.90) for 
suicide in the 30 days after a general psychiatric care visit and 0.88 (95% CI = 
0.87, 0.89) in the 90 days after a visit.32 A possible reason for these differences is 
that short term forecasting may be more likely to yield accurate predictions than 
long term forecasting over a 20 year period for suicide. Another potential reason 
is that combining the ensemble method of multiple machine learning algorithms 
may produce more accurate prognostic models than single algorithms. Thus, if 
ensemble methods (e.g., SuperLearner) were used in the current study, prediction 
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accuracy may have been improved. 
Despite the moderate accuracy of the models, the operating characteristics 
of the random forests yielded promising results. According to the random forests, 
the 20% of men with the highest predicted suicide risk accounted for 44% of all 
suicide cases among men. For women, those in the top 20% of predicted suicide 
risk accounted for 62% of all suicide cases among women. This suggests that a 
suicide prevention program delivered to 20% of persons with the highest predicted 
risk could capture a large proportion of persons who would otherwise die by 
suicide. Suicide prevention interventions that could be delivered to those at high 
risk of suicide include brief interventions to reduce access to lethal means,97,98 
cognitive behavioral therapy,100 dialectical behavioral therapy,101 and psychiatric 
medications.102 Two systematic review and meta-analysis articles on the 
effectiveness of suicide prevention interventions, including psychotherapeutic 
interventions, pharmacotherapeutic interventions, and community approaches 
(i.e., church-based interventions), found that they can help reduce the risk of 
suicide deaths and suicide attempts.22,146 Future work is necessary to examine 
how a suicide risk stratification algorithm may be applied in clinical practice, its 
ability to efficiently target interventions to high-risk persons, and its impact on 
suicide rates.   
This study has several limitations. First, there may be measurement error 
of suicide deaths and the predictors. A validation study of suicide found that the 
PPV of the ICD-10 codes we used for this study to ascertain suicide deaths was 
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92%.82 In addition to the high PPV, we expect there to be near perfect specificity 
of suicide classification since most people who did not die by suicide would be 
classified as such. Given that the outcome is rare and specificity is high, any 
misclassification of suicide deaths would have a limited biasing effect. There may 
also be non-differential misclassification of predictors with respect to the outcome. 
We previously conducted a study that examined the impact of measurement error 
in machine learning using quantitative bias analysis.147 We used data from the 
National Comorbidity Survey Replication (NCS-R) and extensive simulations to 
understand the impact of different misclassification mechanisms on random 
forests results. In both the NCS-R and simulations, we found that non-differential 
predictor misclassification decreased random forest model performance and 
distorted variable importance.147 It is possible that non-differential misclassification 
of the predictors in the current study affected the random forests results in a similar 
way. Unfortunately, we were unable to conduct quantitative bias analyses to 
address measurement error due to computational capacity limitations of the 
analytic servers. The bias analysis would have involved repeating the process of 
bias-adjustment tens of thousands of times to create a distribution of model 
performance metrics and variable importance values. Advances in statistical 
computing power may resolve such issues in the future and allow the incorporation 
of bias analyses to address measurement error in machine learning. 
A second limitation is that we lacked data on non-diagnostic risk factors that 
are important to suicide but are not recorded in Danish registries. We did not have 
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data on affective states (e.g., loneliness, hopelessness, self-hatred, and guilt), 
agitation, social functioning and self-care. These factors may be strong predictors 
in the days and weeks preceding suicide.148 Thus, lack of data on these factors 
may have hindered our ability to accurately predict suicide. Capturing granular 
patient states is a limitation common to much of registry-based research. On the 
other hand, clinical studies that are able to capture such detailed data on the 
emotional states of patients generally lack the breadth of physical and somatic 
diagnoses, prescribed medications, and social data available in nationwide 
registries. Although data on detailed patient states could help improve accurate 
suicide prediction, individual-level characteristics often operate alongside broader 
environmental factors to influence suicide risk. Suicide rates are patterned by 
contextual factors (i.e., access to means, media exposure) which occur outside of 
a healthcare encounter and thus would not be recorded in the registries. As a 
result, the implications of this work are more applicable to suicide risk assessments 
in the healthcare setting, but there may also be other points of intervention that 
involve upstream, structural factors that influence suicide risk. Multilevel suicide 
prevention interventions from the level of an individual healthcare encounter with 
a provider to the level of societal change (i.e., reducing stigma associated with 
mental health conditions) may all contribute to reducing suicide risk. 
Third, although classification trees and random forests were chosen for their 
ability to model complex interactions, there may be other machine learning 
algorithms or ensemble methods that perform better. Previous machine learning 
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studies using multiple classifiers were able to predict suicide with greater accuracy 
than our models.29,32,103 Ensembling methods can be used to combine predictions 
from multiple classifiers and produce a composite algorithm that provides better 
predictions than the individual algorithms from which it was developed.149 
However, many of the classifiers used in prior suicide prediction studies, such as 
elastic net penalized logistic regression and neural network, are criticized for being 
“black box” approaches because of the lack of transparency about the function 
used to predict outcomes. There is an interpretability-accuracy tradeoff such that 
prediction accuracy grows with more complex models such as neural networks, 
but the interpretability decreases.150,151 For the current study, we chose to prioritize 
interpretability because our goal was to identify novel predictors and interactions 
for suicide, which required interpretable, visual representations of interactions and 
relative variable importance, but this may have come at the cost of prediction 
accuracy.  
Finally, it is unclear whether our findings are applicable to the U.S. and other 
populations because our models have not been externally validated. Denmark is 
much more homogenous in terms of race, education, and income than the U.S. 
These are important modifiers of the associations between the predictors and 
suicide. In addition, the landscape of the healthcare and social welfare system 
differs greatly between Denmark and the U.S. The provision of universal health 
care and strong safety net programs in Denmark means that Danes do not have 
to face the same stressors that Americans do in accessing healthcare and 
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achieving financial security, all of which influence mental health. Furthermore, 
there are differences in access to lethal means between the U.S. and Denmark. 
Approximately 31% of all households in the U.S. have firearms152 whereas 1.2% 
of all households in the Denmark have firearms.153 The proportion of all suicide 
deaths that were firearm suicides was 50% in the U.S.154 and 7% in Denmark.155 
Thus, it is important to continue this line of research on predicting suicide among 
persons with depression in Americans. It is worth noting that our findings are 
consistent with much of literature based in the U.S. on risk factors (e.g., psychiatric 
medications, poisonings) associated with suicide, which may provide some 
evidence of the potential generalizability of our findings. Nevertheless, additional 
work is necessary to externally validate the results of our study in different 
populations. A challenge of externally validating our algorithm to a new dataset is 
inherent heterogeneity in which variables are collected and the ways that variables 
are measured between different datasets. Measurement heterogeneity may lead 
to miscalibration and negatively affect discrimination and prediction accuracy.156 
Furthermore, It is currently not possible for a model of the kind we developed in 
this study to be developed on the full general population of Americans since we 
lack universal health care and long-standing medical registries containing 
diagnosis data on the entire population. As such, U.S.-based research is limited to 
the use of existing electronic health records of hospitals/healthcare systems and 
other forms of observational data that are prone to measurement error and 
selection biases.157 Quantitative bias analyses may play a crucial role in future 
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work in addressing these limitations.  
Notwithstanding these limitations, this study is an important step towards 
identifying novel predictors and interactions between risk factors that are 
associated with suicide risk among men and women with depression using a wide 
range of predictors. Future work should aim to address the impact of measurement 
error, examine the contribution of detailed data on patients’ emotional states to 
accurate suicide prediction, investigate the usefulness and interpretability of other 
machine learning algorithms in elucidating suicide risk profiles for persons with 








Table 3.1 Characteristics of the suicide cases and the subcohort, Denmark, January 1, 1995. 
 Men Women 
Variable Suicide 
cases 
(n = 1,606) 
Comparison 
subcohort 
(n = 4,281) 
Suicide 
cases 
(n = 1,168) 
Comparison 
subcohort 
(n = 7,682) 
Age, mean (SD) 43 (17) 42 (21) 45 (18) 43 (24) 
Marital status, N (%)     
   Single   663 (41%) 1843 (43%) 347 (30%) 2974 (39%) 
   Married or registered 
partnership 
712 (44%) 1834 (43%) 538 (46%) 2833 (37%) 
   Divorced/separated/widowed 231 (14%) 604 (14%) 283 (24%) 1875 (24%) 
Immigrant, N (%) 48 (3%) 206 (4.8%) 46 (3.9%) 329 (4.3%) 
Employment status     
   Employed 925 (58%) 1994 (47%) 489 (42%) 2465 (32%) 
   Unemployed 165 (10%) 451 (11%) 135 (12%) 777 (10%) 
   Early retirement 127 (8%) 365 (8.5%) 136 (12%) 769 (10%) 
   State pension 276 (17%) 923 (22%) 315 (27%) 2448 (32%) 
   Age <=14 years 58 (3.6%) 507 (12%) 51 (4.4%) 1150 (15%) 








Figure 3.1 Classification tree depicting suicide predictors in depressed men in Denmark, 1995 - 2015.  
 
Note: aPoisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. bReaction to severe stress, and 
adjustment disorders. Each shaded rectangular bin at the bottom (terminal node) represents the group of people with the characteristic 
profile in the branches above. Within the rectangular bins, n=the number of people who had the characteristic profile and risk=the proportion 






Figure 3.2 Classification tree depicting suicide predictors in depressed women in Denmark, 1995 - 2015.  
	
Note: aPoisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. bAplastic and other anemias and 
other bone marrow failure syndromes. Each shaded rectangular bin at the bottom (terminal node) represents the group of people with the 
characteristic profile in the branches above. Within the rectangular bins, n=the number of people who had the characteristic profile and 






Figure 3.3 Variable importance of suicide predictors in depressed men in Denmark from 10-fold cross-
validation, 1995 - 2015. 
 
Note: aPoisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. bReaction to severe stress, and 
adjustment disorders. cGeneral symptoms and signs include fever, headache, pain, malaise, etc. The black dots represent the mean 
decrease in accuracy (MDA) value from 10-fold cross validation. The vertical line represents the average of the MDA values of all predictors 






Figure 3.4 Variable importance of suicide predictors in depressed women in Denmark from 10-fold cross-
validation, 1995 - 2015. 
 
Note: aPoisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. bReaction to severe stress, and 
adjustment disorders. The black dots represent the mean decrease in accuracy (MDA) value from 10-fold cross validation. The vertical line 
represents the average of the MDA values of all predictors (average = 39; standard deviation = 6).
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Suicide prevention interventions can reduce the risk of suicide deaths and 
suicide attempts.22,97,98,100,101,146 However, interventions that are effective in 
reducing suicide deaths may not be effective in reducing suicide attempts  
according to a 2020 systematic review and meta-analysis of the effectiveness of 
suicide prevention interventions.146 Interventions delivered to patients admitted to 
a psychiatric ward in a general hospital reduced suicide deaths, but interventions 
in other settings showed less of an effect.146 However, for suicide attempts, suicide 
prevention interventions delivered in outpatient specialty mental health settings 
showed a large effect but there was less of an effect of psychiatric admission in a 
general hospital.146 A potential explanation for these differences may be that there 
are different risk profiles for suicide deaths and suicide attempts involving sex, age, 
lethal means, and psychiatric disorders. For example, persons who die by suicide 
are more often middle-aged or elderly men who choose lethal means whereas 
persons who attempt suicide are more often younger women who use less lethal 
means.146,158,159 In addition, suicide attempts that are related to a personality 
disorder may be better treated in an outpatient specialty mental health setting than 
in a psychiatric ward.146 This prior work underscores the importance of 
differentiating risk profiles for suicide attempt from suicide death.    
Machine learning may help us better detect risk profiles for suicide attempts 
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with greater accuracy compared with traditional methods.26,160 For example, in a 
study conducted by Walsh and colleagues (2017),26 random forests predicted 
suicide attempts with AUC ranging from 0.80 to 0.84 whereas traditional logistic 
regression AUC values ranged from 0.66 to 0.68. Their random forests results 
showed that the variables that contributed the most to prediction accuracy for 
suicide attempts were poisonings, psychiatric disorders, substance use, and 
psychiatric medications.26 Another study predicting suicide attempts after 
outpatient visits160 using electronic health records found that the strongest 
predictors of suicide attempt were prior suicide attempt, mental health and 
substance use diagnoses, and prior inpatient or emergency mental health care. 
Our own team has also predicted suicide attempts in the general population in 
Denmark161 and found that substance use disorders/treatment, psychiatric 
medications, previous poisoning diagnoses, and stress disorders were important 
predictive factors for suicide attempts and identified novel interactions between 
these predictors that were associated with suicide attempt risk. Although studies 
on the utility of machine learning methods in predicting suicide attempts is growing, 
there is relatively less research on examining risk profiles of suicide attempts in 
persons with depression, a high-risk subgroup for suicide attempts.   
The existing literature using machine learning to predict suicide attempts 
among persons with depression has shown potential but also has important 
limitations. First, most, if not all, of these studies were cross-sectional or 
retrospective,162–167 which precluded them from being able to establish the 
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temporal ordering of most patient characteristics with respect to suicide 
attempts,164,165 and in some instances,162,163,166 it is clear that the variables used 
to “predict” a suicide attempt occurred after the attempt. Thus, these studies have 
not truly predicted suicide attempts but instead may have found their downstream 
correlates. A major reason for this limitation is that suicide attempts are rare and it 
is difficult and costly to follow a cohort of persons with depression until they make 
a suicide attempt.162 A necessary next step for future research is to obtain 
longitudinal measurements such that the predictors occurred before the suicide 
attempts, and also to obtain an adequately powered sample. Second, little is 
known about how risk profiles that predict suicide attempts among depressed 
persons differ among men and women. Women are more likely to make a suicide 
attempt than men41 and they have a different distribution of risk factors43 (as 
reviewed in Chapter 1), suggesting that there are different suicide attempt risk 
profiles for men and women. Third, previous research has focused largely on 
examining the role of mental disorders, subjective well-being, and personality traits 
in suicide attempts in small clinical samples. Additional research is needed to 
understand what predicts suicide attempts among depressed persons in a larger 
population-based cohort with a broader set of risk factors spanning various 
domains including somatic disorders, prescription medications, and social 
variables.  
Given these gaps in the literature, the purpose of this study was to identify 
novel predictors and interactions that predict non-fatal suicide attempts among 
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persons diagnosed with depression using data collected prospectively with respect 
to outcome occurrence from longitudinal Danish registers. We conducted sex-
stratified machine learning analyses to identify interactions between mental 
disorders, physical illnesses, medical treatments, prescription medications, and 
demographic characteristics that predict suicide attempts among men and women 
diagnosed with depression. 
 
METHODS 
Study Design and Sample 
Cases were persons who made an incident non-fatal suicide attempt 
between January 1, 1995 and December 31, 2015 in Denmark, restricted to 
persons with a depression diagnosis prior to the attempt (n = 6,032). The 
comparison subcohort was identical to the one used in Study 1; it was a 5% 
random sample of all individuals born or residing in Denmark on January 1, 1995, 
restricted to persons who had an incident depression diagnosis between January 
1, 1995 and December 31, 2015 (n = 11,963). Suicide attempts were obtained 
from the Danish National Patient Registry61 using ICD-10 codes X60 - X84 without 
a death recorded in the Danish Cause of Death Registry69 in the subsequent 30 
days. A validation study of suicide attempt ICD-10 codes (X60 - X84) in Denmark 
found that the PPV of suicide attempts was approximately 73%.83 We included 
only the first diagnoses of suicide attempts in the study period. We focused on 
predicting incident suicide attempts because approximately 70% of incident 
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suicide attempters do not make further attempts168 and their risk profile may be 
different from those of repeat attempters who have a greater burden of mental 
disorders and may have a stronger wish to die during their attempt.169  As stated 
in the Comprehensive Methods chapter, depression diagnoses were obtained 
using the ICD-10 codes: major depressive disorder, single episode (F32), major 
depressive disorder, recurrent (F33), persistent mood disorders (F34), and 
unspecified mood disorder (F39). 
 
Predictors 
The variables we included as predictors in the machine learning analyses 
were the same as those described in the Study 1 chapter with the exception of 
suicide attempts. We excluded suicide attempts as predictors from these analyses 
because incident suicide attempts was the outcome of interest for the current 
study. In brief, we included the following predictors: age, marital status, immigrant 
status, citizenship, family suicidal history (parent or spouse), employment, income, 
mental disorders, physical health disorders, surgeries, prescription drugs, and 
psychotherapy (any encounter for psychological services). The Comprehensive 
Methods chapter describes the registries from which these variables were 
gathered. A list of all predictor variables is provided in Appendix 2.  
We created some time-varying predictors to reflect changes in variables 
over time. For suicide attempt cases, we dummy-coded variables to create time-
varying predictors with intervals of 0–6, 0–12, 0–24, and 0–48 months before the 
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date of suicide attempt. For the comparison subcohort members, to estimate the 
prevalence of each predictor in the person-time of the source population that gave 
rise to the cases, we randomly selected a date between the depression diagnosis 
date and their end of follow-up and computed the prevalence of each predictor 0–
6, 0–12, 0–24, and 0–48 months before the selected date. Not all predictors were 
analyzed in a time-varying way (natal sex, age, and immigrant status at baseline; 
employment and income were defined in the year before the date of suicide 
attempt for cases and in the year before the selected date between depression 
diagnosis and end of follow-up for comparison subcohort members).  
 
Descriptive Analyses 
 We examined the distribution of demographic characteristics of the study 
sample by conducting stratified analyses on sex and case status (suicide attempt 
case or comparison subcohort). We calculated the mean and standard deviation 
of age at baseline on January 1, 1995. For marital status, immigrant status, 
employment, and income, we calculated the absolute number and proportion of 
persons in each category of these variables at baseline. 
 
Machine Learning Analyses 
To reduce the risk of overfitting in the machine learning models, we 
performed data reduction which involved removing rare predictors that had 10 or 
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fewer observations in any cell of a 2x2 contingency table of the predictor and 
suicide attempt for men and women separately. The initial analytic dataset 
contained 2543 predictors. After removing rare predictors, the final number of 
included predictors was 841 for men and 1079 for women. The considered and 
retained predictors are shown in Appendix 2.  
 We used classification trees and random forests to identify novel predictors 
and interactions that predict suicide attempts among persons diagnosed with 
depression. For the classification trees, we set the maximum tree depth to five and 
the minimum number of observations in any node to 10. We used 10-fold cross-
validation to reduce the risk of overfitting and used equal priors to address class 
imbalance due to the classes (i.e., suicide attempters and non-suicide attempters) 
not being equal.106 We calculated the risk of suicide attempt for each combination 
of predictors in the classification tree. We used the R package rpart107 to estimate 
classification trees.  
 Each random forest was comprised of 1000 trees and a minimum of 10 
observations were needed to make a split in each tree. To decorrelate the trees, 
the numbers of variables sampled as split candidates at each node were 29 for 
men and 33 for women, corresponding with the square root of the total number of 
predictors for men and women. Each individual tree in the random forest used 
equal proportions of suicide attempt observations and non-suicide attempt 
observations to address class imbalance. We performed 10-fold cross validation 
of the random forests to generate predicted values for each individual and to 
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calculate the mean decrease in accuracy (MDA) of each variable. We evaluated 
random forests’ AUC using 10-fold cross validation and calculated the 
corresponding 95% CI’s using bootstrapping in 1000 replicates.110 We then 
ordered the predicted probabilities from the cross-validated random forests and 
grouped them into ventiles to calculate the operating characteristics among 
individuals in each ventile of the predicted risk distribution. We calculated the 
proportion of all suicide attempt cases that occurred in the top 5%, 10%, and 20% 
of the random forest predicted probabilities for suicide attempts. We then 
calculated the proportion of all non-attempters that occurred in the bottom 95%, 
90%, and 80% of random forest predicted probabilities. All analyses were 
conducted separately for men and women. The analyses were conducted in in 
SAS version 9.4 and R version 3.5.2.111,112 We used the R packages ranger108 and 
caret.109 This study was determined to be exempt from review by the Boston 
University IRB approved by the Danish Data Protection Agency (record number 
2015-57-0002).   
 
RESULTS 
Descriptive Results  
There were 2,093 male cases of non-fatal suicide attempt and there were 
4,281 men in the corresponding comparison subcohort who had a previous 
depression diagnosis during the study period. In women, there were 3,939 suicide 
attempt cases and there were 7,682 women in the corresponding comparison 
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subcohort who had a previous depression diagnosis. Cases were on average 
younger than the comparison subcohort members and a greater proportion of 
cases were single. There was a greater proportion of unemployed persons in 
cases than the subcohort (Table 4.1).  
 
Classification Trees 
Among men diagnosed with depression, the highest risk of suicide attempt 
was among those who were diagnosed with poisoning by, adverse effect of, and 
underdosing of drugs, medications, and biological substances (referred to 
hereafter as “poisoning”) in the preceding 48 months and six months (n = 711; risk 
= 96%). The second highest risk among men diagnosed with depression was in 
those who received a state pension and were diagnosed with toxic effects of 
substances chiefly nonmedicinal as to source (e.g., alcohol, organic solvents, 
pesticides, etc.) in the preceding six months and without a diagnosis of poisoning 
in the preceding 48 months (n = 11; risk = 90%). Men who had a diagnosis of 
reaction to severe stress and adjustment disorder but were not receiving 
psychological help in the preceding 24 months (and did not have a diagnosis of 
poisoning or alcohol related disorders and were not receiving state pension) had 
a high risk of suicide attempt (n = 156; risk = 76%). Other combinations of 
characteristics associated with a high risk of suicide attempt among men 




 Among women diagnosed with depression, the greatest risk of suicide 
attempt was among women who had a poisoning diagnosis in the preceding 48 
months and six months (n = 1,870; risk = 96%). The next highest risk was among 
women who were diagnosed with poisoning in the preceding 48 months but did not 
have a poisoning diagnosis in the preceding six months and were not receiving a 
state pension (n = 696; risk = 78%). Women with a prescription of antipsychotics 
in the preceding 12 months and a diagnosis of specific personality disorders in the 
preceding 24 months but without a diagnosis of poisoning and who were not 
receiving a state pension had a high risk of suicide attempt (n = 308; risk = 74%). 
Other characteristic groupings that were associated with a high risk of suicide 
attempt among women diagnosed with depression are shown in Figure 4.2 (AUC 
= 0.79 [95% CI = 0.78, 0.81]).  
  
Random Forests 
Poisoning in all time intervals had the greatest impact on model accuracy 
for men diagnosed with depression. Other important predictors included alcohol 
related disorders, reaction to severe stress and adjustment disorders, and drugs 
used to treat psychiatric disorders (drugs used in addictive disorders, anxiolytics, 
hypnotics and sedatives). Antithrombotic agents prescribed at several time 
intervals and toxic effects of substances chiefly nonmedicinal as to source 
emerged as important predictors. Social variables such as receipt of state pension 
and remaining single were also important to accurate prediction of suicide attempts 
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among men diagnosed with depression. Figure 4.3 displays the random forests 
variable importance rankings of the top 30 predictors (average MDA value of all 
predictors = 1.2; standard deviation [SD] = 6.6). The cross-validated AUC of the 
random forests was 0.76 (95% CI = 0.74, 0.78). 
 Similar to men, poisoning in all time intervals had the largest influence on 
model accuracy among women diagnosed with depression. Psychiatric disorder 
diagnoses (specific personality disorders, alcohol related disorders, reaction to 
severe stress and adjustment disorders) and psychiatric medication prescriptions 
(antipsychotics, hypnotics and sedatives, and anxiolytics) at all time intervals were 
important predictors of suicide attempts in women. Also similar to the random 
forests results for men, social variables including receipt of state pension and 
remaining single at all time points were among the top 30 most important predictors 
of suicide attempts. Prescription of other analgesics and antipyretics in the 
preceding 48 months emerged as an important predictor of suicide attempts 
among women. Figure 4 displays the random forests MDA values (average MDA 
value of all predictors = 0.73; SD = 5.9). The cross-validated AUC of the random 
forests was 0.80 (95% CI = 0.78, 0.81).  
Men in the top 5%, 10%, and 20% of predicted risk accounted for 13%, 
27%, and 49% of all suicide attempts among men diagnosed with depression, 
respectively. Men in the bottom 95%, 90%, and 80% of predicted suicide risk 
accounted for 99%, 98%, and 94% of all men diagnosed with depression who did 
not make a suicide attempt, respectively. Women in the top 5%, 10%, and 20% of 
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predicted risk accounted for 14%, 28%, and 53% of all suicide attempts among 
women with a depression diagnosis, respectively. Women in the bottom 95%, 
90%, and 80% of predicted suicide risk accounted for 100%, 99%, and 97% of all 
women diagnosed with depression who did not attempt suicide, respectively. 
 
DISCUSSION 
 This study predicted non-fatal suicide attempts among men and women 
diagnosed with depression using machine learning and longitudinal data collected 
from Danish registries. Our findings augment existing literature illustrating the 
complex interplay of psychiatric disorders, substance use, psychiatric medications, 
and poisonings in predicting suicide attempt risk. The random forests achieved fair 
accuracy in predicting suicide attempts among men and women diagnosed with 
depression.  
 There are similarities between the findings of the current study and those of 
previous studies using machine learning to examine suicide attempts among 
persons with depression. We found that personality disorders were among the top 
30 predictors among men and women in the random forests. Borderline personality 
disorder is characterized by unstable self-image and mood, volatile interpersonal 
relationships, self-damaging impulsivity, recurrent suicidal threats or gestures 
and/or self-mutilating behavior.170 Suicidal behavior is common among persons 
with borderline personality disorder, with between 60 to 70% of patients with 
borderline personality disorders making suicide attempts.171,172 Suicidality in 
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borderline personality disorder may be related to aggressive and impulsive traits 
that characterize this disorder.162 In addition, there is a high rate of comorbidity in 
patients with borderline personality disorder. Comorbid personality disorder and 
major depressive disorder are associated with an increased number and 
seriousness of suicide attempts compared to patients with borderline personality 
disorder alone.173–175 Persons with this comorbidity may experience severe 
depressed mood and hopelessness and impulsive-aggression which in turn may 
increase suicide attempt risk.175 Study 3 of this dissertation aims to quantify the 
sex-specific, joint effect of depression and other mental disorders (e.g., personality 
disorders) on suicide and suicide attempts in the Danish population. 
 Consistent with the existing literature, our study found that reaction to 
severe stress and adjustment disorder diagnoses at all time intervals were 
important predictors of suicide attempts in both men and women diagnosed with 
depression. A previous study examining suicide attempts among patients 
diagnosed with mood disorders also identified PTSD as an important predictor 
among patients with mood disorders.167 Reaction to severe stress and adjustment 
disorder encompasses acute stress reaction, PTSD, adjustment disorders, other 
reactions to severe stress, and reaction to severe stress, unspecified. Although 
previous work has found that PTSD is associated with an increased risk of suicide 
attempts among persons with depression,176–178 relatively less is known about how 
other forms of severe stress such as acute stress reaction and adjustment 
disorders affect suicide attempt risk. Acute stress reactions are characterized by 
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significant dissociative states immediately after an overwhelming trauma and by 
definition cannot last longer than one month. Adjustment disorders are a common 
condition in response to a stressful event (e.g., illness, job loss, divorce) involving 
emotional and behavioral symptoms (e.g., depression, anxiety). A 2019 systematic 
review of adjustment disorders and suicidal behaviors found that there were only 
a small number of studies that included examination of adjustment disorders,179 
and the findings based on the sparse literature suggest that adjustment disorder 
is associated with an increased risk of suicidal behaviors, with self-poisonings 
being the most common form of suicide attempt.179 In the realm of suicide deaths, 
Gradus and colleagues (2010) found that persons with acute stress reaction had 
10 times the rate of completed suicide compared to persons without this 
diagnosis.180 In another study also conducted by Gradus et al. (2010), persons 
diagnosed with adjustment disorder had 12 times the rate of suicide death as 
persons without this diagnosis.181 Given the strength of the associations 
documented between stress-related disorders and suicide deaths, additional 
investigation of the associations between these stress disorders and suicide 
attempts is warranted. Accordingly, Study 3 of this dissertation will examine the 
joint effect of depression with anxiety, dissociative, stress-related, and somatoform 
disorders (i.e., neurotic disorders) on suicide attempts. 
 This study builds upon the existing literature on machine learning for 
predicting suicide attempts among persons with depression by not only examining 
psychiatric disorders, but also including investigation of a wide range of variables 
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including psychiatric medications, somatic conditions, and demographic 
characteristics. The classification tree results identified an interaction between 
anxiolytic prescriptions and specific personality disorders that was associated with 
a high risk of suicide in women. Psychiatric medications also emerged as important 
predictors of suicide attempts in the random forests, such as prescriptions for 
drugs used in addictive disorders, anxiolytics, hypnotics and sedatives, and 
antipsychotics. Prescriptions for these medications may represent both the 
underlying severity of psychiatric disorders and also the effect of these medications 
on suicide attempt risk (increased or decreased risk). Interestingly, somatic 
disorders did not appear at all in the classification trees and random forests, 
suggesting that their relative contribution to the accurate prediction of suicide 
attempts is lower compared with poisonings, psychiatric disorders, and psychiatric 
medications.  
 Remaining single at multiple time intervals prior to the suicide attempt was 
among the top 30 predictors of suicide attempts among both men and women 
diagnosed with depression. Previous studies have also reported a link between 
marital status and suicide.182,183 A previous study of suicide attempts in Denmark 
found that the risk of suicide attempts was higher among unmarried, separated or 
divorced, and cohabiting persons than in married persons.184 These associations 
may have been observed because marriage confers security, social support, and 
social and emotional stability, whereas being unmarried is associated with social 
isolation and loneliness.183 A meta-analysis exploring the associations between 
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marital status and suicide found that the risk of suicide among single persons was 
2.2 times (95% CI = 2.2, 2.3) that of married persons.185 Markers of social isolation 
such as remaining single, as identified in our study, may be important to consider 
in future suicide attempt prediction studies. 
 Among men diagnosed with depression, antithrombotic agents prescribed 
in the 12, 24, and 48 months prior to the suicide attempts were important 
predictors. In women diagnosed with depression, other analgesics and antipyretics 
prescribed in the 48 months preceding a suicide attempt emerged as an important 
predictor. These findings are similar to those in Study 1 in which we predicted 
suicide deaths. These medications may be a proxy for chronic pain and 
inflammation in persons with depression. The lifetime prevalence of suicide 
attempts in persons with chronic pain is between 5 - 14%.125 Chronic pain is 
associated with increased risk of suicide attempts after adjusting for comorbid 
mental disorders.186 Persons having two or more types of chronic pain were at 
three times the risk of suicide attempt compared to persons without chronic pain 
after adjusting for other physical health problems and psychopathology 
(depression, drug or alcohol use disorders).187 Persons living with depression are 
more likely to report chronic pain compared to persons without depression.188 
Assessing chronic pain may provide clinicians with valuable information about risk 
of suicide in persons with depression. With regard to inflammation, a study 
examining whether inflammatory markers can identify suicide attempters among 
persons with depression found increased levels of interleukin-6 and tumor necrosis 
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factor-a and decreased interleukin-2 concentrations in suicidal patients compared 
to non-suicidal depressed patients and healthy controls.189 O’Donovan and 
colleagues conducted a study of the association of inflammation in patients with 
major depressive disorder with suicidal ideation and found that patients with major 
depressive disorder and high suicidal ideation had higher levels of inflammation as 
measured by tumor necrosis factor-a, interleukin-6, interleukin-10, and C-reactive 
protein compared with non-depressed controls and patients with depression but 
without suicidal ideation.190 O’Donovan et al. posit that a plausible explanation for 
their findings is that suicidal ideation is more common in persons with 
inflammation-associated depression.190 Future research should examine whether 
measurements of inflammation in depression will improve suicide risk assessment.  
 The discrimination ability of the classification trees were similar to those of 
previous studies using machine learning to predict suicide attempts among 
persons with depression which had AUCs ranging from 0.65 to 0.89.162,163,167 In 
the current study, the AUC of the classification trees was 0.76 (95% CI = 0.74, 
0.78) for men and 0.79 (95% CI = 0.78, 0.81) for women. The AUC of the random 
forests was 0.76 (95% CI = 0.74, 0.78) for men and 0.80 (95% CI = 0.78, 0.81) for 
women. In addition, our random forests’ operating characteristics are comparable 
to those in a study conducted by Passos et al. that used machine learning to predict 
suicide attempts among patients with mood disorders that also reported the 
proportions of suicide attempts captured in each quantile of predicted risk.167 
Passos et al. found that the 20% of patients with the highest predicted risk 
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accounted for 37% of suicide attempts.167 In our study, men in the highest 20% of 
predicted suicide attempt risk accounted for 49% of suicide attempts in men. 
Women in the highest 20% of predicted risk accounted for 53% of suicide attempts 
in women. These findings suggest that risk stratification algorithms may enable 
early detection of high-risk persons who could benefit from enhanced care to 
prevent suicide attempts.191–193  
There are several similarities and differences in the results of the current 
study and the results of Study 1 which focused on suicide deaths. In both studies, 
important predictors included prescriptions for psychiatric medications (e.g., 
hypnotics and sedatives, anxiolytics, antipsychotics), prescriptions for ant-
inflammatory medications (antithrombotic agents and other analgesics and 
antipyretics), and psychiatric disorders (e.g., reaction to severe stress and 
adjustment disorder, alcohol related disorders). Poisonings featured more 
prominently at the top of the list of most important predictors of suicide attempts 
but were less predictive relative to several other variables in the suicide death 
analyses. This suggests that previous self-harm events in which the intent was 
unclear, which may be captured by the ICD-10 poisonings codes, may be more 
predictive of suicide attempts than suicide death. Another difference found in the 
random forests was that specific personality disorders were among the top 30 
predictors of suicide attempts but not for suicide deaths. These results may reflect 
the high levels of suicide attempt and other self-harm behaviors that characterize 
borderline personality disorder. The ICD-10 definition of borderline personality 
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disorder includes self-damaging impulsivity and recurrent suicidal threats or 
gestures and/or self-mutilating behavior. Our findings suggest that among men and 
women diagnosed with depression, having a diagnosis of specific personality 
disorders is more predictive of suicide attempts than suicide death.  
This study is among the first to use machine learning to predict suicide 
attempts among persons with depression and additional work is necessary to 
replicate and build upon our findings. An important area for future research is to 
examine how interventions delivered to those at highest risk of suicide attempt may 
be implemented in clinical practice and evaluate their effectiveness. A recent 
systematic review and meta-analysis of the association of suicide prevention 
interventions with subsequent suicide attempts for acute care settings found that 
brief interventions were associated with decreased suicide attempts (pooled odds 
ratio = 3.0 [95% CI = 1.8, 5.2]).22 Brief interventions delivered in a single in-person 
encounter was effective in reducing suicide attempts and improving patient 
engagement in follow-up mental healthcare. Brief suicide prevention interventions 
include safety planning to identify personalized warning signs for an impending 
suicidal crisis, determine internal coping strategies that distract from suicidal 
thoughts and urges, identify family, friends, and social places that can distract from 
suicidal thoughts and urges, identify persons who can provide support during a 
crisis, list mental health professionals and urgent care services to contact, and 
provide lethal means counseling.22 A potentially fruitful line of research is the 
effectiveness of brief interventions targeted to those at highest risk of suicide 
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attempt. In this study, we found that persons in the top 20% of predicted risk scores 
accounted for approximately half of all suicide attempt cases. By targeting 
individuals in the highest stratum of risk, clinicians may be able to identify and treat 
a substantial number of persons who may have otherwise made a suicide attempt. 
In addition, we found that specific personality disorders was a strong predictor of 
suicide attempts. Treatments that reduce suicidal behavor among persons with 
personality disorder also include brief interventions, dialectical behavioral therapy 
and a psychoanalytically oriented partial hospitalization.101,194,195 Future work 
should examine the effectiveness of these interventions on reducing suicide risk in 
high risk individuals.  
 These findings should be interpreted in light of several limitations. The 
current study is affected by all of the limitations that were previously discussed in 
Study 1, including measurement error of predictors, lack of data on non-diagnostic 
risk factors such as affective states (e.g., hopelessness, loneliness) and social 
factors (e.g., relationship disruption), potential overfitting of classification trees, 
and unclear generalizability of the findings to the U.S. and other populations. Given 
our discussion of these limitations and their potential impact on our findings in 
Study 1, which are also applicable to the current study, we will not repeat them 
here. Instead, we will discuss a different set of limitations present in this study.  
A first limitation is that there was misclassification of the predictors 
poisoning and toxic effects of substances. The classification trees and random 
forests results showed that having multiple poisoning diagnoses was associated 
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with suicide attempts in men and women. Toxic effects of substances were among 
the top 30 predictors of suicide attempts in the random forests for men. In these 
data, diagnoses of poisoning and toxic effects of substances may capture a mix of 
previous non-fatal suicide attempts, non-suicidal self-injury, and drug overdoses 
and adverse reactions. A validation study83 was conducted by Gasse and 
colleagues to assess the validity of suicidal events in Denmark using the Columbia 
Classification Algorithm of Suicide Assessment (C-CASA) as the gold standard.196 
Gasse et al. examined intoxication using ICD-10 intoxication codes (poisoning by, 
adverse effect of and underdosing of nonopioid analgesics, antipyretics and 
antirheumatics [T39], poisoning by, adverse effect of and underdosing of 
antiepileptic, sedative- hypnotic and antiparkinsonism drugs [T42], poisoning by, 
adverse effect of and underdosing of psychotropic drugs, not elsewhere classified 
[T43], and toxic effect of carbon monoxide [T58]), which are a subset of the overall 
poisoning diagnosis (T30 - T50) and toxic effects of substances (T51 - T65). They 
found that the PPV of the intoxication codes was 53% (95% CI = 46%, 60%). This 
suggests that almost half of persons diagnosed with intoxications were not 
classified as such when their ICD-10 codes were validated against C-CASA. There 
may be similar misclassification in the other ICD-10 codes for poisonings and toxic 
effects of substances. Any misclassification of poisonings and toxic effects of 
substances is expected to be independent and non-differential with respect to 
outcome classification in the current study because suicide attempts occurred after 
these predictors. If the codes for poisoning and toxic effects of substances capture 
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some suicide attempts, that may suggest that we did not capture all first suicide 
attempts during the study period. This raises the question of whether the codes for 
poisoning and toxic effects of substances should be included in the definition of 
suicide attempts. In the study by Gasse and colleagues, they found that including 
additional codes in the definition of suicide attempts combined with indeterminate 
and potentially suicidal events actually had a worse PPV (52%) than using just X60 
- X84 (PPV = 73%), the latter approach being what we used in the current study.83 
Furthermore, despite this misclassification, these variables still appeared as the 
top predictors of suicide attempts in the machine learning analyses, suggesting 
that the inclusion of broader variables for which the intent of the poisoning is 
unclear may be useful to include in prediction models for suicide attempts. Prior 
research has demonstrated that a history of self-harm, despite misclassification, is 
among the strongest risk factors for future suicide attempts and death.26,40,160,197,198 
In addition, our finding that poisonings at all time points, including those occurring 
in the 48 months prior to the suicide attempt, is in accordance with studies 
demonstrating that suicide attempt risk persists long after self-poisoning 
episodes.40,197 This underscores the importance of sustained secondary 
prevention initiatives among those who have a history of self-harm.40  
A second important limitation of this study is misclassification of suicide 
attempts. A validation study of suicide attempt ICD-10 codes (X60 - X84) in 
Denmark found that the PPV of suicide attempts was approximately 73%,83 
suggesting that 27% of recorded suicide attempts may not truly be suicide 
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attempts. However, false negatives may be more common; the sensitivity of 
suicide attempt ICD-10 codes in Denmark remains unknown but may be low 
because of suspected under-registration of suicide attempts.83 It is not always 
possible to differentiate between acts of self-harm with and without intention to die. 
Records that do not have evidence of intention or a clear indication of intention to 
die are considered non-suicidal events and may be coded under the ICD-10 
category S00 - T88 “injury, poisoning, and certain other consequences of external 
causes.” Persons who do not have previous psychiatric disorder diagnoses may 
be more likely to have a suicide attempt incorrectly classified as non-suicidal 
events than persons with psychiatric disorder diagnoses. We expect that there is 
differential outcome misclassification with respect to the predictors. Unfortunately, 
we were unable to perform quantitative bias analysis given computational 
constraints that were previously discussed in Study 1. In a previous simulation 
study we conducted, we found that differential outcome misclassification had little 
impact on model performance metrics including accuracy, AUC, sensitivity, and 
NPV, whereas there was a slight decrease in PPV.147 However, differential 
outcome misclassification led to minor changes in the MDA value for the predictor 
by which the outcome was differentially misclassified.147 In the context of suicide 
attempt classification, low specificity would bias the results more than low 
sensitivity given the low prevalence of suicide attempts in both the general 
population and among persons with depression. Thus, improving specificity of 
suicide attempt classification may lead to less biased results. In the current study, 
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we expect that the majority of persons who did not make a suicide attempt to be 
classified as such; in other words, we expect suicide attempts to be measured with 
near perfect specificity. Thus, misclassification of suicide attempts may have had 
a limited biasing effect on our results, though quantitative bias analyses would be 
necessary to confirm this in future work.  
Related to the challenge of measuring suicide attempts, a third limitation of 
this study is potential selection bias due to the lack of data on suicide attempters 
who did not have a recorded diagnosis of suicide attempts and did not receive 
mental health treatment. Although Denmark has virtually complete follow-up of all 
patients (with no unrecorded dropouts) and there is universal access to healthcare 
that may reduce selection biases arising from selective inclusion of specific 
hospitals, health insurance systems, income, or age groups,61 selection bias may 
still be present because of selection procedures for inclusion in a study. Selection 
bias occurs when we condition on a common effect of the exposure(s) and the 
outcome.60 In our case cohort study, we selected all persons who made an incident 
suicide attempt between 1995 and 2015 and who had a previous depression 
diagnosis. Furthermore, persons who are depressed are likely to have comorbid 
psychiatric disorders, and psychiatric disorders were examined as exposures (i.e., 
predictors) in this study. Psychiatric disorders and suicide attempts may go 
undetected in medical registries or less severe suicide attempts could be classified 
as an injury or poisoning without suicidal intent. Thus, it is possible that the 
outcome (suicide attempts) and the exposure(s) (psychiatric disorders) both affect 
	
	 76 
selection (i.e., a common effect) in the study. In traditional epidemiologic studies, 
selection bias can lead to biased effect estimates such that the exposure-outcome 
association among those selected for the analysis differs from the association 
among those eligible due to non-exchangeability between the exposed and 
unexposed.93 In machine learning, the default assumption is that the training and 
test data are independent and identically drawn from the same distribution. Sample 
selection bias arises when the distributions on the training and test set do not 
match.199,200 Selection bias can decrease prediction accuracy, and decision trees 
have previously been found to be sensitive to sample selection bias.199 Future work 
should examine the impact of selection bias in machine learning models predicting 
suicide attempts among persons with depression. 
 A final noteworthy limitation is that we did not examine multiple suicide 
attempts given that our focus was on the first suicide attempt recorded in the 
Danish registries. As such, our findings are only applicable to an incident suicide 
attempt among persons who did not have a previous record of suicide attempts. It 
is unclear whether our prediction models will be generalizable to persons who 
make multiple suicide attempts. Approximately 19% (95% CI = 16%, 23%) of 
persons who attempt suicide make a second attempt in the following year.201 Given 
the high risk of repetition, knowledge of who is likely to make a subsequent suicide 
attempt after an initial suicide attempt may help reduce the burden of suicide 
attempts.  
  Many of the results of this study are in alignment with existing literature 
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from traditional etiologic studies, and we also contributed knowledge of several 
novel interactions and predictors of suicide attempts among persons diagnosed 
with depression. These interactions and predictors should be further evaluated in 
future studies to quantify their causal effect on suicide attempts and their predictive 






Table 4.1 Characteristics of the suicide attempt cases and the subcohort, Denmark, January 1, 1995. 
 Men Women 
Variable Suicide 
attempt cases 
(n = 2,093) 
Comparison 
subcohort 
(n = 4,281) 
Suicide 
attempt cases 
(n = 3,939) 
Comparison 
subcohort 
(n = 7,682) 
Age, mean (SD) 32 (17) 42 (21) 29 (19) 43 (24) 
Marital status, N (%)     
   Single   1267 (61%) 1843 (43%) 2292 (58%) 2974 (39%) 
   Married or registered 
partnership 
586 (28%) 1834 (43%) 1087 (28%) 2833 (37%) 
   Divorced, separated, or 
widowed 
240 (11%) 604 (14%) 560 (14%) 1875 (24%) 
Immigrant, N (%) 93 (4.4%) 206 (4.8%) 149 (3.8%) 329 (4.3%) 
Employment status     
   Employed 1077 (52%) 1994 (47%) 1332 (34%) 2465 (32%) 
   Unemployed 252 (12%) 451 (11%) 539 (14%) 777 (10%) 
   Early retirement 179 (9%) 365 (8.5%) 491 (12%) 769 (10%) 
   State pension 239 (11%) 923 (22%) 532 (14%) 2448 (32%) 
   Age <=14 years 316 (15%) 507 (12%) 1014 (26%) 1150 (15%) 






Figure 4.1 Classification tree depicting suicide attempt predictors in depressed men in Denmark, 1995 - 
2015. 
 
Note: aPoisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. bState pension (reference group: 
employed). cToxic effects of substances chiefly nonmedicinal as to source. dReaction to severe stress, and adjustment disorders. eDrugs for 
peptic ulcer and gastro-oesophageal reflux disease (GORD). Each shaded rectangular bin at the bottom (terminal node) represents the 
group of people with the characteristic profile in the branches above. Within the rectangular bins, n=the number of people who had the 




Figure 4.2 Classification tree depicting suicide attempt predictors in depressed women in Denmark, 1995 - 
2015. 
 
Note: aPoisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. bState pension (reference group: 
employed). cReaction to severe stress, and adjustment disorders. Each shaded rectangular bin at the bottom (terminal node) represents the 
group of people with the characteristic profile in the branches above. Within the rectangular bins, n=the number of people who had the 




Figure 4.3 Variable importance of suicide attempt predictors in depressed men in Denmark from 10-fold 
cross-validation, 1995 - 2015. 
 
Note: aPoisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. bReaction to severe stress, and 
adjustment disorders. cToxic effects of substances chiefly nonmedicinal as to source. The black dots represent the mean decrease in 
accuracy (MDA) value from 10-fold cross validation. The vertical line represents the average of the MDA values of all predictors (average = 




Figure 4.4 Variable importance of suicide attempt predictors in depressed women in Denmark from 10-fold 
cross-validation, 1995 - 2015. 
 
Note: aPoisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances. bReaction to severe stress, and 
adjustment disorders. The black dots represent the mean decrease in accuracy (MDA) value from 10-fold cross validation. The vertical line 
represents the average of the MDA values of all predictors (average = 0.73; standard deviation = 5.9).
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CHAPTER 5. THE JOINT EFFECTS OF DEPRESSION AND COMORBID 




Depression is one of the most common mental disorders globally18 and is 
highly comorbid with other mental disorders such as substance use disorders, 
PTSD, generalized anxiety disorder, and personality disorders.49 In a recent 
nationwide Danish study, mood disorders, a category of psychiatric disorders 
which includes depressive disorders, were associated with an increased risk of all 
other mental disorders.50 Depression and various comorbid mental disorders are 
common in suicide decedents and attempters.37,51,52,56 Depression is a well-
established risk factor for suicide outcomes1,5,17 and suicide mortality risk is also 
higher among persons with personality disorders, bipolar disorder, substance use 
disorders, schizophrenia, and eating disorders compared with the general 
population.16 Understanding the joint effects of depression and comorbid mental 
disorders on suicide death and suicide attempt may help identify high risk groups 
who may benefit from increased suicide risk screening and care. If depression in 
combination with other mental disorders act synergistically to increase the risk of 
suicide and suicide attempt, then this may suggest that it is important to treat 
psychiatric comorbidities with therapies that target transdiagnostic symptoms (e.g., 
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders)202,203 and 
mechanisms (e.g., neuroticism, emotion regulation) shared by multiple disorders 
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in order to reduce the risk of suicide  and suicide attempt.204,205 To date, the 
literature on the joint influence of depression and comorbid mental disorders on 
risk of suicide and suicide attempt has yielded mixed results.  
Some studies have found that depression and comorbid mental disorders 
were associated with increased risk of suicide and suicide attempt. The combined 
effect of depression and PTSD on suicide may be greater than the sum of their 
individual effects, providing evidence of synergism (i.e., super-additive risk).206,207 
Similarly, depression has been found to have a synergistic effect with several other 
mental disorders on suicide and suicide attempt risk including personality 
disorders,173,208,209 atypical autistic traits,210 and substance use disorders.211–213 
However, other studies have found evidence suggesting the presence of 
antagonism (i.e., sub-additive risk) such that the combined effect of depression 
and comorbid mental disorders was less than the sum of their individual effects on 
suicide and suicide attempt. A study of male Veterans Health Administration users 
found sub-additive risk for suicide when examining two way combinations of 
depression with other mental disorders including PTSD, substance use disorders, 
bipolar disorder, anxiety disorder, and schizophrenia.214 Other studies have 
produced similar findings of sub-additive risk for depression and comorbid 
PTSD,215 alcohol use disorder,216 panic disorder.217 Studies finding sub-additive 
risk have posited that the presence of comorbid mental disorders with depression 
may not contribute additional suicide attempt risk.214,218 
There are several potential reasons for these conflicting findings in the 
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literature on the association of depression and mental disorder comorbidity with 
suicide and suicide attempt. When studying the association between any mental 
disorder (e.g., depression) and suicide and suicide attempt, other mental disorders 
are likely to simultaneously act as confounders, effect measure modifiers, 
mediators, and colliders of that association.206 Lack of data on the temporal 
ordering of mental disorders, such as in cross-sectional studies, may lead to 
inappropriate adjustment of variables, creating bias. For example, adjusting for a 
variable that is a mediator may lead to bias toward the null,219 and adjusting for a 
collider may induce spurious upward or downward bias of effect 
estimates.93,94,220,221 Thus, it is crucial to establish the temporal ordering of 
disorders using longitudinal data to avoid inappropriate adjustment of mental 
disorders that are mediators and colliders.222,223 If there is time-varying feedback 
between variables that are measured repeatedly such that there is a time-varying 
cause of the outcome that also affects a time-varying exposure,224–226 as is often 
the case in the study of mental disorders and suicide-related outcomes (i.e., due 
to other mental disorders or physical comorbidities), novel methods such as 
inverse probability weighting and marginal structural models are tools that can be 
used to avoid the bias that arises with standard adjustment of a time-varying 
confounder.58  
The purpose of this study was to estimate the joint effects of depression 
and a wide range of comorbid mental disorders on suicide and suicide attempt. 
We examined pairwise combinations of depression with: 1) organic disorders, 2) 
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substance use disorders, 3) schizophrenia, 4) bipolar disorder, 5) neurotic 
disorders, 6) eating disorders, 7) personality disorders, 8) intellectual disabilities, 
9) developmental disorders, and 10) behavioral disorders. We examined these 
categories of mental disorders because previous studies have documented their 
high degree of comorbidity with depression47,227–233 and their associations with 
suicide and suicide attempt.53,234–236 This approach is also consistent with that of 
previous studies examining psychiatric comorbidity and overall mortality in the 
population of Denmark50,237 which used the same ICD-10 categories of mental 
disorders to keep the number of analyses tractable. We used inverse probability 
weighted estimation of marginal structural Cox proportional hazards models to 
address time-varying confounding. We also conducted sex-stratified analyses 
because there is evidence of differences in the prevalence of psychiatric 
comorbidity and risk of suicide and suicide attempts in men and women.51,52 We 
hypothesized that there would be positive interdependence between depression 
and other mental disorders such that the rate of suicide and non-fatal suicide 
attempt would be greater among persons with depression and comorbid 
psychiatric disorders than would be expected based on the individual effects of the 





Study Design and Sample 
We used the original case-cohort sample as described in the 
Comprehensive Methods section. In brief, we examined two separate case groups: 
1) suicide deaths and 2) non-fatal suicide attempts. Suicide cases were all 
individuals who died by suicide (n = 14,103) and suicide attempt cases were all 
individuals who made a non-fatal suicide attempt (n = 22,974) between January 1, 
1995 and December 31, 2015 in Denmark. We obtained suicide cases from the 
Danish Cause of Death Registry using ICD-10 codes X60 − X84.69 Incident suicide 
attempt cases were identified using inpatient and outpatient ICD-10 codes X60 − 
X84 in the Danish National Patient Registry or Danish Psychiatric Central 
Research Register without a death recorded in the Danish Cause of Death 
Registry in the 30 days after the suicide attempt date. The comparison subcohort 
for both case groups was a 5% random sample of the source population in 
Denmark on January 1, 1995 (n = 265,183).   
 
Exposures 
We obtained psychiatric disorder diagnoses from the Danish Psychiatric 
Central Research Register70 and the Danish National Patient Registry.61 We 
ascertained depression diagnoses using ICD-10 codes: major depressive 
disorder, single episode (F32), major depressive disorder, recurrent (F33), 
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persistent mood disorders (F34), and unspecified mood disorder (F39). We 
examined pairwise combinations of depression with the following ICD-10 
subchapter categories of mental disorders: mental disorders due to known 
physiological conditions (F01 − F09; hereafter referred to as organic disorders; 
includes a range of mental disorders (e.g., dementia) grouped together on the 
basis of their having a common etiology in cerebral disease, brain injury, or other 
insult leading to cerebral dysfunction), substance use disorders (F10 − F19; 
includes alcohol-, opioid-, cannabis-, cocaine-related disorders and other sources 
of psychoactive substance use), schizophrenia (F20 − F29; includes schizotypal 
disorder, delusional disorders, brief psychotic disorder, etc), bipolar disorder (F31), 
anxiety, dissociative, stress-related, and somatoform disorders (F40 − F48; 
hereafter referred to as neurotic disorders; includes phobic anxiety disorders, other 
anxiety disorders, obsessive-compulsive disorder, reaction to severe stress and 
adjustment disorders, etc.), eating disorders (F50), personality disorders (F60), 
intellectual disabilities (F70 − F79; includes mild to profound intellectual disabilities 
as well as other and unspecified intellectual disabilities), developmental disorders 
(F84; includes autistic disorder, Rett’s syndrome, other childhood disintegrative 
disorder, Asperger’s syndrome, and other and unspecified pervasive 
developmental disorders), and behavioral and emotional disorders with onset 
usually occurring in childhood and adolescence (F90 − F98; hereafter referred to 
as behavioral disorders; includes attention-deficit hyperactivity disorders, conduct 
disorders, among others). A full list of the specific mental disorders within each 
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category can be found at https://www.icd10data.com/ICD10CM/Codes/F01-F99. 
All mental disorders were treated as time-varying exposures. Persons were 
considered unexposed until they received an incident diagnosis of a mental 
disorder. Persons were considered exposed on the date of diagnosis and 
afterwards. Figures 5.1 and 5.2 depict exposed and unexposed person-time for 
depression and psychiatric comorbidity.  
 
Confounders 
Potential time-varying confounders of the association between depression 
and psychiatric comorbidity with suicide/suicide attempts included age, marital 
status (single, married/registered partnership, divorced/separated/widowed), 
employment (employed, unemployed, early retirement, state pension), annual 
income, physical health status (Charlson Comorbidity Index; CCI = 0, 1, 2, ³3), 
and neurotic disorders. These variables were chosen as potential confounders 
based on prior literature showing that they predict both psychiatric disorders and 
suicide outcomes.238,239 We obtained data on age and marital status from the 
Danish Civil Registration System.67 Employment and income data were 
ascertained from the Integrated Database for Labor Market Research78 and 
Income Statistics Register.77 We computed the Charlson Comorbidity Index score 
as a measure of overall physical health240 using somatic diagnoses recorded in the 
Danish National Patient Registry.61 Charlson conditions have been shown to have 
excellent positive predictive values in this registry.241 The diagnoses used to 
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construct the CCI score are included in Appendix 2. We included neurotic disorders 
as a confounder because they predict both depression and suicide and they were 




We conducted separate analyses for each outcome: 1) suicide and 2) non-
fatal suicide attempts. Follow-up began on January 1, 1995 and we followed 
participants until the date of the outcome, date of emigration, date of death (non-
suicide related), or December 31, 2015, whichever came first. For descriptive 
analyses, we calculated the frequencies and proportions of sociodemographic 
characteristics, somatic comorbidities, and psychiatric disorders within strata of 
depression status and sex.  
We evaluated the joint effect of depression and other mental disorders on 
suicide and suicide attempts. First, we fit sex-stratified Cox proportional hazards 
regression models to examine the crude associations of depression and 
psychiatric comorbidity with suicide and non-fatal suicide attempts. The exposure 
and modifiers were analyzed in a time-varying fashion to allow for the occurrence 
of depression and other mental disorder diagnoses at different times during the 
study period using a counting process dataset. The crude models did not adjust 
for confounding. We then used marginal structural models to estimate the joint 
effect58 of depression and other mental disorders on suicide and non-fatal suicide 
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attempts adjusting for time-varying covariates. We estimated inverse probability of 
treatment weights (IPTWs). We used stabilized weights because they reduce the 
likelihood of an extreme weight value and improve statistical efficiency.243–245 We 
estimated the following stabilized weights using pooled logistic regression:  
!"#(%) = 
(
)[+#,-(.))/+0#,-(.1#)2, +04,-(.1#)2, 5̅,-(.)2 = 0, 8	³		-(.)]




)[+4,-(.))/+04,-(.1#)2, +0#,-(.)2, 5̅,-(.)2 = 0, 8	³		-(.)]
)[+4,-(.))/+04,-(.1#)2, +0#,-(.)2, ;0,-(.1#)2, 5̅,-(.)2 = 0, 8	³	-(.)]<(.)=>
 
The exposure weights WX1(t) and WX2(t) correct for potential time-varying 
confounders and represents the inverse probability of being exposed (or 
unexposed), conditional on observed time-varying covariates. In a cohort of i 
participants, X1i(k(m)) represents individual i’s depression status at time k(m), 
X2i(k(m)) represents individual i’s mental disorder comorbidity status at time k(m), 
and C(k(m)) represents individual i’s continuation status at time k(m). The letter m 
represents ordered measurement times since study entry. Li(k(m)) is a vector 
containing variables at time k(m) including age, marital status, employment, 
income, physical health status, and neurotic disorders. The overbars represent 
covariate history from study entry up to time k(m). For the analysis of suicide 
deaths, we also included previous suicide attempts as a time-varying confounder. 
We truncated our weights at the 99.9th percentile (i.e., any weight smaller than 
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0.1% of all of the weights was assigned to the percentile of 0.1% and any weight 
larger than the 99.9th percentile was assigned to the 99.9th percentile) to avoid 
extreme weights.244 The inverse probability weights were themselves weighted 
inversely to the sampling fraction for the case-cohort design.246 Cases were given 
a weight of 1 because all suicide cases and non-fatal suicide attempt cases 
between 1995 and 2015 were included. Non-cases in the subcohort were given a 
weight of 20 (1/0.05 = 20) since the sampling fraction for the general population 
subcohort was 5%. The final stabilized weights used for suicide cases and suicide 
attempt cases was calculated by multiplying the truncated stabilized IPTW for 
depression and the truncated stabilized IPTW for the comorbid mental disorder:   
!(%)?@ABA = !"#(%)	!"4(%). 
The final stabilized weights used for the comparison subcohort members was 
calculated by multiplying the truncated stabilized IPTW for depression, truncated 
stabilized IPTW for the comorbid mental disorder, and the inverse sampling 





The inverse probability weights were then used to estimate the parameters of a 
joint marginal structural Cox proportional hazards model with a robust variance 
estimator:  
log(hi(t)) = a(t) * b1X1 + b2X2 + b3X1X2  
where a(t) is the intercept, X1 is depression and X2 is the comorbid mental disorder. 
We used the R package ipw to estimate inverse probability weights and fit marginal 
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structural Cox models.247  
We also conducted a sensitivity analysis to adjust for censoring. We 
calculated stabilized inverse probability of continuation weights (IPCWs): 
!K(%) = 	 (
)[5,-(.)) = 0/+0,-(.)2, 5̅,-(.1#)2 = 0, 8	³		-(.)]
)[5,-(.)) = 0/+0,-(.)2, ;0,-(.)2, 5̅,-(.1#)2 = 0, 8	³	-(.)]<(.)=>
 
The continuation weight WC(t) corrects for potential selection bias due to censoring 
and represents the inverse probability of remaining in the study cohort (i.e., 
uncensored). In the sensitivity analysis, the stabilized weights for suicide cases 
and suicide attempt cases were calculated by multiplying the truncated stabilized 
IPTWs and IPCW (all truncated at the 99.9th percentile):   
!(%)?@ABA = !"#(%)	!"4(%)	!K(%). 
The stabilized weights used in the analysis for the comparison subcohort members 
was calculated by multiplying the truncated stabilized IPTWs, IPCW, and the 





We calculated the relative excess risk due to interdependence (RERI) 
instead of the risk due to interdependence because rates cannot be estimated 
directly in a case-control study and the variables were time-varying, making it 
complex to calculate the risk due to interdependence. The estimates from the Cox 
models were used to calculate the RERI using the formula248,249:  
RERI = exp(b1X1 + b2X2 + b3X1X2) - exp(b1X1) - exp(b2X2) + 1, 
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Where exp(b1) is the hazard ratio (HR) for Depression+ Modifier− relative to 
Depression− Modifier−, exp(b2) is the HR for Depression− Modifier+ relative to 
Depression− Modifier−, and exp(b1 + b2+ b3) is the HR for Depression+ Modifier+ 
relative to Depression– Modifier−. A RERI equal to zero indicates no 
interdependence, a RERI greater than zero indicates positive interdependence 
(i.e., more cases in the doubly exposed than would be expected based on the 
effects of each of the individual mental disorders alone; synergy; super-additive 
risk), and a RERI less than zero indicates negative interdependence (i.e., fewer 
cases in the doubly exposed than would be expected based on the effects of each 
of the individual exposures alone; antagonism; sub-additive risk).250 We estimated 
the 95% confidence intervals (95% CI) for the RERI using the delta method.251 All 
analyses were stratified by sex. 
 
Bias Analysis 
 Given potential misclassification of mental disorders, we conducted bias 
analyses to estimate changes in the observed RERIs due to independent, non-
differential exposure misclassification. We assumed that exposure 
misclassification would be non-differential with respect to the outcome because 
these data were collected prospectively. We used positive predictive values 
(PPVs) found in previous Danish validation studies for depression (PPV =  75%),252 
organic disorders (PPV = 86%),253 schizophrenia (PPV = 98%),254 neurotic 
disorders (PPV = 75%),71 developmental disorders (PPV = 94%),255 and 
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behavioral disorders (PPV = 87%).256 Validation studies of substance use 
disorders, bipolar disorder, eating disorder, personality disorder, and intellectual 
disabilities in the Danish registers have yet to be conducted, so we assumed that 
the PPV for bipolar disorder was 92% and that the PPV for personality disorder 
was 93% based on Swedish validation studies of these disorders257,258 since these 
were the best available validation data for nationwide registries with similar data 
structure and validity.259 For all other disorders for which we had registry data, we 
set their PPV to the mean value of the PPVs of all other mental disorders (mean 
PPV = 88%). We assumed that the negative predictive value for all disorders was 
99%, as all persons who do not have a mental disorder diagnosis in the registries 
were likely to be correctly classified as such given that Denmark has universal 
healthcare and over 92% of Danes receive medical treatment in a given year.63 
We used Vanderweele’s method260 to obtain bias-adjusted RERI estimates: 
LL## −	LL#H 	−	LLH# + 	1 =
(LL##∗ −	LL#H∗ −	LLH#∗ + 1)
(1 −	Q# −	R#)(1 −	Q4 −	R4)
 
LL## −	LL#H 	−	LLH# + 	1 represents the true RERI and LL##∗ −	LL#H∗ −	LLH#∗ + 1 
represents the misclassified RERI. Q# represents 1 minus the positive predictive 
value for the first exposure, R# represents 1 minus the negative predictive value 
for the first exposure, Q4 represents 1 minus the positive predictive value for the 
second exposure, and R4 represents 1 minus the negative predictive value for the 





Descriptive Results  
Suicide Death Outcome  
Table 5.1 displays the descriptive statistics of the study sample in the 
analysis of suicide deaths. There were 5,892 (2.1%) depressed men, 134,851 
(48%) non-depressed men, 8,855 (3.2%) depressed women, and 129,688 (46%) 
non-depressed women. Depressed persons were on average slightly older than 
non-depressed persons. The mean ages for depressed men and women were 42 
(standard deviation [SD] = 20) and 43 (SD = 23), respectively. The mean ages for 
non-depressed men and women were 38 (SD = 22) and 40 (SD = 23), respectively. 
There was a greater proportion of divorced, widowed, and separated persons in 
the depressed group than the non-depressed group. There was a greater 
proportion of depressed persons receiving a state pension and a slightly higher 
proportion of persons with at least two Charlson comorbidity conditions in 
depressed persons than non-depressed persons.  
 The most common psychiatric comorbidities among depressed men during 
the study period were neurotic disorders (31%), substance use disorders (31%), 
organic disorders (13%), and personality disorders (13%) (Table 5.2). In non-
depressed men, the most common psychiatric disorders were substance use 
disorders (6.2%), neurotic disorders (3%), and organic disorders (2.5%). The most 
common mental disorders in depressed women included neurotic disorders (32%), 
substance use disorders (18%), personality disorders (16%), and organic 
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disorders (14%). In non-depressed women, the most common mental disorders 
were neurotic disorders (4.2%), organic disorders (3.3%), and substance use 
disorders (3.2%).  
 
Suicide Attempt Outcome 
 There were 7,292 (2.5%) depressed men, 132,845 (46%) non-depressed 
men, 12,907 (4.5%) depressed women, and 135,113 (47%) non-depressed 
women. The average age of depressed and non-depressed persons were similar 
for men and women (Table 5.3). The mean age of depressed men, non-depressed 
men, depressed women, and non-depressed women were 38 (SD = 20), 37 (SD = 
22), 38 (SD = 23), and 39 (SD = 23), respectively. In men, 13% of the depressed 
and 9% of the non-depressed were divorced, widowed, or separated. In women, 
20% of the depressed and 18% of the non-depressed were divorced, widowed, or 
separated. With respect to CCI score, there were similar proportions of depressed 
and non-depressed persons who had a CCI score of 2 or greater.  
Over the study period, the most common comorbid psychiatric disorders 
among men diagnosed with depression were substance use disorders (37%), 
neurotic disorders (36%), personality disorders (15%), and organic disorders 
(12%) (Table 5.4). In men without a depression diagnosis, the most common 
mental disorders were substance use disorders (7.3%), neurotic disorders (4.6%), 
and organic disorders (2.6%). The most prevalent psychiatric comorbidities in 
depressed women included neurotic disorders (38%), substance use disorders 
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(22%), personality disorders (21%), and organic disorders (10%). In non-
depressed women, the most common mental disorders were neurotic disorders 
(6.7%), substance use disorders (4.3%), and organic disorders (3.2%).  
 
Crude Cox Proportional Hazards Regression Results  
Suicide Death Outcome 
 The crude regression analyses without adjustment for confounding showed 
that for men, the largest crude HR comparing the doubly exposed (Depression+, 
Modifier+) to the doubly unexposed (Depression-, Modifier-) was for persons with 
depression and substance use disorders (Table 5.5). Men who had both 
depression and substance use disorders had 22 times (95% CI = 20, 24) the rate 
of suicide death compared to persons with neither disorder. The crude HR for the 
association of depression with suicide in the absence of substance use disorders 
was 16 (95% CI = 15, 17). The crude HR for the association of substance use with 
suicide in the absence of depression was 8.1 (95% CI = 7.7, 8.6). Although 
depression and substance use disorder had the largest crude HR, this combination 
of disorders had the smallest crude RERI (crude RERI = -1 [95% CI = -3.0, 1.0], 
meaning that the rate of suicide due to the interdependence between depression 
and substance use disorders was -1 times the rate in the doubly unexposed group 
of persons without depression and substance use disorders for men. These crude 
results suggest that there was negative interdependence (i.e., sub-additive risk) 
between depression and substance use on the rate of suicide. Other mental 
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disorders in combination with depression that had a large crude association with 
suicide (comparing the doubly exposed to the doubly unexposed) included 
schizophrenia (crude HR = 20 [95% CI = 17, 23]), bipolar disorder (crude HR = 20 
[95% CI = 16, 24]), neurotic disorders (crude HR = 20 [95% CI = 18, 22]), and 
personality disorders (crude HR = 19 [95% CI = 17, 21]). 
 Figure 5.3 shows the stacked bar plots corresponding to the excess relative 
risk of suicide due to depression and each of the modifying mental disorders in the 
crude analyses for men (synthesized from models in Table 5.5). In each stacked 
bar plot, the blue bar corresponds to the reference group of persons without 
depression and the modifying mental disorder (HR = 1). The green bar displays 
the excess relative risk due to depression; the combined blue and green bars 
indicate the HR for persons with depression but without the modifying mental 
disorder. The orange bar displays the excess relative risk due to the modifying 
mental disorder; the combined blue and orange bars indicate the HR for persons 
with the modifying mental disorder but without depression. The red bar 
corresponds to the RERI. The sum of the blue, green, orange, and red bars is the 
HR for persons with both depression and the modifying mental disorder compared 
with persons with neither disorder (i.e., doubly exposed vs. doubly unexposed). 
The values shown to the left of the bars are the HRs comparing the doubly exposed 
to the doubly unexposed. In Figure 5.3, the excess relative risk due to depression 
(shown in green) was larger than the excess relative risk due to each of the 
modifying mental disorders (shown in orange). Furthermore, all of the RERIs 
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(shown in red) were negative which is indicative of negative interdependence in 
crude analyses for men. The crude RERIs with the largest magnitude was for 
intellectual disabilities (crude RERI = -9.2 [95% CI = -13, -5.5]), bipolar disorder 
(crude RERI = -7 [95% CI = -11, -3.1]), and schizophrenia (crude RERI = -6 [95% 
CI = -9.2, -2.8]).  
 Table 5.5 and Figure 5.4 display the additive interaction of depression and 
modifying mental disorders on the crude rate of suicide in women in crude 
analyses. There was variation in the direction and magnitude of the RERIs. There 
may be positive interdependence between depression and some modifying mental 
disorders including substance use disorders (crude RERI = 15 [95% CI = 9.7, 21]), 
neurotic disorders (crude RERI = 6.9 [95% CI = 3.3 10]), schizophrenia (crude 
RERI = 3.3 [95% CI = -4.1, 11]), bipolar disorder (crude RERI = 0.93 [95% CI = -
7.4, 9.3]), and personality disorders (crude RERI = 0.28 [95% CI = -4.4, 5.0]). 
However, the crude analyses also suggested that there may be negative 
interdependence between depression and other mental disorders including 
behavioral disorders (crude RERI = -15 [95% CI = -22, -9.0]), organic disorders 
(crude RERI = -6.6 [95% CI = -11, -2.3]), eating disorders (crude RERI = -5.5 [95% 
CI = -12, 1.4]), developmental disorders (crude RERI = -5.2 [95% CI = -23, 12]), 
and intellectual disabilities (crude RERI = -0.08 [95% CI = -14, 14]). Notably, these 
RERI estimates were measured imprecisely and some of the 95% CIs contain both 
positive and negative values, likely due to the relative rarity of the outcomes. In 
these cases, positive and negative interdependence cannot be ruled out.  
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Suicide Attempt Outcome 
 Table 5.6 displays the crude Cox regression analysis results for suicide 
attempts. For men, the largest HRs comparing the doubly exposed (Depression+, 
Modifier+) to the doubly unexposed (Depression-, Modifier-) was for depression 
and neurotic disorders (crude HR = 86 [95% CI = 80, 94]), substance use disorders 
(crude HR = 76 [95% CI = 71, 82]), personality disorders (crude HR = 42 [95% CI 
= 38, 46]), and schizophrenia (crude HR = 40 [95% CI = 35, 45]). In the analysis 
with neurotic disorders as the modifying mental disorder, the crude HR for the 
association of depression with suicide attempt in the absence of neurotic disorders 
was 44 (95% CI = 41, 47). The crude HR for the association of neurotic disorders 
with suicide attempt in the absence of depression was 59 (95% CI = 55, 63). The 
corresponding crude RERI was -16 (95% CI = -20, -12), which was the strongest 
RERI of all the modifying mental disorders.  
 The additive interaction between depression and other mental disorders on 
the risk of non-fatal suicide attempts in men shown in Figure 5.5 suggests that 
there was evidence of positive interdependence between depression and 
substance use (crude RERI = 13 [95% CI = 9.9, 16]). There was less evidence of 
positive interdependence between depression and behavioral disorders (crude 
RERI = 0.49 [95% CI = -6.6, 7.5]), which was measured imprecisely. The remaining 
modifying mental disorders had negative RERIs. The excess relative risk due to 
depression (shown in green) was larger than the excess relative risk due to all of 
the modifying mental disorders (shown in orange) except for neurotic disorders 
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where the excess relative risk for neurotic disorders was larger (HR = 58) than the 
excess relative risk for depression (HR = 43).  
 In women, there were also large HRs comparing the doubly exposed to the 
doubly unexposed for all modifying mental disorders; the largest crude HRs were 
observed for neurotic disorders (crude HR = 73 [95% CI = 68, 77]), substance use 
disorders (crude HR = 53 [95% CI = 49, 56]), and behavioral disorders (crude HR 
= 42 [95% CI = 35, 50]) (Table 5.6). Similar to the analyses for men, the crude HR 
for the association of neurotic disorders with suicide attempts in the absence of 
depression (crude HR = 41 [95% CI = 39, 44]) and the crude HR for the association 
of depression with suicide attempts in the absence of neurotic disorders (crude HR 
= 35 [95% CI = 33, 37]) were strong for women. The crude RERI for depression 
and neurotic disorders was -2.1 (95% CI = -4.1, -0.1), suggesting that there were 
fewer cases of suicide attempts among persons with both depression and neurotic 
disorders than would be expected based on their independent effects.  
Figure 5.6 displays the crude relative excess risk of suicide attempts due to 
depression and each of the modifying mental disorders in women. There was 
evidence suggesting positive interdependence between depression and the 
following modifying mental disorders: intellectual disabilities (crude RERI = 11 
[95% CI = 3.8, 19]), substance use disorders (crude RERI = 8.8 [95% CI = 6.7, 
11]), developmental disorders (crude RERI = 7 [95% CI = -5.4, 19]), behavioral 
disorders (crude RERI = 4.6 [95% CI = -1.3, 10]), and eating disorders (crude RERI 
= 0.56 [95% CI = -2.9, 4.0]). As previously mentioned, it is important to note that 
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these are imprecise measures of the RERI and thus it was not possible to eliminate 
the possibility of interdependence in either direction for RERIs with 95% CIs 
containing both positive and negative values. There was also evidence suggesting 
the presence of negative interdependence between depression and the following 
modifying mental disorders: organic disorders (crude RERI = -12 [95% CI = -14, -
9.8]), personality disorders (crude RERI = -6.9 [95% CI = -8.9, -4.8]), bipolar 
disorders (crude RERI = -6.6 [95% CI = -9.4, -3.7]), schizophrenia (crude RERI = 
-5.3 [95% CI = -8.0, -2.6]), and neurotic disorders (crude RERI = -2.1 [95% CI = -
4.1, -0.1]).  
 
Marginal Structural Cox Regression Model Results 
 We conducted marginal structural Cox regression analyses to examine the 
joint effect of depression and comorbid mental disorders on suicide and suicide 
attempt adjusting for time-varying confounding by age, marital status, income, 
employment, physical comorbidity, and neurotic disorders. The mean, standard 
deviation, and range of the stabilized inverse probability weights are shown in 
Appendices 3 and 4. The overall mean of the stabilized weights was approximately 
one.  
 
Suicide Death Outcome 
 Table 5.7 displays the adjusted HRs and RERIs for the joint effects of 
depression and comorbid mental disorders on suicide death in men and women. 
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In men, the rate of suicide among persons with both depression and substance 
use disorders was 18 times (95% CI = 18, 26) the rate in the doubly unexposed. 
We also observed a high rate of suicide among men with comorbid depression and 
neurotic disorders (HR = 20 [95% CI = 15, 26]) and among men with comorbid 
depression and personality disorders (HR = 17 [95% CI = 11, 26]) compared with 
the doubly unexposed. All of the RERIs for men were negative, suggesting the 
presence of negative interdependence between depression and all of the 
examined comorbid mental disorders on the rate of suicide (Table 5.7). The RERIs 
with the largest magnitudes were for depression and substance use disorders 
(RERI = -25 [95% CI = -43, -6.3]) and schizophrenia (RERI = -14 [95% CI = -21, -
6.5]). Figure 5.7 displays the additive interaction between depression and 
comorbid mental disorders on the risk of suicide death. The green bars, 
representing the excess relative risk due to depression, are consistently larger than 
the orange bars which represent the excess relative risk due to each modifying 
mental disorder.  
 In women, there was evidence of both positive and negative 
interdependence between depression and comorbid mental disorders on the rate 
of suicide (Table 5.7). The hazard ratios comparing the doubly exposed and doubly 
unexposed were larger for women than men. In women with comorbid depression 
and substance use disorders, the rate of suicide was 49 times (95% CI = 32, 75) 
that of women with neither disorder. Eating disorders was also strongly associated 
with suicide death in women but its effect was measured imprecisely (RERI = 57 
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[95% CI = 22, 146]). We observed positive RERIs for depression and the following 
comorbid mental disorders: substance use disorders, eating disorders, intellectual 
disabilities, developmental disorders, and behavioral disorders (Figure 5.8). 
Negative RERIs were identified for depression and organic disorders, 
schizophrenia, bipolar disorder, neurotic disorders, and personality disorders.  
 
Suicide Attempt Outcome 
 In men, the largest HR comparing the rate of suicide attempt in the doubly 
exposed to the rate in the doubly unexposed was for depression and neurotic 
disorders (Table 5.8). Persons with both depression and neurotic disorders had 
111 times (95% CI = 92, 135) the rate of suicide attempts compared with persons 
with neither disorder. The HR comparing persons with depression and substance 
use disorders to persons with neither disorder was also large (HR = 107 [95% CI 
= 82, 139]). The majority of the RERIs for men were negative (Table 5.8 and Figure 
5.9). The RERI with the largest magnitude was for the joint effect of depression 
and schizophrenia on suicide attempt: RERI = -40 (95% CI = -53, -28). Negative 
RERIs were also observed for depression and the following modifying disorders: 
behavioral disorders (RERI = -27 [95% CI = -42, -12]), personality disorders (RERI 
= -23 [95% CI = -42, -4.2]), and neurotic disorders (RERI = -22 [95% CI = -45, 
0.21]). The only positive RERIs in men were for substance use disorders (RERI = 
13 [95% CI = -15, 40]) and intellectual disabilities (RERI = 15 [95% CI = -30, 59]). 
The excess relative risk due to depression was generally larger than the excess 
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relative risk due to the modifying mental disorders, with the exception for neurotic 
disorders (excess relative risk due to depression = 58; excess relative risk due to 
neurotic disorders = 57; Figure 5.9). 
 Table 5.8 shows the adjusted HRs and RERIs for women in the analysis of 
suicide attempts. In women, the largest HRs comparing the rate of suicide attempts 
in the doubly exposed with the rate in the doubly unexposed were for neurotic 
disorders (HR = 105 [95% CI = 88, 124]) and substance use disorders (HR = 81 
[95% CI = 64, 104]). The HR for the association of neurotic disorders with suicide 
attempts in the absence of depression was 51 (95% CI = 44, 59) and the HR for 
the association of depression with suicide attempts in the absence of neurotic 
disorders was 49 (95% CI = 43, 57), suggesting that the excess relative risk due 
to neurotic disorders is slightly larger than that due to depression. The excess 
relative risk due to depression was also similar to the excess relative risk due to 
personality disorders (Table 5.8 and Figure 5.10). For all other comorbid mental 
disorders, the excess relative risk due to depression was larger than that of the 
comorbid disorders. Most of the comorbid mental disorders appeared to have a 
synergistic relation with depression on the rate of suicide attempts in women. The 
RERIs were positive for organic disorders, substance use disorders, neurotic 
disorders, intellectual disabilities, developmental disorders, and behavioral 
disorders. However, there appeared to be negative interdependence between 
depression the following mental disorders on the rate of suicide attempts in 
women: schizophrenia, bipolar disorder, eating disorders, and personality 
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disorders.   
 
Assessment of Competitive Antagonism 
To understand why we observed unexpected negative RERIs, we assessed 
for the presence of competitive antagonism. Competitive antagonism includes 
response type 2 (single plus joint causation by both exposures)261 of the 16 
counterfactual susceptibility types for two binary exposures and a binary outcome 
(Table 5.9).261–263 A more in-depth explanation of competitive antagonism is 
provided in the Discussion section below. To empirically assess whether there was 
competitive antagonism for the negative RERIs we identified, we used a simple 
computational procedure developed by Vanderweele and Knol (2011):263  
	LL(#1S)T +	LLS(#1T) −	LLST −	LL(#1S)(#1T) 	> 0 
RRAB is the smallest of the risk ratios (RR11, RR10, RR01, and RR00). In the current 
study, the RRAB was R00 for the majority of analyses, which was equal to 1. Thus, 
the formula we used for the analyses in which R00 was the smallest of the hazard 
ratios was: 
LL#H +	LLH# −	LLHH −	LL## 	> 0 
For intellectual disabilities and developmental disorders in men and for 
developmental disorders in women, RR01 was the smallest of the hazard ratios, 
and thus the formula used for these analyses was:  
LL## +	LLHH −	LLH# −	LL#H 	> 0 
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If the equation is greater than zero and if the two exposures have negative 
monotonic effects on the outcome, then there is evidence for persons of response 
type 2 (competitive antagonism).263 If the equation is less than or equal to zero, 
then there is no evidence of competitive antagonism.263 Tables 5.10 and 5.11 
display the results of the procedure to assess the presence of competitive 
antagonism and the presence of negative monotonicity for the negative RERIs we 
identified in the suicide and suicide attempt analyses.  We found that there was 
indeed evidence of competitive antagonism for the vast majority of the negative 
RERIs observed with no evidence of violation of monotonicity, assuming no 
confounding, selection bias, or measurement error. We found competitive 
antagonism for behavioral disorders in men and women on the rate of suicide 
death, but the monotonicity assumption was violated for these disorders. For the 
suicide death analyses, we did not observe evidence for competitive antagonism 
between depression and intellectual disabilities and developmental disabilities in 
men nor between depression and developmental disabilities in women. 
 
Sensitivity and Bias Analysis 
 The results of the sensitivity analysis to adjust for censoring using IPCWs 
are shown in Appendices 4 and 5. The results are similar to the results of the 
marginal structural models not accounting for censoring, indicating that censoring 
did not meaningfully impact our results. Finally, we conducted a bias analysis to 
assess the impact of non-differential exposure misclassification on the joint effects 
	
	 109 
of depression and comorbid mental disorders on suicide and suicide attempts. The 
results of these analyses are displayed in Tables 5.12 and 5.13. All of the RERIs 
increased in strength after conducting bias-adjustment for exposure 
misclassification. These results suggest that the observed RERIs were 
underestimated, assuming a valid bias model and the accuracy of the values 
assigned to the bias parameters. 
 
DISCUSSION 
This study examines the joint effect of depression and comorbid psychiatric 
disorders on suicide and suicide attempt among men and women using 
prospectively collected Danish registry data. We found that the rate of suicide and 
suicide attempt among those who had depression and a comorbid mental disorder 
was much higher than the rate in those who had neither disorder. There were also 
sex differences in the direction and magnitude of the RERIs. In other words, the 
interaction between depression and other mental disorders was further modified 
by sex. Table 5.14 summarizes the sex-specific interdependence findings for 
suicide deaths and non-fatal suicide attempts. 
 The excess relative risk of suicide and suicide attempt due to depression 
was generally larger than the excess relative risk due to comorbid mental 
disorders. This finding is consistent with prior research demonstrating the central 
role of depression in the etiology of suicide outcomes.1,5,17 Depression is the most 
common mental disorder in suicide decedents and suicide attempters.51,52 
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However, the excess relative risk of suicide attempt due to neurotic disorders was 
larger than that due to depression. These findings suggest that neurotic disorders 
also have a large role in the development of risk for suicide attempts in tandem 
with the influence of depression. It is also worth noting that the large magnitude of 
the HRs and RERIs found in this study are seldom observed in most epidemiologic 
studies in other research areas. However, large effect sizes are relatively more 
common in the study of mental disorders and suicide outcomes206,238,264 because 
of the rarity of suicide and the use of reference groups with a low risk of the 
outcome. The use of a low risk reference group comprised of doubly unexposed 
persons makes effects appears stronger265 and may explain the large HRs and 
RERIs observed in this study.    
 We observed positive interdependence between depression and substance 
use disorders on the rate of suicide attempts in both men and women and on the 
rate of suicide in women. Depression and substance use disorder is an important 
comorbidity that has previously been found to increase the risk of suicide.266–270 
Persons with depression may self-medicate using alcohol and drugs in response 
to depressive symptoms, and having a comorbid substance use disorder could be 
a marker for increased depressive symptom severity.271 Having comorbid 
depression and substance use disorders may lead to reduced quality of life and 
depression recurrence.272–274 Furthermore, they may have reduced rates of 
remission and increased times to reach remission compared with persons who 
have only depression without substance use disorder.275 Persons with comorbid 
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depression and substance use disorder may also experience increased 
aggression and impulsivity, negative affect, and interpersonal conflict that in turn 
could heighten the risk of suicide and suicide attempt.272 These findings indicate 
that clinicians should be aware that patients with comorbid depression and 
substance use disorders are a group that may need greater clinical attention to 
reduce the likelihood of a suicide and suicide attempt, especially since depression 
and substance use disorder are highly comorbid.49 Transdiagnostic treatments that 
enable therapists to intervene on shared mechanisms between depression and 
urges to use substances to relieve negative feelings may be more effective and 
efficient than individual treatments that target individual disorders.204  
There was positive interdependence between depression and a range of 
other mental disorders including organic disorders, neurotic disorders, 
developmental disorders, and behavioral disorders on the rate of suicide attempts 
in women. We also observed positive interdependence between depression and 
organic disorders, and eating disorders on the rate of suicide deaths in women. 
However, due to imprecision of some of the RERIs that included both positive and 
negative values in the 95% CIs, we could not rule out interdependence in either 
direction. Our results are consistent with previous studies that have documented 
increased risk of suicide attempt among persons with these 
comorbidities.207,264,271,276,277 Having depression and an additional mental disorder 
is associated with a poorer depression prognosis,242 greater depressive symptom 
severity,242 more serious functional impairment,48 diminished quality of life,278 and 
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greater depression recurrence,279,280 which may all contribute to suicide and 
suicide attempt risk.281 Comorbid depression and organic disorders such as 
dementia has previously been found to be associated with substantially increased 
risk for suicide.282 In addition, comorbid depression has been found to worsen the 
clinical course of other mental disorders including panic disorder, generalized 
anxiety disorder, and eating disorders.280,283,284 Depression and comorbid 
developmental and behavioral disorders may be associated with poorer quality of 
life and more functional disability compared with each disorder alone.285 These 
challenges may play a role in how depression and comorbid mental disorders act 
synergistically to increase the risk of suicide and suicide attempts in women.  
 There were sex differences in the pattern of the rates of suicide and suicide 
attempts in persons with depression and comorbid mental disorders compared 
with the rates in persons with neither disorder. The HRs for the doubly exposed 
vs. the doubly unexposed were in general much larger in women than men in the 
analysis of suicide deaths but to a smaller extent in the analysis of suicide 
attempts. Again, the baseline risk plays a role in the large magnitude of the HRs in 
women.265 Men are more likely to die by suicide42 than women and the suicide rate 
is very low in women who do not have depression and a comorbid mental disorder. 
Using doubly unexposed women as the reference group will strengthen 
associations. We observed both positive and negative RERIs for depression and 
a wide range of mental disorders and found that there were more positive RERIs 
for women than men. The risk due to interdependence reflects the balance of 
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positive and negative interdependence and is approximately the difference in the 
sum of the positive interdependence counterfactual susceptibility types (Table 11) 
and the sum of the negative interdependence counterfactual susceptibility types. 
Our finding that there were more positive RERIs for women suggests that the 
positive interdependence types outweighed the negative interdependence types 
for women but not for men. A potential mechanistic explanation for these findings 
is that women may be more adversely affected by the presence of psychiatric 
comorbidity than men. Compared with men, women may experience greater 
severity and impairment from multiple mental conditions (e.g., women are more 
sensitive to the physiological effects of substances),286,287 and worse overall 
emotional, psychological, and social role functioning.288 These findings suggest 
that there should be sex-specific tailored interventions given  sex differences in the 
risk of suicide and suicide attempts among persons with psychiatric comorbidities.  
In men, most of the RERIs were negative for suicide attempt and the RERIs 
were completely negative for suicide death. In women, we found several instances 
of negative RERIs. These findings are contrary to our hypothesis that there would 
be positive interdependence between depression and comorbid mental disorders 
on the rate of suicide and suicide attempts. One potential explanation for the 
negative RERIs is that clinicians may provide greater clinical attention to persons 
who have multiple mental disorder diagnoses which may reduce their risk of 
suicide and suicide attempt to some extent. An alternative explanation for our 
results is “competitive antagonism.” Written about by Weinberg in 1986, two 
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independent exposures can compete to cause an outcome and create joint effects 
that are mutually antagonistic through competition.289 Competitive antagonism is 
comprised of type 2 persons. Greenland and Poole (1988) state that in type 2 
persons, both exposures will cause disease when the other exposure is absent, 
but neither exposure can have an effect on the outcome once the other is present 
because they compete with each other to cause the outcome.250,262 Since each 
exposure affects the outcome only in the absence of the other, the estimate for the 
exposures together is less than the sum of either exposure considered separately. 
For example, depression and personality disorders may both have an effect on 
suicide when considered independently. However, competitive antagonism290 may 
occur when both depression and personality disorders are present and compete 
to cause suicide such that the effect of both depression and personality disorders 
together is the same as the effect of just depression or of just personality disorders 
alone. As a result, the effect of both depression and personality disorders together 
is smaller than the sum of just depression and of just personality disorders. We 
found that there was competitive antagonism for the vast majority of the negative 
RERIs observed. These results may explain the conflicting findings in the literature 
to date on the relation between psychiatric comorbidity and suicide outcomes. 
Differences in the positive and negative interdependence types across psychiatric 
comorbidities may give rise to super-additive risk versus sub-additive risk and vice 
versa. Overall, comorbid mental disorders can be harmful both independently and 
jointly and competitive antagonism may create counterintuitive sub-additive risk for 
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the effect of comorbid mental disorders on suicide and suicide attempt.  
This study has several limitations. First, there may be misclassification of 
suicide death and suicide attempt. The Comprehensive Methods section describes 
the process of ascertaining these outcomes and the results of validation studies 
that reported their positive predictive values (PPV; suicide PPV = 92%,82 suicide 
attempt PPV = 73%).83 Jiang and Vanderweele291 provided mathematical proofs 
showing that |LWLXYY∗ | 	≤ |LWLXYY| under the scenario of non-differential outcome 
misclassification with (sensitivity + specificity - 1) ³ 0, where LWLXYY∗  denotes the 
observed RERI and LWLXYY  denotes the true RERI. We expect sensitivity of 
suicide and suicide attempts to be greater than zero and the specificity to be 100% 
as non-suicides and non-suicide attempts would never be reported as suicide and 
suicide attempts, thus satisfying the condition of (sensitivity + specificity - 1) ³ 0. 
The equation |LWLXYY∗ | 	≤ |LWLXYY| shows that the observed RERI will estimate the 
true RERI towards the null. In other words, the RERI calculated using the observed 
misclassified data will be conservative.291 However, it is possible that there is 
differential outcome misclassification instead such that misclassification of suicide 
and non-fatal suicide attempts differs by depression and other mental disorder 
status. Sensitivity of suicide and suicide attempts may be greater in persons with 
a diagnosis of depression (or other mental disorders) than persons without a 
diagnosis of depression. However, as noted earlier, we expect the specificity of 
suicide and suicide attempts to be 100%. Differential outcome measurement error 
with perfect specificity is expected to yield consistent interaction estimates even 
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with imperfect sensitivity.292  
A second limitation of this study is misclassification of depression and other 
mental disorders. We expect any misclassification to be non-differential with 
respect to the outcome because mental disorder diagnoses occurred prior to the 
outcomes. Our bias analysis showed that the observed RERIs were 
underestimated and that the bias-adjusted RERIs increased in magnitude, 
assuming a valid bias model. A limitation of our bias analyses is that we lacked 
data on the PPVs of several mental disorders and we substituted in PPVs from 
national Swedish registries257,258 or the mean value of all the existing PPVs. 
Additional work is needed to validate mental disorders in the Danish registries to 
better understand the accuracy of these diagnoses and to inform future 
quantitative bias analyses.  
 A third limitation is potential residual uncontrolled confounding by other 
mental disorders and psychiatric medications. We only adjusted for neurotic 
disorders as a confounder given its high degree of comorbidity with depression.278 
Due to problems with model convergence, we could not adjust for all other mental 
disorders and psychiatric medications. There may also be residual confounding by 
unmeasured factors, such as stressful life events (e.g., relationship difficulties), 
loneliness, and hopelessness, that may explain part of the observed associations.  
Finally, there was imprecision in the HRs and RERIs after adjustment for 
confounding. The 95% CIs for the HRs and RERIs were wide due to sparse cells, 
particularly for rarer mental disorders in the study sample such as bipolar disorder, 
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eating disorders, intellectual disabilities, developmental disorders, and behavioral 
disorders (Tables 5.2 and 5.4). Furthermore, some of the RERI confidence 
intervals contained both positive and negative values, indicating that it is not 
possible to rule out interdependence in either direction for the effect of depression 
and comorbid mental disorders on suicide and suicide attempt. Fairly large sample 
sizes are required to obtain even moderately precise estimates of interaction.219 
Even with our large study sample capturing all recorded suicide deaths (n = 
14,103) and suicide attempts (n = 22,974) in Denmark over a 20 year period, the 
effect estimates for these disorders were still measured imprecisely. Lack of 
precision is an inherent challenge in studying both rare mental disorders and 
suicide outcomes.   
Several important assumptions must be met to obtain valid estimates from 
inverse probability weighting. The first assumption is consistency. Under 
consistency, a person’s potential outcome under the exposure received is equal to 
the observed outcome.293 Consistency involves having a well-defined intervention. 
An intervention effect is the hypothetical effect that an intervention would have in 
the future. Our results cannot be interpreted as an intervention effect because 
there was no specified intervention to manipulate depression or comorbid mental 
disorder levels. However, the results of our study could be interpreted as 
counterfactual realized causal effects, which is the effect an exposure had in the 
past.294,295 An example of a causal question of a realized causal effect in the 
context of this study is “What was the joint effect of depression and a comorbid 
	
	 118 
mental disorder on suicide in actual people who were exposed to depression and 
a comorbid mental disorder, given how and when they were exposed, compared 
to the absence of depression and a comorbid mental disorder, with everything else 
remaining the same?” Although a realized causal effect also cannot be interpreted 
as an estimate of a potential intervention on the exposure, realized causal effects 
are nevertheless useful to understand how causes work in the world before 
designing interventions.296 Knowledge of the interdependence between 
depression and comorbid mental disorders may inform future treatment 
approaches that target transdiagnostic symptoms of comorbid mental disorders to 
reduce the rate of suicide and suicide attempt. The second assumption for 
obtaining valid estimates from inverse probability weighting is exchangeability, 
which implies no unmeasured confounding.244 For this assumption to hold, there 
should be enough measured shared predictors of the exposure and outcome such 
that the associations between the exposure and outcome that are due to their 
common causes will disappear within levels of these shared predictors. We 
assumed that conditioning on the time-varying covariates included in our analysis 
was sufficient to control for important confounders of the depression-
suicide/suicide attempt and comorbid mental disorder-suicide/suicide attempt 
relations. A third assumption is positivity;244 there should be exposed and 
unexposed persons at all covariate levels. We reduced the risk of positivity 
violations by not including weak confounders and reducing the categories of 
covariates. A fourth assumption is correct model specification.244 We assumed that 
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we correctly specified the exposure models (creating weights), structural model 
(for the exposure-disease relation), and censoring model.  
In summary, this study’s results advance our understanding of the joint 
effect of depression and comorbid mental disorders on suicide and suicide 
attempts in several important ways. Depression and comorbid mental disorders 
are harmful exposures, both independently and jointly. The interdependence of the 
effects of depression and comorbid mental disorders on suicide and suicide 
attempts indicates that the influence of depression depends on the presence or 
absence of comorbid mental disorders, and vice versa. Furthermore, we found 
evidence of competitive antagonism in the instances where we identified negative 
interdependence between depression and comorbid mental disorders on the rate 
of suicide and suicide attempts. These findings shed light on why previous studies 
may have documented sub-additive risk for the association of the psychiatric 
comorbidity with suicide outcomes. When mental disorders compete with each 
other to cause the outcome, the joint effects for both disorders together will be less 
than the sum of the effects of either disorder considered separately. However, 
these findings do not suggest that the comorbidities with negative RERIs are 
unimportant for suicide and suicide attempt risk. To the contrary, for the 
comorbidities with negative RERIs, we found that the rate of suicide and suicide in 
the doubly exposed was much higher than the rate in the doubly unexposed, and 
the excess relative risks due to depression and the modifying mental disorders 
were also large. In addition, the sex-stratified analyses show how interdependence 
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between depression and comorbid mental disorders on the rate of suicide and 
suicide attempt varies by sex. These findings underscore the importance of suicide 
risk screening and support for persons with multiple mental disorders to reduce the 
risk of suicide and suicide attempt. Future research should examine the 
development of transdiagnostic treatments that are tailored to co-occurring mental 








Table 5.1 Baseline demographic characteristics of depressed and non-depressed men and women in 
Denmark in the analysis of suicide deaths, January 1, 1995. 
 Men Women 
Variable 
Depressed 




(n = 8,855) 
Non-depressed 
(n = 129,688) 
Age, mean (SD) 42 (SD = 20) 38 (SD = 22) 43 (SD = 23) 40 (SD = 23) 
Marital status, % 
Single 2,473 (42%) 66,950 (50%) 3,287 (37%) 54,042 (42%) 
Married or registered partner 2,581 (44%) 55,041 (41%) 3,406 (38%) 52,070 (40%) 
Divorced, widowed, or separated 838 (14%) 12,860 (9.5%) 2,162 (24%) 23,576 (18%) 
Employment status, % 
Employed 2,921 (50%) 73,400 (54%) 2,955 (33%) 58,295 (45%) 
Unemployed 616 (10%) 10,859 (8.1%) 912 (10%) 12,471 (9.6%) 
Early retirement 493 (8.4%) 7,503 (5.6%) 906 (10%) 9,319 (7.2%) 
State pension 1,201 (20%) 17,205 (13%) 2,765 (31%) 25,677 (20%) 
Age£14 years 565 (9.6%) 22,045 (16%) 1,201 (14%) 20,373 (16%) 
Missing 96 (1.6%) 3,839 (2.9%) 116 (1.3%) 3,553 (2.7%) 
Charlson Comorbidity Index (CCI) score, % 
CCI = 0 5,518 (94%) 128,344 (95%) 8,287 (94%) 123,297 (95%) 
CCI = 1 225 (3.8%) 3,703 (2.8%) 330 (3.7%) 3,384 (2.6%) 








Table 5.2 Psychiatric disorders in depressed and non-depressed men and women in Denmark in the 
analysis of suicide deaths, January 1, 1995 - December 31, 2015. 
 
 Men Women 
Variable 
Depressed 




(n = 8,855) 
Non-depressed 
(n = 129,688) 
Psychiatric disorders, % 
Organic disorders 795 (13%) 3,335 (2.5%) 1,201 (14%) 4,254 (3.3%) 
Substance use disorders 1,819 (31%) 8,397 (6.2%) 1,552 (18%) 4,194 (3.2%) 
Schizophrenia 528 (9%) 2,193 (1.6%) 725 (8.2%) 1,565 (1.2%) 
Bipolar disorder 372 (6.3%) 440 (0.3%) 558 (6.3%) 533 (0.4%) 
Neurotic disorders 1,811 (31%) 3,981 (3%) 2,859 (32%) 5,474 (4.2%) 
Eating disorders 19 (0.3%) 62 (0.1%) 314 (3.6%) 704 (0.5%) 
Personality disorders 759 (13%) 1,153 (0.9%) 1,404 (16%) 1,499 (1.2%) 
Intellectual disabilities 69 (1.2%) 512 (0.4%) 75 (0.9%) 402 (0.3%) 
Developmental disorders 77 (1.3%) 372 (0.3%) 44 (0.5%) 114 (0.1%) 









Table 5.3 Baseline demographic characteristics of depressed and non-depressed men and women in 
Denmark in the analysis of suicide attempts, January 1, 1995. 
 Men Women 
Variable 
Depressed 
(n = 7292) 
Non-depressed 
(n = 132,845) 
Depressed 
(n = 12,907) 
Non-depressed 
(n = 135,113) 
Age, mean (SD) 38 (SD = 20) 37 (SD = 22) 38 (SD = 23) 39 (SD = 23) 
Marital status, % 
Single 3,578 (49%) 67,832 (51%) 5,893 (46%) 58,936 (44%) 
Married or registered partner 2,783 (38%) 53,014 (40%) 4,403 (34%) 52,522 (39%) 
Divorced / widow / separated 931 (13%) 11,999 (9%) 2,611 (20%) 23,655 (18%) 
Employment status, % 
Employed 3,537 (49%) 71,785 (54%) 4,248 (33%) 59,387 (44%) 
Unemployed 826 (11%) 10,823 (8.2%) 1,472 (11%) 13,139 (9.7%) 
Early retirement 605 (8.3%) 7,501 (5.7%) 1,384 (11%) 9,924 (7.3%) 
State pension 1,259 (17%) 16,322 (12%) 3,136 (24%) 25,688 (19%) 
Age£14 years 978 (13%) 23,164 (17%) 2,551 (20%) 23,619 (17%) 
Missing 87 (1.2%) 3,250 (2.5%) 116 (0.9%) 3,356 (2.5%) 
Charlson Comorbidity Index (CCI) score, % 
CCI = 0 6,882 ( 94.38 %) 126,587 (95%) 12,197 (95%) 128,651 (95%) 
CCI = 1 256 (3.5%) 3,581 (2.7%) 440 (3.4%) 3,460 (2.6%) 








Table 5.4 Psychiatric disorders in depressed and non-depressed men and women in Denmark over study 
period in the analysis of suicide attempts, January 1, 1995 - December 31, 2015. 
 Men Women 
Psychiatric disorder 
Depressed 
(n = 7292) 
Non-depressed 
(n = 132,845) 
Depressed 
(n = 12,907) 
Non-depressed 
(n = 135,113) 
Organic disorders 869 (12%) 3,423 (2.6%) 1,349 (10%) 4,355 (3.2%) 
Substance use disorders 2,679 (37%) 9,752 (7.3%) 2,874 (22%) 5,743 (4.3%) 
Schizophrenia 707 (10%) 2,398 (1.8%) 1,218 (9.4%) 2,171 (1.6%) 
Bipolar disorder 439 (6%) 448 (0.3%) 810 (6.3%) 667 (0.5%) 
Neurotic disorders 2,617 (36%) 6,169 (4.6%) 4,948 (38%) 9,068 (6.7%) 
Eating disorders 26 (0.4%) 63 (0.1%) 595 (4.6%) 1,014 (0.8%) 
Personality disorders 1,079 (15%) 1,632 (1.2%) 2,652 (21%) 2,738 (2%) 
Intellectual disabilities 95 (1.3%) 615 (0.5%) 158 (1.2%) 510 (0.4%) 
Developmental disorders 97 (1.3%) 427 (0.3%) 76 (0.6%) 162 (0.1%) 






Table 5.5 Sex-specific crude hazard ratios for the joint effects of depression and comorbid mental 
disorders on suicide death, Denmark, January 1, 1995 - December 31, 2015. 
  Men Women 








Crude RERI  
(95% CI) 
Organic disorders: yes Depressed 13 (11, 16) -5.2 (-7.7, -2.7) 18 (14, 23) -6.6 (-11, -2.3) 
Non-depressed 3.8 (3.3, 4.5) 3.7 (2.9, 4.8) 
Organic disorders: no Depressed 15 (14, 16) 22 (20, 24) 
Non-depressed Reference Reference 
Substance use disorders: 
yes 
Depressed 22 (20, 24) -1.0 (-3.0, 1.0) 53 (47, 60) 15 (9.7, 21) 
Non-depressed 8.1 (7.7, 8.6) 17 (16, 19) 
Substance use disorders: no Depressed 16 (15, 17) 21 (20, 23) 
Non-depressed Reference Reference 
Schizophrenia: yes Depressed 20 (17, 23) -6.0 (-9.2, -2.8) 48 (41, 57) 3.3 (-4.2, 11) 
Non-depressed 11 (10, 12) 24 (21, 27) 
Schizophrenia: no Depressed 16 (15, 17) 22 (20, 24) 
Non-depressed Reference Reference 
Bipolar disorder: yes Depressed 20 (16, 24) -7.0 (-11, -3.1) 45 (38, 54) 0.93 (-7.4, 9.3) 
Non-depressed 13 (11, 16) 24 (20, 30) 
Bipolar disorder: no Depressed 15 (14, 16) 21 (19, 22) 
Non-depressed Reference Reference 
Neurotic disorders: yes Depressed 20 (18, 22) -2.2 (-4.1, -0.29) 37 (33, 41) 6.9 (3.3, 10) 
Non-depressed 8.7 (8.0, 9.4) 9.5 (8.4, 11) 
Neurotic disorders: no Depressed 15 (14, 16) 21 (19, 23) 
Non-depressed Reference Reference 
Eating disorders: yes Depressed 13 (4.1, 39) -3.8 (-16, 8.7) 21 (15, 29) -5.5  (-12, 1.4) 
Non-depressed 2.7 (1.1, 6.4) 5.8 (4.3, 7.9) 
Eating disorders: no Depressed 15 (14, 16) 21 (20, 23) 
Non-depressed Reference Reference 




Non-depressed 8.1 (7.2, 9.1) 16 (14, 18) 
Personality disorders: no Depressed 15 (14, 16) 21 (19, 23) 
Non-depressed Reference Reference 
Intellectual disabilities: yes Depressed 5.2 (2.5, 11) -9.2 (-13, -5.5) 24 (13, 44) -0.08 (-14, 14) 
Non-depressed 0.65 (0.37, 1.1) 3.6 (2.2, 6.0) 
Intellectual disabilities: no Depressed 15 (14, 16) 21 (20, 23) 
Non-depressed Reference Reference 
Developmental disorders: 
yes 
Depressed 9.4 (5.3, 17) -5.3 (-11, 0.26) 16 (5.2, 48) -5.2 (-23, 12) 
Non-depressed 1.0 (0.61, 1.8) 1.0 (0.14, 
7.4) 
Developmental disorders: no Depressed 15 (14, 16) 21 (20, 23) 
Non-depressed Reference Reference 
Behavioral disorders: yes Depressed 13 (9.1, 18) -2.6 (-7, 1.8) 8.2 (3.9, 17) -15 (-22, -9.0) 
Non-depressed 1.6 (1.2, 2.0) 3.1 (1.9, 5.1) 
Behavioral disorders: no Depressed 15 (14, 16) 21 (20, 23) 
Non-depressed Reference Reference 







Table 5.6 Sex-specific crude hazard ratios for the joint effects of depression and comorbid mental 
disorders on non-fatal suicide attempts, Denmark, January 1, 1995 - December 31, 2015. 
  Men Women 








Crude RERI  
(95% CI) 
Organic disorders: yes Depressed 21 (18, 25) -15 (-18, -11) 13 (11, 15) -12 (-14, -9.8) 
Non-depressed 6.7 (5.9, 7.7) 2.9 (2.5, 3.4) 
Organic disorders: no Depressed 30 (29, 32) 23 (22, 24) 
Non-depressed Reference Reference 
Substance use disorders: yes Depressed 76 (71, 82) 13 (9.9, 16) 53 (49, 56) 8.8 (6.7, 11) 
Non-depressed 24 (23, 26) 20 (19, 22) 
Substance use disorders: no Depressed 40 (37, 43) 24 (23, 26) 
Non-depressed Reference Reference 
Schizophrenia: yes Depressed 40 (35, 45) -8.5 (-13, -4.2) 35 (32, 38) -5.3 (-8.0, -2.6) 
Non-depressed 17 (16, 19) 18 (16, 19) 
Schizophrenia: no Depressed 32 (30, 34) 24 (23, 25) 
Non-depressed Reference Reference 
Bipolar disorder: yes Depressed 32 (27, 37) -12 (-17, -7.9) 29 (25, 32) -6.6 (-9.4, -3.7) 
Non-depressed 16 (14, 19) 14 (12, 16) 
Bipolar disorder: no Depressed 29 (27, 30) 22 (21, 23) 
Non-depressed Reference Reference 
Neurotic disorders: yes Depressed 86 (80, 94) -16 (-20, -12) 73 (68, 77) -2.1 (-4.1, -0.1) 
Non-depressed 59 (55, 63) 41 (39, 44) 
Neurotic disorders: no Depressed 44 (41, 47) 35 (33, 37) 
Non-depressed Reference Reference 
Eating disorders: yes Depressed 28 (14, 56) -2.8 (-19, 13) 34 (29, 38) 0.56 (-2.9, 4.0) 
Non-depressed 3.3 (1.5, 7.5) 3.3 (1.5, 7.5) 
Eating disorders: no Depressed 28 (27, 30) 28 (27, 30) 
Non-depressed Reference Reference 




Non-depressed 23 (21, 25) 25 (24, 27) 
Personality disorders: no Depressed 31 (29, 32) 24 (22, 25) 
Non-depressed Reference Reference 
Intellectual disabilities: yes Depressed 19 (13, 27) -15 (-22, -8.7) 40 (30, 52) 11 (3.8, 19) 
Non-depressed 6.4 (5.3, 7.8) 7.3 (6.1, 8.8) 
Intellectual disabilities: no Depressed 29 (27, 31) 22 (21, 23) 
Non-depressed Reference Reference 
Developmental disorders: yes Depressed 26 (17, 39) -6.7 (-16, 2.4) 39 (25, 59) 7.0 (-5.4, 19) 
Non-depressed 5.2 (4.1, 6.6) 11 (8.1, 15) 
Developmental disorders: no Depressed 29 (27, 30) 22 (21, 23) 
Non-depressed Reference Reference 
Behavioral disorders: yes Depressed 37 (30, 46) 0.49 (-6.6, 7.5) 42 (35, 50) 4.6 (-1.3, 10) 
Non-depressed 8.2 (7.3, 9.2) 16 (14, 18) 
Behavioral disorders: no Depressed 30 (28, 31) 23 (22, 24) 
Non-depressed Reference Reference 






Table 5.7 Sex-specific adjusted hazard ratios for the joint effects of depression and comorbid mental 
disorders on suicide death, Denmark, January 1, 1995 - December 31, 2015. 
  Men Women 








Adjusted RERI  
(95% CI) 
Organic disorders: yes Depressed 11 (4.4, 25) -11 (-22, -0.58) 44 (19, 107) 16 (-22, 53) 
Non-depressed 7.7 (4.3, 14) 8.0 (5.2, 13) 
Organic disorders: no Depressed 15 (12, 18) 22 (17, 28) 
Non-depressed Reference Reference 
Substance use disorders: 
yes 
Depressed 18 (12, 26) -25 (-43, -6.3) 49 (32, 75) 5.5 (-15, 26) 
 Non-depressed 7.5 (5.8, 9.6) 19 (13, 26) 
Substance use disorders: 
no 
Depressed 36 (22, 60) 26 (19, 35) 
Non-depressed Reference Reference 
Schizophrenia: yes Depressed 14 (9.6, 22) -14 (-21, -6.5) 38 (24, 63) -7.7 (-28, 13) 
Non-depressed 13 (11, 17) 24 (17, 35) 
Schizophrenia: no Depressed 16 (13, 20) 23 (18, 30) 
Non-depressed Reference Reference 
Bipolar disorder: yes Depressed 27 (16, 45) -0.38 (-15, 15) 45 (26, 80) -4.6 (-33, 24) 
Non-depressed 15 (9.6, 22) 30 (18, 49) 
Bipolar disorder: no Depressed 14 (11, 17) 21 (16, 27) 
Non-depressed Reference Reference 
Neurotic disorders: yes Depressed 20 (15, 26) -4.4 (-10, 1.6) 31 (23, 42) -3.2 (-14, 7.2) 
Non-depressed 9.5 (7.8, 12) 9.9 (7.2, 14) 
Neurotic disorders: no Depressed 16 (13, 20) 25 (20, 33) 
Non-depressed Reference Reference 
Eating disorders: yes Depressed 7.4 (1.8, 31) -7.1 (-18, 3.8) 57 (22, 146) 33 (-20, 86) 
Non-depressed 1.2 (0.49, 3.2) 4.3 (2.9, 6.2) 
Eating disorders: no Depressed 14 (12, 17) 21 (16, 26) 
Non-depressed Reference Reference 




Non-depressed 13 (8.9, 20) 21 (10, 42) 
Personality disorders: no Depressed 15 (12, 19) 28 (19, 41) 
Non-depressed Reference Reference 
Intellectual disabilities: yes Depressed 2.0 (0.68, 6.1) -12 (-14, -9.5) 12 (4.8, 28) -16 (-30, -2.1) 
Non-depressed 0.36 (0.19, 0.66) 7.7 (2.5, 23) 
Intellectual disabilities: no Depressed 14 (12, 17) 21 (17, 27) 
Non-depressed Reference Reference 
Developmental disorders: 
yes 
Depressed 8.4 (3.5, 20) -5.6 (-12, 1.2) 6.0 (0.95, 37) -14 (-19, -9.8) 
Non-depressed 0.69 (0.37, 1.3) 0.61 (0.08, 4.4) 
Developmental disorders: 
no 
Depressed 14 (12, 17) 21 (16, 26) 
Non-depressed Reference Reference 
Behavioral disorders: yes Depressed 14 (4.8, 40) -2.1 (-17, 13) 1.4 (0.39, 5.0) -23 (-29, -16) 
Non-depressed 2.4 (1.3, 4.3) 4.0 (1.8, 9.0) 
Behavioral disorders: no Depressed 14 (12, 18) 21 (17, 27) 
Non-depressed Reference Reference 
Note: The weighted HR was estimated using a joint marginal structural model to estimate the joint effects of depression and a comorbid 







Table 5.8 Sex-specific adjusted hazard ratios for the joint effects of depression and comorbid mental 
disorders on non-fatal suicide attempts, Denmark, January 1, 1995 - December 31, 2015. 
  Men Women 












Organic disorders: yes Depressed 37 (23, 60) -15 (-34, 5.3) 42 (25, 68) 3.7 (-18, 25) 
Non-depressed 16 (11, 25) 11 (6.4, 19) 
Organic disorders: no Depressed 37 (31, 43) 28 (24, 31) 
Non-depressed Reference Reference 
Substance use disorders: 
yes 
Depressed 107 (82, 139) 13 (-15, 40) 81 (64, 104) 18 (-0.57, 37) 
Non-depressed 31 (26, 37) 25 (20, 31) 
Substance use disorders: no Depressed 64 (50, 81) 39 (33, 46) 
Non-depressed Reference Reference 
Schizophrenia: yes Depressed 27 (19, 38) -40 (-53, -28) 41 (30, 56) -12 (-26, 1.1) 
Non-depressed 26 (20, 33) 21 (17, 27) 
Schizophrenia: no Depressed 43 (36, 50) 33 (29, 38) 
Non-depressed Reference Reference 
Bipolar disorder: yes Depressed 39 (24, 63) -16 (-36, 5.5) 30 (22, 42) -19 (-31, -6.5) 
Non-depressed 21 (13, 33) 22 (15, 31) 
Bipolar disorder: no Depressed 35 (30, 40) 28 (25, 32) 
Non-depressed Reference Reference 
Neurotic disorders: yes Depressed 111 (92, 135) -22 (-45, 0.21) 105 (88, 124) 5.7 (-11, 22) 
Non-depressed 75 (65, 88) 51 (44, 59) 
Neurotic disorders: no Depressed 59 (50, 70) 49 (43, 57) 
Non-depressed Reference Reference 
Eating disorders: yes Depressed 18 (6.2, 50) -16 (-25, 2.4) 32 (21, 48) -9.6 (-23, 4.0) 
Non-depressed 1.9 (0.73, 4.7) 12 (9.0, 17) 
Eating disorders: no Depressed 33 (29, 38) 30 (26, 34) 




Personality disorders: yes Depressed 48 (33, 71) -23 (-42, -4.2) 58 (45, 76) -35 (-56, -15) 
Non-depressed 21 (16, 28) 48 (37, 64) 
Personality disorders: no Depressed 52 (43, 63) 47 (39, 56) 
Non-depressed Reference Reference 
Intellectual disabilities: yes Depressed 52 (22, 122) 15 (-30, 59) 40 (18, 91) 4.6 (-29, 38) 
Non-depressed 5.2 (3.2, 8.3) 9.5 (6.0, 15) 
Intellectual disabilities: no Depressed 33 (28, 38) 27 (24, 30) 
Non-depressed Reference Reference 
Developmental disorders: 
yes 
Depressed 28 (10, 76) -8.0 (-37, 21) 70 (26, 192) 28 (-44, 100) 
Non-depressed 3.8 (2.5, 6.0) 17 (7.5, 37) 
Developmental disorders: no Depressed 34 (29, 39) 27 (24, 30) 
Non-depressed Reference Reference 
Behavioral disorders: yes Depressed 25 (16, 41) -27 (-42, -12) 55 (28, 105) 10 (-26, 47) 
Non-depressed 17 (11, 26) 17 (13, 24) 
Behavioral disorders: no Depressed 37 (31, 43) 28 (25, 32) 
Non-depressed Reference Reference 
Note: The weighted HR was estimated using a joint marginal structural model to estimate the joint effects of depression and a comorbid 
psychiatric disorder on non-fatal suicide attempts, adjusting for confounding by age, marital status, income, employment, physical 






Table 5.9 Response types for two binary exposure variables and a binary outcome. 
	 M=1	 M=0	 Effect of A=1 vs A=0 within M strata	  
Descriptiona Type	A=1		 A=0		 A=1		 A=0		 M=1	 M=0	 Difference	
1	 1	 1	 1	 1	 0	 0	 0	 No effects (doomed) 
2	  1 	 1	 1	 0	 0	 1	 -1	 Single plus joint causation by A=1 and M=1 
3	 1	 1	 0	 1	 0	 -1	 1	 M=1 blocks A=1 effect (preventive antagonism) 
4	 1	 1	 0	 0	 0	 0	 0	 A=1 ineffective, M=1 causal 
5	 1	 0	 1	 1	 1	 0	 1	 A=1 blocks M=1 effect (preventive antagonism) 
6	 1	 0	 1	 0	 1	 1	 0	 A=1 causal, M=1 ineffective 
7	 1	 0	 0	 1	 1	 -1	 2	 Mutual blockage (preventive antagonism) 
8	 1	 0	 0	 0	 1	 0	 1	 A=1 plus M=1 causal (causal synergism) 
9	 0	 1	 1	 1	 -1	 0	 -1	 A=1 plus M=1 preventive (preventive synergism) 
10	 0	 1	 1	 0	 -1	 1	 -2	 Mutual blockage (causal antagonism) 
11	 0	 1	 0	 1	 -1	 -1	 0	 A=1 preventive, M=1 ineffective 
12	 0	 1	 0	 0	 -1	 0	 -1	 A=1 blocks M=1 effect (causal antagonism) 
13	 0	 0	 1	 1	 0	 0	 0	 A=1 ineffective, M=1 preventive 
14	 0	 0	 1	 0	 0	 1	 -1	 M=1 blocks A=1 effect (causal antagonism) 
15	 0	 0	 0	 1	 0	 -1	 1	 Single plus joint prevention by A=1 and M=1 
16	 0	 0	 0	 0	 0	 0	 0	 No effects (immune) 







Table 5.10 Assessment of the presence of competitive antagonism for the observed negative RERIs in the 
analysis of suicide deaths. 
Men 
Mental 
disorder !!"# +	!!#" −	!!## −	!!"" 	> # !!##	<		()*	(!!"#,!!#") !!""	³		(./	(!!"#,!!#") 
Organic 
disorders 15 + 7.7 - 1 - 11 = 10.7 (True, >0) 1 < 15 (True) 11 ³ 7.7 (True) 
Substance use 
disorders 36 + 7.5 - 1 - 18 = 24.5 (True, >0) 1 < 36 (True) 18 ³ 7.5 (True) 
Schizophrenia 16 + 13 - 1 - 14 = 14 (True, >0) 1 < 16 (True) 14 ³ 13 (True) 
Bipolar disorder 14 + 15 - 1 - 27 = 1 (True, >0) 1 < 15 (True) 27 ³ 14 (True) 
Neurotic 
disorders 16 + 9.5 - 1 - 20 = 4.5 (True, >0) 1 < 16 (True) 20 ³ 9.5 (True) 
Eating disorders 14 + 1.2 - 1 - 7.4 = 6.8 (True, >0) 1 < 14 (True) 7.4 ³ 1.2 (True) 
Personality 
disorders 15 + 13 - 1 - 17 =  10 (True, >0) 1 < 15 (True) 17 ³ 13 (True) 
Behavioral 
disorders 14 + 2.4 - 1 - 14 = 1.4 (True, >0) 1 < 14 (True) 1.4 ³ 2.4 (False) 
Mental 
disorder 
!!"" +	!!## −	!!#" −	!!"# 	> # !!#"	<		()*	(!!"",!!##) !!"#	³		(./	(!!"",!!##) 
Intellectual 
disabilities 2.0 + 1 - 0.36 - 14 = -11.36 (False, <0) 0.36 < 2.0 (True) 14 ³ 1 (True) 
Developmental 
disorders 8.4 + 1 - 0.69 - 14 = -5.29 (False, <0) 0.69 < 8.4 (True) 14  ³ 1 (True) 
Women 
Mental 
disorder !!"# +	!!#" −	!!## −	!!"" 	> # !!##	<		()*	(!!"#,!!#") !!""	³		(./	(!!"#,!!#") 
Schizophrenia 23 + 24 - 1 - 38 = 8 (True, >0) 1 < 24 (True) 38 ³ 23 (True) 





disorder 25 + 9.9 - 1 - 31 = 2.9 (True, >0) 1 < 25 (True) 31 ³ 9.9 (True) 
Personality 
disorders 28 + 21 - 1 - 29 = 19 (True, >0) 1 < 28 (True) 29 ³ 21 (True) 
Intellectual 
disabilities 21 + 7.7 - 1 - 12 = 15.7 (True, >0) 1 < 21 (True) 12 ³ 7.7 (True) 
Behavioral 
disorders  21 + 4.0 - 1 - 1.4 = 22.6 (True, >0)  1 < 21 (True) 1.4 ³ 4.0 (False) 
Mental 
disorder !!"" +	!!## −	!!#" −	!!"# 	> # !!#"	<		()*	(!!"",!!##) !!"#	³		(./	(!!"",!!##) 
Developmental 








Table 5.11 Assessment of the presence of competitive antagonism for the observed negative RERIs in the 
analysis of suicide attempts. 
Men 
Mental disorder !!"# +	!!#" −	!!## −	!!"" 	> # !!##	<		()*	(!!"#,!!#") !!""	³		(./	(!!"#,!!#") 
Organic disorders 37 + 16 - 1 - 37 = 15 (True, >0) 1 < 37 (True) 37 ³ 16 (True) 
Schizophrenia 43 + 26 - 1 - 27 = 41 (True, >0) 1 < 43 (True) 27 ³ 26 (True) 
Bipolar disorder 35 + 21 - 1 - 39 = 16 (True, >0) 1 < 35 (True) 39 ³ 21 (True) 
Neurotic disorders 59 + 75 - 1 - 111 = 22 (True, >0) 1 < 75 (True) 111 ³ 59 (True) 
Eating disorders 33 + 1.9 - 1 - 18 = 15.9 (True, >0) 1 < 33 (True)  18 ³ 1.9 (True) 
Personality 
disorders 52 + 21 -1 - 48 = 24 (True, >0) 1 < 52 (True) 48 ³ 21 (True) 
Developmental 
disorders 34 + 3.8 - 1 - 28 = 8.8 (True, >0) 1 < 34 (True) 28 ³ 3.8 (True) 
Behavioral disorders 37 + 17 - 1 - 25 = 28 (True, >0) 1 < 37 (True) 25 ³ 17 (True) 
Women 
Mental disorder !!"# +	!!#" −	!!## −	!!"" 	> # !!##	<		()*	(!!"#,!!#") !!""	³		(./	(!!"#,!!#") 
Schizophrenia 33 + 21 - 1 - 41 = 12 (True, >0) 1 < 33 (True) 41 ³ 21 (True) 
Bipolar disorder 28 + 22 - 1 - 30 = 19 (True, >0) 1 < 28 (True) 30 ³ 22 (True) 
Eating disorders 30 + 12 - 1 - 32 = 9 (True, >0) 1 < 30 (True) 32 ³ 12 (True) 
Personality 









Table 5.12 Bias analysis of non-differential misclassification of mental disorders in the analysis of suicide 
deaths.  
Mental disorder PPV NPV Original RERI 
for mena 
Bias-adjusted 







Organic disorders 86% 99% -11 (-22, -0.58) -18 (-35, -0.9) 16 (-22, 53) 25 (-35, 84) 
Substance use disorders 86% 99% -25 (-43, -6.3) -40 (-68, -10) 5.5 (-15, 26) 8.7 (-24, 41) 
Schizophrenia 98% 99% -14 (-21, -6.5) -20 (-29, -9.1) -7.7 (-28, 13) -11 (-39, 18) 
Bipolar disorder 92% 99% -0.38 (-15, 15) -0.6 (-22, 22) -4.6 (-33, 24) -6.8 (-49, 36) 
Neurotic disorders 75% 99% -4.4 (-10, 1.6) -8 (-18, 2.9) -3.2 (-14, 7.2) -5.8 (-26, 13) 
Eating disorders 86% 99% -7.1 (-18, 3.8) -11 (-29, 6.0) 33 (-20, 86) 53 (-32, 137) 
Personality disorders 93% 99% -11 (-21, -0.65) -16 (-31, -1.0) -19 (-42, 4.3) -28 (-62, 6.3) 
Intellectual disabilities 86% 99% -12 (-14, -9.5) -19 (-22, -15) -16 (-30, -2.1) -25 (-48, -3.3) 
Developmental disorders 94% 99% -5.6 (-12, 1.2) -8.1 (-17, 1.7) -14 (-19, -9.8) -20 (-28, -14) 
Behavioral disorders 87% 99% -2.1 (-17, 13) -3.3 (-27, 20) -23 (-29, -16) -36 (-46, -25) 
Note: aWe used the RERIs from the marginal structural models adjusted for confounding by age, marital status, income, employment, 








Table 5.13 Bias analysis of non-differential misclassification of mental disorders in the analysis of suicide 
attempts.  
Mental disorder PPV NPV Original RERI 
for mena 
Bias-adjusted 







Organic disorders 86% 99% -15 (-34, 5.3) -24 (-54, 8.4) 3.7 (-18, 25) 5.9 (-29, 40) 
Substance use disorders 88% 99% 13 (-15, 40) 20 (-23, 62) 18 (-0.57, 37) 28 (-0.9, 58) 
Schizophrenia 98% 99% -40 (-53, -28) -56 (-74, -39) -12 (-26, 1.1) -17 (-36, 1.5) 
Bipolar disorder 92% 99% -16 (-36, 5.5) -24 (-54, 8.2) -19 (-31, -6.5) -28 (-46, -9.7) 
Neurotic disorders 75% 99% -22 (-45, 0.21) -40 (-82, 0.4) 5.7 (-11, 22) 10 (-20, 40) 
Eating disorders 88% 99% -16 (-25, 2.4) -25 (-40, 3.8) -9.6 (-23, 4.0) -15 (-36, 6.2) 
Personality disorders 93% 99% -23 (-42, -4.2) -34 (-62, -6.2) -35 (-56, -15) -51 (-82, -22) 
Intellectual disabilities 88% 99% 15 (-30, 59) 23 (-47, 92) 4.6 (-29, 38) 7.1 (-45, 59) 
Developmental disorders 94% 99% -8.0 (-37, 21) -12 (-54, 31) 28 (-44, 100) 41 (-64, 145) 
Behavioral disorders 87% 99% -27 (-42, -12) -42 (-66, -19) 10 (-26, 47) 16 (-41, 74) 
Note: aWe used the RERIs from the marginal structural models adjusted for confounding by age, marital status, income, employment, 





Table 5.14 Summary of sex-specific interdependence findings for suicide deaths and suicide attempts from 
marginal structural models. 
  Suicide death Suicide attempt 
Mental disorder Men Women Men Women 
Organic disorders     
Substance use disorders     
Schizophrenia     
Bipolar disorder     
Neurotic disorders     
Eating disorders     
Personality disorders     
Intellectual disabilities     
Developmental disorders     
Behavioral disorders     
Note: The green cells indicate that positive interdependence was found between depression and the corresponding mental disorder. The 
salmon cells indicate that negative interdependence and competitive antagonism was found between depression and the corresponding 
mental disorder. The yellow cells indicate that negative interdependence was found between depression and the corresponding mental 
disorder and there was no evidence suggesting competitive antagonism.  
Negative interdependence; 
presence of competitive 
antagonism 
 
Negative interdependence; no 






Figure 5.1 Exposed and unexposed person-time for depression.  
	
Note: Person A is considered unexposed to depression because they did not have a diagnosis of 
depression during the study period. Person B is considered exposed to depression because they 
received a diagnosis of depression at the beginning of follow-up (January 1, 1995). Person C is 






Figure 5.2 Exposed and unexposed person-time for psychiatric 
comorbidity.  
 
Note: E is depression and M is the modifying mental disorder (substance use disorder). Person B 
is considered to have comorbid depression and substance use disorder on and after the date of 
the substance use disorder diagnosis. Person C is considered to have comorbid substance use 




Figure 5.3 Additive interaction between depression and comorbid mental disorders on the risk of suicide 
death from crude Cox models in men. 
 
Note: The blue bar corresponds to the doubly unexposed group (hazard ratio = 1). The green bar displays the excess relative risk due to 
depression. The orange bar displays the excess relative risk due to the modifying mental disorder. The red bar corresponds to the RERI. 
The sum of the blue, green, orange, and red bars is the hazard ratio comparing the doubly exposed to the doubly unexposed (indicated by 




Figure 5.4 Additive interaction between depression and comorbid mental disorders on the risk of suicide 
death from crude Cox models in women. 
 
Note: The blue bar corresponds to the doubly unexposed group (hazard ratio = 1). The green bar displays the excess relative risk due to 
depression. The orange bar displays the excess relative risk due to the modifying mental disorder. The red bar corresponds to the RERI. 
The sum of the blue, green, orange, and red bars is the hazard ratio comparing the doubly exposed to the doubly unexposed (indicated by 




Figure 5.5 Additive interaction between depression and comorbid mental disorders on the risk of non-fatal 
suicide attempts from crude Cox models in men. 
 
Note: The blue bar corresponds to the doubly unexposed group (hazard ratio = 1). The green bar displays the excess relative risk due to 
depression. The orange bar displays the excess relative risk due to the modifying mental disorder. The red bar corresponds to the RERI. 
The sum of the blue, green, orange, and red bars is the hazard ratio comparing the doubly exposed to the doubly unexposed (indicated by 




Figure 5.6 Additive interaction between depression and comorbid mental disorders on the risk of non-fatal 
suicide attempts from crude Cox models in women. 
 
Note: The blue bar corresponds to the doubly unexposed group (hazard ratio = 1). The green bar displays the excess relative risk due to 
depression. The orange bar displays the excess relative risk due to the modifying mental disorder. The red bar corresponds to the RERI. 
The sum of the blue, green, orange, and red bars is the hazard ratio comparing the doubly exposed to the doubly unexposed (indicated by 





Figure 5.7 Additive interaction between depression and comorbid mental disorders on the risk of suicide 
death from marginal structural models in men. 
 
Note: The blue bar corresponds to the doubly unexposed group (hazard ratio = 1). The green bar displays the excess relative risk due to 
depression. The orange bar displays the excess relative risk due to the modifying mental disorder. The red bar corresponds to the RERI. 
The sum of the blue, green, orange, and red bars is the hazard ratio comparing the doubly exposed to the doubly unexposed (indicated by 





Figure 5.8 Additive interaction between depression and comorbid mental disorders on the risk of suicide 
death from marginal structural models in women. 
 
Note: The blue bar corresponds to the doubly unexposed group (hazard ratio = 1). The green bar displays the excess relative risk due to 
depression. The orange bar displays the excess relative risk due to the modifying mental disorder. The red bar corresponds to the RERI. 
The sum of the blue, green, orange, and red bars is the hazard ratio comparing the doubly exposed to the doubly unexposed (indicated by 





Figure 5.9 Additive interaction between depression and comorbid mental disorders on the risk of non-fatal 
suicide attempts from marginal structural models in men. 
 
Note: The blue bar corresponds to the doubly unexposed group (hazard ratio = 1). The green bar displays the excess relative risk due to 
depression. The orange bar displays the excess relative risk due to the modifying mental disorder. The red bar corresponds to the RERI. 
The sum of the blue, green, orange, and red bars is the hazard ratio comparing the doubly exposed to the doubly unexposed (indicated by 





Figure 5.10 Additive interaction between depression and comorbid mental disorders on the risk of non-
fatal suicide attempts from marginal structural models in women. 
 
Note: The blue bar corresponds to the doubly unexposed group (hazard ratio = 1). The green bar displays the excess relative risk due to 
depression. The orange bar displays the excess relative risk due to the modifying mental disorder. The red bar corresponds to the RERI. 
The sum of the blue, green, orange, and red bars is the hazard ratio comparing the doubly exposed to the doubly unexposed (indicated by 
the bolded value shown to the left of the bars).  
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CHAPTER 6. CONCLUSIONS 
In this dissertation, we predicted suicide and non-fatal suicide attempts 
among persons with depression and we quantified the joint effect of depression 
with comorbid mental disorders on suicide and suicide attempts. These studies 
were conducted using high-quality, comprehensive medical and social data from 
nationwide Danish registers. We used machine learning (classification trees and 
random forests) and marginal structural models to examine interactions between 
a wide range of risk factors and their associations with suicide and suicide 
attempts. 
 In Study 1, there were several combinations of risk factors that were 
associated with suicide risk among men and women with depression. In men, there 
was an interaction between prescriptions for hypnotics and sedatives, 
prescriptions for analgesics and antipyretics, and poisoning that was associated 
with a high risk of suicide. In women, there was an interaction between poisoning 
and prescriptions for anxiolytics. The predictors that contributed the most to 
prediction accuracy were similar in men and women. Poisonings and psychiatric 
medications including hypnotics and sedatives, anxiolytics, and antipsychotics 
were among the top predictors of suicide in men and women. Alcohol related 
disorders and reaction to severe stress and adjustment disorders were also 
important predictors. Surprising predictors of suicide in both men and women were 
antithrombotic agents and other analgesics and antipyretics.  
 In Study 2, we examined interactions and predictors of non-fatal suicide 
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attempts in men and women diagnosed with depression. We identified an 
interaction between receipt of state pension, a diagnosis of toxic effects of 
substances chiefly nonmedicinal as to source, and lack of a poisoning diagnosis 
that was associated with a high risk of suicide attempt in depressed men. In 
depressed women, there was an interaction between specific personality disorders 
and being prescribed antipsychotics that was associated with suicide attempt risk. 
Overlap in the most important predictors of suicide attempts in men and women 
included poisonings, state pension, remaining single, and psychiatric disorders 
(i.e., alcohol related disorders and reaction to severe stress and adjustment 
disorders). However, specific personality disorders appeared to be more important 
for accurate prediction of suicide attempts in women than men. Various psychiatric 
medications also emerged as important predictors in both men and women, 
including anxiolytics, hypnotics and sedatives, and antipsychotics. Drugs used in 
addictive disorders (e.g., nicotine, alcohol, and opioid dependence) were important 
predictors in men but not in women. Similar to the results of Study 1, anti-
inflammatory medications such as antithrombotic agents and other analgesic and 
antipyretics emerged as important predictors of suicide attempts in men and 
women. However, dissimilar to the results for suicide deaths, poisonings were the 
most important predictors of suicide attempts whereas poisonings were less 
predictive relative to several other variables in the suicide death analyses. Yet 
another difference between Studies 1 and 2 is that specific personality disorders 
were in the top 30 predictors of suicide attempts but not for suicide deaths.  
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A goal of this dissertation was to identify novel predictors of suicide and 
suicide attempts among persons with depression. As described earlier, surprising 
predictors of both suicide and suicide attempts were antithrombotic agents and 
other analgesics and antipyretics. These medications are used to treat pain and 
reduce inflammation. In Studies 1 and 2, anti-inflammatory medications may 
represent a proxy for chronic pain and inflammation. Chronic pain may increase 
depressive symptoms, isolation, hopelessness, and fearlessness about death 
which in turn may influence suicide outcomes. In addition, depression is associated 
with activated inflammatory pathways and dysregulation of neurobiological 
systems which in turn can affect emotion and behavior.127–132 Future studies 
should examine the mechanisms underlying the association between depression, 
inflammation, and suicide and understand the effect of anti-inflammatory 
medications on suicide risk among persons with depression.  
In Study 3, we examined the joint effects of depression with comorbid 
mental disorders on suicide and suicide attempts. We found that there were 
instances of synergism and antagonism between depression and specific 
comorbid mental disorders on the rate of suicide and suicide attempts, with 
variation by sex. We found greater evidence of positive interdependence between 
depression and comorbid mental disorders in women than men. For most of the 
combinations of depression and comorbid mental disorders that yielded negative 
RERI values, we identified the presence of competitive antagonism263,297 such that 
depression and comorbid mental disorders affect the outcome only in the absence 
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of the other and they compete with each other to cause the outcome when both 
disorders are present, leading to sub-additive risk.  
We found that the combined effect of depression and comorbid mental 
disorders was greater than, and in some instances less than, the sum of the 
individual effects of the two disorders on suicide and suicide attempts depending 
on the disorder and sex. This indicates that it may be important for clinicians to use 
transdiagnostic treatments that address the mechanisms shared by co-occurring 
mental disorders to more effectively and efficiently reduce the risk of suicide and 
suicide attempts. Mental disorders with the largest magnitude of additive 
interaction (i.e., RERIs) with depression included neurotic disorders and substance 
use disorders. These results are aligned with those of Studies 1 and 2 showing 
that the most important disorders for suicide and suicide attempt prediction among 
depressed men and women were reaction to severe stress and adjustment 
disorder and alcohol related disorders. These findings are consistent with previous 
literature showing that having depression and an additional mental disorder is 
associated with a worse prognosis,242 greater depressive symptom severity,242 
functional impairment,48 and poorer quality of life278 which may exacerbate suicide 
and suicide attempt risk.  
There are several public health implications of the results of these three 
dissertation studies. First, there is a high risk of suicide and suicide attempts 
among depressed persons with specific combinations of risk factors (poisonings, 
psychiatric medications, alcohol related disorders, reaction to severe stress and 
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adjustment disorders, remaining single). These combinations of risk factors may 
be useful to screen for persons at high risk of suicide and suicide attempts among 
persons with depression. Given that accurate prediction of suicide-related 
outcomes among depressed persons is poor,5 considering these additional risk 
factors may help improve the identification of high risk persons who should be 
connected with suicide prevention interventions. Suicide risk screening should 
meet the World Health Organization’s 10 screening criteria298 which include: 1) the 
condition should be an important health problem, 2) there should be an accepted 
treatment for patients with recognized disease, 3) facilities for diagnosis and 
treatment should be available, 4) there should be a recognizable latent or early 
symptomatic stage, 5) there should be a suitable test or examination, 6) the test 
should be acceptable to the population, 7) the natural history of the condition 
should be adequately understood, 8) there should be an agreed policy on whom 
to treat, 9) the cost of case-finding should be economically balanced in relation to 
possible expenditure on medical care as a whole, and 10) case-finding should be 
a continuous process. The first three criteria are met since suicide is a major public 
health problem and there are effective suicide prevention interventions including 
lethal means counseling, rapid mental health referral, resources for contacting 
social and professional support, and safety planning.22,97,98,146 Furthermore, both 
inpatient and outpatient healthcare settings may be able to administer suicide risk 
screenings provided that electronic health records are available. Considering 
additional combinations of psychiatric and social factors could help identify 
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persons at high risk of suicide despite there not being a clear, recognizable latent 
or early symptomatic stage for suicide for all persons (criterion 4). Whether criteria 
5 (suitable test) and 6 (test should be acceptable) are met remains an open 
question because the field of machine learning for suicide prediction is still nascent 
and more work is needed to understand how machine learning algorithms can be 
applied in various settings, their effectiveness, and their acceptability by patients 
and clinicians. There is no widely agreed upon policy on whom to treat (criterion 9) 
either, but one potential approach would be to offer treatment to those in the 
highest quantiles of predicted risk. Finally, automated risk prediction using 
electronic records could help fulfill criterion 10 by ensuring that the process of 
identifying high risk persons is continuous.  
Our results identified both similarities and dissimilarities between the risk 
profiles of men and women. As previously discussed, personality disorders were 
more important for suicide attempt prediction in women than men. In Study 3, we 
found that comorbid depression and personality disorders were strongly 
associated suicide attempts in both women (HR = 58 [95% CI = 45, 76]) and men 
(HR = 48 [95% CI = 33, 71]). Persons with comorbid depression and personality 
disorders may benefit from increased screening and transdiagnostic care. Finally, 
depression in combination with other mental disorders may exert both synergistic 
and antagonistic effects on suicide and suicide attempts. Specifically, pairwise 
combinations of depression with neurotic disorders and substance use disorders 
had the strongest interactive effect. Clinicians should be aware of the additive risk 
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of depression and comorbid mental disorders on suicide and suicide attempts, 
especially in women, and may wish to more closely monitor such persons for 
suicide risk. Furthermore, researchers should be aware that instances of negative 
interdependence between comorbid mental disorders on the rate of suicide 
outcomes may be the result of competitive antagonism.  
Future research directions include replication and further evaluation of the 
interactions and predictors identified in our studies to quantify their causal effect 
on suicide and suicide attempts and their predictive ability in persons with 
depression. Additional work is also needed to develop treatment strategies for 
addressing comorbid psychiatric disorders and reducing suicidal behavior. A 
promising evidence-based intervention for treating suicidal thoughts and behaviors 
in persons with multiple psychiatric comorbidities is the Unified Protocol for 
Transdiagnostic Treatment of Emotional Disorders (UP), which can be applied 
across a range of mental disorders including depression, alcohol misuse, PTSD, 
panic attacks, social anxiety, obsessive thought/compulsions, and impulsive 
behaviors.202 By treating the negative emotions that lead to short-term relief but 
long-term exacerbation of negative affect, UP may reduce the role of intense 
negative affect in contributing to suicide risk.204,205 Furthermore, UP holds promise 
as a more efficient and cost effective approach for treating comorbid mental 
disorders compared to treatments that focus on individual disorders.203,204,299 
Additional work is needed to examine the impact of transdiagnostic treatments like 
UP on suicide attempt and suicide death.205  
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In addition to developing enhanced treatment for psychiatric comorbidities, 
it may also be important to assess multiple risk factors (e.g., multiple mental 
disorders, medications, previous poisonings, etc.) in order to more accurately 
assess suicide risk. Machine learning algorithms built using data from electronic 
medical records are one possible way to incorporate many diagnostic risk factors 
for prediction of suicide and suicide attempts. An example of this is REACH VET 
(Recovery Engagement and Coordination for Health ¾ Veterans Enhanced 
Treatment), which is a suicide prevention program based on a machine learning 
model that identifies veterans at risk for suicide in the Department of Veterans 
Affairs using data from medical records.300 When a patient is identified as “high 
risk,” providers are asked to reach out to veterans to offer support, assess risk, 
and consider treatment changes (e.g., frequency of mental health appointments, 
type of treatment and pharmacotherapy).300 Future research should investigate 
how similar algorithms may be applied in different general population clinical 
settings (e.g., primary care) and the ability of such algorithms to help efficiently 
target suicide prevention interventions to high-risk persons and their overall impact 
on suicide rates.  
Overall, the results of Studies 1 and 2 findings augment existing literature 
illustrating the interplay of psychiatric disorders, psychiatric medications, and 
poisonings in predicting risk of suicide and non-fatal suicide attempts. We 
contributed knowledge of several novel interactions and predictors of suicide and 
suicide attempt among persons diagnosed with depression. Study 3 documented 
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both positive and negative interdependence between depression and comorbid 
mental disorders on the rate of suicide and suicide attempts and also quantitatively 
explored an explanation (competitive antagonism) for counterintuitive findings 
regarding negative interdependence. These results may help inform potential risk 






Table of considered and retained predictors in the machine learning analyses predicting suicide death 





Retained in Suicide 
Attempt Analysis 
Code Variable Label Men Women Men Women 
A00_A09_6m Intestinal infectious diseases_6m No No No Yes 
A00_A09_12m Intestinal infectious diseases_12m No No Yes Yes 
A00_A09_24m Intestinal infectious diseases_24m Yes Yes Yes Yes 
A00_A09_48m Intestinal infectious diseases_48m Yes Yes Yes Yes 
A15_A19_6m Tuberculosis_6m No No No No 
A15_A19_12m Tuberculosis_12m No No No No 
A15_A19_24m Tuberculosis_24m No No No No 
A15_A19_48m Tuberculosis_48m No No No No 
A20_A28_6m 
Certain zoonotic bacterial 
diseases_6m No No No No 
A20_A28_12m 
Certain zoonotic bacterial 
diseases_12m No No No No 
A20_A28_24m 
Certain zoonotic bacterial 
diseases_24m No No No No 
A20_A28_48m 
Certain zoonotic bacterial 
diseases_48m No No No No 
A30_A49_6m Other bacterial diseases_6m Yes No Yes Yes 
A30_A49_12m Other bacterial diseases_12m Yes Yes Yes Yes 
A30_A49_24m Other bacterial diseases_24m Yes Yes Yes Yes 





Infections with a predominantly 
sexual mode of transmission_6m No No No No 
A50_A64_12m 
Infections with a predominantly 
sexual mode of transmission_12m No No No Yes 
A50_A64_24m 
Infections with a predominantly 
sexual mode of transmission_24m No No No Yes 
A50_A64_48m 
Infections with a predominantly 
sexual mode of transmission_48m No No No Yes 
A65_A69_6m Other spirochetal diseases_6m No No No No 
A65_A69_12m Other spirochetal diseases_12m No No No No 
A65_A69_24m Other spirochetal diseases_24m No No No No 
A65_A69_48m Other spirochetal diseases_48m No No No No 
A70_A74_6m 
Other diseases caused by 
chlamydiae_6m No No No No 
A70_A74_12m 
Other diseases caused by 
chlamydiae_12m No No No No 
A70_A74_24m 
Other diseases caused by 
chlamydiae_24m No No No No 
A70_A74_48m 
Other diseases caused by 
chlamydiae_48m No No No No 
A75_A79_6m Rickettsioses_6m No No No No 
A75_A79_12m Rickettsioses_12m No No No No 
A75_A79_24m Rickettsioses_24m No No No No 
A75_A79_48m Rickettsioses_48m No No No No 
A80_A89_6m 
Viral and prion infections of the 
central nervous system_6m No No No No 
A80_A89_12m 
Viral and prion infections of the 





Viral and prion infections of the 
central nervous system_24m No No No No 
A80_A89_48m 
Viral and prion infections of the 
central nervous system_48m No No No No 
A90_A99_6m 
Arthropod-borne viral fevers and 
viral hemorrhagic fevers_6m No No No No 
A90_A99_12m 
Arthropod-borne viral fevers and 
viral hemorrhagic fevers_12m No No No No 
A90_A99_24m 
Arthropod-borne viral fevers and 
viral hemorrhagic fevers_24m No No No No 
A90_A99_48m 
Arthropod-borne viral fevers and 
viral hemorrhagic fevers_48m No No No No 
B00_B09_6m 
Viral infections characterized by 
skin and mucous membrane 
lesions_6m No No No No 
B00_B09_12m 
Viral infections characterized by 
skin and mucous membrane 
lesions_12m No No No No 
B00_B09_24m 
Viral infections characterized by 
skin and mucous membrane 
lesions_24m No No No No 
B00_B09_48m 
Viral infections characterized by 
skin and mucous membrane 
lesions_48m No No No No 
B10_B10_6m Other human herpesviruses_6m No No No No 
B10_B10_12m Other human herpesviruses_12m No No No No 
B10_B10_24m Other human herpesviruses_24m No No No No 
B10_B10_48m Other human herpesviruses_48m No No No No 




B15_B19_12m Viral hepatitis_12m No No No No 
B15_B19_24m Viral hepatitis_24m No No No No 
B15_B19_48m Viral hepatitis_48m Yes No Yes Yes 
B20_B20_6m 
Human immunodeficiency virus 
[HIV] disease_6m No No No No 
B20_B20_12m 
Human immunodeficiency virus 
[HIV] disease_12m No No No No 
B20_B20_24m 
Human immunodeficiency virus 
[HIV] disease_24m No No No No 
B20_B20_48m 
Human immunodeficiency virus 
[HIV] disease_48m No No No No 
B25_B34_6m Other viral diseases_6m No No No No 
B25_B34_12m Other viral diseases_12m No No No No 
B25_B34_24m Other viral diseases_24m No No No No 
B25_B34_48m Other viral diseases_48m No No No Yes 
B35_B49_6m Mycoses_6m No No No No 
B35_B49_12m Mycoses_12m No No Yes No 
B35_B49_24m Mycoses_24m No No Yes Yes 
B35_B49_48m Mycoses_48m No No Yes Yes 
B50_B64_6m Protozoal diseases_6m No No No No 
B50_B64_12m Protozoal diseases_12m No No No No 
B50_B64_24m Protozoal diseases_24m No No No No 
B50_B64_48m Protozoal diseases_48m No No No No 
B65_B83_6m Helminthiases_6m No No No No 
B65_B83_12m Helminthiases_12m No No No No 
B65_B83_24m Helminthiases_24m No No No No 





Pediculosis, acariasis and other 
infestations_6m No No No No 
B85_B89_12m 
Pediculosis, acariasis and other 
infestations_12m No No No No 
B85_B89_24m 
Pediculosis, acariasis and other 
infestations_24m No No No No 
B85_B89_48m 
Pediculosis, acariasis and other 
infestations_48m No No No No 
B90_B94_6m 
Sequelae of infectious and 
parasitic diseases_6m No No No No 
B90_B94_12m 
Sequelae of infectious and 
parasitic diseases_12m No No No No 
B90_B94_24m 
Sequelae of infectious and 
parasitic diseases_24m No No No No 
B90_B94_48m 
Sequelae of infectious and 
parasitic diseases_48m No No No No 
B95_B97_6m 
Bacterial and viral infectious 
agents_6m No No No No 
B95_B97_12m 
Bacterial and viral infectious 
agents_12m No No No No 
B95_B97_24m 
Bacterial and viral infectious 
agents_24m No No No No 
B95_B97_48m 
Bacterial and viral infectious 
agents_48m No No No No 
B99_B99_6m Other infectious diseases_6m No No No No 
B99_B99_12m Other infectious diseases_12m No No No No 
B99_B99_24m Other infectious diseases_24m No No No No 
B99_B99_48m Other infectious diseases_48m No No No No 
C00_C14_6m 
Malignant neoplasms of lip, oral 





Malignant neoplasms of lip, oral 
cavity and pharynx_12m No No No No 
C00_C14_24m 
Malignant neoplasms of lip, oral 
cavity and pharynx_24m No No No No 
C00_C14_48m 
Malignant neoplasms of lip, oral 
cavity and pharynx_48m No No No No 
C7A_C7A_6m 
Malignant neuroendocrine 
tumors_6m No No No No 
C7A_C7A_12m 
Malignant neuroendocrine 
tumors_12m No No No No 
C7A_C7A_24m 
Malignant neuroendocrine 
tumors_24m No No No No 
C7A_C7A_48m 
Malignant neuroendocrine 
tumors_48m No No No No 
C7B_C7B_6m 
Secondary neuroendocrine 
tumors_6m No No No No 
C7B_C7B_12m 
Secondary neuroendocrine 
tumors_12m No No No No 
C7B_C7B_24m 
Secondary neuroendocrine 
tumors_24m No No No No 
C7B_C7B_48m 
Secondary neuroendocrine 
tumors_48m No No No No 
C15_C26_6m 
Malignant neoplasms of digestive 
organs_6m No No No No 
C15_C26_12m 
Malignant neoplasms of digestive 
organs_12m No No No No 
C15_C26_24m 
Malignant neoplasms of digestive 
organs_24m No No No No 
C15_C26_48m 
Malignant neoplasms of digestive 





Malignant neoplasms of 
respiratory and intrathoracic 
organs_6m No No No No 
C30_C39_12m 
Malignant neoplasms of 
respiratory and intrathoracic 
organs_12m No No No No 
C30_C39_24m 
Malignant neoplasms of 
respiratory and intrathoracic 
organs_24m No No No No 
C30_C39_48m 
Malignant neoplasms of 
respiratory and intrathoracic 
organs_48m No No No No 
C40_C41_6m 
Malignant neoplasms of bone and 
articular cartilage_6m No No No No 
C40_C41_12m 
Malignant neoplasms of bone and 
articular cartilage_12m No No No No 
C40_C41_24m 
Malignant neoplasms of bone and 
articular cartilage_24m No No No No 
C40_C41_48m 
Malignant neoplasms of bone and 
articular cartilage_48m No No No No 
C43_C44_6m 
Melanoma and other malignant 
neoplasms of skin_6m No No No No 
C43_C44_12m 
Melanoma and other malignant 
neoplasms of skin_12m No No No No 
C43_C44_24m 
Melanoma and other malignant 
neoplasms of skin_24m No No No Yes 
C43_C44_48m 
Melanoma and other malignant 
neoplasms of skin_48m Yes No Yes Yes 
C45_C49_6m 
Malignant neoplasms of 





Malignant neoplasms of 
mesothelial and soft tissue_12m No No No No 
C45_C49_24m 
Malignant neoplasms of 
mesothelial and soft tissue_24m No No No No 
C45_C49_48m 
Malignant neoplasms of 
mesothelial and soft tissue_48m No No No No 
C50_C50_6m 
Malignant neoplasms of 
breast_6m No Yes No Yes 
C50_C50_12m 
Malignant neoplasms of 
breast_12m No Yes No Yes 
C50_C50_24m 
Malignant neoplasms of 
breast_24m No Yes No Yes 
C50_C50_48m 
Malignant neoplasms of 
breast_48m No Yes No Yes 
C51_C58_6m 
Malignant neoplasms of female 
genital organs_6m No No No No 
C51_C58_12m 
Malignant neoplasms of female 
genital organs_12m No No No No 
C51_C58_24m 
Malignant neoplasms of female 
genital organs_24m No No No No 
C51_C58_48m 
Malignant neoplasms of female 
genital organs_48m No Yes No No 
C60_C63_6m 
Malignant neoplasms of male 
genital organs_6m No No No No 
C60_C63_12m 
Malignant neoplasms of male 
genital organs_12m No No Yes No 
C60_C63_24m 
Malignant neoplasms of male 
genital organs_24m Yes No Yes No 
C60_C63_48m 
Malignant neoplasms of male 





Malignant neoplasms of urinary 
tract_6m No No No No 
C64_C68_12m 
Malignant neoplasms of urinary 
tract_12m No No No No 
C64_C68_24m 
Malignant neoplasms of urinary 
tract_24m No No No No 
C64_C68_48m 
Malignant neoplasms of urinary 
tract_48m No No No No 
C69_C72_6m 
Malignant neoplasms of eye, brain 
and other parts of central nervous 
system_6m No No No No 
C69_C72_12m 
Malignant neoplasms of eye, brain 
and other parts of central nervous 
system_12m No No No No 
C69_C72_24m 
Malignant neoplasms of eye, brain 
and other parts of central nervous 
system_24m No No No No 
C69_C72_48m 
Malignant neoplasms of eye, brain 
and other parts of central nervous 
system_48m No No No No 
C73_C75_6m 
Malignant neoplasms of thyroid 
and other endocrine glands_6m No No No No 
C73_C75_12m 
Malignant neoplasms of thyroid 
and other endocrine glands_12m No No No No 
C73_C75_24m 
Malignant neoplasms of thyroid 
and other endocrine glands_24m No No No No 
C73_C75_48m 
Malignant neoplasms of thyroid 





Malignant neoplasms of ill-
defined, other secondary and 
unspecified sites_6m No No No No 
C76_C80_12m 
Malignant neoplasms of ill-
defined, other secondary and 
unspecified sites_12m No No No No 
C76_C80_24m 
Malignant neoplasms of ill-
defined, other secondary and 
unspecified sites_24m No No No No 
C76_C80_48m 
Malignant neoplasms of ill-
defined, other secondary and 
unspecified sites_48m No No No No 
C81_C96_6m 
Malignant neoplasms of lymphoid, 
hematopoietic and related 
tissue_6m No No No No 
C81_C96_12m 
Malignant neoplasms of lymphoid, 
hematopoietic and related 
tissue_12m No No No No 
C81_C96_24m 
Malignant neoplasms of lymphoid, 
hematopoietic and related 
tissue_24m No No No No 
C81_C96_48m 
Malignant neoplasms of lymphoid, 
hematopoietic and related 
tissue_48m No No No No 
D00_D09_6m In situ neoplasms_6m No No No No 
D00_D09_12m In situ neoplasms_12m No No No No 
D00_D09_24m In situ neoplasms_24m No No No No 
D00_D09_48m In situ neoplasms_48m No No No Yes 
D3A_D3A_6m 
Benign neuroendocrine 






tumors_12m No No No No 
D3A_D3A_24m 
Benign neuroendocrine 
tumors_24m No No No No 
D3A_D3A_48m 
Benign neuroendocrine 
tumors_48m No No No No 
D10_D36_6m 
Benign neoplasms, except benign 
neuroendocrine tumors_6m Yes Yes Yes Yes 
D10_D36_12m 
Benign neoplasms, except benign 
neuroendocrine tumors_12m Yes Yes Yes Yes 
D10_D36_24m 
Benign neoplasms, except benign 
neuroendocrine tumors_24m Yes Yes Yes Yes 
D10_D36_48m 
Benign neoplasms, except benign 
neuroendocrine tumors_48m Yes Yes Yes Yes 
D37_D48_6m 
Neoplasms of uncertain behavior, 
polycythemia vera and 
myelodysplastic syndromes_6m No No No No 
D37_D48_12m 
Neoplasms of uncertain behavior, 
polycythemia vera and 
myelodysplastic syndromes_12m No No No No 
D37_D48_24m 
Neoplasms of uncertain behavior, 
polycythemia vera and 
myelodysplastic syndromes_24m Yes No No No 
D37_D48_48m 
Neoplasms of uncertain behavior, 
polycythemia vera and 
myelodysplastic syndromes_48m Yes No No Yes 
D49_D49_6m 
Neoplasms of unspecified 
behavior_6m No No No No 
D49_D49_12m 
Neoplasms of unspecified 





Neoplasms of unspecified 
behavior_24m No No No No 
D49_D49_48m 
Neoplasms of unspecified 
behavior_48m No No No No 
D50_D53_6m Nutritional anemias_6m No No No Yes 
D50_D53_12m Nutritional anemias_12m No No No Yes 
D50_D53_24m Nutritional anemias_24m Yes No No Yes 
D50_D53_48m Nutritional anemias_48m Yes Yes Yes Yes 
D55_D59_6m Hemolytic anemias_6m No No No No 
D55_D59_12m Hemolytic anemias_12m No No No No 
D55_D59_24m Hemolytic anemias_24m No No No No 
D55_D59_48m Hemolytic anemias_48m No No No No 
D60_D64_6m 
Aplastic and other anemias and 
other bone marrow failure 
syndromes_6m Yes No Yes Yes 
D60_D64_12m 
Aplastic and other anemias and 
other bone marrow failure 
syndromes_12m Yes Yes Yes Yes 
D60_D64_24m 
Aplastic and other anemias and 
other bone marrow failure 
syndromes_24m Yes Yes Yes Yes 
D60_D64_48m 
Aplastic and other anemias and 
other bone marrow failure 
syndromes_48m Yes Yes Yes Yes 
D65_D69_6m 
Coagulation defects, purpura and 
other hemorrhagic conditions_6m No No No No 
D65_D69_12m 
Coagulation defects, purpura and 
other hemorrhagic 





Coagulation defects, purpura and 
other hemorrhagic 
conditions_24m No No Yes Yes 
D65_D69_48m 
Coagulation defects, purpura and 
other hemorrhagic 
conditions_48m No Yes Yes Yes 
D70_D77_6m 
Other disorders of blood and 
blood-forming organs_6m No No No No 
D70_D77_12m 
Other disorders of blood and 
blood-forming organs_12m No No No No 
D70_D77_24m 
Other disorders of blood and 
blood-forming organs_24m No No No No 
D70_D77_48m 
Other disorders of blood and 
blood-forming organs_48m No No No No 
D78_D78_6m 
Intraoperative and postprocedural 
complications of the spleen_6m No No No No 
D78_D78_12m 
Intraoperative and postprocedural 
complications of the spleen_12m No No No No 
D78_D78_24m 
Intraoperative and postprocedural 
complications of the spleen_24m No No No No 
D78_D78_48m 
Intraoperative and postprocedural 
complications of the spleen_48m No No No No 
D80_D89_6m 
Certain disorders involving the 
immune mechanism_6m No No No No 
D80_D89_12m 
Certain disorders involving the 
immune mechanism_12m No No No No 
D80_D89_24m 
Certain disorders involving the 
immune mechanism_24m No No No No 
D80_D89_48m 
Certain disorders involving the 




E00_E07_6m Disorders of thyroid gland_6m No Yes No Yes 
E00_E07_12m Disorders of thyroid gland_12m Yes Yes Yes Yes 
E00_E07_24m Disorders of thyroid gland_24m Yes Yes Yes Yes 
E00_E07_48m Disorders of thyroid gland_48m Yes Yes Yes Yes 
E08_E13_6m Diabetes mellitus_6m Yes Yes Yes Yes 
E08_E13_12m Diabetes mellitus_12m Yes Yes Yes Yes 
E08_E13_24m Diabetes mellitus_24m Yes Yes Yes Yes 
E08_E13_48m Diabetes mellitus_48m Yes Yes Yes Yes 
E15_E16_6m 
Other disorders of glucose 
regulation and pancreatic internal 
secretion_6m No No No No 
E15_E16_12m 
Other disorders of glucose 
regulation and pancreatic internal 
secretion_12m No No No No 
E15_E16_24m 
Other disorders of glucose 
regulation and pancreatic internal 
secretion_24m No No Yes Yes 
E15_E16_48m 
Other disorders of glucose 
regulation and pancreatic internal 
secretion_48m No No Yes Yes 
E20_E35_6m 
Disorders of other endocrine 
glands_6m No No No Yes 
E20_E35_12m 
Disorders of other endocrine 
glands_12m No No No Yes 
E20_E35_24m 
Disorders of other endocrine 
glands_24m No No Yes Yes 
E20_E35_48m 
Disorders of other endocrine 





Intraoperative complications of 
endocrine system_6m No No No No 
E36_E36_12m 
Intraoperative complications of 
endocrine system_12m No No No No 
E36_E36_24m 
Intraoperative complications of 
endocrine system_24m No No No No 
E36_E36_48m 
Intraoperative complications of 
endocrine system_48m No No No No 
E40_E46_6m Malnutrition_6m No No No No 
E40_E46_12m Malnutrition_12m No No No No 
E40_E46_24m Malnutrition_24m No No No No 
E40_E46_48m Malnutrition_48m No No No No 
E50_E64_6m Other nutritional deficiencies_6m No No No No 
E50_E64_12m Other nutritional deficiencies_12m No No No Yes 
E50_E64_24m Other nutritional deficiencies_24m No Yes Yes Yes 
E50_E64_48m Other nutritional deficiencies_48m No Yes Yes Yes 
E65_E68_6m 
Overweight, obesity and other 
hyperalimentation_6m No No Yes Yes 
E65_E68_12m 
Overweight, obesity and other 
hyperalimentation_12m No Yes Yes Yes 
E65_E68_24m 
Overweight, obesity and other 
hyperalimentation_24m Yes Yes Yes Yes 
E65_E68_48m 
Overweight, obesity and other 
hyperalimentation_48m Yes Yes Yes Yes 
E70_E88_6m Metabolic disorders_6m Yes Yes Yes Yes 
E70_E88_12m Metabolic disorders_12m Yes Yes Yes Yes 
E70_E88_24m Metabolic disorders_24m Yes Yes Yes Yes 





Postprocedural endocrine and 
metabolic complications and 
disorders, not elsewhere 
classified_6m No No No No 
E89_E89_12m 
Postprocedural endocrine and 
metabolic complications and 
disorders, not elsewhere 
classified_12m No No No No 
E89_E89_24m 
Postprocedural endocrine and 
metabolic complications and 
disorders, not elsewhere 
classified_24m No No No No 
E89_E89_48m 
Postprocedural endocrine and 
metabolic complications and 
disorders, not elsewhere 
classified_48m No No No No 
G00_G09_6m 
Inflammatory diseases of the 
central nervous system_6m No No No No 
G00_G09_12m 
Inflammatory diseases of the 
central nervous system_12m No No No No 
G00_G09_24m 
Inflammatory diseases of the 
central nervous system_24m No No No No 
G00_G09_48m 
Inflammatory diseases of the 
central nervous system_48m No No No No 
G10_G14_6m 
Systemic atrophies primarily 
affecting the central nervous 
system_6m No No No No 
G10_G14_12m 
Systemic atrophies primarily 
affecting the central nervous 





Systemic atrophies primarily 
affecting the central nervous 
system_24m No No No No 
G10_G14_48m 
Systemic atrophies primarily 
affecting the central nervous 
system_48m No No No No 
G20_G26_6m 
Extrapyramidal and movement 
disorders_6m No No No No 
G20_G26_12m 
Extrapyramidal and movement 
disorders_12m No Yes Yes Yes 
G20_G26_24m 
Extrapyramidal and movement 
disorders_24m Yes Yes Yes Yes 
G20_G26_48m 
Extrapyramidal and movement 
disorders_48m Yes Yes Yes Yes 
G30_G32_6m 
Other degenerative diseases of 
the nervous system_6m No No No No 
G30_G32_12m 
Other degenerative diseases of 
the nervous system_12m No No No No 
G30_G32_24m 
Other degenerative diseases of 
the nervous system_24m No No No No 
G30_G32_48m 
Other degenerative diseases of 
the nervous system_48m No No No Yes 
G35_G37_6m 
Demyelinating diseases of the 
central nervous system_6m No No No No 
G35_G37_12m 
Demyelinating diseases of the 
central nervous system_12m No No No Yes 
G35_G37_24m 
Demyelinating diseases of the 
central nervous system_24m No No No Yes 
G35_G37_48m 
Demyelinating diseases of the 





Episodic and paroxysmal 
disorders_6m Yes Yes Yes Yes 
G40_G47_12m 
Episodic and paroxysmal 
disorders_12m Yes Yes Yes Yes 
G40_G47_24m 
Episodic and paroxysmal 
disorders_24m Yes Yes Yes Yes 
G40_G47_48m 
Episodic and paroxysmal 
disorders_48m Yes Yes Yes Yes 
G50_G59_6m 
Nerve, nerve root and plexus 
disorders_6m No No No Yes 
G50_G59_12m 
Nerve, nerve root and plexus 
disorders_12m No Yes Yes Yes 
G50_G59_24m 
Nerve, nerve root and plexus 
disorders_24m Yes Yes Yes Yes 
G50_G59_48m 
Nerve, nerve root and plexus 
disorders_48m Yes Yes Yes Yes 
G60_G65_6m 
Polyneuropathies and other 
disorders of the peripheral 
nervous system_6m No No No No 
G60_G65_12m 
Polyneuropathies and other 
disorders of the peripheral 
nervous system_12m No No Yes No 
G60_G65_24m 
Polyneuropathies and other 
disorders of the peripheral 
nervous system_24m Yes No Yes Yes 
G60_G65_48m 
Polyneuropathies and other 
disorders of the peripheral 
nervous system_48m Yes Yes Yes Yes 
G70_G73_6m 
Diseases of myoneural junction 





Diseases of myoneural junction 
and muscle_12m No No No No 
G70_G73_24m 
Diseases of myoneural junction 
and muscle_24m No No No No 
G70_G73_48m 
Diseases of myoneural junction 
and muscle_48m No No No No 
G80_G83_6m 
Cerebral palsy and other paralytic 
syndromes_6m No No No No 
G80_G83_12m 
Cerebral palsy and other paralytic 
syndromes_12m No No No No 
G80_G83_24m 
Cerebral palsy and other paralytic 
syndromes_24m No No No No 
G80_G83_48m 
Cerebral palsy and other paralytic 
syndromes_48m Yes Yes Yes Yes 
G89_G99_6m 
Other disorders of the nervous 
system_6m Yes Yes Yes Yes 
G89_G99_12m 
Other disorders of the nervous 
system_12m Yes Yes Yes Yes 
G89_G99_24m 
Other disorders of the nervous 
system_24m Yes Yes Yes Yes 
G89_G99_48m 
Other disorders of the nervous 
system_48m Yes Yes Yes Yes 
H00_H05_6m 
Disorders of eyelid, lacrimal 
system and orbit_6m No No No No 
H00_H05_12m 
Disorders of eyelid, lacrimal 
system and orbit_12m No No No No 
H00_H05_24m 
Disorders of eyelid, lacrimal 
system and orbit_24m No No No Yes 
H00_H05_48m 
Disorders of eyelid, lacrimal 




H10_H11_6m Disorders of conjunctiva_6m No No No No 
H10_H11_12m Disorders of conjunctiva_12m No No No No 
H10_H11_24m Disorders of conjunctiva_24m No No No No 
H10_H11_48m Disorders of conjunctiva_48m No No No No 
H15_H22_6m 
Disorders of sclera, cornea, iris 
and ciliary body_6m No No No No 
H15_H22_12m 
Disorders of sclera, cornea, iris 
and ciliary body_12m No No No Yes 
H15_H22_24m 
Disorders of sclera, cornea, iris 
and ciliary body_24m No No No Yes 
H15_H22_48m 
Disorders of sclera, cornea, iris 
and ciliary body_48m No No No Yes 
H25_H28_6m Disorders of lens_6m No Yes No No 
H25_H28_12m Disorders of lens_12m Yes Yes No Yes 
H25_H28_24m Disorders of lens_24m Yes Yes Yes Yes 
H25_H28_48m Disorders of lens_48m Yes Yes Yes Yes 
H30_H36_6m 
Disorders of choroid and 
retina_6m Yes No No No 
H30_H36_12m 
Disorders of choroid and 
retina_12m Yes No No Yes 
H30_H36_24m 
Disorders of choroid and 
retina_24m Yes Yes Yes Yes 
H30_H36_48m 
Disorders of choroid and 
retina_48m Yes Yes Yes Yes 
H40_H42_6m Glaucoma_6m No No No No 
H40_H42_12m Glaucoma_12m No No No No 
H40_H42_24m Glaucoma_24m No No No No 





Disorders of vitreous body and 
globe_6m No No No No 
H43_H44_12m 
Disorders of vitreous body and 
globe_12m No No No No 
H43_H44_24m 
Disorders of vitreous body and 
globe_24m No No No No 
H43_H44_48m 
Disorders of vitreous body and 
globe_48m No No No No 
H46_H47_6m 
Disorders of optic nerve and visual 
pathways_6m No No No No 
H46_H47_12m 
Disorders of optic nerve and visual 
pathways_12m No No No No 
H46_H47_24m 
Disorders of optic nerve and visual 
pathways_24m No No No No 
H46_H47_48m 
Disorders of optic nerve and visual 
pathways_48m No No No Yes 
H49_H52_6m 
Disorders of ocular muscles, 
binocular movement, 
accommodation and 
refraction_6m No No No No 
H49_H52_12m 
Disorders of ocular muscles, 
binocular movement, 
accommodation and 
refraction_12m No No No Yes 
H49_H52_24m 
Disorders of ocular muscles, 
binocular movement, 
accommodation and 
refraction_24m No No No Yes 
H49_H52_48m 
Disorders of ocular muscles, 







Visual disturbances and 
blindness_6m No No No No 
H53_H54_12m 
Visual disturbances and 
blindness_12m No No No No 
H53_H54_24m 
Visual disturbances and 
blindness_24m No No Yes Yes 
H53_H54_48m 
Visual disturbances and 
blindness_48m Yes No Yes Yes 
H55_H57_6m 
Other disorders of eye and 
adnexa_6m No No No No 
H55_H57_12m 
Other disorders of eye and 
adnexa_12m No No No No 
H55_H57_24m 
Other disorders of eye and 
adnexa_24m No No No No 
H55_H57_48m 
Other disorders of eye and 
adnexa_48m No No No No 
H59_H59_6m 
Intraoperative and postprocedural 
complications and disorders of 
eye and adnexa, not elsewhere 
classified_6m No No No No 
H59_H59_12m 
Intraoperative and postprocedural 
complications and disorders of 
eye and adnexa, not elsewhere 
classified_12m No No No No 
H59_H59_24m 
Intraoperative and postprocedural 
complications and disorders of 
eye and adnexa, not elsewhere 





Intraoperative and postprocedural 
complications and disorders of 
eye and adnexa, not elsewhere 
classified_48m No No No No 
H60_H62_6m Diseases of external ear_6m No No No No 
H60_H62_12m Diseases of external ear_12m No No No No 
H60_H62_24m Diseases of external ear_24m No No No No 
H60_H62_48m Diseases of external ear_48m No No No Yes 
H65_H75_6m 
Diseases of middle ear and 
mastoid_6m No No No No 
H65_H75_12m 
Diseases of middle ear and 
mastoid_12m No No No No 
H65_H75_24m 
Diseases of middle ear and 
mastoid_24m No No No No 
H65_H75_48m 
Diseases of middle ear and 
mastoid_48m No No No Yes 
H80_H83_6m Diseases of inner ear_6m No No No No 
H80_H83_12m Diseases of inner ear_12m Yes No Yes Yes 
H80_H83_24m Diseases of inner ear_24m Yes No Yes Yes 
H80_H83_48m Diseases of inner ear_48m Yes Yes Yes Yes 
H90_H94_6m Other disorders of ear_6m Yes No Yes Yes 
H90_H94_12m Other disorders of ear_12m Yes Yes Yes Yes 
H90_H94_24m Other disorders of ear_24m Yes Yes Yes Yes 
H90_H94_48m Other disorders of ear_48m Yes Yes Yes Yes 
H95_H95_6m 
Intraoperative and postprocedural 
complications and disorders of ear 
and mastoid process, not 





Intraoperative and postprocedural 
complications and disorders of ear 
and mastoid process, not 
elsewhere classified_12m No No No No 
H95_H95_24m 
Intraoperative and postprocedural 
complications and disorders of ear 
and mastoid process, not 
elsewhere classified_24m No No No No 
H95_H95_48m 
Intraoperative and postprocedural 
complications and disorders of ear 
and mastoid process, not 
elsewhere classified_48m No No No No 
I00_I02_6m Acute rheumatic fever_6m No No No No 
I00_I02_12m Acute rheumatic fever_12m No No No No 
I00_I02_24m Acute rheumatic fever_24m No No No No 
I00_I02_48m Acute rheumatic fever_48m No No No No 
I05_I09_6m 
Chronic rheumatic heart 
diseases_6m No No No No 
I05_I09_12m 
Chronic rheumatic heart 
diseases_12m No No No No 
I05_I09_24m 
Chronic rheumatic heart 
diseases_24m No No No No 
I05_I09_48m 
Chronic rheumatic heart 
diseases_48m No No No No 
I10_I16_6m Hypertensive diseases_6m Yes Yes Yes Yes 
I10_I16_12m Hypertensive diseases_12m Yes Yes Yes Yes 
I10_I16_24m Hypertensive diseases_24m Yes Yes Yes Yes 
I10_I16_48m Hypertensive diseases_48m Yes Yes Yes Yes 




I20_I25_12m Ischemic heart diseases_12m Yes Yes Yes Yes 
I20_I25_24m Ischemic heart diseases_24m Yes Yes Yes Yes 
I20_I25_48m Ischemic heart diseases_48m Yes Yes Yes Yes 
I26_I28_6m 
Pulmonary heart disease and 
diseases of pulmonary 
circulation_6m No No No No 
I26_I28_12m 
Pulmonary heart disease and 
diseases of pulmonary 
circulation_12m No No No No 
I26_I28_24m 
Pulmonary heart disease and 
diseases of pulmonary 
circulation_24m No No No Yes 
I26_I28_48m 
Pulmonary heart disease and 
diseases of pulmonary 
circulation_48m No No Yes Yes 
I30_I52_6m Other forms of heart disease_6m Yes Yes Yes Yes 
I30_I52_12m Other forms of heart disease_12m Yes Yes Yes Yes 
I30_I52_24m Other forms of heart disease_24m Yes Yes Yes Yes 
I30_I52_48m Other forms of heart disease_48m Yes Yes Yes Yes 
I60_I69_6m Cerebrovascular diseases_6m Yes Yes Yes Yes 
I60_I69_12m Cerebrovascular diseases_12m Yes Yes Yes Yes 
I60_I69_24m Cerebrovascular diseases_24m Yes Yes Yes Yes 
I60_I69_48m Cerebrovascular diseases_48m Yes Yes Yes Yes 
I70_I79_6m 
Diseases of arteries, arterioles 
and capillaries_6m No No No Yes 
I70_I79_12m 
Diseases of arteries, arterioles 





Diseases of arteries, arterioles 
and capillaries_24m Yes Yes Yes Yes 
I70_I79_48m 
Diseases of arteries, arterioles 
and capillaries_48m Yes Yes Yes Yes 
I80_I89_6m 
Diseases of veins, lymphatic 
vessels and lymph nodes, not 
elsewhere classified_6m Yes No Yes Yes 
I80_I89_12m 
Diseases of veins, lymphatic 
vessels and lymph nodes, not 
elsewhere classified_12m Yes Yes Yes Yes 
I80_I89_24m 
Diseases of veins, lymphatic 
vessels and lymph nodes, not 
elsewhere classified_24m Yes Yes Yes Yes 
I80_I89_48m 
Diseases of veins, lymphatic 
vessels and lymph nodes, not 
elsewhere classified_48m Yes Yes Yes Yes 
I95_I99_6m 
Other and unspecified disorders of 
the circulatory system_6m No No No No 
I95_I99_12m 
Other and unspecified disorders of 
the circulatory system_12m No No Yes Yes 
I95_I99_24m 
Other and unspecified disorders of 
the circulatory system_24m No No Yes Yes 
I95_I99_48m 
Other and unspecified disorders of 
the circulatory system_48m Yes No Yes Yes 
J00_J06_6m 
Acute upper respiratory 
infections_6m No No No No 
J00_J06_12m 
Acute upper respiratory 
infections_12m No No No No 
J00_J06_24m 
Acute upper respiratory 





Acute upper respiratory 
infections_48m No No Yes Yes 
J09_J18_6m Influenza and pneumonia_6m Yes Yes Yes Yes 
J09_J18_12m Influenza and pneumonia_12m Yes Yes Yes Yes 
J09_J18_24m Influenza and pneumonia_24m Yes Yes Yes Yes 
J09_J18_48m Influenza and pneumonia_48m Yes Yes Yes Yes 
J20_J22_6m 
Other acute lower respiratory 
infections_6m No No No Yes 
J20_J22_12m 
Other acute lower respiratory 
infections_12m No No No Yes 
J20_J22_24m 
Other acute lower respiratory 
infections_24m No Yes No Yes 
J20_J22_48m 
Other acute lower respiratory 
infections_48m No Yes Yes Yes 
J30_J39_6m 
Other diseases of upper 
respiratory tract_6m No No No Yes 
J30_J39_12m 
Other diseases of upper 
respiratory tract_12m No No Yes Yes 
J30_J39_24m 
Other diseases of upper 
respiratory tract_24m Yes Yes Yes Yes 
J30_J39_48m 
Other diseases of upper 
respiratory tract_48m Yes Yes Yes Yes 
J40_J47_6m 
Chronic lower respiratory 
diseases_6m Yes Yes Yes Yes 
J40_J47_12m 
Chronic lower respiratory 
diseases_12m Yes Yes Yes Yes 
J40_J47_24m 
Chronic lower respiratory 
diseases_24m Yes Yes Yes Yes 
J40_J47_48m 
Chronic lower respiratory 





Lung diseases due to external 
agents_6m No No No No 
J60_J70_12m 
Lung diseases due to external 
agents_12m No Yes No Yes 
J60_J70_24m 
Lung diseases due to external 
agents_24m Yes Yes Yes Yes 
J60_J70_48m 
Lung diseases due to external 
agents_48m Yes Yes Yes Yes 
J80_J84_6m 
Other respiratory diseases 
principally affecting the 
interstitium_6m No No No No 
J80_J84_12m 
Other respiratory diseases 
principally affecting the 
interstitium_12m No No No No 
J80_J84_24m 
Other respiratory diseases 
principally affecting the 
interstitium_24m No No No No 
J80_J84_48m 
Other respiratory diseases 
principally affecting the 
interstitium_48m No No No No 
J85_J86_6m 
Suppurative and necrotic 
conditions of the lower respiratory 
tract_6m No No No No 
J85_J86_12m 
Suppurative and necrotic 
conditions of the lower respiratory 
tract_12m No No No No 
J85_J86_24m 
Suppurative and necrotic 
conditions of the lower respiratory 





Suppurative and necrotic 
conditions of the lower respiratory 
tract_48m No No No No 
J90_J94_6m Other diseases of the pleura_6m No No No No 
J90_J94_12m Other diseases of the pleura_12m No No No No 
J90_J94_24m Other diseases of the pleura_24m No No No No 
J90_J94_48m Other diseases of the pleura_48m Yes No Yes No 
J95_J95_6m 
Intraoperative and postprocedural 
complications and disorders of 
respiratory system, not elsewhere 
classified_6m No No No No 
J95_J95_12m 
Intraoperative and postprocedural 
complications and disorders of 
respiratory system, not elsewhere 
classified_12m No No No No 
J95_J95_24m 
Intraoperative and postprocedural 
complications and disorders of 
respiratory system, not elsewhere 
classified_24m No No No No 
J95_J95_48m 
Intraoperative and postprocedural 
complications and disorders of 
respiratory system, not elsewhere 
classified_48m No No No No 
J96_J99_6m 
Other diseases of the respiratory 
system_6m Yes Yes Yes Yes 
J96_J99_12m 
Other diseases of the respiratory 
system_12m Yes Yes Yes Yes 
J96_J99_24m 
Other diseases of the respiratory 





Other diseases of the respiratory 
system_48m Yes Yes Yes Yes 
K00_K14_6m 
Diseases of oral cavity and 
salivary glands_6m No No No Yes 
K00_K14_12m 
Diseases of oral cavity and 
salivary glands_12m No No Yes Yes 
K00_K14_24m 
Diseases of oral cavity and 
salivary glands_24m No Yes Yes Yes 
K00_K14_48m 
Diseases of oral cavity and 
salivary glands_48m Yes Yes Yes Yes 
K20_K31_6m 
Diseases of esophagus, stomach 
and duodenum_6m Yes Yes Yes Yes 
K20_K31_12m 
Diseases of esophagus, stomach 
and duodenum_12m Yes Yes Yes Yes 
K20_K31_24m 
Diseases of esophagus, stomach 
and duodenum_24m Yes Yes Yes Yes 
K20_K31_48m 
Diseases of esophagus, stomach 
and duodenum_48m Yes Yes Yes Yes 
K35_K38_6m Diseases of appendix_6m No No No No 
K35_K38_12m Diseases of appendix_12m No No No No 
K35_K38_24m Diseases of appendix_24m No No No Yes 
K35_K38_48m Diseases of appendix_48m No No Yes Yes 
K40_K46_6m Hernia_6m Yes No Yes Yes 
K40_K46_12m Hernia_12m Yes Yes Yes Yes 
K40_K46_24m Hernia_24m Yes Yes Yes Yes 
K40_K46_48m Hernia_48m Yes Yes Yes Yes 
K50_K52_6m 
Noninfective enteritis and 





Noninfective enteritis and 
colitis_12m Yes No Yes Yes 
K50_K52_24m 
Noninfective enteritis and 
colitis_24m Yes Yes Yes Yes 
K50_K52_48m 
Noninfective enteritis and 
colitis_48m Yes Yes Yes Yes 
K55_K64_6m Other diseases of intestines_6m Yes Yes Yes Yes 
K55_K64_12m Other diseases of intestines_12m Yes Yes Yes Yes 
K55_K64_24m Other diseases of intestines_24m Yes Yes Yes Yes 
K55_K64_48m Other diseases of intestines_48m Yes Yes Yes Yes 
K65_K68_6m 
Diseases of peritoneum and 
retroperitoneum_6m No No No No 
K65_K68_12m 
Diseases of peritoneum and 
retroperitoneum_12m No No No No 
K65_K68_24m 
Diseases of peritoneum and 
retroperitoneum_24m No No No No 
K65_K68_48m 
Diseases of peritoneum and 
retroperitoneum_48m No No No Yes 
K70_K77_6m Diseases of liver_6m Yes Yes Yes Yes 
K70_K77_12m Diseases of liver_12m Yes Yes Yes Yes 
K70_K77_24m Diseases of liver_24m Yes Yes Yes Yes 
K70_K77_48m Diseases of liver_48m Yes Yes Yes Yes 
K80_K87_6m 
Disorders of gallbladder, biliary 
tract and pancreas_6m No Yes Yes Yes 
K80_K87_12m 
Disorders of gallbladder, biliary 
tract and pancreas_12m Yes Yes Yes Yes 
K80_K87_24m 
Disorders of gallbladder, biliary 





Disorders of gallbladder, biliary 
tract and pancreas_48m Yes Yes Yes Yes 
K90_K95_6m 
Other diseases of the digestive 
system_6m No Yes Yes Yes 
K90_K95_12m 
Other diseases of the digestive 
system_12m Yes Yes Yes Yes 
K90_K95_24m 
Other diseases of the digestive 
system_24m Yes Yes Yes Yes 
K90_K95_48m 
Other diseases of the digestive 
system_48m Yes Yes Yes Yes 
L00_L08_6m 
Infections of the skin and 
subcutaneous tissue_6m No No Yes Yes 
L00_L08_12m 
Infections of the skin and 
subcutaneous tissue_12m Yes No Yes Yes 
L00_L08_24m 
Infections of the skin and 
subcutaneous tissue_24m Yes Yes Yes Yes 
L00_L08_48m 
Infections of the skin and 
subcutaneous tissue_48m Yes Yes Yes Yes 
L10_L14_6m Bullous disorders_6m No No No No 
L10_L14_12m Bullous disorders_12m No No No No 
L10_L14_24m Bullous disorders_24m No No No No 
L10_L14_48m Bullous disorders_48m No No No No 
L20_L30_6m Dermatitis and eczema_6m No No No No 
L20_L30_12m Dermatitis and eczema_12m No No No Yes 
L20_L30_24m Dermatitis and eczema_24m Yes Yes Yes Yes 
L20_L30_48m Dermatitis and eczema_48m Yes Yes Yes Yes 
L40_L45_6m Papulosquamous disorders_6m No No No No 




L40_L45_24m Papulosquamous disorders_24m No No No Yes 
L40_L45_48m Papulosquamous disorders_48m No No Yes Yes 
L49_L54_6m Urticaria and erythema_6m No No No No 
L49_L54_12m Urticaria and erythema_12m No No No No 
L49_L54_24m Urticaria and erythema_24m No No No No 
L49_L54_48m Urticaria and erythema_48m No No No Yes 
L55_L59_6m 
Radiation-related disorders of the 
skin and subcutaneous tissue_6m No No No No 
L55_L59_12m 
Radiation-related disorders of the 
skin and subcutaneous 
tissue_12m No No No No 
L55_L59_24m 
Radiation-related disorders of the 
skin and subcutaneous 
tissue_24m No No No No 
L55_L59_48m 
Radiation-related disorders of the 
skin and subcutaneous 
tissue_48m No No No No 
L60_L75_6m Disorders of skin appendages_6m No No No No 
L60_L75_12m 
Disorders of skin 
appendages_12m No No No Yes 
L60_L75_24m 
Disorders of skin 
appendages_24m No No No Yes 
L60_L75_48m 
Disorders of skin 
appendages_48m No Yes Yes Yes 
L76_L76_6m 
Intraoperative and postprocedural 
complications of skin and 





Intraoperative and postprocedural 
complications of skin and 
subcutaneous tissue_12m No No No No 
L76_L76_24m 
Intraoperative and postprocedural 
complications of skin and 
subcutaneous tissue_24m No No No No 
L76_L76_48m 
Intraoperative and postprocedural 
complications of skin and 
subcutaneous tissue_48m No No No No 
L80_L99_6m 
Other disorders of the skin and 
subcutaneous tissue_6m No No Yes Yes 
L80_L99_12m 
Other disorders of the skin and 
subcutaneous tissue_12m No Yes Yes Yes 
L80_L99_24m 
Other disorders of the skin and 
subcutaneous tissue_24m Yes Yes Yes Yes 
L80_L99_48m 
Other disorders of the skin and 
subcutaneous tissue_48m Yes Yes Yes Yes 
M00_M02_6m Infectious arthropathies_6m No No No No 
M00_M02_12m Infectious arthropathies_12m No No No No 
M00_M02_24m Infectious arthropathies_24m No No No No 
M00_M02_48m Infectious arthropathies_48m No No No No 
M04_M04_6m Autoinflammatory syndromes_6m No No No No 
M04_M04_12m 
Autoinflammatory 
syndromes_12m No No No No 
M04_M04_24m 
Autoinflammatory 
syndromes_24m No No No No 
M04_M04_48m 
Autoinflammatory 






polyarthropathies_6m No No No Yes 
M05_M14_12m 
Inflammatory 
polyarthropathies_12m No No No Yes 
M05_M14_24m 
Inflammatory 
polyarthropathies_24m No Yes Yes Yes 
M05_M14_48m 
Inflammatory 
polyarthropathies_48m Yes Yes Yes Yes 
M15_M19_6m Osteoarthritis_6m Yes Yes Yes Yes 
M15_M19_12m Osteoarthritis_12m Yes Yes Yes Yes 
M15_M19_24m Osteoarthritis_24m Yes Yes Yes Yes 
M15_M19_48m Osteoarthritis_48m Yes Yes Yes Yes 
M20_M25_6m Other joint disorders_6m No No Yes Yes 
M20_M25_12m Other joint disorders_12m Yes Yes Yes Yes 
M20_M25_24m Other joint disorders_24m Yes Yes Yes Yes 
M20_M25_48m Other joint disorders_48m Yes Yes Yes Yes 
M26_M27_6m 
Dentofacial anomalies [including 
malocclusion] and other disorders 
of jaw_6m No No No No 
M26_M27_12m 
Dentofacial anomalies [including 
malocclusion] and other disorders 
of jaw_12m No No No No 
M26_M27_24m 
Dentofacial anomalies [including 
malocclusion] and other disorders 
of jaw_24m No No No No 
M26_M27_48m 
Dentofacial anomalies [including 
malocclusion] and other disorders 





Systemic connective tissue 
disorders_6m No No No No 
M30_M36_12m 
Systemic connective tissue 
disorders_12m No No No Yes 
M30_M36_24m 
Systemic connective tissue 
disorders_24m No Yes No Yes 
M30_M36_48m 
Systemic connective tissue 
disorders_48m No Yes No Yes 
M40_M43_6m Deforming dorsopathies_6m No No No No 
M40_M43_12m Deforming dorsopathies_12m No No No No 
M40_M43_24m Deforming dorsopathies_24m No No No Yes 
M40_M43_48m Deforming dorsopathies_48m No No Yes Yes 
M45_M49_6m Spondylopathies_6m No No No No 
M45_M49_12m Spondylopathies_12m Yes No Yes Yes 
M45_M49_24m Spondylopathies_24m Yes Yes Yes Yes 
M45_M49_48m Spondylopathies_48m Yes Yes Yes Yes 
M50_M54_6m Other dorsopathies_6m Yes Yes Yes Yes 
M50_M54_12m Other dorsopathies_12m Yes Yes Yes Yes 
M50_M54_24m Other dorsopathies_24m Yes Yes Yes Yes 
M50_M54_48m Other dorsopathies_48m Yes Yes Yes Yes 
M60_M63_6m Disorders of muscles_6m No No No Yes 
M60_M63_12m Disorders of muscles_12m No No No Yes 
M60_M63_24m Disorders of muscles_24m Yes Yes Yes Yes 
M60_M63_48m Disorders of muscles_48m Yes Yes Yes Yes 
M65_M67_6m 
Disorders of synovium and 





Disorders of synovium and 
tendon_12m No No No Yes 
M65_M67_24m 
Disorders of synovium and 
tendon_24m No No Yes Yes 
M65_M67_48m 
Disorders of synovium and 
tendon_48m Yes Yes Yes Yes 
M70_M79_6m Other soft tissue disorders_6m Yes Yes Yes Yes 
M70_M79_12m Other soft tissue disorders_12m Yes Yes Yes Yes 
M70_M79_24m Other soft tissue disorders_24m Yes Yes Yes Yes 
M70_M79_48m Other soft tissue disorders_48m Yes Yes Yes Yes 
M80_M85_6m 
Disorders of bone density and 
structure_6m No Yes No Yes 
M80_M85_12m 
Disorders of bone density and 
structure_12m Yes Yes No Yes 
M80_M85_24m 
Disorders of bone density and 
structure_24m Yes Yes Yes Yes 
M80_M85_48m 
Disorders of bone density and 
structure_48m Yes Yes Yes Yes 
M86_M90_6m Other osteopathies_6m No No No No 
M86_M90_12m Other osteopathies_12m No No No No 
M86_M90_24m Other osteopathies_24m No No No No 
M86_M90_48m Other osteopathies_48m No No No Yes 
M91_M94_6m Chondropathies_6m No No No No 
M91_M94_12m Chondropathies_12m No No No No 
M91_M94_24m Chondropathies_24m No No No No 





Other disorders of the 
musculoskeletal system and 
connective tissue_6m No No No No 
M95_M95_12m 
Other disorders of the 
musculoskeletal system and 
connective tissue_12m No No No No 
M95_M95_24m 
Other disorders of the 
musculoskeletal system and 
connective tissue_24m No No No No 
M95_M95_48m 
Other disorders of the 
musculoskeletal system and 
connective tissue_48m No No No No 
M96_M96_6m 
Intraoperative and postprocedural 
complications and disorders of 
musculoskeletal system, not 
elsewhere classified_6m No No No No 
M96_M96_12m 
Intraoperative and postprocedural 
complications and disorders of 
musculoskeletal system, not 
elsewhere classified_12m No No No No 
M96_M96_24m 
Intraoperative and postprocedural 
complications and disorders of 
musculoskeletal system, not 
elsewhere classified_24m No No No No 
M96_M96_48m 
Intraoperative and postprocedural 
complications and disorders of 
musculoskeletal system, not 
elsewhere classified_48m No No No No 
M97_M97_6m 
Periprosthetic fracture around 





Periprosthetic fracture around 
internal prosthetic joint_12m No No No No 
M97_M97_24m 
Periprosthetic fracture around 
internal prosthetic joint_24m No No No No 
M97_M97_48m 
Periprosthetic fracture around 
internal prosthetic joint_48m No No No No 
M99_M99_6m 
Biomechanical lesions, not 
elsewhere classified_6m No No No No 
M99_M99_12m 
Biomechanical lesions, not 
elsewhere classified_12m No No No No 
M99_M99_24m 
Biomechanical lesions, not 
elsewhere classified_24m No No No No 
M99_M99_48m 
Biomechanical lesions, not 
elsewhere classified_48m No No No No 
N00_N08_6m Glomerular diseases_6m No No No No 
N00_N08_12m Glomerular diseases_12m No No No No 
N00_N08_24m Glomerular diseases_24m No No No No 
N00_N08_48m Glomerular diseases_48m No No No No 
N10_N16_6m 
Renal tubulo-interstitial 
diseases_6m No No No No 
N10_N16_12m 
Renal tubulo-interstitial 
diseases_12m No No No Yes 
N10_N16_24m 
Renal tubulo-interstitial 
diseases_24m No No No Yes 
N10_N16_48m 
Renal tubulo-interstitial 
diseases_48m No Yes Yes Yes 
N17_N19_6m 
Acute kidney failure and chronic 
kidney disease_6m Yes Yes Yes Yes 
N17_N19_12m 
Acute kidney failure and chronic 





Acute kidney failure and chronic 
kidney disease_24m Yes Yes Yes Yes 
N17_N19_48m 
Acute kidney failure and chronic 
kidney disease_48m Yes Yes Yes Yes 
N20_N23_6m Urolithiasis_6m No No No No 
N20_N23_12m Urolithiasis_12m No No No Yes 
N20_N23_24m Urolithiasis_24m No No No Yes 
N20_N23_48m Urolithiasis_48m Yes Yes Yes Yes 
N25_N29_6m 
Other disorders of kidney and 
ureter_6m No No No No 
N25_N29_12m 
Other disorders of kidney and 
ureter_12m No No No No 
N25_N29_24m 
Other disorders of kidney and 
ureter_24m No No No No 
N25_N29_48m 
Other disorders of kidney and 
ureter_48m No No No No 
N30_N39_6m 
Other diseases of the urinary 
system_6m Yes Yes Yes Yes 
N30_N39_12m 
Other diseases of the urinary 
system_12m Yes Yes Yes Yes 
N30_N39_24m 
Other diseases of the urinary 
system_24m Yes Yes Yes Yes 
N30_N39_48m 
Other diseases of the urinary 
system_48m Yes Yes Yes Yes 
N40_N53_6m 
Diseases of male genital 
organs_6m Yes No Yes No 
N40_N53_12m 
Diseases of male genital 
organs_12m Yes No Yes No 
N40_N53_24m 
Diseases of male genital 





Diseases of male genital 
organs_48m Yes No Yes No 
N60_N65_6m Disorders of breast_6m No No No Yes 
N60_N65_12m Disorders of breast_12m No Yes No Yes 
N60_N65_24m Disorders of breast_24m No Yes Yes Yes 
N60_N65_48m Disorders of breast_48m No Yes Yes Yes 
N70_N77_6m 
Inflammatory diseases of female 
pelvic organs_6m No No No No 
N70_N77_12m 
Inflammatory diseases of female 
pelvic organs_12m No No No Yes 
N70_N77_24m 
Inflammatory diseases of female 
pelvic organs_24m No No No Yes 
N70_N77_48m 
Inflammatory diseases of female 
pelvic organs_48m No Yes No Yes 
N80_N98_6m 
Noninflammatory disorders of 
female genital tract_6m No Yes No Yes 
N80_N98_12m 
Noninflammatory disorders of 
female genital tract_12m No Yes No Yes 
N80_N98_24m 
Noninflammatory disorders of 
female genital tract_24m No Yes No Yes 
N80_N98_48m 
Noninflammatory disorders of 
female genital tract_48m No Yes No Yes 
N99_N99_6m 
Intraoperative and postprocedural 
complications and disorders of 
genitourinary system, not 
elsewhere classified_6m No No No No 
N99_N99_12m 
Intraoperative and postprocedural 
complications and disorders of 
genitourinary system, not 





Intraoperative and postprocedural 
complications and disorders of 
genitourinary system, not 
elsewhere classified_24m No No No No 
N99_N99_48m 
Intraoperative and postprocedural 
complications and disorders of 
genitourinary system, not 
elsewhere classified_48m No No No No 
O00_O08_6m 
Pregnancy with abortive 
outcome_6m No No No Yes 
O00_O08_12m 
Pregnancy with abortive 
outcome_12m No Yes No Yes 
O00_O08_24m 
Pregnancy with abortive 
outcome_24m No Yes No Yes 
O00_O08_48m 
Pregnancy with abortive 
outcome_48m No Yes No Yes 
O09_O09_6m 
Supervision of high risk 
pregnancy_6m No No No No 
O09_O09_12m 
Supervision of high risk 
pregnancy_12m No No No No 
O09_O09_24m 
Supervision of high risk 
pregnancy_24m No No No No 
O09_O09_48m 
Supervision of high risk 
pregnancy_48m No No No No 
O10_O16_6m 
Edema, proteinuria and 
hypertensive disorders in 
pregnancy, childbirth and the 
puerperium_6m No No No No 
O10_O16_12m 
Edema, proteinuria and 




pregnancy, childbirth and the 
puerperium_12m 
O10_O16_24m 
Edema, proteinuria and 
hypertensive disorders in 
pregnancy, childbirth and the 
puerperium_24m No No No No 
O10_O16_48m 
Edema, proteinuria and 
hypertensive disorders in 
pregnancy, childbirth and the 
puerperium_48m No No No Yes 
O20_O29_6m 
Other maternal disorders 
predominantly related to 
pregnancy_6m No No No No 
O20_O29_12m 
Other maternal disorders 
predominantly related to 
pregnancy_12m No No No Yes 
O20_O29_24m 
Other maternal disorders 
predominantly related to 
pregnancy_24m No No No Yes 
O20_O29_48m 
Other maternal disorders 
predominantly related to 
pregnancy_48m No No No Yes 
O30_O48_6m 
Maternal care related to the fetus 
and amniotic cavity and possible 
delivery problems_6m No No No No 
O30_O48_12m 
Maternal care related to the fetus 
and amniotic cavity and possible 





Maternal care related to the fetus 
and amniotic cavity and possible 
delivery problems_24m No No No Yes 
O30_O48_48m 
Maternal care related to the fetus 
and amniotic cavity and possible 
delivery problems_48m No No No Yes 
O60_O77_6m 
Complications of labor and 
delivery_6m No No No No 
O60_O77_12m 
Complications of labor and 
delivery_12m No No No Yes 
O60_O77_24m 
Complications of labor and 
delivery_24m No No No Yes 
O60_O77_48m 
Complications of labor and 
delivery_48m No Yes No Yes 
O80_O82_6m Encounter for delivery_6m No No No Yes 
O80_O82_12m Encounter for delivery_12m No No No Yes 
O80_O82_24m Encounter for delivery_24m No Yes No Yes 
O80_O82_48m Encounter for delivery_48m No Yes No Yes 
O85_O92_6m 
Complications predominantly 
related to the puerperium_6m No No No No 
O85_O92_12m 
Complications predominantly 
related to the puerperium_12m No No No No 
O85_O92_24m 
Complications predominantly 
related to the puerperium_24m No No No Yes 
O85_O92_48m 
Complications predominantly 
related to the puerperium_48m No No No Yes 
O94_O9A_6m 
Other obstetric conditions, not 
elsewhere classified_6m No No No No 
O94_O9A_12m 
Other obstetric conditions, not 





Other obstetric conditions, not 
elsewhere classified_24m No No No Yes 
O94_O9A_48m 
Other obstetric conditions, not 
elsewhere classified_48m No No No Yes 
P00_P04_6m 
Newborn affected by maternal 
factors and by complications of 
pregnancy, labor, and delivery_6m No No No No 
P00_P04_12m 
Newborn affected by maternal 
factors and by complications of 
pregnancy, labor, and 
delivery_12m No No No No 
P00_P04_24m 
Newborn affected by maternal 
factors and by complications of 
pregnancy, labor, and 
delivery_24m No No No No 
P00_P04_48m 
Newborn affected by maternal 
factors and by complications of 
pregnancy, labor, and 
delivery_48m No No No No 
P05_P08_6m 
Disorders of newborn related to 
length of gestation and fetal 
growth_6m No No No No 
P05_P08_12m 
Disorders of newborn related to 
length of gestation and fetal 
growth_12m No No No No 
P05_P08_24m 
Disorders of newborn related to 
length of gestation and fetal 





Disorders of newborn related to 
length of gestation and fetal 
growth_48m No No No No 
P09_P09_6m 
Abnormal findings on neonatal 
screening_6m No No No No 
P09_P09_12m 
Abnormal findings on neonatal 
screening_12m No No No No 
P09_P09_24m 
Abnormal findings on neonatal 
screening_24m No No No No 
P09_P09_48m 
Abnormal findings on neonatal 
screening_48m No No No No 
P10_P15_6m Birth trauma_6m No No No No 
P10_P15_12m Birth trauma_12m No No No No 
P10_P15_24m Birth trauma_24m No No No No 
P10_P15_48m Birth trauma_48m No No No No 
P19_P29_6m 
Respiratory and cardiovascular 
disorders specific to the perinatal 
period_6m No No No No 
P19_P29_12m 
Respiratory and cardiovascular 
disorders specific to the perinatal 
period_12m No No No No 
P19_P29_24m 
Respiratory and cardiovascular 
disorders specific to the perinatal 
period_24m No No No No 
P19_P29_48m 
Respiratory and cardiovascular 
disorders specific to the perinatal 
period_48m No No No No 
P35_P39_6m 
Infections specific to the perinatal 





Infections specific to the perinatal 
period_12m No No No No 
P35_P39_24m 
Infections specific to the perinatal 
period_24m No No No No 
P35_P39_48m 
Infections specific to the perinatal 
period_48m No No No No 
P50_P61_6m 
Hemorrhagic and hematological 
disorders of newborn_6m No No No No 
P50_P61_12m 
Hemorrhagic and hematological 
disorders of newborn_12m No No No No 
P50_P61_24m 
Hemorrhagic and hematological 
disorders of newborn_24m No No No No 
P50_P61_48m 
Hemorrhagic and hematological 
disorders of newborn_48m No No No No 
P70_P74_6m 
Transitory endocrine and 
metabolic disorders specific to 
newborn_6m No No No No 
P70_P74_12m 
Transitory endocrine and 
metabolic disorders specific to 
newborn_12m No No No No 
P70_P74_24m 
Transitory endocrine and 
metabolic disorders specific to 
newborn_24m No No No No 
P70_P74_48m 
Transitory endocrine and 
metabolic disorders specific to 
newborn_48m No No No No 
P76_P78_6m 
Digestive system disorders of 
newborn_6m No No No No 
P76_P78_12m 
Digestive system disorders of 





Digestive system disorders of 
newborn_24m No No No No 
P76_P78_48m 
Digestive system disorders of 
newborn_48m No No No No 
P80_P83_6m 
Conditions involving the 
integument and temperature 
regulation of newborn_6m No No No No 
P80_P83_12m 
Conditions involving the 
integument and temperature 
regulation of newborn_12m No No No No 
P80_P83_24m 
Conditions involving the 
integument and temperature 
regulation of newborn_24m No No No No 
P80_P83_48m 
Conditions involving the 
integument and temperature 
regulation of newborn_48m No No No No 
P84_P84_6m Other problems with newborn_6m No No No No 
P84_P84_12m 
Other problems with 
newborn_12m No No No No 
P84_P84_24m 
Other problems with 
newborn_24m No No No No 
P84_P84_48m 
Other problems with 
newborn_48m No No No No 
P90_P96_6m 
Other disorders originating in the 
perinatal period_6m No No No No 
P90_P96_12m 
Other disorders originating in the 
perinatal period_12m No No No No 
P90_P96_24m 
Other disorders originating in the 





Other disorders originating in the 
perinatal period_48m No No No No 
Q00_Q07_6m 
Congenital malformations of the 
nervous system_6m No No No No 
Q00_Q07_12m 
Congenital malformations of the 
nervous system_12m No No No No 
Q00_Q07_24m 
Congenital malformations of the 
nervous system_24m No No No No 
Q00_Q07_48m 
Congenital malformations of the 
nervous system_48m No No No No 
Q10_Q18_6m 
Congenital malformations of eye, 
ear, face and neck_6m No No No No 
Q10_Q18_12m 
Congenital malformations of eye, 
ear, face and neck_12m No No No No 
Q10_Q18_24m 
Congenital malformations of eye, 
ear, face and neck_24m No No No No 
Q10_Q18_48m 
Congenital malformations of eye, 
ear, face and neck_48m No No No Yes 
Q20_Q28_6m 
Congenital malformations of the 
circulatory system_6m No No No No 
Q20_Q28_12m 
Congenital malformations of the 
circulatory system_12m No No No No 
Q20_Q28_24m 
Congenital malformations of the 
circulatory system_24m No No No No 
Q20_Q28_48m 
Congenital malformations of the 
circulatory system_48m No No No No 
Q30_Q34_6m 
Congenital malformations of the 
respiratory system_6m No No No No 
Q30_Q34_12m 
Congenital malformations of the 





Congenital malformations of the 
respiratory system_24m No No No No 
Q30_Q34_48m 
Congenital malformations of the 
respiratory system_48m No No No No 
Q35_Q37_6m Cleft lip and cleft palate_6m No No No No 
Q35_Q37_12m Cleft lip and cleft palate_12m No No No No 
Q35_Q37_24m Cleft lip and cleft palate_24m No No No No 
Q35_Q37_48m Cleft lip and cleft palate_48m No No No No 
Q38_Q45_6m 
Other congenital malformations of 
the digestive system_6m No No No No 
Q38_Q45_12m 
Other congenital malformations of 
the digestive system_12m No No No No 
Q38_Q45_24m 
Other congenital malformations of 
the digestive system_24m No No No No 
Q38_Q45_48m 
Other congenital malformations of 
the digestive system_48m No No No No 
Q50_Q56_6m 
Congenital malformations of 
genital organs_6m No No No No 
Q50_Q56_12m 
Congenital malformations of 
genital organs_12m No No No No 
Q50_Q56_24m 
Congenital malformations of 
genital organs_24m No No No No 
Q50_Q56_48m 
Congenital malformations of 
genital organs_48m No No No No 
Q60_Q64_6m 
Congenital malformations of the 
urinary system_6m No No No No 
Q60_Q64_12m 
Congenital malformations of the 
urinary system_12m No No No No 
Q60_Q64_24m 
Congenital malformations of the 





Congenital malformations of the 
urinary system_48m No No No No 
Q65_Q79_6m 
Congenital malformations and 
deformations of the 
musculoskeletal system_6m No No No No 
Q65_Q79_12m 
Congenital malformations and 
deformations of the 
musculoskeletal system_12m No No No No 
Q65_Q79_24m 
Congenital malformations and 
deformations of the 
musculoskeletal system_24m No No No No 
Q65_Q79_48m 
Congenital malformations and 
deformations of the 
musculoskeletal system_48m No No No Yes 
Q80_Q89_6m 
Other congenital 
malformations_6m No No No No 
Q80_Q89_12m 
Other congenital 
malformations_12m No No No No 
Q80_Q89_24m 
Other congenital 
malformations_24m No No No No 
Q80_Q89_48m 
Other congenital 
malformations_48m No No No Yes 
Q90_Q99_6m 
Chromosomal abnormalities, not 
elsewhere classified_6m No No No No 
Q90_Q99_12m 
Chromosomal abnormalities, not 
elsewhere classified_12m No No No No 
Q90_Q99_24m 
Chromosomal abnormalities, not 
elsewhere classified_24m No No No No 
Q90_Q99_48m 
Chromosomal abnormalities, not 





Symptoms and signs involving the 
circulatory and respiratory 
systems_6m Yes Yes Yes Yes 
R00_R09_12m 
Symptoms and signs involving the 
circulatory and respiratory 
systems_12m Yes Yes Yes Yes 
R00_R09_24m 
Symptoms and signs involving the 
circulatory and respiratory 
systems_24m Yes Yes Yes Yes 
R00_R09_48m 
Symptoms and signs involving the 
circulatory and respiratory 
systems_48m Yes Yes Yes Yes 
R10_R19_6m 
Symptoms and signs involving the 
digestive system and 
abdomen_6m Yes Yes Yes Yes 
R10_R19_12m 
Symptoms and signs involving the 
digestive system and 
abdomen_12m Yes Yes Yes Yes 
R10_R19_24m 
Symptoms and signs involving the 
digestive system and 
abdomen_24m Yes Yes Yes Yes 
R10_R19_48m 
Symptoms and signs involving the 
digestive system and 
abdomen_48m Yes Yes Yes Yes 
R20_R23_6m 
Symptoms and signs involving the 
skin and subcutaneous tissue_6m No No No No 
R20_R23_12m 
Symptoms and signs involving the 
skin and subcutaneous 





Symptoms and signs involving the 
skin and subcutaneous 
tissue_24m No No No Yes 
R20_R23_48m 
Symptoms and signs involving the 
skin and subcutaneous 
tissue_48m No Yes No Yes 
R25_R29_6m 
Symptoms and signs involving the 
nervous and musculoskeletal 
systems_6m Yes Yes Yes Yes 
R25_R29_12m 
Symptoms and signs involving the 
nervous and musculoskeletal 
systems_12m Yes Yes Yes Yes 
R25_R29_24m 
Symptoms and signs involving the 
nervous and musculoskeletal 
systems_24m Yes Yes Yes Yes 
R25_R29_48m 
Symptoms and signs involving the 
nervous and musculoskeletal 
systems_48m Yes Yes Yes Yes 
R30_R39_6m 
Symptoms and signs involving the 
genitourinary system_6m Yes No Yes Yes 
R30_R39_12m 
Symptoms and signs involving the 
genitourinary system_12m Yes Yes Yes Yes 
R30_R39_24m 
Symptoms and signs involving the 
genitourinary system_24m Yes Yes Yes Yes 
R30_R39_48m 
Symptoms and signs involving the 
genitourinary system_48m Yes Yes Yes Yes 
R40_R46_6m 
Symptoms and signs involving 
cognition, perception, emotional 





Symptoms and signs involving 
cognition, perception, emotional 
state and behavior_12m Yes Yes Yes Yes 
R40_R46_24m 
Symptoms and signs involving 
cognition, perception, emotional 
state and behavior_24m Yes Yes Yes Yes 
R40_R46_48m 
Symptoms and signs involving 
cognition, perception, emotional 
state and behavior_48m Yes Yes Yes Yes 
R47_R49_6m 
Symptoms and signs involving 
speech and voice_6m No No No No 
R47_R49_12m 
Symptoms and signs involving 
speech and voice_12m No No No No 
R47_R49_24m 
Symptoms and signs involving 
speech and voice_24m No No No No 
R47_R49_48m 
Symptoms and signs involving 
speech and voice_48m No No No Yes 
R50_R69_6m General symptoms and signs_6m Yes Yes Yes Yes 
R50_R69_12m 
General symptoms and 
signs_12m Yes Yes Yes Yes 
R50_R69_24m 
General symptoms and 
signs_24m Yes Yes Yes Yes 
R50_R69_48m 
General symptoms and 
signs_48m Yes Yes Yes Yes 
R70_R79_6m 
Abnormal findings on examination 
of blood, without diagnosis_6m No No No No 
R70_R79_12m 
Abnormal findings on examination 
of blood, without diagnosis_12m Yes No No Yes 
R70_R79_24m 
Abnormal findings on examination 





Abnormal findings on examination 
of blood, without diagnosis_48m Yes No Yes Yes 
R80_R82_6m 
Abnormal findings on examination 
of urine, without diagnosis_6m No No No No 
R80_R82_12m 
Abnormal findings on examination 
of urine, without diagnosis_12m No No No No 
R80_R82_24m 
Abnormal findings on examination 
of urine, without diagnosis_24m No No No No 
R80_R82_48m 
Abnormal findings on examination 
of urine, without diagnosis_48m No No No No 
R83_R89_6m 
Abnormal findings on examination 
of other body fluids, substances 
and tissues, without diagnosis_6m No No No No 
R83_R89_12m 
Abnormal findings on examination 
of other body fluids, substances 
and tissues, without 
diagnosis_12m No No No No 
R83_R89_24m 
Abnormal findings on examination 
of other body fluids, substances 
and tissues, without 
diagnosis_24m No No No No 
R83_R89_48m 
Abnormal findings on examination 
of other body fluids, substances 
and tissues, without 
diagnosis_48m No No No Yes 
R90_R94_6m 
Abnormal findings on diagnostic 
imaging and in function studies, 





Abnormal findings on diagnostic 
imaging and in function studies, 
without diagnosis_12m Yes Yes No Yes 
R90_R94_24m 
Abnormal findings on diagnostic 
imaging and in function studies, 
without diagnosis_24m Yes Yes Yes Yes 
R90_R94_48m 
Abnormal findings on diagnostic 
imaging and in function studies, 
without diagnosis_48m Yes Yes Yes Yes 
R97_R97_6m Abnormal tumor markers_6m No No No No 
R97_R97_12m Abnormal tumor markers_12m No No No No 
R97_R97_24m Abnormal tumor markers_24m No No No No 
R97_R97_48m Abnormal tumor markers_48m No No No No 
R99_R99_6m 
Ill-defined and unknown cause of 
mortality_6m No No No No 
R99_R99_12m 
Ill-defined and unknown cause of 
mortality_12m No No No No 
R99_R99_24m 
Ill-defined and unknown cause of 
mortality_24m No No No No 
R99_R99_48m 
Ill-defined and unknown cause of 
mortality_48m No No No No 
S00_S09_6m Injuries to the head_6m Yes Yes Yes Yes 
S00_S09_12m Injuries to the head_12m Yes Yes Yes Yes 
S00_S09_24m Injuries to the head_24m Yes Yes Yes Yes 
S00_S09_48m Injuries to the head_48m Yes Yes Yes Yes 
S10_S19_6m Injuries to the neck_6m No No No No 
S10_S19_12m Injuries to the neck_12m No No No No 




S10_S19_48m Injuries to the neck_48m Yes Yes Yes Yes 
S20_S29_6m Injuries to the thorax_6m Yes No Yes Yes 
S20_S29_12m Injuries to the thorax_12m Yes No Yes Yes 
S20_S29_24m Injuries to the thorax_24m Yes Yes Yes Yes 
S20_S29_48m Injuries to the thorax_48m Yes Yes Yes Yes 
S30_S39_6m 
Injuries to the abdomen, lower 
back, lumbar spine, pelvis and 
external genitals_6m Yes Yes Yes Yes 
S30_S39_12m 
Injuries to the abdomen, lower 
back, lumbar spine, pelvis and 
external genitals_12m Yes Yes Yes Yes 
S30_S39_24m 
Injuries to the abdomen, lower 
back, lumbar spine, pelvis and 
external genitals_24m Yes Yes Yes Yes 
S30_S39_48m 
Injuries to the abdomen, lower 
back, lumbar spine, pelvis and 
external genitals_48m Yes Yes Yes Yes 
S40_S49_6m 
Injuries to the shoulder and upper 
arm_6m Yes Yes Yes Yes 
S40_S49_12m 
Injuries to the shoulder and upper 
arm_12m Yes Yes Yes Yes 
S40_S49_24m 
Injuries to the shoulder and upper 
arm_24m Yes Yes Yes Yes 
S40_S49_48m 
Injuries to the shoulder and upper 
arm_48m Yes Yes Yes Yes 
S50_S59_6m 
Injuries to the elbow and 
forearm_6m No Yes Yes Yes 
S50_S59_12m 
Injuries to the elbow and 





Injuries to the elbow and 
forearm_24m Yes Yes Yes Yes 
S50_S59_48m 
Injuries to the elbow and 
forearm_48m Yes Yes Yes Yes 
S60_S69_6m 
Injuries to the wrist, hand and 
fingers_6m Yes Yes Yes Yes 
S60_S69_12m 
Injuries to the wrist, hand and 
fingers_12m Yes Yes Yes Yes 
S60_S69_24m 
Injuries to the wrist, hand and 
fingers_24m Yes Yes Yes Yes 
S60_S69_48m 
Injuries to the wrist, hand and 
fingers_48m Yes Yes Yes Yes 
S70_S79_6m Injuries to the hip and thigh_6m No No No Yes 
S70_S79_12m Injuries to the hip and thigh_12m No Yes No Yes 
S70_S79_24m Injuries to the hip and thigh_24m Yes Yes Yes Yes 
S70_S79_48m Injuries to the hip and thigh_48m Yes Yes Yes Yes 
S80_S89_6m 
Injuries to the knee and lower 
leg_6m No Yes Yes Yes 
S80_S89_12m 
Injuries to the knee and lower 
leg_12m Yes Yes Yes Yes 
S80_S89_24m 
Injuries to the knee and lower 
leg_24m Yes Yes Yes Yes 
S80_S89_48m 
Injuries to the knee and lower 
leg_48m Yes Yes Yes Yes 
S90_S99_6m Injuries to the ankle and foot_6m No No No Yes 
S90_S99_12m Injuries to the ankle and foot_12m No No No Yes 
S90_S99_24m Injuries to the ankle and foot_24m Yes No Yes Yes 





Injuries involving multiple body 
regions_6m No No No No 
T07_T07_12m 
Injuries involving multiple body 
regions_12m No No No No 
T07_T07_24m 
Injuries involving multiple body 
regions_24m No No No No 
T07_T07_48m 
Injuries involving multiple body 
regions_48m No No No Yes 
T14_T14_6m 
Injury of unspecified body 
region_6m No No No No 
T14_T14_12m 
Injury of unspecified body 
region_12m No No No No 
T14_T14_24m 
Injury of unspecified body 
region_24m No No Yes No 
T14_T14_48m 
Injury of unspecified body 
region_48m Yes No Yes Yes 
T15_T19_6m 
Effects of foreign body entering 
through natural orifice_6m No No No No 
T15_T19_12m 
Effects of foreign body entering 
through natural orifice_12m No No No No 
T15_T19_24m 
Effects of foreign body entering 
through natural orifice_24m No No No Yes 
T15_T19_48m 
Effects of foreign body entering 
through natural orifice_48m No No Yes Yes 
T20_T25_6m 
Burns and corrosions of external 
body surface, specified by site_6m No No No No 
T20_T25_12m 
Burns and corrosions of external 
body surface, specified by 





Burns and corrosions of external 
body surface, specified by 
site_24m No No No No 
T20_T25_48m 
Burns and corrosions of external 
body surface, specified by 
site_48m No No No Yes 
T26_T28_6m 
Burns and corrosions confined to 
eye and internal organs_6m No No No No 
T26_T28_12m 
Burns and corrosions confined to 
eye and internal organs_12m No No No No 
T26_T28_24m 
Burns and corrosions confined to 
eye and internal organs_24m No No No No 
T26_T28_48m 
Burns and corrosions confined to 
eye and internal organs_48m No No No No 
T30_T32_6m 
Burns and corrosions of multiple 
and unspecified body regions_6m No No No No 
T30_T32_12m 
Burns and corrosions of multiple 
and unspecified body 
regions_12m No No No No 
T30_T32_24m 
Burns and corrosions of multiple 
and unspecified body 
regions_24m No No No No 
T30_T32_48m 
Burns and corrosions of multiple 
and unspecified body 
regions_48m No No No No 
T33_T34_6m Frostbite_6m No No No No 
T33_T34_12m Frostbite_12m No No No No 
T33_T34_24m Frostbite_24m No No No No 





Poisoning by, adverse effect of 
and underdosing of drugs, 
medicaments and biological 
substances_6m Yes Yes Yes Yes 
T36_T50_12m 
Poisoning by, adverse effect of 
and underdosing of drugs, 
medicaments and biological 
substances_12m Yes Yes Yes Yes 
T36_T50_24m 
Poisoning by, adverse effect of 
and underdosing of drugs, 
medicaments and biological 
substances_24m Yes Yes Yes Yes 
T36_T50_48m 
Poisoning by, adverse effect of 
and underdosing of drugs, 
medicaments and biological 
substances_48m Yes Yes Yes Yes 
T51_T65_6m 
Toxic effects of substances chiefly 
nonmedicinal as to source_6m Yes No Yes No 
T51_T65_12m 
Toxic effects of substances chiefly 
nonmedicinal as to source_12m Yes Yes Yes Yes 
T51_T65_24m 
Toxic effects of substances chiefly 
nonmedicinal as to source_24m Yes Yes Yes Yes 
T51_T65_48m 
Toxic effects of substances chiefly 
nonmedicinal as to source_48m Yes Yes Yes Yes 
T66_T78_6m 
Other and unspecified effects of 
external causes_6m No Yes No Yes 
T66_T78_12m 
Other and unspecified effects of 
external causes_12m Yes Yes Yes Yes 
T66_T78_24m 
Other and unspecified effects of 





Other and unspecified effects of 
external causes_48m Yes Yes Yes Yes 
T79_T79_6m 
Certain early complications of 
trauma_6m No No No No 
T79_T79_12m 
Certain early complications of 
trauma_12m No No No No 
T79_T79_24m 
Certain early complications of 
trauma_24m No No No Yes 
T79_T79_48m 
Certain early complications of 
trauma_48m No No Yes Yes 
T80_T88_6m 
Complications of surgical and 
medical care, not elsewhere 
classified_6m Yes Yes Yes Yes 
T80_T88_12m 
Complications of surgical and 
medical care, not elsewhere 
classified_12m Yes Yes Yes Yes 
T80_T88_24m 
Complications of surgical and 
medical care, not elsewhere 
classified_24m Yes Yes Yes Yes 
T80_T88_48m 
Complications of surgical and 
medical care, not elsewhere 
classified_48m Yes Yes Yes Yes 
V00_V09_6m Placental characteristics_6m No No No No 
V00_V09_12m Placental characteristics_12m No No No No 
V00_V09_24m Placental characteristics_24m No No No No 
V00_V09_48m Placental characteristics_48m No No No No 
V10_V19_6m Placental characteristics_6m No No No No 
V10_V19_12m Placental characteristics_12m No No No No 




V10_V19_48m Placental characteristics_48m No No No No 
V20_V29_6m Placental characteristics_6m No No No No 
V20_V29_12m Placental characteristics_12m No No No No 
V20_V29_24m Placental characteristics_24m No No No No 
V20_V29_48m Placental characteristics_48m No No No No 
V30_V39_6m Placental characteristics_6m No No No No 
V30_V39_12m Placental characteristics_12m No No No No 
V30_V39_24m Placental characteristics_24m No No No No 
V30_V39_48m Placental characteristics_48m No No No No 
V40_V49_6m Placental characteristics_6m No No No No 
V40_V49_12m Placental characteristics_12m No No No No 
V40_V49_24m Placental characteristics_24m No No No No 
V40_V49_48m Placental characteristics_48m No No No No 
V50_V59_6m Placental characteristics_6m No No No No 
V50_V59_12m Placental characteristics_12m No No No No 
V50_V59_24m Placental characteristics_24m No No No No 
V50_V59_48m Placental characteristics_48m No No No No 
V60_V69_6m Placental characteristics_6m No No No No 
V60_V69_12m Placental characteristics_12m No No No No 
V60_V69_24m Placental characteristics_24m No No No No 
V60_V69_48m Placental characteristics_48m No No No No 
V70_V79_6m Placental characteristics_6m No No No No 
V70_V79_12m Placental characteristics_12m No No No No 
V70_V79_24m Placental characteristics_24m No No No No 
V70_V79_48m Placental characteristics_48m No No No No 




V80_V89_12m Placental characteristics_12m No No No No 
V80_V89_24m Placental characteristics_24m No No No No 
V80_V89_48m Placental characteristics_48m No No No No 
V90_V94_6m Placental characteristics_6m No No No No 
V90_V94_12m Placental characteristics_12m No No No No 
V90_V94_24m Placental characteristics_24m No No No No 
V90_V94_48m Placental characteristics_48m No No No No 
V95_V97_6m Placental characteristics_6m No No No No 
V95_V97_12m Placental characteristics_12m No No No No 
V95_V97_24m Placental characteristics_24m No No No No 
V95_V97_48m Placental characteristics_48m No No No No 
V98_V99_6m Placental characteristics_6m No No No No 
V98_V99_12m Placental characteristics_12m No No No No 
V98_V99_24m Placental characteristics_24m No No No No 
V98_V99_48m Placental characteristics_48m No No No No 
W00_W19_6m 
Slipping, tripping, stumbling and 
falls_6m No No No No 
W00_W19_12m 
Slipping, tripping, stumbling and 
falls_12m No No No No 
W00_W19_24m 
Slipping, tripping, stumbling and 
falls_24m No No No No 
W00_W19_48m 
Slipping, tripping, stumbling and 
falls_48m No No No No 
W20_W49_6m 
Exposure to inanimate mechanical 
forces_6m No No No No 
W20_W49_12m 
Exposure to inanimate mechanical 





Exposure to inanimate mechanical 
forces_24m No No No No 
W20_W49_48m 
Exposure to inanimate mechanical 
forces_48m No No No No 
W50_W64_6m 
Exposure to animate mechanical 
forces_6m No No No No 
W50_W64_12m 
Exposure to animate mechanical 
forces_12m No No No No 
W50_W64_24m 
Exposure to animate mechanical 
forces_24m No No No No 
W50_W64_48m 
Exposure to animate mechanical 
forces_48m No No No No 
W65_W74_6m 
Accidental non-transport drowning 
and submersion_6m No No No No 
W65_W74_12m 
Accidental non-transport drowning 
and submersion_12m No No No No 
W65_W74_24m 
Accidental non-transport drowning 
and submersion_24m No No No No 
W65_W74_48m 
Accidental non-transport drowning 
and submersion_48m No No No No 
W85_W99_6m 
Exposure to electric current, 
radiation and extreme ambient air 
temperature and pressure_6m No No No No 
W85_W99_12m 
Exposure to electric current, 
radiation and extreme ambient air 
temperature and pressure_12m No No No No 
W85_W99_24m 
Exposure to electric current, 
radiation and extreme ambient air 





Exposure to electric current, 
radiation and extreme ambient air 
temperature and pressure_48m No No No No 
X00_X08_6m 
Exposure to smoke, fire and 
flames_6m No No No No 
X00_X08_12m 
Exposure to smoke, fire and 
flames_12m No No No No 
X00_X08_24m 
Exposure to smoke, fire and 
flames_24m No No No No 
X00_X08_48m 
Exposure to smoke, fire and 
flames_48m No No No No 
X10_X19_6m 
Contact with heat and hot 
substances_6m No No No No 
X10_X19_12m 
Contact with heat and hot 
substances_12m No No No No 
X10_X19_24m 
Contact with heat and hot 
substances_24m No No No No 
X10_X19_48m 
Contact with heat and hot 
substances_48m No No No No 
X30_X39_6m Exposure to forces of nature_6m No No No No 
X30_X39_12m Exposure to forces of nature_12m No No No No 
X30_X39_24m Exposure to forces of nature_24m No No No No 
X30_X39_48m Exposure to forces of nature_48m No No No No 
X50_X50_6m 
Overexertion and strenuous or 
repetitive movements_6m No No No No 
X50_X50_12m 
Overexertion and strenuous or 
repetitive movements_12m No No No No 
X50_X50_24m 
Overexertion and strenuous or 





Overexertion and strenuous or 
repetitive movements_48m No No No No 
X52_X58_6m 
Accidental exposure to other 
specified factors_6m No No No No 
X52_X58_12m 
Accidental exposure to other 
specified factors_12m No No No No 
X52_X58_24m 
Accidental exposure to other 
specified factors_24m No No No No 
X52_X58_48m 
Accidental exposure to other 
specified factors_48m No No No No 
X71_X83_6m Intentional self-harm_6m No No No No 
X71_X83_12m Intentional self-harm_12m No No No No 
X71_X83_24m Intentional self-harm_24m No No No No 
X71_X83_48m Intentional self-harm_48m No No No No 
X92_Y09_6m Assault_6m No No No No 
X92_Y09_12m Assault_12m No No No No 
X92_Y09_24m Assault_24m No No No No 
X92_Y09_48m Assault_48m No No No No 
Y21_Y33_6m Event of undetermined intent_6m No No No No 
Y21_Y33_12m Event of undetermined intent_12m No No No No 
Y21_Y33_24m Event of undetermined intent_24m No No No No 
Y21_Y33_48m Event of undetermined intent_48m No No No No 
Y35_Y38_6m 
Legal intervention, operations of 
war, military operations, and 
terrorism_6m No No No No 
Y35_Y38_12m 
Legal intervention, operations of 
war, military operations, and 





Legal intervention, operations of 
war, military operations, and 
terrorism_24m No No No No 
Y35_Y38_48m 
Legal intervention, operations of 
war, military operations, and 
terrorism_48m No No No No 
Y62_Y69_6m 
Misadventures to patients during 
surgical and medical care_6m No No No No 
Y62_Y69_12m 
Misadventures to patients during 
surgical and medical care_12m No No No No 
Y62_Y69_24m 
Misadventures to patients during 
surgical and medical care_24m No No No No 
Y62_Y69_48m 
Misadventures to patients during 
surgical and medical care_48m No No No No 
Y70_Y82_6m 
Medical devices associated with 
adverse incidents in diagnostic 
and therapeutic use_6m No No No No 
Y70_Y82_12m 
Medical devices associated with 
adverse incidents in diagnostic 
and therapeutic use_12m No No No No 
Y70_Y82_24m 
Medical devices associated with 
adverse incidents in diagnostic 
and therapeutic use_24m No No No No 
Y70_Y82_48m 
Medical devices associated with 
adverse incidents in diagnostic 
and therapeutic use_48m No No No No 
Y83_Y84_6m 
Surgical and other medical 
procedures as the cause of 
abnormal reaction of the patient, 




mention of misadventure at the 
time of the procedure_6m 
Y83_Y84_12m 
Surgical and other medical 
procedures as the cause of 
abnormal reaction of the patient, 
or of later complication, without 
mention of misadventure at the 
time of the procedure_12m No No No No 
Y83_Y84_24m 
Surgical and other medical 
procedures as the cause of 
abnormal reaction of the patient, 
or of later complication, without 
mention of misadventure at the 
time of the procedure_24m No No No No 
Y83_Y84_48m 
Surgical and other medical 
procedures as the cause of 
abnormal reaction of the patient, 
or of later complication, without 
mention of misadventure at the 
time of the procedure_48m No No No No 
Y90_Y99_6m 
Supplementary factors related to 
causes of morbidity classified 
elsewhere_6m No No No No 
Y90_Y99_12m 
Supplementary factors related to 
causes of morbidity classified 
elsewhere_12m No No No No 
Y90_Y99_24m 
Supplementary factors related to 
causes of morbidity classified 





Supplementary factors related to 
causes of morbidity classified 
elsewhere_48m No No No No 
Z00_Z13_6m 
Persons encountering health 
services for examinations_6m Yes Yes Yes Yes 
Z00_Z13_12m 
Persons encountering health 
services for examinations_12m Yes Yes Yes Yes 
Z00_Z13_24m 
Persons encountering health 
services for examinations_24m Yes Yes Yes Yes 
Z00_Z13_48m 
Persons encountering health 
services for examinations_48m Yes Yes Yes Yes 
Z14_Z15_6m 
Genetic carrier and genetic 
susceptibility to disease_6m No No No No 
Z14_Z15_12m 
Genetic carrier and genetic 
susceptibility to disease_12m No No No No 
Z14_Z15_24m 
Genetic carrier and genetic 
susceptibility to disease_24m No No No No 
Z14_Z15_48m 
Genetic carrier and genetic 
susceptibility to disease_48m No No No No 
Z16_Z16_6m 
Resistance to antimicrobial 
drugs_6m No No No No 
Z16_Z16_12m 
Resistance to antimicrobial 
drugs_12m No No No No 
Z16_Z16_24m 
Resistance to antimicrobial 
drugs_24m No No No No 
Z16_Z16_48m 
Resistance to antimicrobial 
drugs_48m No No No No 
Z17_Z17_6m Estrogen receptor status_6m No No No No 
Z17_Z17_12m Estrogen receptor status_12m No No No No 




Z17_Z17_48m Estrogen receptor status_48m No No No No 
Z18_Z18_6m 
Retained foreign body 
fragments_6m No No No No 
Z18_Z18_12m 
Retained foreign body 
fragments_12m No No No No 
Z18_Z18_24m 
Retained foreign body 
fragments_24m No No No No 
Z18_Z18_48m 
Retained foreign body 
fragments_48m No No No No 
Z19_Z19_6m 
Hormone sensitivity malignancy 
status_6m No No No No 
Z19_Z19_12m 
Hormone sensitivity malignancy 
status_12m No No No No 
Z19_Z19_24m 
Hormone sensitivity malignancy 
status_24m No No No No 
Z19_Z19_48m 
Hormone sensitivity malignancy 
status_48m No No No No 
Z20_Z29_6m 
Persons with potential health 
hazards related to communicable 
diseases_6m No No No No 
Z20_Z29_12m 
Persons with potential health 
hazards related to communicable 
diseases_12m No No No Yes 
Z20_Z29_24m 
Persons with potential health 
hazards related to communicable 
diseases_24m No No Yes Yes 
Z20_Z29_48m 
Persons with potential health 
hazards related to communicable 





Persons encountering health 
services in circumstances related 
to reproduction_6m No Yes No Yes 
Z30_Z39_12m 
Persons encountering health 
services in circumstances related 
to reproduction_12m No Yes No Yes 
Z30_Z39_24m 
Persons encountering health 
services in circumstances related 
to reproduction_24m No Yes No Yes 
Z30_Z39_48m 
Persons encountering health 
services in circumstances related 
to reproduction_48m No Yes Yes Yes 
Z40_Z53_6m 
Encounters for other specific 
health care_6m Yes Yes Yes Yes 
Z40_Z53_12m 
Encounters for other specific 
health care_12m Yes Yes Yes Yes 
Z40_Z53_24m 
Encounters for other specific 
health care_24m Yes Yes Yes Yes 
Z40_Z53_48m 
Encounters for other specific 
health care_48m Yes Yes Yes Yes 
Z55_Z65_6m 
Persons with potential health 
hazards related to socioeconomic 
and psychosocial 
circumstances_6m No No No No 
Z55_Z65_12m 
Persons with potential health 
hazards related to socioeconomic 
and psychosocial 
circumstances_12m No No No No 
Z55_Z65_24m 
Persons with potential health 







Persons with potential health 
hazards related to socioeconomic 
and psychosocial 
circumstances_48m No No No Yes 
Z66_Z66_6m Do not resuscitate status_6m No No No No 
Z66_Z66_12m Do not resuscitate status_12m No No No No 
Z66_Z66_24m Do not resuscitate status_24m No No No No 
Z66_Z66_48m Do not resuscitate status_48m No No No No 
Z67_Z67_6m Blood type_6m No No No No 
Z67_Z67_12m Blood type_12m No No No No 
Z67_Z67_24m Blood type_24m No No No No 
Z67_Z67_48m Blood type_48m No No No No 
Z68_Z68_6m Body mass index (BMI)_6m No No No No 
Z68_Z68_12m Body mass index (BMI)_12m No No No No 
Z68_Z68_24m Body mass index (BMI)_24m No No No No 
Z68_Z68_48m Body mass index (BMI)_48m No No No No 
Z69_Z76_6m 
Persons encountering health 
services in other 
circumstances_6m Yes Yes Yes Yes 
Z69_Z76_12m 
Persons encountering health 
services in other 
circumstances_12m Yes Yes Yes Yes 
Z69_Z76_24m 
Persons encountering health 
services in other 





Persons encountering health 
services in other 
circumstances_48m Yes Yes Yes Yes 
Z77_Z99_6m 
Persons with potential health 
hazards related to family and 
personal history and certain 
conditions influencing health 
status_6m Yes Yes Yes Yes 
Z77_Z99_12m 
Persons with potential health 
hazards related to family and 
personal history and certain 
conditions influencing health 
status_12m Yes Yes Yes Yes 
Z77_Z99_24m 
Persons with potential health 
hazards related to family and 
personal history and certain 
conditions influencing health 
status_24m Yes Yes Yes Yes 
Z77_Z99_48m 
Persons with potential health 
hazards related to family and 
personal history and certain 
conditions influencing health 
status_48m Yes Yes Yes Yes 
F01_6m Vascular dementia_6m No No No No 
F01_12m Vascular dementia_12m No No No No 
F01_24m Vascular dementia_24m No No No No 
F01_48m Vascular dementia_48m No No No No 
F02_6m 
Dementia in other diseases 





Dementia in other diseases 
classified elsewhere_12m No No No No 
F02_24m 
Dementia in other diseases 
classified elsewhere_24m No No No No 
F02_48m 
Dementia in other diseases 
classified elsewhere_48m No No No No 
F03_6m Unspecified dementia_6m Yes No No No 
F03_12m Unspecified dementia_12m Yes Yes Yes Yes 
F03_24m Unspecified dementia_24m Yes Yes Yes Yes 
F03_48m Unspecified dementia_48m Yes Yes Yes Yes 
F04_6m 
Amnestic disorder due to known 
physiological condition_6m No No No No 
F04_12m 
Amnestic disorder due to known 
physiological condition_12m No No No No 
F04_24m 
Amnestic disorder due to known 
physiological condition_24m No No No No 
F04_48m 
Amnestic disorder due to known 
physiological condition_48m No No No No 
F05_6m 
Delirium due to known 
physiological condition_6m No No No Yes 
F05_12m 
Delirium due to known 
physiological condition_12m No No Yes Yes 
F05_24m 
Delirium due to known 
physiological condition_24m Yes No Yes Yes 
F05_48m 
Delirium due to known 
physiological condition_48m Yes No Yes Yes 
F06_6m 
Other mental disorders due to 





Other mental disorders due to 
known physiological 
condition_12m Yes Yes Yes Yes 
F06_24m 
Other mental disorders due to 
known physiological 
condition_24m Yes Yes Yes Yes 
F06_48m 
Other mental disorders due to 
known physiological 
condition_48m Yes Yes Yes Yes 
F07_6m 
Personality and behavioral 
disorders due to known 
physiological condition_6m No No No No 
F07_12m 
Personality and behavioral 
disorders due to known 
physiological condition_12m No No Yes Yes 
F07_24m 
Personality and behavioral 
disorders due to known 
physiological condition_24m Yes No Yes Yes 
F07_48m 
Personality and behavioral 
disorders due to known 
physiological condition_48m Yes No Yes Yes 
F09_6m 
Unspecified mental disorder due 
to known physiological 
condition_6m No No No No 
F09_12m 
Unspecified mental disorder due 
to known physiological 
condition_12m No No No No 
F09_24m 
Unspecified mental disorder due 
to known physiological 





Unspecified mental disorder due 
to known physiological 
condition_48m No No No No 
F10_6m Alcohol related disorders_6m Yes Yes Yes Yes 
F10_12m Alcohol related disorders_12m Yes Yes Yes Yes 
F10_24m Alcohol related disorders_24m Yes Yes Yes Yes 
F10_48m Alcohol related disorders_48m Yes Yes Yes Yes 
F11_6m Opioid related disorders_6m No No No No 
F11_12m Opioid related disorders_12m Yes Yes Yes Yes 
F11_24m Opioid related disorders_24m Yes Yes Yes Yes 
F11_48m Opioid related disorders_48m Yes Yes Yes Yes 
F12_6m Cannabis related disorders_6m Yes No Yes No 
F12_12m Cannabis related disorders_12m Yes No Yes Yes 
F12_24m Cannabis related disorders_24m Yes No Yes Yes 
F12_48m Cannabis related disorders_48m Yes No Yes Yes 
F13_6m 
Sedative, hypnotic, or anxiolytic 
related disorders_6m Yes Yes Yes Yes 
F13_12m 
Sedative, hypnotic, or anxiolytic 
related disorders_12m Yes Yes Yes Yes 
F13_24m 
Sedative, hypnotic, or anxiolytic 
related disorders_24m Yes Yes Yes Yes 
F13_48m 
Sedative, hypnotic, or anxiolytic 
related disorders_48m Yes Yes Yes Yes 
F14_6m Cocaine related disorders_6m No No No No 
F14_12m Cocaine related disorders_12m No No No No 
F14_24m Cocaine related disorders_24m No No No No 





Other stimulant related 
disorders_6m No No No No 
F15_12m 
Other stimulant related 
disorders_12m No No No No 
F15_24m 
Other stimulant related 
disorders_24m No No Yes No 
F15_48m 
Other stimulant related 
disorders_48m Yes No Yes Yes 
F16_6m 
Hallucinogen related 
disorders_6m No No No No 
F16_12m 
Hallucinogen related 
disorders_12m No No No No 
F16_24m 
Hallucinogen related 
disorders_24m No No No No 
F16_48m 
Hallucinogen related 
disorders_48m No No No No 
F17_6m Nicotine dependence_6m No No Yes Yes 
F17_12m Nicotine dependence_12m Yes No Yes Yes 
F17_24m Nicotine dependence_24m Yes Yes Yes Yes 
F17_48m Nicotine dependence_48m Yes Yes Yes Yes 
F18_6m Inhalant related disorders_6m No No No No 
F18_12m Inhalant related disorders_12m No No No No 
F18_24m Inhalant related disorders_24m No No No No 
F18_48m Inhalant related disorders_48m No No No No 
F19_6m 
Other psychoactive substance 
related disorders_6m Yes Yes Yes Yes 
F19_12m 
Other psychoactive substance 





Other psychoactive substance 
related disorders_24m Yes Yes Yes Yes 
F19_48m 
Other psychoactive substance 
related disorders_48m Yes Yes Yes Yes 
F20_6m Schizophrenia_6m Yes Yes Yes Yes 
F20_12m Schizophrenia_12m Yes Yes Yes Yes 
F20_24m Schizophrenia_24m Yes Yes Yes Yes 
F20_48m Schizophrenia_48m Yes Yes Yes Yes 
F21_6m Schizotypal disorder_6m Yes No Yes No 
F21_12m Schizotypal disorder_12m Yes No Yes Yes 
F21_24m Schizotypal disorder_24m Yes Yes Yes Yes 
F21_48m Schizotypal disorder_48m Yes Yes Yes Yes 
F22_6m Delusional disorders_6m No Yes No Yes 
F22_12m Delusional disorders_12m Yes Yes Yes Yes 
F22_24m Delusional disorders_24m Yes Yes Yes Yes 
F22_48m Delusional disorders_48m Yes Yes Yes Yes 
F23_6m Brief psychotic disorder_6m Yes Yes Yes Yes 
F23_12m Brief psychotic disorder_12m Yes Yes Yes Yes 
F23_24m Brief psychotic disorder_24m Yes Yes Yes Yes 
F23_48m Brief psychotic disorder_48m Yes Yes Yes Yes 
F24_6m Shared psychotic disorder_6m No No No No 
F24_12m Shared psychotic disorder_12m No No No No 
F24_24m Shared psychotic disorder_24m No No No No 
F24_48m Shared psychotic disorder_48m No No No No 
F25_6m Schizoaffective disorders_6m No No No No 




F25_24m Schizoaffective disorders_24m No Yes No Yes 
F25_48m Schizoaffective disorders_48m Yes Yes Yes Yes 
F28_6m 
Other psychotic disorder not due 
to a substance or known 
physiological condition_6m No No No No 
F28_12m 
Other psychotic disorder not due 
to a substance or known 
physiological condition_12m No No No No 
F28_24m 
Other psychotic disorder not due 
to a substance or known 
physiological condition_24m No No No No 
F28_48m 
Other psychotic disorder not due 
to a substance or known 
physiological condition_48m No No No No 
F29_6m 
Unspecified psychosis not due to 
a substance or known 
physiological condition_6m No No No No 
F29_12m 
Unspecified psychosis not due to 
a substance or known 
physiological condition_12m No No No No 
F29_24m 
Unspecified psychosis not due to 
a substance or known 
physiological condition_24m No No No Yes 
F29_48m 
Unspecified psychosis not due to 
a substance or known 
physiological condition_48m No Yes Yes Yes 
F30_6m Manic episode_6m No No No No 
F30_12m Manic episode_12m No No No No 




F30_48m Manic episode_48m No No No No 
F31_6m Bipolar disorder_6m Yes Yes Yes Yes 
F31_12m Bipolar disorder_12m Yes Yes Yes Yes 
F31_24m Bipolar disorder_24m Yes Yes Yes Yes 
F31_48m Bipolar disorder_48m Yes Yes Yes Yes 
F40_6m Phobic anxiety disorders_6m No No Yes Yes 
F40_12m Phobic anxiety disorders_12m No No Yes Yes 
F40_24m Phobic anxiety disorders_24m Yes No Yes Yes 
F40_48m Phobic anxiety disorders_48m Yes Yes Yes Yes 
F41_6m Other anxiety disorders_6m Yes Yes Yes Yes 
F41_12m Other anxiety disorders_12m Yes Yes Yes Yes 
F41_24m Other anxiety disorders_24m Yes Yes Yes Yes 
F41_48m Other anxiety disorders_48m Yes Yes Yes Yes 
F42_6m 
Obsessive-compulsive 
disorder_6m No No No Yes 
F42_12m 
Obsessive-compulsive 
disorder_12m No No Yes Yes 
F42_24m 
Obsessive-compulsive 
disorder_24m No No Yes Yes 
F42_48m 
Obsessive-compulsive 
disorder_48m No Yes Yes Yes 
F43_6m 
Reaction to severe stress, and 
adjustment disorders_6m Yes Yes Yes Yes 
F43_12m 
Reaction to severe stress, and 
adjustment disorders_12m Yes Yes Yes Yes 
F43_24m 
Reaction to severe stress, and 





Reaction to severe stress, and 
adjustment disorders_48m Yes Yes Yes Yes 
F44_6m 
Dissociative and conversion 
disorders_6m No No No No 
F44_12m 
Dissociative and conversion 
disorders_12m No No No Yes 
F44_24m 
Dissociative and conversion 
disorders_24m No No No Yes 
F44_48m 
Dissociative and conversion 
disorders_48m No Yes No Yes 
F45_6m Somatoform disorders_6m No Yes No Yes 
F45_12m Somatoform disorders_12m No Yes No Yes 
F45_24m Somatoform disorders_24m No Yes Yes Yes 
F45_48m Somatoform disorders_48m No Yes Yes Yes 
F48_6m 
Other nonpsychotic mental 
disorders_6m No No No No 
F48_12m 
Other nonpsychotic mental 
disorders_12m No No No Yes 
F48_24m 
Other nonpsychotic mental 
disorders_24m No No No Yes 
F48_48m 
Other nonpsychotic mental 
disorders_48m No Yes No Yes 
F50_6m Eating disorders_6m No No No Yes 
F50_12m Eating disorders_12m No Yes No Yes 
F50_24m Eating disorders_24m No Yes No Yes 
F50_48m Eating disorders_48m No Yes No Yes 
F51_6m 
Sleep disorders not due to a 
substance or known physiological 





Sleep disorders not due to a 
substance or known physiological 
condition_12m No No No No 
F51_24m 
Sleep disorders not due to a 
substance or known physiological 
condition_24m No No No No 
F51_48m 
Sleep disorders not due to a 
substance or known physiological 
condition_48m No No No No 
F52_6m 
Sexual dysfunction not due to a 
substance or known physiological 
condition_6m No No No No 
F52_12m 
Sexual dysfunction not due to a 
substance or known physiological 
condition_12m No No No No 
F52_24m 
Sexual dysfunction not due to a 
substance or known physiological 
condition_24m No No No No 
F52_48m 
Sexual dysfunction not due to a 
substance or known physiological 
condition_48m No No No Yes 
F53_6m Puerperal psychosis_6m No No No No 
F53_12m Puerperal psychosis_12m No No No No 
F53_24m Puerperal psychosis_24m No No No No 
F53_48m Puerperal psychosis_48m No No No No 
F54_6m 
Psychological and behavioral 
factors associated with disorders 
or diseases classified 





Psychological and behavioral 
factors associated with disorders 
or diseases classified 
elsewhere_12m No No No No 
F54_24m 
Psychological and behavioral 
factors associated with disorders 
or diseases classified 
elsewhere_24m No No No No 
F54_48m 
Psychological and behavioral 
factors associated with disorders 
or diseases classified 
elsewhere_48m No No No No 
F55_6m 
Abuse of non-psychoactive 
substances_6m No No No No 
F55_12m 
Abuse of non-psychoactive 
substances_12m No No No No 
F55_24m 
Abuse of non-psychoactive 
substances_24m No No No No 
F55_48m 
Abuse of non-psychoactive 
substances_48m No No No No 
F59_6m 
Unspecified behavioral syndromes 
associated with physiological 
disturbances and physical 
factors_6m No No No No 
F59_12m 
Unspecified behavioral syndromes 
associated with physiological 
disturbances and physical 
factors_12m No No No No 
F59_24m 
Unspecified behavioral syndromes 




disturbances and physical 
factors_24m 
F59_48m 
Unspecified behavioral syndromes 
associated with physiological 
disturbances and physical 
factors_48m No No No No 
F60_6m Specific personality disorders_6m Yes Yes Yes Yes 
F60_12m 
Specific personality 
disorders_12m Yes Yes Yes Yes 
F60_24m 
Specific personality 
disorders_24m Yes Yes Yes Yes 
F60_48m 
Specific personality 
disorders_48m Yes Yes Yes Yes 
F63_6m Impulse disorders_6m No No No No 
F63_12m Impulse disorders_12m No No No No 
F63_24m Impulse disorders_24m No No No No 
F63_48m Impulse disorders_48m No No No No 
F64_6m Gender identity disorders_6m No No No No 
F64_12m Gender identity disorders_12m No No No No 
F64_24m Gender identity disorders_24m No No No No 
F64_48m Gender identity disorders_48m No No No No 
F65_6m Paraphilias_6m No No No No 
F65_12m Paraphilias_12m No No No No 
F65_24m Paraphilias_24m No No No No 
F65_48m Paraphilias_48m No No No No 
F66_6m Other sexual disorders_6m No No No No 




F66_24m Other sexual disorders_24m No No No No 
F66_48m Other sexual disorders_48m No No No No 
F68_6m 
Other disorders of adult 
personality and behavior_6m No No No No 
F68_12m 
Other disorders of adult 
personality and behavior_12m No No No No 
F68_24m 
Other disorders of adult 
personality and behavior_24m No No No No 
F68_48m 
Other disorders of adult 
personality and behavior_48m No No No No 
F69_6m 
Unspecified disorder of adult 
personality and behavior_6m No No No No 
F69_12m 
Unspecified disorder of adult 
personality and behavior_12m No No No No 
F69_24m 
Unspecified disorder of adult 
personality and behavior_24m No No No No 
F69_48m 
Unspecified disorder of adult 
personality and behavior_48m No No No No 
F70_6m Mild intellectual disabilities_6m No No No Yes 
F70_12m Mild intellectual disabilities_12m No No No Yes 
F70_24m Mild intellectual disabilities_24m No No No Yes 
F70_48m Mild intellectual disabilities_48m No No Yes Yes 
F71_6m 
Moderate intellectual 
disabilities_6m No No No No 
F71_12m 
Moderate intellectual 
disabilities_12m No No No No 
F71_24m 
Moderate intellectual 






disabilities_48m No No No No 
F72_6m Severe intellectual disabilities_6m No No No No 
F72_12m 
Severe intellectual 
disabilities_12m No No No No 
F72_24m 
Severe intellectual 
disabilities_24m No No No No 
F72_48m 
Severe intellectual 
disabilities_48m No No No No 
F73_6m 
Profound intellectual 
disabilities_6m No No No No 
F73_12m 
Profound intellectual 
disabilities_12m No No No No 
F73_24m 
Profound intellectual 
disabilities_24m No No No No 
F73_48m 
Profound intellectual 
disabilities_48m No No No No 
F78_6m Other intellectual disabilities_6m No No No No 
F78_12m Other intellectual disabilities_12m No No No No 
F78_24m Other intellectual disabilities_24m No No No No 
F78_48m Other intellectual disabilities_48m No No No No 
F79_6m 
Unspecified intellectual 
disabilities_6m No No No No 
F79_12m 
Unspecified intellectual 
disabilities_12m No No No No 
F79_24m 
Unspecified intellectual 
disabilities_24m No No No Yes 
F79_48m 
Unspecified intellectual 





Specific developmental disorders 
of speech and language_6m No No No No 
F80_12m 
Specific developmental disorders 
of speech and language_12m No No No No 
F80_24m 
Specific developmental disorders 
of speech and language_24m No No No No 
F80_48m 
Specific developmental disorders 
of speech and language_48m No No No No 
F81_6m 
Specific developmental disorders 
of scholastic skills_6m No No No No 
F81_12m 
Specific developmental disorders 
of scholastic skills_12m No No No No 
F81_24m 
Specific developmental disorders 
of scholastic skills_24m No No No No 
F81_48m 
Specific developmental disorders 
of scholastic skills_48m No No No No 
F82_6m 
Specific developmental disorder of 
motor function_6m No No No No 
F82_12m 
Specific developmental disorder of 
motor function_12m No No No No 
F82_24m 
Specific developmental disorder of 
motor function_24m No No No No 
F82_48m 
Specific developmental disorder of 
motor function_48m No No No No 
F84_6m 
Pervasive developmental 
disorders_6m No No Yes No 
F84_12m 
Pervasive developmental 
disorders_12m No No Yes Yes 
F84_24m 
Pervasive developmental 






disorders_48m No No Yes Yes 
F88_6m 
Other disorders of psychological 
development_6m No No No No 
F88_12m 
Other disorders of psychological 
development_12m No No No No 
F88_24m 
Other disorders of psychological 
development_24m No No No No 
F88_48m 
Other disorders of psychological 
development_48m No No No No 
F89_6m 
Unspecified disorder of 
psychological development_6m No No No No 
F89_12m 
Unspecified disorder of 
psychological development_12m No No No No 
F89_24m 
Unspecified disorder of 
psychological development_24m No No No No 
F89_48m 
Unspecified disorder of 
psychological development_48m No No No No 
F90_6m 
Attention-deficit hyperactivity 
disorders_6m No No Yes Yes 
F90_12m 
Attention-deficit hyperactivity 
disorders_12m Yes No Yes Yes 
F90_24m 
Attention-deficit hyperactivity 
disorders_24m Yes No Yes Yes 
F90_48m 
Attention-deficit hyperactivity 
disorders_48m Yes No Yes Yes 
F91_6m Conduct disorders_6m No No No No 
F91_12m Conduct disorders_12m No No No No 
F91_24m Conduct disorders_24m No No No No 





Emotional disorders with onset 
specific to childhood_6m No No No No 
F93_12m 
Emotional disorders with onset 
specific to childhood_12m No No No No 
F93_24m 
Emotional disorders with onset 
specific to childhood_24m No No No No 
F93_48m 
Emotional disorders with onset 
specific to childhood_48m No No No No 
F94_6m 
Disorders of social functioning 
with onset specific to childhood 
and adolescence_6m No No No No 
F94_12m 
Disorders of social functioning 
with onset specific to childhood 
and adolescence_12m No No No No 
F94_24m 
Disorders of social functioning 
with onset specific to childhood 
and adolescence_24m No No No No 
F94_48m 
Disorders of social functioning 
with onset specific to childhood 
and adolescence_48m No No No No 
F95_6m Tic disorder_6m No No No No 
F95_12m Tic disorder_12m No No No No 
F95_24m Tic disorder_24m No No No No 
F95_48m Tic disorder_48m No No No No 
F98_6m 
Other behavioral and emotional 
disorders with onset usually 
occurring in childhood and 
adolescence_6m No No No No 
F98_12m 
Other behavioral and emotional 




occurring in childhood and 
adolescence_12m 
F98_24m 
Other behavioral and emotional 
disorders with onset usually 
occurring in childhood and 
adolescence_24m No No No Yes 
F98_48m 
Other behavioral and emotional 
disorders with onset usually 
occurring in childhood and 
adolescence_48m No No No Yes 
F99_6m 
Mental disorder, not otherwise 
specified_6m Yes Yes Yes Yes 
F99_12m 
Mental disorder, not otherwise 
specified_12m Yes Yes Yes Yes 
F99_24m 
Mental disorder, not otherwise 
specified_24m Yes Yes Yes Yes 
F99_48m 
Mental disorder, not otherwise 
specified_48m Yes Yes Yes Yes 
A_6m Nervous system surgeries_6m Yes No Yes Yes 
A_12m Nervous system surgeries_12m Yes No Yes Yes 
A_24m Nervous system surgeries_24m Yes Yes Yes Yes 
A_48m Nervous system surgeries_48m Yes Yes Yes Yes 
B_6m Endocrine system surgeries_6m No No No No 
B_12m Endocrine system surgeries_12m No No No No 
B_24m Endocrine system surgeries_24m No No No No 
B_48m Endocrine system surgeries_48m No No No No 
C_6m 
Eye and adjacent structure 





Eye and adjacent structure 
surgery_12m Yes Yes Yes Yes 
C_24m 
Eye and adjacent structure 
surgery_24m Yes Yes Yes Yes 
C_48m 
Eye and adjacent structure 
surgery_48m Yes Yes Yes Yes 
D_6m 
Ear, nose and larynx 
surgeries_6m No No No No 
D_12m 
Ear, nose and larynx 
surgeries_12m No No No Yes 
D_24m 
Ear, nose and larynx 
surgeries_24m Yes No Yes Yes 
D_48m 
Ear, nose and larynx 
surgeries_48m Yes Yes Yes Yes 
E_6m 
Teeth, jaw, mouth and pharynx 
surgeries_6m No No Yes Yes 
E_12m 
Teeth, jaw, mouth and pharynx 
surgeries_12m No No Yes Yes 
E_24m 
Teeth, jaw, mouth and pharynx 
surgeries_24m Yes Yes Yes Yes 
E_48m 
Teeth, jaw, mouth and pharynx 
surgeries_48m Yes Yes Yes Yes 
F_6m 
Heart and major thoracic 
vessels_6m Yes No No No 
F_12m 
Heart and major thoracic 
vessels_12m Yes No Yes No 
F_24m 
Heart and major thoracic 
vessels_24m Yes No Yes Yes 
F_48m 
Heart and major thoracic 





Chest wall, pleura, mediastinum, 
diaphragm, trachea, bronchus and 
lung surgeries_6m Yes Yes Yes No 
G_12m 
Chest wall, pleura, mediastinum, 
diaphragm, trachea, bronchus and 
lung surgeries_12m Yes Yes Yes Yes 
G_24m 
Chest wall, pleura, mediastinum, 
diaphragm, trachea, bronchus and 
lung surgeries_24m Yes Yes Yes Yes 
G_48m 
Chest wall, pleura, mediastinum, 
diaphragm, trachea, bronchus and 
lung surgeries_48m Yes Yes Yes Yes 
H_6m Mammary gland surgeries_6m No No No No 
H_12m Mammary gland surgeries_12m No No No Yes 
H_24m Mammary gland surgeries_24m No Yes No Yes 
H_48m Mammary gland surgeries_48m No Yes No Yes 
J_6m 
Digestive system and spleen 
surgeries_6m Yes Yes Yes Yes 
J_12m 
Digestive system and spleen 
surgeries_12m Yes Yes Yes Yes 
J_24m 
Digestive system and spleen 
surgeries_24m Yes Yes Yes Yes 
J_48m 
Digestive system and spleen 
surgeries_48m Yes Yes Yes Yes 
K_6m 
Urinary system, male genital 
organs and retroperitoneal space 
surgeries_6m Yes No Yes No 
K_12m 
Urinary system, male genital 
organs and retroperitoneal space 





Urinary system, male genital 
organs and retroperitoneal space 
surgeries_24m Yes Yes Yes Yes 
K_48m 
Urinary system, male genital 
organs and retroperitoneal space 
surgeries_48m Yes Yes Yes Yes 
L_6m 
Female genital organ 
surgeries_6m No Yes No Yes 
L_12m 
Female genital organ 
surgeries_12m No Yes No Yes 
L_24m 
Female genital organ 
surgeries_24m No Yes No Yes 
L_48m 
Female genital organ 
surgeries_48m No Yes No Yes 
M_6m Obstetric procedures_6m No No No Yes 
M_12m Obstetric procedures_12m No No No Yes 
M_24m Obstetric procedures_24m No Yes No Yes 
M_48m Obstetric procedures_48m No Yes No Yes 
N_6m 
Musculoskeletal system 
surgeries_6m Yes Yes Yes Yes 
N_12m 
Musculoskeletal system 
surgeries_12m Yes Yes Yes Yes 
N_24m 
Musculoskeletal system 
surgeries_24m Yes Yes Yes Yes 
N_48m 
Musculoskeletal system 
surgeries_48m Yes Yes Yes Yes 
P_6m 
Peripheral vessels and lymphatic 
system surgeries_6m No No Yes Yes 
P_12m 
Peripheral vessels and lymphatic 





Peripheral vessels and lymphatic 
system surgeries_24m Yes Yes Yes Yes 
P_48m 
Peripheral vessels and lymphatic 
system surgeries_48m Yes Yes Yes Yes 
Q_6m Skin surgeries_6m Yes Yes Yes Yes 
Q_12m Skin surgeries_12m Yes Yes Yes Yes 
Q_24m Skin surgeries_24m Yes Yes Yes Yes 
Q_48m Skin surgeries_48m Yes Yes Yes Yes 
T_6m Minor surgical procedures_6m Yes Yes Yes Yes 
T_12m Minor surgical procedures_12m Yes Yes Yes Yes 
T_24m Minor surgical procedures_24m Yes Yes Yes Yes 
T_48m Minor surgical procedures_48m Yes Yes Yes Yes 
U_6m Transluminal endoscopy_6m Yes Yes Yes Yes 
U_12m Transluminal endoscopy_12m Yes Yes Yes Yes 
U_24m Transluminal endoscopy_24m Yes Yes Yes Yes 
U_48m Transluminal endoscopy_48m Yes Yes Yes Yes 
X_6m 
Investigative procedures 
connected with surgery_6m No No No No 
X_12m 
Investigative procedures 
connected with surgery_12m No No No No 
X_24m 
Investigative procedures 
connected with surgery_24m No No No No 
X_48m 
Investigative procedures 
connected with surgery_48m No No No No 
A01A_6m Stomatological preparations_6m Yes Yes Yes Yes 
A01A_12m Stomatological preparations_12m Yes Yes Yes Yes 




A01A_48m Stomatological preparations_48m Yes Yes Yes Yes 
A02A_6m Antacids_6m Yes Yes Yes Yes 
A02A_12m Antacids_12m Yes Yes Yes Yes 
A02A_24m Antacids_24m Yes Yes Yes Yes 
A02A_48m Antacids_48m Yes Yes Yes Yes 
A02B_6m 
Drugs for peptic ulcer and gastro-
oesophageal reflux disease 
(GORD)_6m Yes Yes Yes Yes 
A02B_12m 
Drugs for peptic ulcer and gastro-
oesophageal reflux disease 
(GORD)_12m Yes Yes Yes Yes 
A02B_24m 
Drugs for peptic ulcer and gastro-
oesophageal reflux disease 
(GORD)_24m Yes Yes Yes Yes 
A02B_48m 
Drugs for peptic ulcer and gastro-
oesophageal reflux disease 
(GORD)_48m Yes Yes Yes Yes 
A02X_6m 
Other drugs for acid related 
disorders_6m No No No No 
A02X_12m 
Other drugs for acid related 
disorders_12m No No No No 
A02X_24m 
Other drugs for acid related 
disorders_24m No No No No 
A02X_48m 
Other drugs for acid related 
disorders_48m No No No No 
A03A_6m 
Drugs for functional 
gastrointestinal disorders_6m Yes Yes No Yes 
A03A_12m 
Drugs for functional 





Drugs for functional 
gastrointestinal disorders_24m Yes Yes Yes Yes 
A03A_48m 
Drugs for functional 
gastrointestinal disorders_48m Yes Yes Yes Yes 
A03B_6m 
Belladonna and derivatives, 
plain_6m No No No Yes 
A03B_12m 
Belladonna and derivatives, 
plain_12m No No No Yes 
A03B_24m 
Belladonna and derivatives, 
plain_24m No Yes Yes Yes 
A03B_48m 
Belladonna and derivatives, 
plain_48m Yes Yes Yes Yes 
A03C_6m 
Antispasmodics in combination 
with psycholeptics_6m No No No No 
A03C_12m 
Antispasmodics in combination 
with psycholeptics_12m No No No No 
A03C_24m 
Antispasmodics in combination 
with psycholeptics_24m No No No No 
A03C_48m 
Antispasmodics in combination 
with psycholeptics_48m No No No No 
A03D_6m 
Antispasmodics in combination 
with analgesics_6m No No No No 
A03D_12m 
Antispasmodics in combination 
with analgesics_12m No No No No 
A03D_24m 
Antispasmodics in combination 
with analgesics_24m No No No No 
A03D_48m 
Antispasmodics in combination 






anticholinergics in combination 
with other drugs_6m No No No No 
A03E_12m 
Antispasmodics and 
anticholinergics in combination 
with other drugs_12m No No No No 
A03E_24m 
Antispasmodics and 
anticholinergics in combination 
with other drugs_24m No No No No 
A03E_48m 
Antispasmodics and 
anticholinergics in combination 
with other drugs_48m No No No No 
A03F_6m Propulsives_6m Yes Yes Yes Yes 
A03F_12m Propulsives_12m Yes Yes Yes Yes 
A03F_24m Propulsives_24m Yes Yes Yes Yes 
A03F_48m Propulsives_48m Yes Yes Yes Yes 
A04A_6m 
Antiemetics and 
antinauseants_6m No No No No 
A04A_12m 
Antiemetics and 
antinauseants_12m No No No Yes 
A04A_24m 
Antiemetics and 
antinauseants_24m No Yes No Yes 
A04A_48m 
Antiemetics and 
antinauseants_48m No Yes No Yes 
A05A_6m Bile therapy_6m No No No No 
A05A_12m Bile therapy_12m No No No No 
A05A_24m Bile therapy_24m No No No No 
A05A_48m Bile therapy_48m No No No No 




A05B_12m Liver therapy, lipotropics_12m No No No No 
A05B_24m Liver therapy, lipotropics_24m No No No No 
A05B_48m Liver therapy, lipotropics_48m No No No No 
A05C_6m 
Drugs for bile therapy and 
lipotropics in combination_6m No No No No 
A05C_12m 
Drugs for bile therapy and 
lipotropics in combination_12m No No No No 
A05C_24m 
Drugs for bile therapy and 
lipotropics in combination_24m No No No No 
A05C_48m 
Drugs for bile therapy and 
lipotropics in combination_48m No No No No 
A06A_6m Drugs for constipation_6m Yes Yes Yes Yes 
A06A_12m Drugs for constipation_12m Yes Yes Yes Yes 
A06A_24m Drugs for constipation_24m Yes Yes Yes Yes 
A06A_48m Drugs for constipation_48m Yes Yes Yes Yes 
A07A_6m Intestinal anti-infectives_6m No Yes Yes Yes 
A07A_12m Intestinal anti-infectives_12m Yes Yes Yes Yes 
A07A_24m Intestinal anti-infectives_24m Yes Yes Yes Yes 
A07A_48m Intestinal anti-infectives_48m Yes Yes Yes Yes 
A07B_6m Intestinal adsorbents_6m No No No No 
A07B_12m Intestinal adsorbents_12m No No No No 
A07B_24m Intestinal adsorbents_24m No No No No 
A07B_48m Intestinal adsorbents_48m No No No No 
A07C_6m 
Electrolytes with 
carbohydrates_6m No No No No 
A07C_12m 
Electrolytes with 






carbohydrates_24m No No No No 
A07C_48m 
Electrolytes with 
carbohydrates_48m No No No No 
A07D_6m Antipropulsives_6m Yes Yes Yes Yes 
A07D_12m Antipropulsives_12m Yes Yes Yes Yes 
A07D_24m Antipropulsives_24m Yes Yes Yes Yes 
A07D_48m Antipropulsives_48m Yes Yes Yes Yes 
A07E_6m 
Intestinal anti-inflammatory 
agents_6m No No No Yes 
A07E_12m 
Intestinal anti-inflammatory 
agents_12m No No No Yes 
A07E_24m 
Intestinal anti-inflammatory 
agents_24m No No Yes Yes 
A07E_48m 
Intestinal anti-inflammatory 
agents_48m Yes Yes Yes Yes 
A07F_6m Antidiarrheal micro-organisms_6m No No No No 
A07F_12m 
Antidiarrheal micro-
organisms_12m No No No No 
A07F_24m 
Antidiarrheal micro-
organisms_24m No No No Yes 
A07F_48m 
Antidiarrheal micro-
organisms_48m No No No Yes 
A07X_6m Other antidiarrheals_6m No No No No 
A07X_12m Other antidiarrheals_12m No No No No 
A07X_24m Other antidiarrheals_24m No No No No 
A07X_48m Other antidiarrheals_48m No No No No 
A08A_6m 
Antiobesity preparations, 






excluding diet products_12m No Yes No Yes 
A08A_24m 
Antiobesity preparations, 
excluding diet products_24m No Yes Yes Yes 
A08A_48m 
Antiobesity preparations, 
excluding diet products_48m Yes Yes Yes Yes 
A09A_6m Digestives, including enzymes_6m No No No No 
A09A_12m 
Digestives, including 
enzymes_12m No No No No 
A09A_24m 
Digestives, including 
enzymes_24m No No No No 
A09A_48m 
Digestives, including 
enzymes_48m No No No No 
A10A_6m Insulins and analogues_6m Yes Yes Yes Yes 
A10A_12m Insulins and analogues_12m Yes Yes Yes Yes 
A10A_24m Insulins and analogues_24m Yes Yes Yes Yes 
A10A_48m Insulins and analogues_48m Yes Yes Yes Yes 
A10B_6m 
Blood glucose lowering drugs, 
excluding insulins_6m Yes Yes Yes Yes 
A10B_12m 
Blood glucose lowering drugs, 
excluding insulins_12m Yes Yes Yes Yes 
A10B_24m 
Blood glucose lowering drugs, 
excluding insulins_24m Yes Yes Yes Yes 
A10B_48m 
Blood glucose lowering drugs, 
excluding insulins_48m Yes Yes Yes Yes 
A10X_6m Other drugs used in diabetes_6m No No No No 
A10X_12m Other drugs used in diabetes_12m No No No No 
A10X_24m Other drugs used in diabetes_24m No No No No 




A11A_6m Multivitamins, combinations_6m No No No No 
A11A_12m Multivitamins, combinations_12m No No No No 
A11A_24m Multivitamins, combinations_24m No No No No 
A11A_48m Multivitamins, combinations_48m No No No No 
A11B_6m Multivitamins, plain_6m No No No No 
A11B_12m Multivitamins, plain_12m No No No No 
A11B_24m Multivitamins, plain_24m No No No No 
A11B_48m Multivitamins, plain_48m No No No No 
A11C_6m 
Vitamin A and D, including 
combinations of the two_6m No No No No 
A11C_12m 
Vitamin A and D, including 
combinations of the two_12m No No No No 
A11C_24m 
Vitamin A and D, including 
combinations of the two_24m No No No Yes 
A11C_48m 
Vitamin A and D, including 
combinations of the two_48m No Yes No Yes 
A11D_6m 
Vitamin B1, plain and in 
combination with vitamin B6and 
B12_6m No No No No 
A11D_12m 
Vitamin B1, plain and in 
combination with vitamin B6and 
B12_12m No No No No 
A11D_24m 
Vitamin B1, plain and in 
combination with vitamin B6and 
B12_24m No No No No 
A11D_48m 
Vitamin B1, plain and in 
combination with vitamin B6and 





Vitamin B-complex, including 
combinations_6m No No No No 
A11E_12m 
Vitamin B-complex, including 
combinations_12m No No No No 
A11E_24m 
Vitamin B-complex, including 
combinations_24m No No No Yes 
A11E_48m 
Vitamin B-complex, including 
combinations_48m No Yes Yes Yes 
A11G_6m 
Ascorbic acid (vitamin C), 
including combinations_6m No No No No 
A11G_12m 
Ascorbic acid (vitamin C), 
including combinations_12m No No No No 
A11G_24m 
Ascorbic acid (vitamin C), 
including combinations_24m No No No No 
A11G_48m 
Ascorbic acid (vitamin C), 
including combinations_48m No No No No 
A11H_6m 
Other plain vitamin 
preparations_6m No No No No 
A11H_12m 
Other plain vitamin 
preparations_12m No No No No 
A11H_24m 
Other plain vitamin 
preparations_24m No No No No 
A11H_48m 
Other plain vitamin 
preparations_48m No No No No 
A11J_6m 
Other vitamin products, 
combinations_6m No No No No 
A11J_12m 
Other vitamin products, 
combinations_12m No No No No 
A11J_24m 
Other vitamin products, 





Other vitamin products, 
combinations_48m No No No No 
A12A_6m Calcium_6m No Yes No Yes 
A12A_12m Calcium_12m No Yes No Yes 
A12A_24m Calcium_24m No Yes No Yes 
A12A_48m Calcium_48m Yes Yes Yes Yes 
A12B_6m Potassium_6m Yes Yes Yes Yes 
A12B_12m Potassium_12m Yes Yes Yes Yes 
A12B_24m Potassium_24m Yes Yes Yes Yes 
A12B_48m Potassium_48m Yes Yes Yes Yes 
A12C_6m Other mineral supplements_6m No No No No 
A12C_12m Other mineral supplements_12m No No No No 
A12C_24m Other mineral supplements_24m No No No No 
A12C_48m Other mineral supplements_48m No No No No 
A14A_6m Anabolic steroids_6m No No No No 
A14A_12m Anabolic steroids_12m No No No No 
A14A_24m Anabolic steroids_24m No No No No 
A14A_48m Anabolic steroids_48m No No No No 
A14B_6m Other anabolic agents_6m No No No No 
A14B_12m Other anabolic agents_12m No No No No 
A14B_24m Other anabolic agents_24m No No No No 
A14B_48m Other anabolic agents_48m No No No No 
A16A_6m 
Other alimentary tract and 
metabolism products_6m No No No No 
A16A_12m 
Other alimentary tract and 





Other alimentary tract and 
metabolism products_24m No No No No 
A16A_48m 
Other alimentary tract and 
metabolism products_48m No No No No 
B01A_6m Antithrombotic agents_6m Yes Yes Yes Yes 
B01A_12m Antithrombotic agents_12m Yes Yes Yes Yes 
B01A_24m Antithrombotic agents_24m Yes Yes Yes Yes 
B01A_48m Antithrombotic agents_48m Yes Yes Yes Yes 
B02A_6m Antifibrinolytics_6m No No No Yes 
B02A_12m Antifibrinolytics_12m No No No Yes 
B02A_24m Antifibrinolytics_24m No No No Yes 
B02A_48m Antifibrinolytics_48m No Yes No Yes 
B02B_6m 
Vitamin K and other 
hemostatics_6m No No No No 
B02B_12m 
Vitamin K and other 
hemostatics_12m No No No No 
B02B_24m 
Vitamin K and other 
hemostatics_24m No No No No 
B02B_48m 
Vitamin K and other 
hemostatics_48m No No Yes No 
B03A_6m Iron preparations_6m Yes Yes Yes Yes 
B03A_12m Iron preparations_12m Yes Yes Yes Yes 
B03A_24m Iron preparations_24m Yes Yes Yes Yes 
B03A_48m Iron preparations_48m Yes Yes Yes Yes 
B03B_6m Vitamin B12and folic acid_6m Yes Yes Yes Yes 
B03B_12m Vitamin B12and folic acid_12m Yes Yes Yes Yes 




B03B_48m Vitamin B12and folic acid_48m Yes Yes Yes Yes 
B03X_6m 
Other antianemic 
preparations_6m No No No No 
B03X_12m 
Other antianemic 
preparations_12m No No No No 
B03X_24m 
Other antianemic 
preparations_24m No No No No 
B03X_48m 
Other antianemic 
preparations_48m No No No No 
B05A_6m Blood and related products_6m No No No No 
B05A_12m Blood and related products_12m No No No No 
B05A_24m Blood and related products_24m No No No No 
B05A_48m Blood and related products_48m No No No No 
B05B_6m I.v. solutions_6m No No No No 
B05B_12m I.v. solutions_12m No No No No 
B05B_24m I.v. solutions_24m No No No No 
B05B_48m I.v. solutions_48m No No No No 
B05C_6m Irrigating solutions_6m No No No No 
B05C_12m Irrigating solutions_12m No No No No 
B05C_24m Irrigating solutions_24m No No No No 
B05C_48m Irrigating solutions_48m No No No No 
B05D_6m Peritoneal dialytics_6m No No No No 
B05D_12m Peritoneal dialytics_12m No No No No 
B05D_24m Peritoneal dialytics_24m No No No No 
B05D_48m Peritoneal dialytics_48m No No No No 
B05X_6m I.v. solution additives_6m No No No No 




B05X_24m I.v. solution additives_24m No No No No 
B05X_48m I.v. solution additives_48m No No No No 
B05Z_6m 
Hemodialytics and 
hemofiltrates_6m No No No No 
B05Z_12m 
Hemodialytics and 
hemofiltrates_12m No No No No 
B05Z_24m 
Hemodialytics and 
hemofiltrates_24m No No No No 
B05Z_48m 
Hemodialytics and 
hemofiltrates_48m No No No No 
B06A_6m Other hematological agents_6m No No No No 
B06A_12m Other hematological agents_12m No No No No 
B06A_24m Other hematological agents_24m No No No No 
B06A_48m Other hematological agents_48m No No No No 
C01A_6m Cardiac glycosides_6m Yes Yes Yes Yes 
C01A_12m Cardiac glycosides_12m Yes Yes Yes Yes 
C01A_24m Cardiac glycosides_24m Yes Yes Yes Yes 
C01A_48m Cardiac glycosides_48m Yes Yes Yes Yes 
C01B_6m Antiarrhythmics, class I and III_6m No No No No 
C01B_12m 
Antiarrhythmics, class I and 
III_12m No No No No 
C01B_24m 
Antiarrhythmics, class I and 
III_24m No No No No 
C01B_48m 
Antiarrhythmics, class I and 
III_48m Yes No No Yes 
C01C_6m 
Cardiac stimulants excluding 





Cardiac stimulants excluding 
cardiac glycosides_12m No No No No 
C01C_24m 
Cardiac stimulants excluding 
cardiac glycosides_24m No No No No 
C01C_48m 
Cardiac stimulants excluding 
cardiac glycosides_48m No No Yes No 
C01D_6m 
Vasodilators used in cardiac 
diseases_6m Yes Yes Yes Yes 
C01D_12m 
Vasodilators used in cardiac 
diseases_12m Yes Yes Yes Yes 
C01D_24m 
Vasodilators used in cardiac 
diseases_24m Yes Yes Yes Yes 
C01D_48m 
Vasodilators used in cardiac 
diseases_48m Yes Yes Yes Yes 
C01E_6m Other cardiac preparations_6m No No No No 
C01E_12m Other cardiac preparations_12m No No No No 
C01E_24m Other cardiac preparations_24m No No No No 
C01E_48m Other cardiac preparations_48m No No No No 
C02A_6m 
Antiadrenergic agents, centrally 
acting_6m No No No No 
C02A_12m 
Antiadrenergic agents, centrally 
acting_12m No No No No 
C02A_24m 
Antiadrenergic agents, centrally 
acting_24m No No No No 
C02A_48m 
Antiadrenergic agents, centrally 
acting_48m No No No No 
C02B_6m 
Antiadrenergic agents, ganglion-
blocking_6m No No No No 
C02B_12m 
Antiadrenergic agents, ganglion-






blocking_24m No No No No 
C02B_48m 
Antiadrenergic agents, ganglion-
blocking_48m No No No No 
C02C_6m 
Antiadrenergic agents, 
peripherally acting_6m No No No No 
C02C_12m 
Antiadrenergic agents, 
peripherally acting_12m Yes No No No 
C02C_24m 
Antiadrenergic agents, 
peripherally acting_24m Yes No No No 
C02C_48m 
Antiadrenergic agents, 
peripherally acting_48m Yes No Yes No 
C02D_6m 
Arteriolar smooth muscle, agents 
acting on_6m No No No No 
C02D_12m 
Arteriolar smooth muscle, agents 
acting on_12m No No No No 
C02D_24m 
Arteriolar smooth muscle, agents 
acting on_24m No No No No 
C02D_48m 
Arteriolar smooth muscle, agents 
acting on_48m No No No No 
C02K_6m Other antihypertensives_6m No No No No 
C02K_12m Other antihypertensives_12m No No No No 
C02K_24m Other antihypertensives_24m No No No No 
C02K_48m Other antihypertensives_48m No No No No 
C02L_6m 
Antihypertensives and diuretics in 
combination_6m No No No No 
C02L_12m 
Antihypertensives and diuretics in 
combination_12m No No No No 
C02L_24m 
Antihypertensives and diuretics in 





Antihypertensives and diuretics in 
combination_48m No No No No 
C02N_6m 
Combinations of antihypertensives 
in ATC-group C02_6m No No No No 
C02N_12m 
Combinations of antihypertensives 
in ATC-group C02_12m No No No No 
C02N_24m 
Combinations of antihypertensives 
in ATC-group C02_24m No No No No 
C02N_48m 
Combinations of antihypertensives 
in ATC-group C02_48m No No No No 
C03A_6m 
Low-ceiling diuretics, 
thiazides_6m Yes Yes Yes Yes 
C03A_12m 
Low-ceiling diuretics, 
thiazides_12m Yes Yes Yes Yes 
C03A_24m 
Low-ceiling diuretics, 
thiazides_24m Yes Yes Yes Yes 
C03A_48m 
Low-ceiling diuretics, 
thiazides_48m Yes Yes Yes Yes 
C03B_6m 
Low-ceiling diuretics, excluding 
thiazides_6m No No No No 
C03B_12m 
Low-ceiling diuretics, excluding 
thiazides_12m No No No No 
C03B_24m 
Low-ceiling diuretics, excluding 
thiazides_24m No No No No 
C03B_48m 
Low-ceiling diuretics, excluding 
thiazides_48m No No No No 
C03C_6m High-ceiling diuretics_6m Yes Yes Yes Yes 
C03C_12m High-ceiling diuretics_12m Yes Yes Yes Yes 
C03C_24m High-ceiling diuretics_24m Yes Yes Yes Yes 




C03D_6m Potassium-sparing agents_6m Yes Yes Yes Yes 
C03D_12m Potassium-sparing agents_12m Yes Yes Yes Yes 
C03D_24m Potassium-sparing agents_24m Yes Yes Yes Yes 
C03D_48m Potassium-sparing agents_48m Yes Yes Yes Yes 
C03E_6m 
Diuretics and potassium-sparing 
agents in combination_6m No No No Yes 
C03E_12m 
Diuretics and potassium-sparing 
agents in combination_12m No Yes No Yes 
C03E_24m 
Diuretics and potassium-sparing 
agents in combination_24m No Yes No Yes 
C03E_48m 
Diuretics and potassium-sparing 
agents in combination_48m Yes Yes Yes Yes 
C03X_6m Other diuretics_6m No No No No 
C03X_12m Other diuretics_12m No No No No 
C03X_24m Other diuretics_24m No No No No 
C03X_48m Other diuretics_48m No No No No 
C04A_6m Peripheral vasodilators_6m No No No No 
C04A_12m Peripheral vasodilators_12m No No No No 
C04A_24m Peripheral vasodilators_24m No No No No 
C04A_48m Peripheral vasodilators_48m No No No No 
C05A_6m 
Agents for treatment of 
hemorrhoids and anal fissures for 
topical use_6m Yes Yes Yes Yes 
C05A_12m 
Agents for treatment of 
hemorrhoids and anal fissures for 





Agents for treatment of 
hemorrhoids and anal fissures for 
topical use_24m Yes Yes Yes Yes 
C05A_48m 
Agents for treatment of 
hemorrhoids and anal fissures for 
topical use_48m Yes Yes Yes Yes 
C05B_6m Antivaricose therapy_6m No No No No 
C05B_12m Antivaricose therapy_12m No No No Yes 
C05B_24m Antivaricose therapy_24m Yes No No Yes 
C05B_48m Antivaricose therapy_48m Yes Yes Yes Yes 
C05C_6m Capillary stabilising agents_6m No No No No 
C05C_12m Capillary stabilising agents_12m No No No No 
C05C_24m Capillary stabilising agents_24m No No No No 
C05C_48m Capillary stabilising agents_48m No No No No 
C07A_6m Beta blocking agents_6m Yes Yes Yes Yes 
C07A_12m Beta blocking agents_12m Yes Yes Yes Yes 
C07A_24m Beta blocking agents_24m Yes Yes Yes Yes 
C07A_48m Beta blocking agents_48m Yes Yes Yes Yes 
C07B_6m 
Beta blocking agents and 
thiazides_6m No No No No 
C07B_12m 
Beta blocking agents and 
thiazides_12m No No No No 
C07B_24m 
Beta blocking agents and 
thiazides_24m No No No No 
C07B_48m 
Beta blocking agents and 
thiazides_48m No No No No 
C07C_6m 
Beta blocking agents and other 





Beta blocking agents and other 
diuretics_12m No No No No 
C07C_24m 
Beta blocking agents and other 
diuretics_24m No No No No 
C07C_48m 
Beta blocking agents and other 
diuretics_48m No No No No 
C07D_6m 
Beta blocking agents, thiazides 
and other diuretics_6m No No No No 
C07D_12m 
Beta blocking agents, thiazides 
and other diuretics_12m No No No No 
C07D_24m 
Beta blocking agents, thiazides 
and other diuretics_24m No No No No 
C07D_48m 
Beta blocking agents, thiazides 
and other diuretics_48m No No No No 
C07E_6m 
Beta blocking agents and 
vasodilators_6m No No No No 
C07E_12m 
Beta blocking agents and 
vasodilators_12m No No No No 
C07E_24m 
Beta blocking agents and 
vasodilators_24m No No No No 
C07E_48m 
Beta blocking agents and 
vasodilators_48m No No No No 
C07F_6m 
Beta blocking agents, other 
combinations_6m No No No No 
C07F_12m 
Beta blocking agents, other 
combinations_12m No No No No 
C07F_24m 
Beta blocking agents, other 
combinations_24m No No No No 
C07F_48m 
Beta blocking agents, other 





Selective calcium channel 
blockers with mainly vascular 
effects_6m Yes Yes Yes Yes 
C08C_12m 
Selective calcium channel 
blockers with mainly vascular 
effects_12m Yes Yes Yes Yes 
C08C_24m 
Selective calcium channel 
blockers with mainly vascular 
effects_24m Yes Yes Yes Yes 
C08C_48m 
Selective calcium channel 
blockers with mainly vascular 
effects_48m Yes Yes Yes Yes 
C08D_6m 
Selective calcium channel 
blockers with direct cardiac 
effects_6m Yes Yes Yes Yes 
C08D_12m 
Selective calcium channel 
blockers with direct cardiac 
effects_12m Yes Yes Yes Yes 
C08D_24m 
Selective calcium channel 
blockers with direct cardiac 
effects_24m Yes Yes Yes Yes 
C08D_48m 
Selective calcium channel 
blockers with direct cardiac 
effects_48m Yes Yes Yes Yes 
C08E_6m 
Non-selective calcium channel 
blockers_6m No No No No 
C08E_12m 
Non-selective calcium channel 
blockers_12m No No No No 
C08E_24m 
Non-selective calcium channel 





Non-selective calcium channel 
blockers_48m No No No No 
C08G_6m 
Calcium channel blockers and 
diuretics_6m No No No No 
C08G_12m 
Calcium channel blockers and 
diuretics_12m No No No No 
C08G_24m 
Calcium channel blockers and 
diuretics_24m No No No No 
C08G_48m 
Calcium channel blockers and 
diuretics_48m No No No No 
C09A_6m ACE inhibitors, plain_6m Yes Yes Yes Yes 
C09A_12m ACE inhibitors, plain_12m Yes Yes Yes Yes 
C09A_24m ACE inhibitors, plain_24m Yes Yes Yes Yes 
C09A_48m ACE inhibitors, plain_48m Yes Yes Yes Yes 
C09B_6m ACE inhibitors, combinations_6m Yes No Yes Yes 
C09B_12m ACE inhibitors, combinations_12m Yes No Yes Yes 
C09B_24m ACE inhibitors, combinations_24m Yes Yes Yes Yes 
C09B_48m ACE inhibitors, combinations_48m Yes Yes Yes Yes 
C09C_6m 
Angiotensin II antagonists, 
plain_6m Yes Yes Yes Yes 
C09C_12m 
Angiotensin II antagonists, 
plain_12m Yes Yes Yes Yes 
C09C_24m 
Angiotensin II antagonists, 
plain_24m Yes Yes Yes Yes 
C09C_48m 
Angiotensin II antagonists, 
plain_48m Yes Yes Yes Yes 
C09D_6m 
Angiotensin II antagonists, 





Angiotensin II antagonists, 
combinations_12m Yes Yes Yes Yes 
C09D_24m 
Angiotensin II antagonists, 
combinations_24m Yes Yes Yes Yes 
C09D_48m 
Angiotensin II antagonists, 
combinations_48m Yes Yes Yes Yes 
C09X_6m 
Other agents acting on the 
reninª_ï _angiotensin system_6m No No No No 
C09X_12m 
Other agents acting on the 
reninª_ï _angiotensin system_12m No No No No 
C09X_24m 
Other agents acting on the 
reninª_ï _angiotensin system_24m No No No No 
C09X_48m 
Other agents acting on the 
reninª_ï _angiotensin system_48m No No No No 
C10A_6m Lipid modifying agents, plain_6m Yes Yes Yes Yes 
C10A_12m Lipid modifying agents, plain_12m Yes Yes Yes Yes 
C10A_24m Lipid modifying agents, plain_24m Yes Yes Yes Yes 
C10A_48m Lipid modifying agents, plain_48m Yes Yes Yes Yes 
C10B_6m 
Lipid modifying agents, 
combinations_6m No No No No 
C10B_12m 
Lipid modifying agents, 
combinations_12m No No No No 
C10B_24m 
Lipid modifying agents, 
combinations_24m No No No No 
C10B_48m 
Lipid modifying agents, 
combinations_48m No No No No 
D01A_6m Antifungals for topical use_6m Yes Yes Yes Yes 
D01A_12m Antifungals for topical use_12m Yes Yes Yes Yes 




D01A_48m Antifungals for topical use_48m Yes Yes Yes Yes 
D01B_6m Antifungals for systemic use_6m Yes No Yes No 
D01B_12m Antifungals for systemic use_12m Yes No Yes Yes 
D01B_24m Antifungals for systemic use_24m Yes No Yes Yes 
D01B_48m Antifungals for systemic use_48m Yes Yes Yes Yes 
D02A_6m Emollients and protectives_6m No No No No 
D02A_12m Emollients and protectives_12m No No No No 
D02A_24m Emollients and protectives_24m No No No No 
D02A_48m Emollients and protectives_48m No No No Yes 
D02B_6m 
Protectives against UV-
radiation_6m No No No No 
D02B_12m 
Protectives against UV-
radiation_12m No No No No 
D02B_24m 
Protectives against UV-
radiation_24m No No No No 
D02B_48m 
Protectives against UV-
radiation_48m No No No No 
D03A_6m Cicatrizants_6m No No No No 
D03A_12m Cicatrizants_12m No No No No 
D03A_24m Cicatrizants_24m No No No No 
D03A_48m Cicatrizants_48m No No No No 
D03B_6m Enzymes_6m No No No No 
D03B_12m Enzymes_12m No No No No 
D03B_24m Enzymes_24m No No No No 



















etc._48m No No No Yes 
D05A_6m Antipsoriatics for topical use_6m No Yes No Yes 
D05A_12m Antipsoriatics for topical use_12m Yes Yes Yes Yes 
D05A_24m Antipsoriatics for topical use_24m Yes Yes Yes Yes 
D05A_48m Antipsoriatics for topical use_48m Yes Yes Yes Yes 
D05B_6m 
Antipsoriatics for systemic 
use_6m No No No No 
D05B_12m 
Antipsoriatics for systemic 
use_12m No No No No 
D05B_24m 
Antipsoriatics for systemic 
use_24m No No No No 
D05B_48m 
Antipsoriatics for systemic 
use_48m No No No No 
D06A_6m Antibiotics for topical use_6m Yes Yes Yes Yes 
D06A_12m Antibiotics for topical use_12m Yes Yes Yes Yes 
D06A_24m Antibiotics for topical use_24m Yes Yes Yes Yes 





Chemotherapeutics for topical 
use_6m Yes Yes Yes Yes 
D06B_12m 
Chemotherapeutics for topical 
use_12m Yes Yes Yes Yes 
D06B_24m 
Chemotherapeutics for topical 
use_24m Yes Yes Yes Yes 
D06B_48m 
Chemotherapeutics for topical 
















combinations_48m No No No No 
D07A_6m Corticosteroids, plain_6m Yes Yes Yes Yes 
D07A_12m Corticosteroids, plain_12m Yes Yes Yes Yes 
D07A_24m Corticosteroids, plain_24m Yes Yes Yes Yes 
D07A_48m Corticosteroids, plain_48m Yes Yes Yes Yes 
D07B_6m 
Corticosteroids, combinations with 
antiseptics_6m No Yes Yes Yes 
D07B_12m 
Corticosteroids, combinations with 
antiseptics_12m Yes Yes Yes Yes 
D07B_24m 
Corticosteroids, combinations with 





Corticosteroids, combinations with 
antiseptics_48m Yes Yes Yes Yes 
D07C_6m 
Corticosteroids, combinations with 
antibiotics_6m Yes Yes Yes Yes 
D07C_12m 
Corticosteroids, combinations with 
antibiotics_12m Yes Yes Yes Yes 
D07C_24m 
Corticosteroids, combinations with 
antibiotics_24m Yes Yes Yes Yes 
D07C_48m 
Corticosteroids, combinations with 
antibiotics_48m Yes Yes Yes Yes 
D07X_6m 
Corticosteroids, other 
combinations_6m No No No No 
D07X_12m 
Corticosteroids, other 
combinations_12m Yes No No Yes 
D07X_24m 
Corticosteroids, other 
combinations_24m Yes Yes Yes Yes 
D07X_48m 
Corticosteroids, other 
combinations_48m Yes Yes Yes Yes 
D08A_6m Antiseptics and disinfectants_6m No No No No 
D08A_12m Antiseptics and disinfectants_12m No No No No 
D08A_24m Antiseptics and disinfectants_24m No No No No 
D08A_48m Antiseptics and disinfectants_48m No No No No 
D09A_6m Medicated dressings_6m No No No No 
D09A_12m Medicated dressings_12m No No No No 
D09A_24m Medicated dressings_24m No No No No 
D09A_48m Medicated dressings_48m No No No No 
D10A_6m 
Anti-acne preparations for topical 





Anti-acne preparations for topical 
use_12m Yes Yes Yes Yes 
D10A_24m 
Anti-acne preparations for topical 
use_24m Yes Yes Yes Yes 
D10A_48m 
Anti-acne preparations for topical 
use_48m Yes Yes Yes Yes 
D10B_6m 
Anti-acne preparations for 
systemic use_6m No No No No 
D10B_12m 
Anti-acne preparations for 
systemic use_12m No No No No 
D10B_24m 
Anti-acne preparations for 
systemic use_24m No No No Yes 
D10B_48m 
Anti-acne preparations for 
systemic use_48m No No Yes Yes 
D11A_6m 
Other dermatological 
preparations_6m No No No No 
D11A_12m 
Other dermatological 
preparations_12m Yes No Yes Yes 
D11A_24m 
Other dermatological 
preparations_24m Yes Yes Yes Yes 
D11A_48m 
Other dermatological 
preparations_48m Yes Yes Yes Yes 
G01A_6m 
Antiinfectives and antiseptics, 
excluding combinations with 
corticosteroids_6m No Yes No Yes 
G01A_12m 
Antiinfectives and antiseptics, 
excluding combinations with 





Antiinfectives and antiseptics, 
excluding combinations with 
corticosteroids_24m No Yes No Yes 
G01A_48m 
Antiinfectives and antiseptics, 
excluding combinations with 
















corticosteroids_48m No No No No 
G02A_6m Uterotonics_6m No No No No 
G02A_12m Uterotonics_12m No No No No 
G02A_24m Uterotonics_24m No No No No 
G02A_48m Uterotonics_48m No No No No 
G02B_6m Contraceptives for topical use_6m No No No Yes 
G02B_12m 
Contraceptives for topical 
use_12m No Yes No Yes 
G02B_24m 
Contraceptives for topical 
use_24m No Yes No Yes 
G02B_48m 
Contraceptives for topical 




G02C_6m Other gynecologicals_6m No No No No 
G02C_12m Other gynecologicals_12m No No No No 
G02C_24m Other gynecologicals_24m No No No No 
G02C_48m Other gynecologicals_48m No No No Yes 
G03A_6m 
Hormonal contraceptives for 
systemic use_6m No Yes No Yes 
G03A_12m 
Hormonal contraceptives for 
systemic use_12m No Yes No Yes 
G03A_24m 
Hormonal contraceptives for 
systemic use_24m No Yes No Yes 
G03A_48m 
Hormonal contraceptives for 
systemic use_48m No Yes No Yes 
G03B_6m Androgens_6m No No No No 
G03B_12m Androgens_12m No No No No 
G03B_24m Androgens_24m No No No No 
G03B_48m Androgens_48m No No No No 
G03C_6m Estrogens_6m No Yes No Yes 
G03C_12m Estrogens_12m No Yes No Yes 
G03C_24m Estrogens_24m No Yes No Yes 
G03C_48m Estrogens_48m No Yes No Yes 
G03D_6m Progestogens_6m No Yes No Yes 
G03D_12m Progestogens_12m No Yes No Yes 
G03D_24m Progestogens_24m No Yes No Yes 
G03D_48m Progestogens_48m No Yes No Yes 
G03E_6m 
Androgens and female sex 





Androgens and female sex 
hormones in combination_12m No No No No 
G03E_24m 
Androgens and female sex 
hormones in combination_24m No No No No 
G03E_48m 
Androgens and female sex 
hormones in combination_48m No No No No 
G03F_6m 
Progestogens and estrogens in 
combination_6m No Yes No Yes 
G03F_12m 
Progestogens and estrogens in 
combination_12m No Yes No Yes 
G03F_24m 
Progestogens and estrogens in 
combination_24m No Yes No Yes 
G03F_48m 
Progestogens and estrogens in 
combination_48m No Yes No Yes 
G03G_6m 
Gonadotropins and other ovulation 
stimulants_6m No No No No 
G03G_12m 
Gonadotropins and other ovulation 
stimulants_12m No No No No 
G03G_24m 
Gonadotropins and other ovulation 
stimulants_24m No No No No 
G03G_48m 
Gonadotropins and other ovulation 
stimulants_48m No No No Yes 
G03H_6m Antiandrogens_6m No No No Yes 
G03H_12m Antiandrogens_12m No No No Yes 
G03H_24m Antiandrogens_24m No Yes No Yes 
G03H_48m Antiandrogens_48m No Yes No Yes 
G03X_6m 
Other sex hormones and 
modulators of the genital 





Other sex hormones and 
modulators of the genital 
system_12m No No No No 
G03X_24m 
Other sex hormones and 
modulators of the genital 
system_24m No No No No 
G03X_48m 
Other sex hormones and 
modulators of the genital 
system_48m No No No No 
G04B_6m Urologicals_6m Yes Yes Yes Yes 
G04B_12m Urologicals_12m Yes Yes Yes Yes 
G04B_24m Urologicals_24m Yes Yes Yes Yes 
G04B_48m Urologicals_48m Yes Yes Yes Yes 
G04C_6m 
Drugs used in benign prostatic 
hypertrophy_6m Yes No Yes No 
G04C_12m 
Drugs used in benign prostatic 
hypertrophy_12m Yes No Yes No 
G04C_24m 
Drugs used in benign prostatic 
hypertrophy_24m Yes No Yes No 
G04C_48m 
Drugs used in benign prostatic 
hypertrophy_48m Yes No Yes No 
H01A_6m 
Anterior pituitary lobe hormones 
and analogues_6m No No No No 
H01A_12m 
Anterior pituitary lobe hormones 
and analogues_12m No No No No 
H01A_24m 
Anterior pituitary lobe hormones 
and analogues_24m No No No No 
H01A_48m 
Anterior pituitary lobe hormones 





Posterior pituitary lobe 
hormones_6m No No No Yes 
H01B_12m 
Posterior pituitary lobe 
hormones_12m No No No Yes 
H01B_24m 
Posterior pituitary lobe 
hormones_24m No No No Yes 
H01B_48m 
Posterior pituitary lobe 
hormones_48m No No Yes Yes 
H01C_6m Hypothalamic hormones_6m No No No No 
H01C_12m Hypothalamic hormones_12m No No No No 
H01C_24m Hypothalamic hormones_24m No No No No 
H01C_48m Hypothalamic hormones_48m No No No No 
H02A_6m 
Corticosteroids for systemic use, 
plain_6m Yes Yes Yes Yes 
H02A_12m 
Corticosteroids for systemic use, 
plain_12m Yes Yes Yes Yes 
H02A_24m 
Corticosteroids for systemic use, 
plain_24m Yes Yes Yes Yes 
H02A_48m 
Corticosteroids for systemic use, 
plain_48m Yes Yes Yes Yes 
H02B_6m 
Corticosteroids for systemic use, 
combinations_6m No No No No 
H02B_12m 
Corticosteroids for systemic use, 
combinations_12m No No No No 
H02B_24m 
Corticosteroids for systemic use, 
combinations_24m No No No No 
H02B_48m 
Corticosteroids for systemic use, 
combinations_48m No No No No 




H02C_12m Antiadrenal preparations_12m No No No No 
H02C_24m Antiadrenal preparations_24m No No No No 
H02C_48m Antiadrenal preparations_48m No No No No 
H03A_6m Thyroid preparations_6m Yes Yes Yes Yes 
H03A_12m Thyroid preparations_12m Yes Yes Yes Yes 
H03A_24m Thyroid preparations_24m Yes Yes Yes Yes 
H03A_48m Thyroid preparations_48m Yes Yes Yes Yes 
H03B_6m Antithyroid preparations_6m No Yes No Yes 
H03B_12m Antithyroid preparations_12m No Yes No Yes 
H03B_24m Antithyroid preparations_24m No Yes No Yes 
H03B_48m Antithyroid preparations_48m No Yes No Yes 
H03C_6m Iodine therapy_6m No No No No 
H03C_12m Iodine therapy_12m No No No No 
H03C_24m Iodine therapy_24m No No No No 
H03C_48m Iodine therapy_48m No No No No 
H04A_6m Glycogenolytic hormones_6m No No No No 
H04A_12m Glycogenolytic hormones_12m No No No No 
H04A_24m Glycogenolytic hormones_24m No No No Yes 
H04A_48m Glycogenolytic hormones_48m No No No Yes 
H05A_6m 
Parathyroid hormones and 
analogues_6m No No No No 
H05A_12m 
Parathyroid hormones and 
analogues_12m No No No No 
H05A_24m 
Parathyroid hormones and 
analogues_24m No No No No 
H05A_48m 
Parathyroid hormones and 




H05B_6m Anti-parathyroid agents_6m No No No No 
H05B_12m Anti-parathyroid agents_12m No No No No 
H05B_24m Anti-parathyroid agents_24m No No No No 
H05B_48m Anti-parathyroid agents_48m No No No No 
J01A_6m Tetracyclines_6m Yes Yes Yes Yes 
J01A_12m Tetracyclines_12m Yes Yes Yes Yes 
J01A_24m Tetracyclines_24m Yes Yes Yes Yes 
J01A_48m Tetracyclines_48m Yes Yes Yes Yes 
J01B_6m Amphenicols_6m No No No No 
J01B_12m Amphenicols_12m No No No No 
J01B_24m Amphenicols_24m No No No No 
J01B_48m Amphenicols_48m No No No No 
J01C_6m 
Beta-lactam antibacterials, 
penicillins_6m Yes Yes Yes Yes 
J01C_12m 
Beta-lactam antibacterials, 
penicillins_12m Yes Yes Yes Yes 
J01C_24m 
Beta-lactam antibacterials, 
penicillins_24m Yes Yes Yes Yes 
J01C_48m 
Beta-lactam antibacterials, 
penicillins_48m Yes Yes Yes Yes 
J01D_6m 
Other beta-lactam 
antibacterials_6m No No No No 
J01D_12m 
Other beta-lactam 
antibacterials_12m No No No No 
J01D_24m 
Other beta-lactam 
antibacterials_24m No No No No 
J01D_48m 
Other beta-lactam 






trimethoprim_6m Yes Yes Yes Yes 
J01E_12m 
Sulfonamides and 
trimethoprim_12m Yes Yes Yes Yes 
J01E_24m 
Sulfonamides and 
trimethoprim_24m Yes Yes Yes Yes 
J01E_48m 
Sulfonamides and 
trimethoprim_48m Yes Yes Yes Yes 
J01F_6m 
Macrolides, lincosamides and 
streptogramins_6m Yes Yes Yes Yes 
J01F_12m 
Macrolides, lincosamides and 
streptogramins_12m Yes Yes Yes Yes 
J01F_24m 
Macrolides, lincosamides and 
streptogramins_24m Yes Yes Yes Yes 
J01F_48m 
Macrolides, lincosamides and 
streptogramins_48m Yes Yes Yes Yes 
J01G_6m Aminoglycoside antibacterials_6m No No No No 
J01G_12m 
Aminoglycoside 
antibacterials_12m No No No No 
J01G_24m 
Aminoglycoside 
antibacterials_24m No No No No 
J01G_48m 
Aminoglycoside 
antibacterials_48m No No No No 
J01M_6m Quinolone antibacterials_6m Yes Yes Yes Yes 
J01M_12m Quinolone antibacterials_12m Yes Yes Yes Yes 
J01M_24m Quinolone antibacterials_24m Yes Yes Yes Yes 
J01M_48m Quinolone antibacterials_48m Yes Yes Yes Yes 






antibacterials_12m No No No No 
J01R_24m 
Combinations of 
antibacterials_24m No No No No 
J01R_48m 
Combinations of 
antibacterials_48m No No No No 
J01X_6m Other antibacterials_6m Yes Yes Yes Yes 
J01X_12m Other antibacterials_12m Yes Yes Yes Yes 
J01X_24m Other antibacterials_24m Yes Yes Yes Yes 
J01X_48m Other antibacterials_48m Yes Yes Yes Yes 
J02A_6m Antimycotics for systemic use_6m Yes Yes Yes Yes 
J02A_12m 
Antimycotics for systemic 
use_12m Yes Yes Yes Yes 
J02A_24m 
Antimycotics for systemic 
use_24m Yes Yes Yes Yes 
J02A_48m 
Antimycotics for systemic 
use_48m Yes Yes Yes Yes 
J04A_6m 
Drugs for treatment of 
tuberculosis_6m No No No No 
J04A_12m 
Drugs for treatment of 
tuberculosis_12m No No No No 
J04A_24m 
Drugs for treatment of 
tuberculosis_24m No No No No 
J04A_48m 
Drugs for treatment of 
tuberculosis_48m No No No No 
J04B_6m Drugs for treatment of lepra_6m No No No No 
J04B_12m Drugs for treatment of lepra_12m No No No No 
J04B_24m Drugs for treatment of lepra_24m No No No No 




J05A_6m Direct acting antiviral drugs_6m No Yes Yes Yes 
J05A_12m Direct acting antiviral drugs_12m Yes Yes Yes Yes 
J05A_24m Direct acting antiviral drugs_24m Yes Yes Yes Yes 
J05A_48m Direct acting antiviral drugs_48m Yes Yes Yes Yes 
J06A_6m Immune sera_6m No No No No 
J06A_12m Immune sera_12m No No No No 
J06A_24m Immune sera_24m No No No No 
J06A_48m Immune sera_48m No No No No 
J06B_6m Immunoglobulins_6m No No No No 
J06B_12m Immunoglobulins_12m No No No No 
J06B_24m Immunoglobulins_24m No No No No 
J06B_48m Immunoglobulins_48m No No No No 
J07A_6m Bacterial vaccines_6m No No No No 
J07A_12m Bacterial vaccines_12m No No No No 
J07A_24m Bacterial vaccines_24m No No No No 
J07A_48m Bacterial vaccines_48m No No No Yes 
J07B_6m Viral vaccines_6m No No No No 
J07B_12m Viral vaccines_12m No No No Yes 
J07B_24m Viral vaccines_24m Yes No Yes Yes 
J07B_48m Viral vaccines_48m Yes Yes Yes Yes 
J07C_6m Bacterial and viral vaccines_6m No No No No 
J07C_12m Bacterial and viral vaccines_12m No No No No 
J07C_24m Bacterial and viral vaccines_24m No No No No 
J07C_48m Bacterial and viral vaccines_48m No No No No 
J07X_6m Other vaccines_6m No No No No 




J07X_24m Other vaccines_24m No No No No 
J07X_48m Other vaccines_48m No No No No 
L01A_6m Alkylating agents_6m No No No No 
L01A_12m Alkylating agents_12m No No No No 
L01A_24m Alkylating agents_24m No No No No 
L01A_48m Alkylating agents_48m No No No No 
L01B_6m Antimetabolites_6m No No No No 
L01B_12m Antimetabolites_12m No No No No 
L01B_24m Antimetabolites_24m No No No No 
L01B_48m Antimetabolites_48m No No No No 
L01C_6m 
Plant alkaloids and other natural 
products_6m No No No No 
L01C_12m 
Plant alkaloids and other natural 
products_12m No No No No 
L01C_24m 
Plant alkaloids and other natural 
products_24m No No No No 
L01C_48m 
Plant alkaloids and other natural 
products_48m No No No No 
L01D_6m 
Cytotoxic antibiotics and related 
substances_6m No No No No 
L01D_12m 
Cytotoxic antibiotics and related 
substances_12m No No No No 
L01D_24m 
Cytotoxic antibiotics and related 
substances_24m No No No No 
L01D_48m 
Cytotoxic antibiotics and related 
substances_48m No No No No 
L01X_6m Other antineoplastic agents_6m No No No No 




L01X_24m Other antineoplastic agents_24m No No No No 
L01X_48m Other antineoplastic agents_48m No No No No 
L02A_6m Hormones and related agents_6m No No No No 
L02A_12m 
Hormones and related 
agents_12m No No No No 
L02A_24m 
Hormones and related 
agents_24m No No No No 
L02A_48m 
Hormones and related 
agents_48m No No No No 
L02B_6m 
Hormone antagonists and related 
agents_6m No No No No 
L02B_12m 
Hormone antagonists and related 
agents_12m No No No No 
L02B_24m 
Hormone antagonists and related 
agents_24m No No No No 
L02B_48m 
Hormone antagonists and related 
agents_48m No No No No 
L03A_6m Immunostimulants_6m No No No No 
L03A_12m Immunostimulants_12m No No No No 
L03A_24m Immunostimulants_24m No No No No 
L03A_48m Immunostimulants_48m No No No No 
L04A_6m Immunosuppressants_6m No No No Yes 
L04A_12m Immunosuppressants_12m Yes No Yes Yes 
L04A_24m Immunosuppressants_24m Yes No Yes Yes 



















steroids_48m Yes Yes Yes Yes 
M01B_6m 
Anti-inflammatory/antirheumatic 
agents in combination_6m No No No No 
M01B_12m 
Anti-inflammatory/antirheumatic 
agents in combination_12m No No No No 
M01B_24m 
Anti-inflammatory/antirheumatic 
agents in combination_24m No No No No 
M01B_48m 
Anti-inflammatory/antirheumatic 
agents in combination_48m No No No No 
M01C_6m Specific antirheumatic agents_6m No No No No 
M01C_12m 
Specific antirheumatic 
agents_12m No No No No 
M01C_24m 
Specific antirheumatic 
agents_24m No No No No 
M01C_48m 
Specific antirheumatic 
agents_48m No No No No 
M02A_6m 
Topical products for joint and 
muscular pain_6m No No No Yes 
M02A_12m 
Topical products for joint and 
muscular pain_12m No No No Yes 
M02A_24m 
Topical products for joint and 





Topical products for joint and 
muscular pain_48m Yes Yes Yes Yes 
M03A_6m 
Muscle relaxants, peripherally 
acting agents_6m No No No No 
M03A_12m 
Muscle relaxants, peripherally 
acting agents_12m No No No No 
M03A_24m 
Muscle relaxants, peripherally 
acting agents_24m No No No No 
M03A_48m 
Muscle relaxants, peripherally 
acting agents_48m No No No No 
M03B_6m 
Muscle relaxants, centrally acting 
agents_6m Yes Yes Yes Yes 
M03B_12m 
Muscle relaxants, centrally acting 
agents_12m Yes Yes Yes Yes 
M03B_24m 
Muscle relaxants, centrally acting 
agents_24m Yes Yes Yes Yes 
M03B_48m 
Muscle relaxants, centrally acting 
agents_48m Yes Yes Yes Yes 
M03C_6m 
Muscle relaxants, directly acting 
agents_6m No No No No 
M03C_12m 
Muscle relaxants, directly acting 
agents_12m No No No No 
M03C_24m 
Muscle relaxants, directly acting 
agents_24m No No No No 
M03C_48m 
Muscle relaxants, directly acting 
agents_48m No No No No 
M04A_6m Antigout preparations_6m Yes No Yes No 
M04A_12m Antigout preparations_12m Yes No Yes No 
M04A_24m Antigout preparations_24m Yes No Yes Yes 





Drugs affecting bone structure and 
mineralization_6m Yes Yes No Yes 
M05B_12m 
Drugs affecting bone structure and 
mineralization_12m Yes Yes Yes Yes 
M05B_24m 
Drugs affecting bone structure and 
mineralization_24m Yes Yes Yes Yes 
M05B_48m 
Drugs affecting bone structure and 
mineralization_48m Yes Yes Yes Yes 
M09A_6m 
Other drugs for disorders of the 
musculo-skeletal system_6m No No No No 
M09A_12m 
Other drugs for disorders of the 
musculo-skeletal system_12m No No No No 
M09A_24m 
Other drugs for disorders of the 
musculo-skeletal system_24m No No No No 
M09A_48m 
Other drugs for disorders of the 
musculo-skeletal system_48m No No No No 
N01A_6m Anesthetics, general_6m No No No No 
N01A_12m Anesthetics, general_12m No No No No 
N01A_24m Anesthetics, general_24m No No No No 
N01A_48m Anesthetics, general_48m No No No No 
N01B_6m Anesthetics, local_6m No No No No 
N01B_12m Anesthetics, local_12m No No No Yes 
N01B_24m Anesthetics, local_24m No No No Yes 
N01B_48m Anesthetics, local_48m Yes Yes No Yes 
N02A_6m Opioids_6m Yes Yes Yes Yes 
N02A_12m Opioids_12m Yes Yes Yes Yes 
N02A_24m Opioids_24m Yes Yes Yes Yes 





Other analgesics and 
antipyretics_6m Yes Yes Yes Yes 
N02B_12m 
Other analgesics and 
antipyretics_12m Yes Yes Yes Yes 
N02B_24m 
Other analgesics and 
antipyretics_24m Yes Yes Yes Yes 
N02B_48m 
Other analgesics and 
antipyretics_48m Yes Yes Yes Yes 
N02C_6m Antimigraine preparations_6m Yes Yes Yes Yes 
N02C_12m Antimigraine preparations_12m Yes Yes Yes Yes 
N02C_24m Antimigraine preparations_24m Yes Yes Yes Yes 
N02C_48m Antimigraine preparations_48m Yes Yes Yes Yes 
N03A_6m Antiepileptics_6m Yes Yes Yes Yes 
N03A_12m Antiepileptics_12m Yes Yes Yes Yes 
N03A_24m Antiepileptics_24m Yes Yes Yes Yes 
N03A_48m Antiepileptics_48m Yes Yes Yes Yes 
N04A_6m Anticholinergic agents_6m Yes Yes Yes Yes 
N04A_12m Anticholinergic agents_12m Yes Yes Yes Yes 
N04A_24m Anticholinergic agents_24m Yes Yes Yes Yes 
N04A_48m Anticholinergic agents_48m Yes Yes Yes Yes 
N04B_6m Dopaminergic agents_6m Yes Yes Yes Yes 
N04B_12m Dopaminergic agents_12m Yes Yes Yes Yes 
N04B_24m Dopaminergic agents_24m Yes Yes Yes Yes 
N04B_48m Dopaminergic agents_48m Yes Yes Yes Yes 
N05A_6m Antipsychotics_6m Yes Yes Yes Yes 
N05A_12m Antipsychotics_12m Yes Yes Yes Yes 




N05A_48m Antipsychotics_48m Yes Yes Yes Yes 
N05B_6m Anxiolytics_6m Yes Yes Yes Yes 
N05B_12m Anxiolytics_12m Yes Yes Yes Yes 
N05B_24m Anxiolytics_24m Yes Yes Yes Yes 
N05B_48m Anxiolytics_48m Yes Yes Yes Yes 
N05C_6m Hypnotics and sedatives_6m Yes Yes Yes Yes 
N05C_12m Hypnotics and sedatives_12m Yes Yes Yes Yes 
N05C_24m Hypnotics and sedatives_24m Yes Yes Yes Yes 
N05C_48m Hypnotics and sedatives_48m Yes Yes Yes Yes 
N06A_6m Antidepressants_6m Yes Yes Yes Yes 
N06A_12m Antidepressants_12m Yes Yes Yes Yes 
N06A_24m Antidepressants_24m Yes Yes Yes Yes 
N06A_48m Antidepressants_48m Yes Yes Yes Yes 
N06B_6m 
Psychostimulants, agents used for 
ADHD and nootropics_6m Yes No Yes Yes 
N06B_12m 
Psychostimulants, agents used for 
ADHD and nootropics_12m Yes No Yes Yes 
N06B_24m 
Psychostimulants, agents used for 
ADHD and nootropics_24m Yes Yes Yes Yes 
N06B_48m 
Psychostimulants, agents used for 



















combination_48m No No No No 
N06D_6m Anti-dementia drugs_6m No No No No 
N06D_12m Anti-dementia drugs_12m No No No No 
N06D_24m Anti-dementia drugs_24m No No No No 
N06D_48m Anti-dementia drugs_48m No No No No 
N07A_6m Parasympathomimetics_6m No No No No 
N07A_12m Parasympathomimetics_12m No No No No 
N07A_24m Parasympathomimetics_24m No No No No 
N07A_48m Parasympathomimetics_48m No No No No 
N07B_6m 
Drugs used in addictive 
disorders_6m Yes Yes Yes Yes 
N07B_12m 
Drugs used in addictive 
disorders_12m Yes Yes Yes Yes 
N07B_24m 
Drugs used in addictive 
disorders_24m Yes Yes Yes Yes 
N07B_48m 
Drugs used in addictive 
disorders_48m Yes Yes Yes Yes 
N07C_6m Antivertigo preparations_6m No No No No 
N07C_12m Antivertigo preparations_12m No No No No 
N07C_24m Antivertigo preparations_24m Yes No No Yes 
N07C_48m Antivertigo preparations_48m Yes No No Yes 
N07X_6m Other nervous system drugs_6m No No No No 




N07X_24m Other nervous system drugs_24m No No No No 
N07X_48m Other nervous system drugs_48m No No No No 
P01A_6m 
Agents against amoebiasis and 
other protozoal diseases_6m Yes Yes Yes Yes 
P01A_12m 
Agents against amoebiasis and 
other protozoal diseases_12m Yes Yes Yes Yes 
P01A_24m 
Agents against amoebiasis and 
other protozoal diseases_24m Yes Yes Yes Yes 
P01A_48m 
Agents against amoebiasis and 
other protozoal diseases_48m Yes Yes Yes Yes 
P01B_6m Antimalarials_6m Yes Yes Yes Yes 
P01B_12m Antimalarials_12m Yes Yes Yes Yes 
P01B_24m Antimalarials_24m Yes Yes Yes Yes 
P01B_48m Antimalarials_48m Yes Yes Yes Yes 
P01C_6m 
Agents against leishmaniasis and 
trypanosomiasis_6m No No No No 
P01C_12m 
Agents against leishmaniasis and 
trypanosomiasis_12m No No No No 
P01C_24m 
Agents against leishmaniasis and 
trypanosomiasis_24m No No No No 
P01C_48m 
Agents against leishmaniasis and 
trypanosomiasis_48m No No No No 
P02B_6m Antitrematodals_6m No No No No 
P02B_12m Antitrematodals_12m No No No No 
P02B_24m Antitrematodals_24m No No No No 
P02B_48m Antitrematodals_48m No No No No 
P02C_6m Antinematodal agents_6m No No No No 




P02C_24m Antinematodal agents_24m Yes Yes Yes Yes 
P02C_48m Antinematodal agents_48m Yes Yes Yes Yes 
P02D_6m Anticestodals_6m No No No No 
P02D_12m Anticestodals_12m No No No No 
P02D_24m Anticestodals_24m No No No No 
P02D_48m Anticestodals_48m No No No No 
P03A_6m 
Ectoparasiticides, including 
scabicides_6m No No No No 
P03A_12m 
Ectoparasiticides, including 
scabicides_12m No No No No 
P03A_24m 
Ectoparasiticides, including 
scabicides_24m No No No Yes 
P03A_48m 
Ectoparasiticides, including 
scabicides_48m No No No Yes 
P03B_6m Insecticides and repellents_6m No No No No 
P03B_12m Insecticides and repellents_12m No No No No 
P03B_24m Insecticides and repellents_24m No No No No 
P03B_48m Insecticides and repellents_48m No No No No 
R01A_6m 
Decongestants and other nasal 
preparations for topical use_6m Yes Yes Yes Yes 
R01A_12m 
Decongestants and other nasal 
preparations for topical use_12m Yes Yes Yes Yes 
R01A_24m 
Decongestants and other nasal 
preparations for topical use_24m Yes Yes Yes Yes 
R01A_48m 
Decongestants and other nasal 
preparations for topical use_48m Yes Yes Yes Yes 
R01B_6m 
Nasal decongestants for systemic 





Nasal decongestants for systemic 
use_12m No No No No 
R01B_24m 
Nasal decongestants for systemic 
use_24m No No No No 
R01B_48m 
Nasal decongestants for systemic 
use_48m No No No Yes 
R02A_6m Throat preparations_6m No No No Yes 
R02A_12m Throat preparations_12m No No No Yes 
R02A_24m Throat preparations_24m No Yes No Yes 
R02A_48m Throat preparations_48m Yes Yes Yes Yes 
R03A_6m Adrenergics, inhalants_6m Yes Yes Yes Yes 
R03A_12m Adrenergics, inhalants_12m Yes Yes Yes Yes 
R03A_24m Adrenergics, inhalants_24m Yes Yes Yes Yes 
R03A_48m Adrenergics, inhalants_48m Yes Yes Yes Yes 
R03B_6m 
Other drugs for obstructive airway 
diseases, inhalants_6m Yes Yes Yes Yes 
R03B_12m 
Other drugs for obstructive airway 
diseases, inhalants_12m Yes Yes Yes Yes 
R03B_24m 
Other drugs for obstructive airway 
diseases, inhalants_24m Yes Yes Yes Yes 
R03B_48m 
Other drugs for obstructive airway 
diseases, inhalants_48m Yes Yes Yes Yes 
R03C_6m Adrenergics for systemic use_6m No No No Yes 
R03C_12m Adrenergics for systemic use_12m No Yes Yes Yes 
R03C_24m Adrenergics for systemic use_24m No Yes Yes Yes 
R03C_48m Adrenergics for systemic use_48m Yes Yes Yes Yes 
R03D_6m 
Other systemic drugs for 





Other systemic drugs for 
obstructive airway diseases_12m Yes No Yes Yes 
R03D_24m 
Other systemic drugs for 
obstructive airway diseases_24m Yes Yes Yes Yes 
R03D_48m 
Other systemic drugs for 
obstructive airway diseases_48m Yes Yes Yes Yes 
R05C_6m 
Expectorants, excluding 
combinations with cough 
suppressants_6m Yes Yes Yes Yes 
R05C_12m 
Expectorants, excluding 
combinations with cough 
suppressants_12m Yes Yes Yes Yes 
R05C_24m 
Expectorants, excluding 
combinations with cough 
suppressants_24m Yes Yes Yes Yes 
R05C_48m 
Expectorants, excluding 
combinations with cough 
suppressants_48m Yes Yes Yes Yes 
R05D_6m 
Cough suppressants, excluding 
combinations with 
expectorants_6m Yes Yes Yes Yes 
R05D_12m 
Cough suppressants, excluding 
combinations with 
expectorants_12m Yes Yes Yes Yes 
R05D_24m 
Cough suppressants, excluding 
combinations with 
expectorants_24m Yes Yes Yes Yes 
R05D_48m 
Cough suppressants, excluding 
combinations with 





Cough suppressants and 
expectorants, combinations_6m Yes Yes Yes Yes 
R05F_12m 
Cough suppressants and 
expectorants, combinations_12m Yes Yes Yes Yes 
R05F_24m 
Cough suppressants and 
expectorants, combinations_24m Yes Yes Yes Yes 
R05F_48m 
Cough suppressants and 
expectorants, combinations_48m Yes Yes Yes Yes 
R05X_6m Other cold preparations_6m No No No No 
R05X_12m Other cold preparations_12m No No No No 
R05X_24m Other cold preparations_24m No No No No 
R05X_48m Other cold preparations_48m No No No No 
R06A_6m 
Antihistamines for systemic 
use_6m Yes Yes Yes Yes 
R06A_12m 
Antihistamines for systemic 
use_12m Yes Yes Yes Yes 
R06A_24m 
Antihistamines for systemic 
use_24m Yes Yes Yes Yes 
R06A_48m 
Antihistamines for systemic 
use_48m Yes Yes Yes Yes 
R07A_6m 
Other respiratory system 
products_6m No No No No 
R07A_12m 
Other respiratory system 
products_12m No No No No 
R07A_24m 
Other respiratory system 
products_24m No No No No 
R07A_48m 
Other respiratory system 
products_48m No No No No 




S01A_12m Anti-infectives_12m Yes Yes Yes Yes 
S01A_24m Anti-infectives_24m Yes Yes Yes Yes 
S01A_48m Anti-infectives_48m Yes Yes Yes Yes 
S01B_6m Anti-inflammatory agents_6m Yes Yes No Yes 
S01B_12m Anti-inflammatory agents_12m Yes Yes Yes Yes 
S01B_24m Anti-inflammatory agents_24m Yes Yes Yes Yes 
S01B_48m Anti-inflammatory agents_48m Yes Yes Yes Yes 
S01C_6m 
Anti-inflammatory agents and anti-
infectives in combination_6m Yes Yes No Yes 
S01C_12m 
Anti-inflammatory agents and anti-
infectives in combination_12m Yes Yes Yes Yes 
S01C_24m 
Anti-inflammatory agents and anti-
infectives in combination_24m Yes Yes Yes Yes 
S01C_48m 
Anti-inflammatory agents and anti-
infectives in combination_48m Yes Yes Yes Yes 
S01E_6m 
Antiglaucoma preparations and 
miotics_6m Yes Yes Yes Yes 
S01E_12m 
Antiglaucoma preparations and 
miotics_12m Yes Yes Yes Yes 
S01E_24m 
Antiglaucoma preparations and 
miotics_24m Yes Yes Yes Yes 
S01E_48m 
Antiglaucoma preparations and 
miotics_48m Yes Yes Yes Yes 
S01F_6m Mydriatics and cycloplegics_6m No No No No 
S01F_12m Mydriatics and cycloplegics_12m No No No No 
S01F_24m Mydriatics and cycloplegics_24m No No No Yes 






antiallergics_6m Yes Yes Yes Yes 
S01G_12m 
Decongestants and 
antiallergics_12m Yes Yes Yes Yes 
S01G_24m 
Decongestants and 
antiallergics_24m Yes Yes Yes Yes 
S01G_48m 
Decongestants and 
antiallergics_48m Yes Yes Yes Yes 
S01H_6m Local anesthetics_6m No No No No 
S01H_12m Local anesthetics_12m No No No No 
S01H_24m Local anesthetics_24m No No No No 
S01H_48m Local anesthetics_48m No No No No 
S01J_6m Diagnostic agents_6m No No No No 
S01J_12m Diagnostic agents_12m No No No No 
S01J_24m Diagnostic agents_24m No No No No 
S01J_48m Diagnostic agents_48m No No No No 
S01K_6m Surgical aids_6m No No No No 
S01K_12m Surgical aids_12m No No No No 
S01K_24m Surgical aids_24m No No No No 
S01K_48m Surgical aids_48m No No No No 
S01L_6m 
Ocular vascular disorder 
agents_6m No No No No 
S01L_12m 
Ocular vascular disorder 
agents_12m No No No No 
S01L_24m 
Ocular vascular disorder 
agents_24m No No No No 
S01L_48m 
Ocular vascular disorder 




S01X_6m Other ophthalmologicals_6m Yes Yes Yes Yes 
S01X_12m Other ophthalmologicals_12m Yes Yes Yes Yes 
S01X_24m Other ophthalmologicals_24m Yes Yes Yes Yes 
S01X_48m Other ophthalmologicals_48m Yes Yes Yes Yes 
S02A_6m Anti-infectives_6m No No No No 
S02A_12m Anti-infectives_12m No No No No 
S02A_24m Anti-infectives_24m No No No Yes 
S02A_48m Anti-infectives_48m Yes No No Yes 
S02B_6m Corticosteroids_6m No No No No 
S02B_12m Corticosteroids_12m No No No No 
S02B_24m Corticosteroids_24m No No No No 
S02B_48m Corticosteroids_48m No No No No 
S02C_6m 
Corticosteroids and anti-infectives 
in combination_6m No No Yes Yes 
S02C_12m 
Corticosteroids and anti-infectives 
in combination_12m Yes No Yes Yes 
S02C_24m 
Corticosteroids and anti-infectives 
in combination_24m Yes Yes Yes Yes 
S02C_48m 
Corticosteroids and anti-infectives 
in combination_48m Yes Yes Yes Yes 
S02D_6m Other otologicals_6m No No No No 
S02D_12m Other otologicals_12m No No No No 
S02D_24m Other otologicals_24m No No No No 
S02D_48m Other otologicals_48m No No No No 
S03A_6m Anti-infectives_6m No No No No 
S03A_12m Anti-infectives_12m No No No No 




S03A_48m Anti-infectives_48m No No No No 
S03B_6m Corticosteroids_6m No No No No 
S03B_12m Corticosteroids_12m No No No No 
S03B_24m Corticosteroids_24m No No No No 
S03B_48m Corticosteroids_48m No No No No 
S03C_6m 
Corticosteroids and anti-infectives 
in combination_6m No Yes Yes Yes 
S03C_12m 
Corticosteroids and anti-infectives 
in combination_12m Yes Yes Yes Yes 
S03C_24m 
Corticosteroids and anti-infectives 
in combination_24m Yes Yes Yes Yes 
S03C_48m 
Corticosteroids and anti-infectives 
in combination_48m Yes Yes Yes Yes 
S03D_6m 
Other ophthalmological and 
otological preparations_6m No No No No 
S03D_12m 
Other ophthalmological and 
otological preparations_12m No No No No 
S03D_24m 
Other ophthalmological and 
otological preparations_24m No No No No 
S03D_48m 
Other ophthalmological and 
otological preparations_48m No No No No 
V01A_6m Allergens_6m No No No No 
V01A_12m Allergens_12m No No No No 
V01A_24m Allergens_24m No No No No 
V01A_48m Allergens_48m No No No No 
V03A_6m All other therapeutic products_6m No No No No 
V03A_12m 
All other therapeutic 





All other therapeutic 
products_24m No No No No 
V03A_48m 
All other therapeutic 
products_48m No No No No 
V04B_6m Urine tests_6m No No No No 
V04B_12m Urine tests_12m No No No No 
V04B_24m Urine tests_24m No No No No 
V04B_48m Urine tests_48m No No No No 
V04C_6m Other diagnostic agents_6m No No No No 
V04C_12m Other diagnostic agents_12m No No No No 
V04C_24m Other diagnostic agents_24m No No No No 
V04C_48m Other diagnostic agents_48m No No No No 
V06A_6m 
Diet formulations for treatment of 
obesity_6m No No No No 
V06A_12m 
Diet formulations for treatment of 
obesity_12m No No No No 
V06A_24m 
Diet formulations for treatment of 
obesity_24m No No No No 
V06A_48m 
Diet formulations for treatment of 
obesity_48m No No No No 
V06B_6m Protein supplements_6m No No No No 
V06B_12m Protein supplements_12m No No No No 
V06B_24m Protein supplements_24m No No No No 
V06B_48m Protein supplements_48m No No No No 
V06C_6m Infant formulas_6m No No No No 
V06C_12m Infant formulas_12m No No No No 




V06C_48m Infant formulas_48m No No No No 
V06D_6m Other nutrients_6m No No No No 
V06D_12m Other nutrients_12m No No No No 
V06D_24m Other nutrients_24m No No No No 
V06D_48m Other nutrients_48m No No No No 
V07A_6m 
All other non-therapeutic 
products_6m No No No No 
V07A_12m 
All other non-therapeutic 
products_12m No No No No 
V07A_24m 
All other non-therapeutic 
products_24m No No No No 
V07A_48m 
All other non-therapeutic 
products_48m No No No No 
V08A_6m 
X-ray contrast media, 
iodinated_6m No No No No 
V08A_12m 
X-ray contrast media, 
iodinated_12m No No No No 
V08A_24m 
X-ray contrast media, 
iodinated_24m No No No No 
V08A_48m 
X-ray contrast media, 
iodinated_48m No No No No 
V08B_6m 
X-ray contrast media, non-
iodinated_6m No No No No 
V08B_12m 
X-ray contrast media, non-
iodinated_12m No No No No 
V08B_24m 
X-ray contrast media, non-
iodinated_24m No No No No 
V08B_48m 
X-ray contrast media, non-





Magnetic resonance imaging 
contrast media_6m No No No No 
V08C_12m 
Magnetic resonance imaging 
contrast media_12m No No No No 
V08C_24m 
Magnetic resonance imaging 
contrast media_24m No No No No 
V08C_48m 
Magnetic resonance imaging 
contrast media_48m No No No No 
V08D_6m Ultrasound contrast media_6m No No No No 
V08D_12m Ultrasound contrast media_12m No No No No 
V08D_24m Ultrasound contrast media_24m No No No No 
V08D_48m Ultrasound contrast media_48m No No No No 
V09A_6m Central nervous system_6m No No No No 
V09A_12m Central nervous system_12m No No No No 
V09A_24m Central nervous system_24m No No No No 
V09A_48m Central nervous system_48m No No No No 
V09B_6m Skeleton_6m No No No No 
V09B_12m Skeleton_12m No No No No 
V09B_24m Skeleton_24m No No No No 
V09B_48m Skeleton_48m No No No No 
V09C_6m Renal system_6m No No No No 
V09C_12m Renal system_12m No No No No 
V09C_24m Renal system_24m No No No No 
V09C_48m Renal system_48m No No No No 
V09D_6m 
Hepatic and reticulo endothelial 





Hepatic and reticulo endothelial 
system_12m No No No No 
V09D_24m 
Hepatic and reticulo endothelial 
system_24m No No No No 
V09D_48m 
Hepatic and reticulo endothelial 
system_48m No No No No 
V09E_6m Respiratory system_6m No No No No 
V09E_12m Respiratory system_12m No No No No 
V09E_24m Respiratory system_24m No No No No 
V09E_48m Respiratory system_48m No No No No 
V09F_6m Thyroid_6m No No No No 
V09F_12m Thyroid_12m No No No No 
V09F_24m Thyroid_24m No No No No 
V09F_48m Thyroid_48m No No No No 
V09G_6m Cardiovascular system_6m No No No No 
V09G_12m Cardiovascular system_12m No No No No 
V09G_24m Cardiovascular system_24m No No No No 
V09G_48m Cardiovascular system_48m No No No No 
V09H_6m 
Inflammation and infection 
detection_6m No No No No 
V09H_12m 
Inflammation and infection 
detection_12m No No No No 
V09H_24m 
Inflammation and infection 
detection_24m No No No No 
V09H_48m 
Inflammation and infection 
detection_48m No No No No 
V09I_6m Tumour detection_6m No No No No 




V09I_24m Tumour detection_24m No No No No 
V09I_48m Tumour detection_48m No No No No 
V09X_6m 
Other diagnostic 
radiopharmaceuticals_6m No No No No 
V09X_12m 
Other diagnostic 
radiopharmaceuticals_12m No No No No 
V09X_24m 
Other diagnostic 
radiopharmaceuticals_24m No No No No 
V09X_48m 
Other diagnostic 
radiopharmaceuticals_48m No No No No 
V10A_6m Anti-inflammatory agents_6m No No No No 
V10A_12m Anti-inflammatory agents_12m No No No No 
V10A_24m Anti-inflammatory agents_24m No No No No 
V10A_48m Anti-inflammatory agents_48m No No No No 
V10B_6m 
Pain palliation (bone seeking 
agents)_6m No No No No 
V10B_12m 
Pain palliation (bone seeking 
agents)_12m No No No No 
V10B_24m 
Pain palliation (bone seeking 
agents)_24m No No No No 
V10B_48m 
Pain palliation (bone seeking 
agents)_48m No No No No 
V10X_6m 
Other therapeutic 
radiopharmaceuticals_6m No No No No 
V10X_12m 
Other therapeutic 
radiopharmaceuticals_12m No No No No 
V10X_24m 
Other therapeutic 






radiopharmaceuticals_48m No No No No 
immigrant Immigration Yes Yes Yes Yes 












m Yes Yes Yes Yes 
MARRIED_PARTNER_6m Married_partner_6m No No No Yes 
MARRIED_PARTNER_12m Married_partner_12m No No Yes Yes 
MARRIED_PARTNER_24m Married_partner_24m Yes Yes Yes Yes 
MARRIED_PARTNER_48m Married_partner_48m Yes Yes Yes Yes 
REMAINEDSINGLE_6m Remained_single_6m Yes Yes Yes Yes 
REMAINEDSINGLE_12m Remained_single_12m Yes Yes Yes Yes 
REMAINEDSINGLE_24m Remained_single_24m Yes Yes Yes Yes 
REMAINEDSINGLE_48m Remained_single_48m Yes Yes Yes Yes 
FAMILYMEMBER_SD_6m 
Suicide death of a family member 
(mother/father/partner)_6m No No No No 
FAMILYMEMBER_SD_12m 
Suicide death of a family member 
(mother/father/partner)_12m No No No No 
FAMILYMEMBER_SD_24m 
Suicide death of a family member 
(mother/father/partner)_24m No No No No 
FAMILYMEMBER_SD_48m 
Suicide death of a family member 





Suicide attempt of a family 
member 
(mother/father/partner)_6m No No No No 
FAMILYMEMBER_SA_12m 
Suicide attempt of a family 
member 
(mother/father/partner)_12m No No No No 
FAMILYMEMBER_SA_24m 
Suicide attempt of a family 
member 
(mother/father/partner)_24m No No No No 
FAMILYMEMBER_SA_48m 
Suicide attempt of a family 
member 
(mother/father/partner)_48m No No No No 
ageA30 Age>30 No No No No 
ageA40 Age>40 No No No No 
ageA50 Age>50 No No No No 
ageA60 Age>60 No No No No 
HI_24_6m 
Health insurance_psychiatry 
treatment_6m Yes Yes Yes Yes 
HI_24_12m 
Health insurance_psychiatry 
treatment_12m Yes Yes Yes Yes 
HI_24_24m 
Health insurance_psychiatry 
treatment_24m Yes Yes Yes Yes 
HI_24_48m 
Health insurance_psychiatry 
treatment_48m Yes Yes Yes Yes 
HI_26_6m 
Health insurance_child psychiatry 
treatment_6m No No No No 
HI_26_12m 
Health insurance_child psychiatry 
treatment_12m No No No No 
HI_26_24m 
Health insurance_child psychiatry 





Health insurance_child psychiatry 
treatment_48m No No No No 
HI_63_6m 
Health insurance_psychological 
help_6m Yes Yes Yes Yes 
HI_63_12m 
Health insurance_psychological 
help_12m Yes Yes Yes Yes 
HI_63_24m 
Health insurance_psychological 
help_24m Yes Yes Yes Yes 
HI_63_48m 
Health insurance_psychological 
help_48m Yes Yes Yes Yes 





























Income quartile 2 (ref. income 
quartile 1) Yes Yes Yes Yes 
INCOME_Q3_Q1 
Income quartile 3 (ref. income 
quartile 1) Yes Yes Yes Yes 
INCOME_Q4_Q1 
Income quartile 4 (ref. income 
quartile 1) Yes Yes Yes Yes 
INCOME_ageB14_Q1 
Age £14 years (ref. income 





Missing income (ref. income 
quartile 1) No No No No 
Unemployed_Employed Unemployed (ref. employed) Yes Yes Yes Yes 
EarlyRetir_Employed Early retirement (ref. employed) Yes Yes Yes Yes 
StatePension_Employed State pension (ref. employed) Yes Yes Yes Yes 
AgeB14_Employed Age <=14 years (ref. employed) No No No No 
Missing_Employed 
Missing employment status (ref. 









International Classification of Diseases (ICD) codes used for the conditions included in the Charlson 
Comorbidity Index. 
  Disease ICD8 ICD10 Score 
1 Myocardial infarction 410 I21;I22;I23 1 
2 Congestive heart failure 427.09; 427.10; 427.11; 427.19; 428.99; 782.49 I50; I11.0; I13.0; I13.2 1 
3 Peripheral vascular disease 440; 441; 442; 443; 444; 445 I70; I71; I72; I73; I74; I77 1 
4 Cerebrovascular disease 430–438 I60–I69; G45; G46 1 
5 Dementia 290.09–290.19; 293.09 F00–F03; F05.1; G30 1 
6 Chronic pulmonary disease 490–493; 515–518 
J40–J47; J60–J67; J68.4; J70.1; 
J70.3; J84.1; J92.0; J96.1; J98.2; 
J98.3 
1 
7 Connective tissue disease 712; 716; 734; 446; 135.99 
M05; M06; M08; M09;M30;M31; 
M32; M33; M34; M35; M36; D86 
1 
8 Ulcer disease 530.91; 530.98; 531–534 K22.1; K25–K28 1 




249.00; 249.06; 249.07; 249.09 
250.00; 250.06; 250.07; 250.09 
E10.0, E10.1; E10.9 
E11.0; E11.1; E11.9 
1 
11 Hemiplegia 344 G81; G82 2 
12 Moderate to severe renal disease 
403; 404; 580–583; 584; 590.09; 
593.19; 753.10–753.19; 792 
I12; I13; N00–N05; N07; N11; N14; 
N17–N19; Q61 2 
13 
Diabetes with end-organ 
damage    type1 











14 Any tumor 140–194 C00–C75 2 
15 Leukemia 204–207 C91–C95 2 
16 Lymphoma 200–203; 275.59 C81–C85; C88; C90; C96 2 
17 Moderate to severe liver disease 
070.00; 070.02; 070.04; 070.06; 
070.08; 573.00; 456.00–456.09 
B15.0; B16.0; B16.2; B19.0; K70.4; 
K72; K76.6; I85 3 
18 Metastatic solid tumor 195–198; 199 C76–C80 6 





Distribution of truncated stabilized inverse probability weights for the suicide death analysis. 










Organic disorder Depression IPTW 1.0 (0.10) (0.08, 2.4) 1.0 (0.12) (0.08, 2.4) 
Organic disorder IPTW 1.0 (0.13) (0.09, 4.1) 1.0 (0.17) (0.07, 5.3) 
IPCW 0.99 (0.06) (0.19, 1.3) 0.99 (0.06) (0.22, 1.2) 
Substance use disorder Depression IPTW 1.0 (0.52) (0.07, 14) 1.0 (0.16) (0.09, 3.9) 
Substance use disorder IPTW 1.0 (0.12) (0.16, 3.0) 1.0 (0.08) (0.21, 2.5) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.07) (0.20, 1.2) 
Schizophrenia  Depression IPTW 1.0 (0.11) (0.07, 2.7) 1.0 (0.14) (0.08, 2.7) 
Schizophrenia IPTW 1.0 (0.06) (0.31, 1.9) 1.0 (0.05) (0.34, 1.9) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.07) (0.20, 1.2) 
Bipolar disorder Depression IPTW 1.0 (0.10) (0.07, 2.6) 1.0 (0.13) (0.07, 2.5) 
Bipolar disorder IPTW 1.0 (0.01) (0.92, 1.1) 1.0 (0.02) (0.68, 1.2) 
IPCW 1.0 (0.07) (0.18, 1.3) 0.99 (0.07) (0.20, 1.1) 
Neurotic disorders Depression IPTW 1.0 (0.07) (0.28, 2.1) 1.0 (0.09) (0.24, 2.0) 
Neurotic disorders IPTW 1.0 (0.05) (0.48, 1.8) 1.0 (0.07) (0.47, 2.0) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.07) (0.20, 1.1) 
Eating disorders Depression IPTW 1.0 (0.10) (0.07, 2.5) 1.0 (0.14) (0.07, 2.6) 
Eating disorders IPTW 1.0 (0.006) (1.0, 1.0) 1.0 (0.03) (0.33, 1.1) 




Personality disorders Depression IPTW 1.0 (0.11) (0.09, 3.0) 1.0 (0.22) (0.09, 6.0) 
Personality disorders IPTW 1.0 (0.07) (0.08, 2.5) 1.0 (0.11) (0.06, 3.1) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.07) (0.20, 1.1) 
Intellectual disabilities Depression IPTW 1.0 (0.10) (0.07, 2.5) 1.0 (0.13) (0.07, 2.5) 
Intellectual disabilities IPTW 1.0 (0.03) (0.33, 1.1) 1.0 (0.02) (0.32, 1.1) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.07) (0.20, 1.1) 
Developmental 
disorders 
Depression IPTW 1.0 (0.10) (0.07, 2.5) 1.0 (0.13) (0.07, 2.5) 
Developmental disorders IPTW 1.0 (0.03) (0.23, 1.0) 1.0 (0.001) (0.99, 1.0) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.07) (0.20, 1.1) 
Behavioral disorders Depression IPTW 1.0 (0.10) (0.07, 2.5) 1.0 (0.13) (0.07, 2.5) 
Behavioral disorders IPTW 1.0 (0.05) (0.16, 1.2) 1.0 (0.04) (0.18, 1.1) 





Distribution of truncated stabilized inverse probability weights for the suicide attempt analysis.	










Organic disorder Depression IPTW 1 (0.10) (0.06, 2.3) 1 (0.13) (0.07, 2.4) 
Organic disorder IPTW 1 (0.13) (0.10, 4.0) 1 (0.18) (0.08, 5.6) 
IPCW 0.99 (0.06) (0.19, 1.3) 0.99 (0.06) (0, 4.0) 
Substance use disorder Depression IPTW 1 (0.13) (0.11, 3.4) 1 (0.17)  (0.09, 3.9) 
Substance use disorder IPTW 1 (0.15) (0.11, 3.6) 1 (0.11) (0.15, 3.0) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.06) (0.22, 1.1)  
Schizophrenia  Depression IPTW 1 (0.10) (0.06, 2.5) 1 (0.15) (0.07, 3.1) 
Schizophrenia IPTW 1 (0.06) (0.24, 2.0) 1 (0.06) (0.21, 2.2) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.06) (0.22, 1.1) 
Bipolar disorder Depression IPTW 1 (0.10) (0.06, 2.3) 1 (0.14) (0.07, 2.5) 
Bipolar disorder IPTW 1 (0.1) (0.87, 1.1) 1 (0.02) (0.64, 1.3) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.06) (0.22, 1.1) 
Neurotic disorders Depression IPTW 1 (0.05) (0.36, 1.7) 1 (0.07) (0.34, 1.6) 
Neurotic disorders IPTW 1 (0.06) (0.46, 1.9) 1 (0.09) (0.44, 2.4) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.06) (0.22, 1.1) 
Eating disorders Depression IPTW 1 (0.10) (0.06, 2.3) 1 (0.14) (0.07, 2.9) 
Eating disorders IPTW 1 (0.0007) (0.99, 1.0) 1 (0.04) (0.32, 1.3) 




Personality disorders Depression IPTW 1 (0.14) (0.08, 4.3) 1 (0.22) (0.09, 5.5) 
Personality disorders IPTW 1 (0.10) (0.06, 3.2) 1 (0.14) (0.06, 3.8) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.06) (0.22, 1.1) 
Intellectual disabilities Depression IPTW 1 (0.10) (0.06, 2.3) 1 (0.13) (0.07, 2.4) 
Intellectual disabilities IPTW 1 (0.03) (0.34, 1.1) 1 (0.02) (0.38, 1.1) 
IPCW 1 (0.07) (0.18, 1.3) 0.99 (0.06) (0.22, 1.1) 
Developmental 
disorders 
Depression IPTW 1 (0.10) (0.06, 2.3) 1 (0.13) (0.07, 2.3) 
Developmental disorders IPTW 1 (0.03) (0.23, 1.0) 1 (0.002) (0.99, 1.0) 
IPCW 0.99 (0.07) (0.18, 1.3) 0.99 (0.06) (0.22, 1.1) 
Behavioral disorders Depression IPTW 1 (0.10) (0.06, 2.4) 1 (0.13) (0.07, 2.3) 
Behavioral disorders IPTW 1 (0.06) (0.16, 1.2) 1 (0.04) (0.17, 1.2) 






Sex-specific adjusted hazard ratios for the joint effects of depression and comorbid mental disorders on 
suicide death, adjusted for censoring, Denmark, January 1, 1995 - December 31, 2015. 
  Men Women 








Adjusted RERI  
(95% CI) 
Organic disorders: yes Depressed 11 (4.4, 25) -11 (-22, -0.67) 44 (18, 107) 16 (-22, 53) 
Non-depressed 7.7 (4.3, 14) 8.0 (5.2, 13) 
Organic disorders: no Depressed 15 (12, 18) 22 (17, 28) 
Non-depressed Reference Reference 
Substance use 
disorders: yes 
Depressed 18 (12, 26) -25 (-43, -6.3) 49 (32, 75) 5.4 (-15, 26) 
 Non-depressed 7.5 (5.8, 9.6) 19 (13, 26) 
Substance use 
disorders: no 
Depressed 36 (22, 60) 26 (19, 35) 
Non-depressed Reference Reference 
Schizophrenia: yes Depressed 14 (9.6, 22) -14 (-21, -6.6) 39 (24, 63) -7.7 (-28, 13) 
Non-depressed 13 (11, 17) 24 (17, 35) 
Schizophrenia: no Depressed 16 (13, 20) 23 (18, 30) 
Non-depressed Reference Reference 
Bipolar disorder: yes Depressed 27 (16, 45) -0.46 (-15, 15) 45 (26, 80) -4.6 (-33, 24) 
Non-depressed 15 (9.7, 22) 30 (18, 49) 
Bipolar disorder: no Depressed 14 (11, 17) 21 (16, 27) 
Non-depressed Reference Reference 
Neurotic disorders: yes Depressed 20 (15, 26) -4.5 (-11, 1.5) 
 
31 (23, 42) -3.3 (-14, 7.1) 
Non-depressed 9.6 (7.8, 12) 10 (7.2, 14) 
Neurotic disorders: no Depressed 16 (13, 20) 25 (20, 33) 




Eating disorders: yes Depressed 7.4 (1.8, 31) -7.1 (-18, 3.7) 57 (22, 146) 33 (-20, 86) 
Non-depressed 1.2 (0.49, 3.2) 4.3 (2.9, 6.2) 
Eating disorders: no Depressed 14 (12, 17) 21 (16, 26) 
Non-depressed Reference Reference 
Personality disorders: 
yes 
Depressed 17 (11, 26) -11 (-21, -0.69) 29 (17, 49) -19 (-42, 4.2) 
Non-depressed 13 (8.9, 20) 21 (10, 42) 
Personality disorders: 
no 
Depressed 15 (12, 19) 28 (19, 41) 
Non-depressed Reference Reference 
Intellectual disabilities: 
yes 
Depressed 2.0 (0.68, 6.1) -12 (-14, -9.5) 
 
12 (4.8, 28) -16 (-30, -2.2) 
 Non-depressed 0.36 (0.19, 0.66) 7.7 (2.5, 23) 
Intellectual disabilities: 
no 
Depressed 14 (12, 17) 21 (17, 27) 
Non-depressed Reference Reference 
Developmental 
disorders: yes 
Depressed 8.4 (3.5, 20) -5.7 (-12, 1.1) 5.9 (0.95, 37) -14 (-19, -9.8) 
Non-depressed 0.69 (0.37, 1.3) 0.61 (0.08, 4.4) 
Developmental 
disorders: no 
Depressed 14 (12, 17) 21 (16, 26) 
Non-depressed Reference Reference 
Behavioral disorders: 
yes 
Depressed 14 (4.7, 40) -2.2 (-17, 13) 1.4 (0.39, 5.0) -23 (-29, -16) 
Non-depressed 2.4 (1.3, 4.3) 4.0 (1.8, 9.0) 
Behavioral disorders: no Depressed 14 (12, 18) 21 (17, 27) 







Sex-specific adjusted hazard ratios for the joint effects of depression and comorbid mental disorders on 
non-fatal suicide attempts, adjusted for censoring, Denmark, January 1, 1995 - December 31, 2015. 
  Men Women 








Adjusted RERI  
(95% CI) 
Organic disorders: yes Depressed 37 (23, 60) -15 (-34, 5.0) 41 (25, 68) 3.5 (-18, 25) 
Non-depressed 16 (11, 25) 11 (6.4, 19) 
Organic disorders: no Depressed 37 (31, 43) 28 (25, 31) 
Non-depressed Reference Reference 
Substance use 
disorders: yes 
Depressed 107 (82, 139) 12 (-16, 40) 81 (64, 104) 18 (-0.74, 37) 
Non-depressed 31 (26, 38) 25 (20, 31) 
Substance use 
disorders: no 
Depressed 64 (51, 82) 39 (33, 46) 
Non-depressed Reference Reference 
Schizophrenia: yes Depressed 27 (19, 38) -41 (-53, -28) 41 (30, 56) -12 (-26, 1.0) 
Non-depressed 26 (20, 33) 21 (17, 27) 
Schizophrenia: no Depressed 43 (37, 50) 33 (29, 38) 
Non-depressed Reference Reference 
Bipolar disorder: yes Depressed 39 (24, 63) -16 (-37, 5.4) 30 (22, 42) -19 (-32, -6.6) 
Non-depressed 21 (14, 33) 22 (16, 31) 
Bipolar disorder: no Depressed 35 (30, 40) 28 (25, 32) 
Non-depressed Reference Reference 
Neurotic disorders: yes Depressed 111 (92, 135) -23 (-45, -0.25) 105 (88, 125) 5.5 (-11, 22) 
Non-depressed 76 (65, 88) 51 (44, 59) 
Neurotic disorders: no Depressed 59 (50, 70) 50 (43, 57) 




Eating disorders: yes Depressed 18 (6.2, 50) -16 (-35, 2.2) 32 (21, 48) -9.7 (-23, 3.9) 
Non-depressed 1.9 (0.73, 4.7) 12 (9.0, 17) 
Eating disorders: no Depressed 33 (29, 38) 30 (26, 34) 
Non-depressed Reference Reference 
Personality disorders: 
yes 
Depressed 48 (33, 71) -23 (-43, -4.4) 58 (45, 75) -36 (-56, -15) 
Non-depressed 21 (16, 28) 48 (37, 64) 
Personality disorders: 
no 
Depressed 52 (43, 63) 47 (39, 56) 
Non-depressed Reference Reference 
Intellectual disabilities: 
yes 
Depressed 52 (22, 122) 15 (-30, 59) 40 (18, 91) 4.4 (-29, 38) 
Non-depressed 5.2 (3.2, 8.3) 9.5 (6.0, 15) 
Intellectual disabilities: 
no 
Depressed 33 (28, 38) 27 (24, 30) 
Non-depressed Reference Reference 
Developmental 
disorders: yes 
Depressed 28 (10, 77) -8.2 (-37, 20) 70 (26, 191) 28 (-44, 99) 
Non-depressed 3.8 (2.5, 6.0) 17 (7.5, 37) 
Developmental 
disorders: no 
Depressed 34 (29, 39) 27 (24, 30) 
Non-depressed Reference Reference 
Behavioral disorders: 
yes 
Depressed 25 (16, 41) -27 (-42, -12) 54 (28, 105) 10 (-26, 46) 
Non-depressed 17 (11, 26) 17 (13, 23) 
Behavioral disorders: 
no 
Depressed 37 (32, 43) 28 (25, 32) 
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